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Foreword
Substance use and dependence cause a significant burden to individuals and
societies throughout the world. The World Health Report 2002 indicated that
8.9% of the total burden of disease comes from the use of psychoactive
substances. The report showed that tobacco accounted for 4.1%, alcohol 4%,
and illicit drugs 0.8% of the burden of disease in 2000. Much of the burden
attributable to substance use and dependence is the result of a wide variety
of health and social problems, including HIV/AIDS, which is driven in many
countries by injecting drug use.
This neuroscience report is the first attempt by WHO to provide a
comprehensive overview of the biological factors related to substance use
and dependence by summarizing the vast amount of knowledge gained in
the last 20-30 years. The report highlights the current state of knowledge of
the mechanisms of action of different types of psychoactive substances, and
explains how the use of these substances can lead to the development of
dependence syndrome.
Though the focus is on brain mechanisms, the report nevertheless
addresses the social and environmental factors which influence substance
use and dependence. It also deals with neuroscience aspects of interventions
and, in particular, the ethical implications of new biological intervention
strategies.
The various health and social problems associated with use of and
dependence on tobacco, alcohol and illicit substances require greater
attention by the public health community and appropriate policy responses
are needed to address these problems in different societies. Many gaps remain
to be filled in our understanding of the issues related to substance use and
dependence but this report shows that we already know a great deal about
the nature of these problems that can be used to shape policy responses.
This is an important report and I recommend it to a wide audience of health
care professionals, policy makers, scientists and students.
LEE Jong-wook
Director General
World Health Organization
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11. INTRODUCTION
CHAPTER 1
Introduction
This report describes our current understanding of the neuroscience of
psychoactive substance use and dependence. It draws on the explosive growth
in knowledge in this area in recent decades, which has transformed our
understanding of the biochemical action of psychoactive substances, and
contributed new insights into why many people use them, and why some
use them to the extent of causing harm or of becoming dependent on them.
Structure of the report
The report is divided into eight chapters. The present introductory chapter is
intended to provide the context and background for the report. Chapter 2
provides a brief overview of basic neuroanatomy, neurobiology and
neurochemistry. Chapter 3 presents the “biobehavioural” view of dependence,
which is based on both learning theory and knowledge of the brain’s functions.
Chapter 4 discusses the pharmacology and behavioural effects of different
classes of psychoactive substances, a branch of science also known as
psychopharmacology. In Chapters 2–4 we consider neurobiological processes
which are to a large extent the common heritage of all human beings. In
Chapter 5, we turn to genetic studies, which focus instead on the
differentiations that may exist between humans in their genetic heritage. The
chapter reviews the evidence for a genetic contribution to substance
dependence, and compares the interaction of genetics and environmental
factors in the development and maintenance of dependence. Chapter 6
considers the neuroscientific evidence on specific interconnections between
substance use and mental disorders, focusing particularly on schizophrenia
and depression. The frame of reference changes again in Chapter 7, which is
concerned with ethical issues in research, treatment and prevention of
substance use disorders, and in particular how these issues may apply to
neuroscientific research and its applications. Chapter 8 deals with the public
health implications of neuroscience research and ends with specific
recommendations for policy.
Psychoactive substances and their sociolegal status
Psychoactive substances, more commonly known as psychoactive drugs, are
substances that, when taken, have the ability to change an individual’s
Chapter_1 19.1.2004, 11:221
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consciousness, mood or thinking processes. As later chapters will explain,
advances in neuroscience have given us a much better understanding of the
physical processes by which these substances act. Psychoactive substances
act in the brain on mechanisms that exist normally to regulate the functions
of mood, thoughts, and motivations. In this report, our emphasis will be on
alcohol and other hypnotics and sedatives, nicotine, opioids, cannabis,
cocaine, amphetamines and other stimulants, hallucinogens, and
psychoactive inhalants.
Use of these substances is defined into three categories according to their
sociolegal status. First, many of the substances are used as medications.
Western and other systems of medicine have long recognized the usefulness
of these substances as medications in relieving pain, promoting either sleep
or wakefulness, and relieving mood disorders. Currently, most psychoactive
medications are restricted to use under a doctor’s orders, through a
prescription system. In many countries, as much as one-third of all
prescriptions written are for such medications. An example of this is the use
of the stimulant methylphenidate to treat childhood attention deficit
hyperactivity disorder (ADHD), which will be discussed in Chapter 4. As
described in Chapter 6, some of the substances are also often used as “self-
medications” to relieve distress from mental or physical disorders, or to
alleviate the side-effects of other medications.
A second category of use is illegal, or illicit, use. Under three international
conventions (see Box 1.1), most nations have bound themselves to outlaw
trade in and non-medical use of opiates, cannabis, hallucinogens, cocaine
and many other stimulants, and many hypnotics and sedatives. In addition
to this list, countries or local jurisdictions often add their own prohibited
substances, e.g. alcoholic beverages and various inhalants.
Despite these prohibitions, illicit use of psychoactive substances is fairly
widespread in many societies, particularly among young adults, the usual
purpose being to enjoy or benefit from the psychoactive properties of the
substance. The fact that it is illegal may also add an attractive frisson, and
thus strengthen the identification of users with an alienated subculture.
The third category of use is legal, or licit, consumption, for whatever
purpose the consumer chooses. These purposes may be quite varied, and
are not necessarily connected with the psychoactive properties of the
substance. For instance, an alcoholic beverage can be a source of nutrition,
of heating or cooling the body, or of thirst-quenching; or it may serve a
symbolic purpose in a round of toasting or as a sacrament. However, whatever
the purpose of use, the psychoactive properties of the substance inevitably
accompany its use.
The most widely used psychoactive substances are the following: caffeine
and related stimulants, commonly used in the form of coffee, tea and many
soft drinks; nicotine, currently most often used by smoking tobacco cigarettes;
and alcoholic beverages, which come in many forms, including beer, wine
Chapter_1 19.1.2004, 11:222
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BOX 1.1
United Nations drug control conventions
The three major international drug control treaties are mutually supportive and
complementary. An important purpose of the first two treaties is to codify
internationally applicable control measures in order to ensure the availability of
narcotic drugs and psychotropic substances for medical and scientific purposes,
and to prevent their diversion into illicit channels. They also include general
provisions on illicit trafficking and drug abuse.
Single Convention on Narcotic Drugs, 1961
This Convention recognizes that effective measures against abuse of narcotic
drugs require coordinated and international action. There are two forms of
intervention and control that work together. First, it seeks to limit the possession,
use, trade in, distribution, import, export, manufacture and production of drugs
exclusively to medical and scientific purposes. Second, it combats drug
trafficking through international cooperation to deter and discourage drug
traffickers.
Convention on Psychotropic Substances, 1971
The Convention noted with concern the public health and social problems resulting
from the abuse of certain psychotropic substances and was determined to prevent
and combat abuse of such substances and the illicit traffic which it gives rise to.
The Convention establishes an international control system for psychotropic
substances by responding to the diversification and expansion of the spectrum
of drugs of abuse, and introduced controls over a number of synthetic drugs
according to their abuse potential on the one hand and their therapeutic value on
the other.
United Nations Convention against Illicit Traffic in Narcotic Drugs and
Psychotropic Substances, 1988
This Convention sets out a comprehensive, effective and operative international
treaty that was directed specifically against illicit traffic and that considered
various aspects of the problem as a whole, in particular those aspects not
envisaged in the existing treaties in the field of narcotic drugs and psychotropic
substances. The Convention provides comprehensive measures against drug
trafficking, including provisions against money laundering and the diversion of
precursor chemicals. It provides for international cooperation through, for
example, extradition of drug traffickers, controlled deliveries and transfer of
proceedings.
Source: United Nations Office for Drug Control and Crime Prevention (available on the
Internet at http://www.odccp.org/odccp/un_treaties_and_resolutions.html).
Note: In October 2002 the United Nations Office for Drug Control and Crime
Prevention (ODCCP) changed its name to the United Nations Office on Drugs and
Crime (ODC).
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and distilled spirits. Because the use of caffeinated substances is relatively
unproblematic, it is not further considered in this report. While inhalants are
also widely available, they are mostly used for psychoactive purposes by those
below the age of easy access to alcohol, tobacco and other psychoactive
substances.
While there is a clear rationale for a separate legal status for medications,
the rationale for the distinction between substances that are under
international control and those that are not is more problematic. The
substances which are included in the international conventions reflect
historical understandings in particular cultural settings about what should
be viewed as uniquely dangerous or alien. Some psychopharmacologists or
epidemiologists today, for instance, would argue that alcohol is inherently
no less dangerous or harmful than the drugs included in the international
conventions. Moreover, as discussed below, dependence on nicotine in
tobacco is associated with more death and ill-health than dependence on
other psychoactive substances. As will be seen in the chapters which follow,
the growing knowledge of the neuroscience of psychoactive substance use
has emphasized the commonalities in action which span the three sociolegal
statuses into which the substances are divided.
Global use of psychoactive substances
Tobacco
Many types of tobacco products are consumed throughout the world but the
most popular form of nicotine use is cigarette smoking. Smoking is a
ubiquitous activity: more than 5500 billion cigarettes are manufactured
annually and there are 1.2 billion smokers in the world. This number is
expected to increase to 2 billion by 2030 (Mackay & Eriksen, 2002; World Bank,
1999). Smoking is spreading rapidly in developing countries and among
women. Currently, 50% of men and 9% of women in developing countries
smoke, as compared with 35% of men and 22% of women in developed
countries. China, in particular, contributes significantly to the epidemic in
developing countries. Indeed, the per capita consumption of cigarettes in
Asia and the Far East is higher than in other parts of the world, with the
Americas and eastern Europe following closely behind (Mackay & Eriksen,
2002).
A conceptual framework for describing the different stages of cigarette
smoking epidemics in different regions of the world has been proposed by
Lopez, Collishaw & Piha (1994). In this model, there are four stages of the
epidemic on a continuum ranging from low prevalence of smoking to a stage
in which about one-third of deaths among men in a particular country are
attributable to smoking. In Stage 1, less than 20% of the men and a
considerably lower percentage of women smoke. Available epidemiological
data show that many countries in sub-Saharan Africa fall into this category
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although smoking is increasing in this region. It has been shown that annual
per capita consumption of cigarettes there is less than 100 (Corrao et al., 2000).
There is widespread use of other tobacco products (such as snuff and chewing
tobacco) in some countries, but the extent of adverse health consequences
of use of these forms of tobacco is still not clear.
In Stage 2 of the epidemic, about 50% of the men smoke and there is an
increasing percentage of women smokers. This is the case in China and Japan,
and in some countries in northern Africa and Latin America. In contrast, Stage
3 describes a situation in which there is a noticeable decrease in smoking
among men and women but there is increased mortality from smoking-
related diseases. Some countries in Latin America and eastern and southern
Europe fall into this category. A final stage is marked by decreasing smoking
prevalence, a peaking of deaths from tobacco-related disease among men
(accounting for about one-third of the total), and a continued increase in
deaths from tobacco-related disease among women. This is currently the case
in Australia, Canada, the USA, and western Europe. Table 1.1 shows the rates
of smoking for males and females and per capita consumption of cigarettes
in selected countries with data from all categories of smokers.
Table 1.1 Prevalence of smoking among adults and youths in selected
countries
Annual Prevalence of smoking (%)
per capita
Adults Youthsconsumption
Country of cigarettes Males Females Males Females
Argentina 1495 46.8 34.4 25.7 30.0
Bolivia 274 42.7 18.1 31.0 22.0
Chile 1202 26.0 18.3 34.0 43.4
China 1791 66.9 4.2 14.0   7.0
Ghana 161 28.4 3.5 16.2 17.3
Indonesia 1742 59.0 3.7 38.0   5.3
Jordan 1832 48.0 10.0 27.0 13.4
Kenya 200 66.8 31.9 16.0 10.0
Malawi 123 20.0  9.0 18.0 15.0
Mexico 754 51.2 18.4 27.9 16.0
Nepal 619 48.0 29.0 12.0   6.0
Peru  1849 41.5 15.7 22.0 15.0
Poland 2061 44.0 25.0 29.0 20.0
Singapore 1230 26.9  3.1 10.5   7.5
Sri Lanka 374 25.7  1.7 13.7   5.8
USA 2255 25.7 21.5 27.5 24.2
Source: Mackay & Eriksen, 2002.
Alcohol
Alcohol and tobacco are similar in several ways: both are legal substances,
both are widely available in most parts of the world, and both are marketed
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aggressively by transnational corporations that target young people in
advertising and promotion campaigns. According to the Global status report
on alcohol (WHO, 1999) and as shown in Fig. 1.1 below, the level of
consumption of alcohol has declined in the past twenty years in developed
countries but is increasing in developing countries, especially in the Western
Pacific Region where the annual per capita consumption among adults ranges
from 5 to 9 litres of pure alcohol, and also in countries of the former Soviet
Union (WHO, 1999). To a great extent the rise in the rate of alcohol
consumption in developing countries is driven by rates in Asian countries.
The level of consumption of alcohol is much lower in the African, Eastern
Mediterranean, and South-East Asia Regions.
There is a long tradition of research on the epidemiology of alcohol use in
developed countries and we have learnt much about the distribution and
determinants of drinking in different populations. For many years,
researchers focused on average volume of alcohol consumption in
determining the level of drinking in a particular country. Using production
or sales data from official records has tended to underestimate consumption,
especially in developing countries, where unrecorded consumption of locally
brewed beverages is significant. In order to improve the measurement of per
Fig. 1.1 Annual per capita alcohol consumption among adults aged
15 years or morey
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capita consumption, WHO has sponsored research projects in four countries
(Brazil, China, India and Nigeria) to determine the level of unrecorded
consumption in these countries.
It is expected that more precise estimates of alcohol use will lead to better
understanding of the association between use and problems. In this regard
the comparative risk analysis (CRA) project of WHO is noteworthy. The CRA
uses per capita consumption data together with patterns of drinking to link
use to disease burden (Rehm et al., 2002). A patterns approach to alcohol
consumption assumes that the way in which alcohol is consumed is closely
linked to disease outcome. Drinking during meals, for example, is associated
with less risk of problems than drinking during fiestas or drinking in public
places. In the CRA analysis, four pattern values have been developed, with 1
as the least hazardous and 4 as the most detrimental. At pattern value 1 there
are few occasions of heavy drinking, and drinking is often done with meals,
while pattern value 4 is characterized by many heavy drinking occasions and
drinking outside meals. Table 1.2 shows the pattern values for different WHO
regions, with each region divided into at least two subregions. Values for some
regions are based on limited aggregate data and are only indicative of the
pattern of drinking in these regions.
In the African Region, there was a steady rise in per capita consumption
in the 1970s and a decline beginning from the early 1980s. However, the
pattern of drinking has tended towards the higher levels with men in most
countries drinking at pattern value 3 of the CRA estimates. This is the case
for Gabon, Ghana, Kenya, Lesotho, Senegal, and South Africa, for example.
However, it is only in very few countries (e.g. Zambia and Zimbabwe) that
the pattern value is 4. The detrimental pattern of drinking in many sub-
Saharan countries has been shown in several surveys (e.g. Mustonen, Beukes
& Du Preez, 2001; Obot, 2001). In most countries women drink much less
than men and in some of these countries the abstention rate for older
women is very high.
In the Region of the Americas, heavy drinking (i.e. drinking five or more
drinks on at least one occasion in the past month) is a common drinking
behaviour among young people. Both alcohol consumption and heavy
drinking are reported much more often among males than females in both
Mexico and the USA (WHO, 1999; Medina-Mora et al., 2001). Though Mexico
has a relatively low per capita consumption of alcohol, the pattern value for
that country is 4. This is because there is high frequency of heavy drinking,
especially by young people, on fiesta occasions.
Heavy drinking among young people is also common in the Western Pacific
Region. Though there has been some decline in the rates of drinking in
Australia and New Zealand, 50% of male youths in these countries as well as
in South Korea and Japan often drink to intoxication. Table 1.2 shows
abstention rates for males and females, annual per capita consumption in
the general population and among drinkers, and patterns of drinking in WHO
subregions.
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Illicit use of controlled substances
Data from the United Nations Office on Drugs and Crime (ODC) show large-
scale seizures of cocaine, heroin, cannabis and amphetamine-type stimulants
in different parts of the world. Availability of cocaine, heroin and cannabis
depends on the level of cultivation in source countries and on the success or
failure of trafficking organizations. However, even with increased levels of
law enforcement activities, there always seems to be enough drugs available
to users.
According to ODC estimates (UNODCCP, 2002), about 185 million people
make illicit use of one type of illicit substance or another. Table 1.3 shows
that cannabis is consumed by the largest number of illicit drug users, followed
by amphetamines, cocaine and the opiates.
Illicit drug use is a predominantly male activity, much more so than
cigarette smoking and alcohol consumption. Drug use is also more prevalent
among young people than in older age groups. Several national and multi-
national surveys have provided data on drug use in different groups. For
example, in the USA, the National Household Survey on Drug Abuse (NHSDA)
has served as a source of useful information on drug use in the general
population, and the Monitoring the Future project provides data on drug use
by young people in secondary schools. The European School Survey Project
on Alcohol and Other Drugs (ESPAD), an initiative of the Council of Europe,
has become a data source on youth drug use for many European countries.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
also provides regular data on drug use (including hazardous methods of use,
such as injecting drug use (IDU)) in European countries. While national
surveys of youth and adults are held on a regular basis in some countries,
reliable data on drug use is generally lacking in most developing countries.
Table 1.3 Annual prevalence of global illicit drug use over the period 1998–
2001
All Cannabis Amphetamine- Cocaine All opiates Heroin
illicit drugs type stimulants
Amphe- Ecstasy
tamines
Number of users    185.0 147.4 33.4 7.0 13.4 12.9 9.20
(in millions)
Proportion of 3.1  2.5 0.6  0.1 0.2 0.2 0.15
global population (%)
Proportion of 4.3  3.5 0.8  0.2 0.3 0.3 0.22
population 15 years
and above (%)
Source: UNODCCP, 2002.
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Projects such as the South African Community Epidemiology Network on
Drug Use (SACENDU) and its related regional network have been started to
address this lack of information.
The data in Table 1.3 show that 2.5% of the total global population and
3.5% of people 15 years and above had used cannabis at least once in a year
between 1998 and 2001. In many developed countries, for example Canada,
the USA and European countries, more than 2% of youths reported heroin
use and almost 5% reported smoking cocaine in their lifetime. Indeed, 8% of
youths in western Europe and more than 20% of those in the USA have
reported using at least one type of illicit drug other than cannabis (UNODCCP,
2002). There is evidence of rapid increases in the use of amphetamine-type
stimulants among teenagers in Asia and Europe. Injecting drug use is also a
growing phenomenon, with implications for the spread of HIV infections in
an increasing number of countries.
The nonmedical use of medications (e.g. benzodiazepines, pain killers,
amphetamines, etc.) is known to be fairly common but global statistics are
lacking.
Adverse effects of psychoactive substances and
their mechanisms of action
In the majority of cases, people use psychoactive substances because they
expect to benefit from their use, whether through the experience of pleasure
or the avoidance of pain. The benefit is not necessarily gained directly from
the psychoactive action of the substance. Someone drinking beer with
colleagues may be more motivated by the feeling of fellowship this brings
than by the psychoactive effect of the ethanol.
However, the psychoactive effect is nevertheless present, and is usually at
least peripherally involved in the decision to use.
In spite of the real or apparent benefits, the use of psychoactive substances
also carries with it the potential for harm, whether in the short term or long
term. Such harm can result from the cumulative amount of psychoactive
substance used, for example, the toxic effect of alcohol in producing liver
cirrhosis. Harmful effects can also result from the pattern of use, or from the
form or medium in which it is taken (see Fig. 1.2). Pattern of use is of obvious
importance – for instance, in the case of deaths due to overdose – not only in
terms of the amount on a particular occasion, but also in terms of the context
of use (e.g. heroin use accompanied by heavy alcohol use). The form or
medium of use may also be crucially important. Most of the adverse health
effects of tobacco smoking, for instance, come not from the nicotine itself,
but from the tars and carbon monoxide which are released when nicotine is
taken in cigarette form. Similarly, the adverse effects from taking the drug by
injection are evident in the case of heroin use.
The main harmful effects due to substance use can be divided into four
categories (see Fig. 1.2). First there are the chronic health effects. For alcohol
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this includes liver cirrhosis and a host of other chronic illnesses; for nicotine
taken in cigarette form, this includes lung cancer, emphysema and other
chronic illnesses. Through the sharing of needles, heroin use by injection is a
main vector for transmission of infectious agents such as HIV and hepatitis
C virus. Second there are the acute or short-term biological health effects of
the substance. Notably, for drugs such as opioids and alcohol, these include
overdose. Also classed in this category are the casualties due to the substance’s
effects on physical coordination, concentration and judgement, in
circumstances where these qualities are demanded. Casualties resulting from
driving after drinking alcohol or after other drug use feature prominently in
this category, but other accidents, suicide and (at least for alcohol) assaults
are also included. The third and fourth categories of harmful effects comprise
the adverse social consequences of the substance use: acute social problems,
such as a break in a relationship or an arrest, and chronic social problems,
such as defaults in working life or in family roles. These last categories are
important in relation to alcohol and many illicit drugs, but are poorly
measured and mostly excluded from measurements of health effects such as
in the Global Burden of Disease (GBD).
Fig. 1.2 Mechanisms relating psychoactive substance use to health and
social problems
Note that some effects are beneficial rather than toxic, e.g. regular light alcohol 
use as potentially reducing risk of coronary heart disease.
Source: adapted from Babor et al., 2003.
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As earlier noted, the probability of the occurrence of these categories of
harmful effects also depends on how much of the substance is used, in what
forms, and with what patterns of use. These aspects of use may be thought of
as linked to the different kinds of health and social problems by three main
mechanisms of action (see Fig. 1.2). One mechanism concerns the direct toxic
effects of the substance, either immediate (e.g. poisoning) or cumulative over
time (e.g. cirrhosis). A second mechanism concerns the intoxicating or other
psychoactive effects of the substance. A traffic accident may result, for
instance, from the fact that a car driver is under the influence of sedatives. A
retail store employee may be intoxicated at work after using cannabis, and
because of this, may be fired by the manager.
The third mechanism concerns dependence on the substance. Substance
dependence – or dependence syndrome – is the current technical terminology
for the concept of “addiction”. At the heart of this concept is the idea that the
user’s control over and volition about use of the drug has been lost or
impaired. The user is no longer choosing to use simply because of the
apparent benefits; the use has become habitual, and cravings to reuse mean
that the user feels that the habit is no longer under control. The user’s
dependence is thus seen as propelling further use despite adverse
consequences which might have deterred others who are not dependent, from
further use.
The link between substance use and harm in a particular case may, of
course, involve more than one of the three mechanisms. Benzodiazepines
may be involved in a case of suicide, for instance, both through the user’s
despair over the disruption brought to his or her life by dependence on the
drugs, and as the actual means of suicide through overdose. However, the
mechanisms can also operate alone. It is important to keep in mind, moreover,
that dependence is not the only mechanism potentially linking substance
use to health and social harm.
Substance dependence in relation to neuroscience
Social historians have found that the concept of dependence has a specific
history, becoming a common idea first in industrialized cultures in the early
nineteenth century. The term was initially applied to alcohol and later
extended to apply to opioids and other psychoactive substances (Ferentzy,
2001; Room, 2001). In the case of alcohol, the equivalent term became
“alcoholism” by the 1950s, while general application of the concept of
dependence on tobacco smoking is more recent. While the general idea of
dependence is now well established in most of the world, comparative
research has found that there is substantial variation between cultures in the
applicability and recognition of specific notions and concepts associated with
it (Room et al., 1996).
As defined in The ICD-10 classification of mental and behavioural disorders,
substance use dependence includes six criteria (see Box 1.2); a case which is
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positive on at least three of these is diagnosable as “dependent”. Some of the
criteria are measurable in biological terms, while others are not. The two criteria
most easily measured biologically are the third and fourth in Box 1.2: with-
drawal – the occurrence of unpleasant physical and psychological symptoms
when use of the substance is reduced or discontinued, and tolerance – the
idea that increased amounts of the drug are required to achieve the same effect,
or that the same amount produces less effect. The other four criteria for
dependence include elements of cognition, which are less accessible to
biological measurement, but are becoming measurable using improved
neuroimaging techniques (see Chapter 3). In the sixth criterion, for instance,
the user’s knowledge of specific causal connections is to be ascertained,
something not accessible to direct biological measurement or to an animal
model. The first criterion, “strong desire or sense of compulsion”, requires
inquiry into the user’s self-perceptions, and relates to the idea of craving for
the substance. It has proved difficult to agree on a definition of the concept of
craving, and the applicability of biological models to the concept remains
controversial (Drummond et al., 2000). The criteria for substance dependence
in the fourth edition of the Diagnostic and Statistical Manual (DSM-IV) of the
BOX 1.2
Criteria for substance dependence in ICD-10
Three or more of the following must have been experienced or exhibited together
at some time during the previous year:
1. a strong desire or sense of compulsion to take the substance;
2. difficulties in controlling substance-taking behaviour in terms of its onset,
termination, or levels of use;
3. a physiological withdrawal state when substance use has ceased or been
reduced, as evidenced by: the characteristic withdrawal syndrome for the
substance; or use of the same (or a closely related) substance with the intention
of relieving or avoiding withdrawal symptoms;
4. evidence of tolerance, such that increased doses of the psychoactive substance
are required in order to achieve effects originally produced by lower doses;
5. progressive neglect of alternative pleasures or interests because of
psychoactive substance use, increased amount of time necessary to obtain
or take the substance or to recover from its effects;
6. persisting with substance use despite clear evidence of overtly harmful
consequences, such as harm to the liver through excessive drinking, depressive
mood states consequent to heavy substance use, or drug-related impairment of
cognitive functioning. Efforts should be made to determine that the user was
actually, or could be expected to be, aware of the nature and extent of the harm.
Source: WHO, 1992.
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American Psychiatric Association (1994) are similar to those of ICD-10 (Box 1.3),
as well as those in many research studies. Other terms used in relation to the
use of psychoactive substances are presented in Box 1.4.
A further difficulty is that the diagnostic definition of dependence, as noted
above, requires that the case is positive on any three of the six criteria. This
means that a case can qualify for dependence without being positive on either
of the two biologically-measurable criteria; and it means that any case
BOX 1.3
Criteria for substance dependence in DSM-IV
According to the DSM-IV, substance dependence is:
a maladaptive pattern of substance use, leading to clinically significant impairment
or distress, as manifested by three (or more) of the following, occurring at any
time in the same 12-month period:
1. tolerance, as defined by either of the following:
(a) a need for markedly increased amounts of the substance to achieve
intoxication or desired effect
(b) markedly diminished effect with continued use of the same amount of the
substance
2. withdrawal, as manifested by either of the following:
(a) the characteristic withdrawal syndrome for the substance
(b) the same (or a closely related) substance is taken to relieve or avoid
withdrawal symptoms
3. the substance is often taken in larger amounts or over a longer period than
was intended
4. there is a persistent desire or unsuccessful efforts to cut down or control
substance use
5. a great deal of time is spent in activities necessary to obtain the substance
(e.g. visiting multiple doctors or driving long distances), use the substance
(e.g. chain-smoking), or recover from its effects
6. important social, occupational, or recreational activities are given up or reduced
because of substance use
7. the substance use is continued despite knowledge of having a persistent or
recurrent physical or psychological problem that is likely to have been caused
or exacerbated by the substance (e.g. current cocaine use despite recognition
of cocaine-induced depression, or continued drinking despite recognition that
an ulcer was made worse by alcohol consumption)
Source: American Psychiatric Association, 1994.
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qualifying as dependent must be positive on at least one criterion which is
not fully biologically measurable.
Thus a continuing difficulty in the neuroscience of psychoactive
substances is that, while most of their effects shown in Fig. 1.2 are directly
measurable, drug dependence is not, both as it is currently technically defined
and as it is generally understood in the wider society.
However, as will be discussed later in the report, neuroscientists have made
a number of advances in understanding why humans find using these
substances attractive in the first place, what the mechanisms of psychoactivity
are, and the neurobiological changes which occur with repeated heavy use of
a substance.
BOX 1.4
Definitions of terms related to use of psychoactive substances
Harmful use
A pattern of psychoactive substance use that is causing damage to health. The
damage may be physical or mental.
Hazardous use
A pattern of psychoactive substance use that increases the risk of harmful
consequences for the user.
Intoxication
A condition that follows the administration of a psychoactive substance and results
in disturbances in the level of consciousness, cognition, perception, affect, or
behaviour, or other psychophysiological functions and responses. The
disturbances are related to the acute pharmacological effects of, and learned
responses to, the substance and resolve with time, with complete recovery, except
where tissue damage or other complications have arisen. Complications may
include trauma, inhalation of vomitus, delirium, coma and convulsions, and other
medical complications. The nature of these complications depends on the
pharmacological class of substance and mode of administration.
Substance abuse
Persistent or sporadic drug use inconsistent with or unrelated to acceptable
medical practice. A maladaptive pattern of substance use leading to clinically
significant impairment or distress, as manifested by one (or more) of the following:
failure to fulfil major role obligations at home, school or work; substance use in
situations in which it is physically hazardous; recurrent substance-related legal
problems; continued substance use despite having persistent or recurrent social
or interpersonal problems exacerbated by the effects of the substance.
Source: adapted from Lexicon of alcohol and drug terms, WHO (1994).
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The burden of harm to health from psychoactive substance use
No global assessments are available for social harm from substance use (as
shown in Fig. 1.2). However, there is now a developing tradition of estimating
the contribution of alcohol, tobacco and illicit drug use to the global burden
of disease. The first significant attempt at this was in the earlier WHO project
on global burden of disease and injury (Murray & Lopez, 1996). Based on a
standard of measurement known as disability-adjusted life years (DALYs),
estimates of the burden imposed on society due to premature death and years
lived with disability were assessed. The global burden of disease (GBD) project
showed that tobacco and alcohol were major causes of mortality and disability
in developed countries, with the impact of tobacco expected to increase in
other parts of the world.
The reliability of the GBD and other estimates of deaths and disease
depends on the quality of the data they are based upon. Data used in these
analyses were mostly from studies conducted in developed countries
(especially the USA and European countries) and a few, often non-
representative, surveys in developing countries. The inherent difficulty of
assessing the prevalence of substance use and the association between use
and problems also means that the burden estimates were highly approximate.
However, the GBD provided for the first time a set of global data on the burden
of alcohol and other drug use/dependence and there are continuing efforts
to come up with more precise estimates of death and disease burden
associated with licit and illicit substances.
The 2002 World health report (WHO, 2002) includes a new set of estimates
for the year 2000 of the burden attributable to tobacco, alcohol and other
drugs. These estimates are based on data that are significantly more
complete and on more defensible methodologies, and there is no doubt
that they will be improved further in future years. Table 1.4 shows the results
from the estimates for 2000, in terms of the mortality attributable to each
class of substances, as well as a measure of the years of life lost or impaired
due to disability (DALYs). Note that estimated protective effects for heart
disease from moderate drinking have been subtracted to yield the net
negative burden for alcohol (this accounts for the negative number in the
table).
Among the 10 leading risk factors in terms of avoidable burden, tobacco
was fourth and alcohol fifth for 2000, and both remain high on the list in the
projections for 2010 and 2020. The estimated attributable burden in 2000
was 59 million DALYs for tobacco, 58 million for alcohol, and 11 million for
illicit drugs. In other words, tobacco and alcohol accounted for 4.1% and 4.0%,
respectively, of the burden of ill-health in 2000, while illicit drugs accounted
for 0.8%. The burdens attributable to tobacco and alcohol are particularly
acute among males in developed countries (mainly North America and
Europe), where tobacco, alcohol and illicit drugs account for 17.1%, 14.0%
and 2.3%, respectively of the total burden (see Table 1.4).
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Table 1.4 offers ample evidence that the burden of ill-health from use of
psychoactive substances, taken together, is substantial: 8.9% in terms of
DALYs. However, GBD findings re-emphasize that the main global health
burden is due to licit rather than illicit substances.
The primary emphasis in this report, however, is not on the harmful
consequences which can result from substance use (except as they occur in
the body’s nervous system) and neither is it primarily on the toxic qualities of
the substances. Rather the emphasis is on patterns of substance use, and on
the mechanisms of psychoactivity and of dependence (as indicated in Fig. 1.2).
Since dependence refers to mechanisms by which use is sustained over time –
thereby multiplying the probabilities of harmful consequences of use – special
attention is given in this report to the neuroscience of dependence.
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CHAPTER 2
Brain Mechanisms: Neurobiology
and Neuroanatomy
Introduction
Substance dependence is a disorder that involves the motivational systems
of the brain. As with any disorder specific to an organ or system, one must
first understand the normal function of that organ or system to understand
its dysfunction. Because the output of the brain is behaviour and thoughts,
disorders of the brain can result in highly complex behavioural symptoms.
The brain can suffer many types of disease and traumas, from neurological
conditions such as stroke and epilepsy, to neurodegenerative diseases such
as Parkinson disease and Alzheimer disease, to infections or traumatic brain
injuries. In each of these cases, the behavioural output is recognized as being
part of the disorder.
Similarly, with dependence, the behavioural output is complex, but is
mostly related to the effects of drugs on the brain. The tremors of Parkinson
disease, the seizures of epilepsy, even the melancholy of depression are widely
recognized and accepted as symptoms of an underlying brain pathology.
Dependence has not previously been recognized as a disorder of the brain,
in the same way that psychiatric and mental illnesses were not previously
viewed as being a result of a disorder of the brain. However, with recent
advances in neuroscience, it is clear that dependence is as much a disorder
of the brain as any other neurological or psychiatric illness. New technologies
and research provide a means to visualize and measure changes in brain
function from the molecular and cellular levels to changes in complex
cognitive processes, that occur with short-term and long-term substance use.
This chapter reviews basic principles of brain anatomy and function to
provide a framework within which the neuroscience of dependence can be
discussed.
Organization of the brain
The nervous system is the body’s major communication system, and is
divided into central and peripheral regions. The central nervous system
consists of the brain and spinal cord, and the peripheral nervous system
consists of all nerves outside of this. The spinal cord controls reflex actions,
and relays sensory and motor information between the body and the brain,
so that the organism can respond appropriately to its environment.
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The region of the brain where it meets the spinal cord is called the
rhombencephalon or hindbrain, and is composed of the myelencephalon
(medulla) and metencephalon (pons and cerebellum) (Fig. 2.1). The medulla
is vital to sustaining life, and controls processes such as breathing, heartbeat
and blood flow. The medulla also contains receptors for the opioid drugs,
such as heroin and morphine, which is why these drugs can cause respiratory
depression and death. The pons is a relay station for signals being carried
from the cortex to the cerebellum, which is involved in body movements and
coordination.
Fig. 2.1 Central nervous system
Source: Reproduced from Kandel, Schwartz, & Jessell, 1995, with permission from the
publishers.
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Above the hindbrain is the mesencephalon or midbrain (Fig. 2.1), which
contains two areas that are very important in substance dependence. The
ventral tegmental area (VTA) is rich in dopamine cell bodies, and projects to
the limbic system and forebrain regions. The VTA is involved in signalling the
importance of stimuli that are critical to survival such as those associated
with feeding and reproduction. However, many psychoactive drugs also have
powerful effects on this brain area, which contributes to the development of
dependence by signalling to the brain that psychoactive substances are very
important from a motivational perspective. The dopaminergic projection
from the VTA to the nucleus accumbens (discussed below) is known as the
mesolimbic dopamine system, and is the neurotransmitter system that is
most strongly implicated in the dependence-producing potential of
psychoactive drugs (Wise, 1998). This key concept will be discussed in more
detail in Chapters 3 and 4. Another important midbrain structure is the
substantia nigra, which also has dopaminergic projections to the forebrain,
but these pathways are involved in coordinating and executing movements
of the body. Degeneration of neurons in the substantia nigra leads to the
characteristic symptoms of Parkinson disease.
Finally, there is the prosencephalon or forebrain, which is composed of
the diencephalon and the telencephalon (cerebral hemispheres) (Fig. 2.1).
Important areas of the diencephalon (Fig. 2.2) are the thalamus, the
hypothalamus, and the posterior lobe of the pituitary gland. The
hypothalamus is critical for regulating hormonal signals and basic bodily
Fig. 2.2 Diencephalon
The figure shows the location of the two lobes of the thalamus, joined by the
massa intermedia. Beneath the thalamus lies the hypothalamus and posterior
pituitary gland, which regulate autonomic, endocrine and visceral functions.
Source: Reproduced from Pinel, 1990, with permission from the publishers.
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functions – concerning, for example, water balance, body temperature and
reproductive hormones – as well as for responding to changes in these
functions. The hypothalamus also secretes hormones that travel to the nearby
posterior lobe of the pituitary gland. The thalamus functions as a relay station
for sensory and motor information going to and from the cortex to other areas
of the brain and body.
The telencephalon of the forebrain is the most highly developed area of
the brain, and is composed of two cerebral hemispheres separated by the
longitudinal fissure (Fig. 2.3). The outermost layer of the brain is the cortex,
which is made up of layers of nerve cells or neurons, and has a highly folded
organization that increases its surface area and the number of neurons that
it contains. Beneath the cortex run millions of axons that interconnect the
neurons and allow the different areas of the brain to communicate and to
coordinate behaviour.
Each hemisphere of the brain is divided into four lobes: frontal, parietal,
temporal, and occipital (Fig. 2.3). Different areas of the cortex are specialized
for different functions (Fig. 2.4). The motor association cortex, for example,
is involved in coordinating movements of the body, and the primary motor
Fig. 2.3 Cerebral hemispheres
The telencephalon is composed of two cerebral hemisphere separated
by the medial longitudinal fissure. Each hemisphere is subdivided into
four lobes: frontal, parietal, occipital, and temporal.
Source: Reproduced from Kolb & Whishaw, 1996, with permission from the publishers.
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cortex is involved in executing this function. Similarly, there is a primary
sensory cortex that receives information from each of these sense organs.
Information from the primary sensory areas goes to sensory association areas
of the cortex, which are involved in perception and memory connected with
the sense organs. Here information from several sense organs can be
combined to form complex perceptions (Fig. 2.5). The cortex is involved in
many aspects of substance dependence, from the primary effects of
psychoactive drugs on sensations and perceptions, to the complex behaviours
and thoughts involved in drug craving and uncontrolled substance use.
Neuroimaging techniques such as positron emission tomography (PET) have
shown changes in areas of the cortex following both short-term and long-
term substance use (see Box 2.1 and Chapter 4 for details).
Beneath the cortex are several other important structures. The basal ganglia
(Fig. 2.6) are structures involved in voluntary motor behaviour and consist
of the caudate, putamen, globus pallidus and amygdala (the amygdala is also
part of the limbic system, and will be discussed in the next section). The
caudate and putamen together are known as the striatum. Just below the
striatum is a key area for substance dependence and motivation, known as
the nucleus accumbens, which is made up of core and shell regions. (Note:
clusters of neurons with similar structure and function make up “nuclei” of
the brain, not to be confused with the nuclei of individual cells). The nucleus
Fig. 2.4 Structural and functional regions of the cerebral cortex
The cerebral cortex is structurally differentiated into four lobes. The cerebral
cortex can also be differentiated into functionally specialized areas.
Source: Reproduced from Carlson, 1988, with permission from the publishers.
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accumbens is a very important brain area involved in motivation and
learning, and signalling the motivational value of stimuli (Robbins & Everitt,
1996; Cardinal et al., 2002). Psychoactive substances increase the production
of dopamine in the nucleus accumbens, which is thought to be an important
event in drug reinforcement. This will be discussed further in Chapters 3
and 4.
Fig. 2.5 The relation between different functional brain regions
Information received from primary sensory cortices is integrated in sensory
association areas, which are involved in perception and memories.
Source: Reproduced from Carlson, 1988, with permission from the publishers.
Fig. 2.6 Basal ganglia
The basal ganglia are shown, comprised of a number of structures involved
in the performance of voluntary motor responses.
Source: Reproduced from Pinel, 1990, with permission from the publishers.
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Another region relevant to the neuroscience of dependence is the limbic
system (Fig. 2.7). This is an interconnected series of structures that are
important in relation to emotion, motivation and learning. The limbic system
plays a vital role in the development of dependence, and interacts with the
cortex and nucleus accumbens. Important structures of the limbic system
are the hippocampus, which plays an important role in memory, and the
amygdala, which is critical in emotional regulation. All of these areas receive
sensory information from other brain areas to help coordinate the
appropriate emotional and behavioural response to external stimuli.
The neuron
Communication in the brain takes place between nerve cells or neurons.
Psychoactive substances alter many aspects of communication between
neurons, as will be discussed below. Neurons are highly specialized cells that
exist in many shapes, sizes and varieties. However, they share the following
basic structural regions: cell body or soma, dendrites, axon, and terminal
buttons (Fig. 2.8) (Carlson, 1988).
Fig. 2.7 Major structures of the limbic system
Source: Reproduced from Pinel, 1990, with permission from the publishers.
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Cell body
The cell body, or soma, is the metabolic centre of the neuron, and contains
the nucleus and other structures that sustain the neuron. A specialized
membrane that helps to regulate the internal environment of the cell
surrounds the cell body. It is selectively permeable in that it allows only certain
molecules into or out of the cell body, in order to maintain the proper
functioning of the cell.
By definition, the cell body is the part of the neuron that contains the
nucleus (Fig. 2.9). The nucleus contains the genetic material deoxyribonucleic
acid (DNA). DNA is used in cell division and growth, but also plays a role in
mature neurons, where it is used to synthesize proteins in response to a wide
variety of stimuli. Psychoactive substances can affect the expression of DNA,
resulting in short-term or long-term changes in neuronal function, and
ultimately, behaviour. This will be discussed in more detail at the end of the
chapter.
Dendrites
Dendrites are highly branched processes extending from the cell body of the
neuron, that receive chemical messages from other neurons (see Fig. 2.8).
This branching, and the presence of dendritic spines (small swellings on the
Fig. 2.8 Structure of a neuron
Source: Reproduced from Pinel, 1990, with permission from the publishers.
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Fig. 2.9 Synthesis of proteins
Portions of DNA in the nucleus of a neuron are encoded into messenger
RNA. Ribosomes in the cell body use messenger RNA to synthesize proteins.
Source: Reproduced from Pinel, 1990, with permission from the publishers.
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surface of a dendrite with which a terminal button from another neuron forms
a synapse), allows many different neurons to converge on a single nerve cell,
facilitating the coordination and integration of many complex messages. The
number of dendritic spines can increase or decrease following exposure to
psychoactive substances (Sklair-Tavron et al., 1996; Robinson & Kolb, 1999;
Eisch et al., 2000), thus altering communication between neurons, and most
likely contributing to the behavioural and neurological effects of the
substances. This will also be discussed in more detail at the end of the chapter.
Axon
The axon is a long slender process extending from the cell body, that carries
information from the cell body to the terminal buttons (see Fig. 2.8). Certain
chemicals such as neurotransmitters are transported along the axon, and it
also propagates nerve impulses (see below). The area where the axon leaves
the cell body is known as the axon hillock.
Terminal buttons
The terminal buttons are the bulbous structures found at the end of axons
(see Figs 2.8 and 2.10). At the terminal button, chemical signalling molecules
(which will be discussed more in the section on neurotransmission) are stored
in small packages, or vesicles. When an appropriate signal arrives at the
terminal button, neurotransmitter is released into the synapse or synaptic
cleft, the space between the terminal button and the membrane of the next
cell or dendrite with which it is communicating. The membrane of the
terminal button that is transmitting the message is known as the presynaptic
Fig. 2.10 A terminal button and synapse
Source: Reproduced from Pinel, 1990, with permission from the publishers.
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membrane, and the membrane of the receiving neuron is known as the
postsynaptic membrane. The synaptic cleft contains extracellular fluid
through which chemical substances can diffuse to interact with a variety of
membrane proteins known as receptors.
Changes in the release or reuptake of neurotransmitters play an important
role in the mechanism of action of many psychoactive substances. Cocaine
and amphetamine, for example, block the reuptake of the neurotransmitters
dopamine and norepinephrine, thereby prolonging the actions of these
transmitters. These mechanisms will be examined in more detail in Chapter 4.
Neurotransmission
Action potential
Neurons communicate with each other through a highly specialized, precise
and rapid method. The action potential is a brief electrical impulse that travels
along an axon and allows one neuron to communicate with another through
the release of neurotransmitter. The action potential is possible because of
the selectively permeable membrane that maintains a chemical and electrical
gradient across the membrane known as the membrane potential. The
membrane at rest is polarized; however, it can become depolarized if diffusion
Fig.2.11 The action potential
During an action potential, voltage-sensitive sodium channels open causing
a rapid influx of sodium and resulting depolarization of the cell. The cell is
repolarized by the opening of potassium channels that permit the efflux of
potassium from the cell and restore the resting membrane potential.
Active ion pumps later exchange sodium for potassium within the cell.
Source: Reproduced from Rosenzweig, Leiman, & Breedlove, 1999, with permission from the
publishers.
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of ions is allowed to occur, which is what happens during an action potential
(Fig. 2.11).
An ion channel is a pore in the membrane through which ions can pass
under certain circumstances (e.g. there are Na+, K+, and Ca2+ channels). There
are channels that only open under certain circumstances, such as at a
particular membrane voltage (known as voltage-gated ion channels).
Depolarization in a local area of a neuron changes the voltage in that area,
and if it is of sufficient strength, may cause voltage-sensitive ion channels to
open, allowing ionic diffusion. Thus, adjacent areas become sequentially
depolarized, allowing propagation of the signal. This signal can be propagated
along an axon extremely rapidly. An action potential is an “all-or-none” event,
in that if the depolarizing stimulus is sufficient to reach a threshold value,
the action potential will be initiated and will travel without decrement to the
end of the axon.
After depolarization, the membrane rapidly becomes repolarized by the
opening of voltage-dependent K+ channels that are also opened by
depolarization, but only after a slight delay (approximately 1 millisecond).
Na+ channels also, do not stay open, but are inactivated after a certain period
of time. These factors enable rapid transmission and termination of messages.
Neurotransmitter release
Action potentials allow a message to be propagated along an axon within
one neuron. However, for communication to be complete, this message must
be transmitted between neurons. This is accomplished at the synapses of
the terminal buttons, through the release of neurotransmitter.
Neurotransmitters are chemical substances that are released from one neuron
and that interact with receptors on another neuron to affect a change in that
neuron. They will be discussed in further detail below.
The terminal buttons contain small structures known as vesicles, which
are packages of neurotransmitter that have been transported to the cell body.
When an action potential arrives at the terminal button, voltage-sensitive
Ca2+ channels open, allowing Ca2+ to flow into the terminal button and activate
a number of processes that cause the release of neurotransmitter into the
synaptic cleft. Once in the cleft, neurotransmitters diffuse across and bind to
postsynaptic receptors.
The chemical message needs a means of termination, and this occurs by
several mechanisms. One is by enzymatic degradation of the neurotransmitter
in the cleft, and another is by active reuptake of the neurotransmitter by the
presynaptic membrane. One of cocaine’s primary mechanisms of action is
to block the reuptake of neurotransmitters, thereby increasing their
concentration in the synaptic cleft, and increasing their effects. Amphetamine
acts by reversing the uptake mechanism, so that neurotransmitter is released
into the synaptic cleft independently of action potentials. These mechanisms
will be discussed in more detail in Chapter 4.
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When the neurotransmitter binds to its receptors on the postsynaptic cell,
the postsynaptic cell can either become more or less excitable, and thus more
or less likely to fire an action potential. These are known as excitatory and
inhibitory postsynaptic potentials, respectively.
Receptors
Receptors are protein complexes that are located in distinct regions of the
cell membrane, and that neurotransmitters bind with to initiate the
communication of a signal between neurons. There are specific receptors
for each specific neurotransmitter found in the brain. Psychoactive
substances are able to bind to these receptors, interfering with normal
transmitter function. Different classes of substances bind with distinct
receptors, thus giving the characteristic effects of each substance class – e.g.
opioids such as heroin and morphine bind to opioid receptors, cannabinoids
bind to cannabinoid receptors, and nicotine binds to nicotinic receptors in
the brain – and have powerful effects on behaviour. These and other
mechanisms will be discussed in more detail in Chapter 4.
There are two basic mechanisms of signal transduction that are important
when considering the actions of psychoactive substances. Binding of
neurotransmitters to receptors can cause the opening of ion channels directly,
through ligand-gated ion channels (Fig. 2.12). Binding of a ligand to the
receptor opens the ion channel, allowing rapid changes in the postsynaptic
membrane. An example of this type of channel is the γ-aminobutyric acid
(GABA)-A receptor, to which benzodiazepines and barbiturates can bind to
increase the opening of this channel. Alternatively, binding of the ligand can
Fig. 2.12 Two types of chemical synapses
The first diagram shows binding to and opening of a ligand-gated ion channel.
The second diagram demonstrates activation of a G protein-coupled receptor
resulting in the opening of an ion channel via a second messenger.
Source: Reproduced from Rosenzweig, Leiman, & Breedlove, 1999, with permission from the
publishers.
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result in the propagation of a signal through the generation of second
messengers. The second messenger can either open an ion channel, or can
initiate a series of biochemical reactions leading to longer-term changes in
neuronal function in the postsynaptic cell. There are many different second
messenger pathways; this increases the diversity of signals that can be sent,
and the consequences of those signals. An example of this type of receptor is
called a G protein-coupled receptor. Dopamine receptors are G protein-
coupled receptors, and depending upon the subtype of dopamine receptor,
ligand binding can either stimulate or inhibit the production of cyclic
adenosine monophosphate (cAMP). Psychoactive substances can have long-
term effects on cAMP function, as will be discussed in more detail at the end
of this chapter.
Receptors play a role not only in the immediate, reinforcing effects of
psychoactive substances, but also in the processes of tolerance and
withdrawal. Specific examples will be discussed in Chapter 4, but as one
example, tolerance to benzodiazepines and barbiturates develops through
changes in GABA-A receptor structure. The receptor adapts to the presence
of the substance, leading to tolerance. Thus, higher doses are required to have
an effect. When the substance is removed, withdrawal symptoms appear,
because of these structural changes which have occurred to accommodate
the presence of the substance.
Neurotransmitters
A neurotransmitter can be defined as a chemical substance that is released
synaptically from one neuron and that affects another cell in a specific
manner (Kandel & Schwartz, 1985). A neurotransmitter must also meet the
following criteria:
— synthesized in the neuron;
— present in the presynaptic neuron;
— released in sufficient quantity to have a postsynaptic effect;
— has the same effect whether released by natural means (endogenously)
or whether applied as a drug (exogenously).
It must also have a specific mechanism for its removal from the synaptic cleft.
Many types of neurotransmitters have been discovered so far, but in general
there are three categories: amino acid neurotransmitters, amino acid-derived
neurotransmitters, and peptides, which are chains of amino acids. The amino
acid transmitters include glutamate, GABA, glycine and aspartate. The
monoamines (norepinephrine and dopamine (catecholamines) and
serotonin (indoleamine) are derived from amino acids. Large molecule
peptide neurotransmitters are generally synthesized in the cell body, and
transported along the axons to the terminal buttons. Small molecule
neurotransmitters can be synthesized in the terminals.
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There are distinct regions of the brain where cell bodies for a specific
neurotransmitter exist, and other regions or “projection areas” where the
axons from those cell bodies project to, and where the neurotransmitter is
ultimately released. Thus, not every neurotransmitter is released in every area
of the brain. This allows certain areas of the brain to perform specific
functions. Some of the more important neurotransmitters with respect to
the neuroscience of dependence are discussed below.
Acetylcholine
Acetylcholine is a neurotransmitter formed from choline, which is derived
from the diet. It is formed by an enzymatic reaction with coenzyme A.
Acetylcholine plays an important role in learning and memory, and is thought
to be involved in Alzheimer disease. Neurons that synthesize and release
acetylcholine are called cholinergic neurons. The cell bodies are located in
the basal nucleus, but they project widely throughout the cortex.
Acetylcholine receptors are ligand-gated cation channels, and there are two
main subtypes, nicotinic and muscarinic, named on account of their
responsiveness to nicotine and muscarine respectively. Receptors for
acetylcholine have been implicated in nicotine dependence and may also
contribute to the effects of cocaine and amphetamine.
γ-aminobutyric acid
GABA is widely distributed throughout the nervous system, and is an amino
acid formed from the amino acid glutamate. GABA is an inhibitory
neurotransmitter that acts through two distinct receptor subtypes, named
GABA-A and GABA-B. The GABA-A receptors form a chloride ion channel.
The binding of GABA to GABA-A receptors opens this channel resulting in
the rapid diffusion of chloride ions into the cell, thus hyperpolarizing the
cell and making it less likely to fire an action potential. The sedative, anxiety-
reducing effects of benzodiazepines, barbiturates and alcohol are derived
from their effects on the GABA-A receptor. Anti-epileptic medications also
act to facilitate the function of the GABA-A receptor, and blocking the effects
of GABA can lead to seizures. This is why withdrawal from benzodiazepines
or alcohol can be associated with seizures. The GABA-B receptors are G
protein-coupled receptors, and binding of GABA to the GABA-B receptor
opens a potassium channel.
Glutamate
Glutamate is an excitatory amino acid neurotransmitter found throughout
the brain. It is derived from proteins in the diet and is produced by the
metabolic processes of the cells. Glutamate acts at four receptor subtypes;
NMDA, AMPA, kainate, and metabotropic glutamate receptors. Some of
Chapter_2 19.1.2004, 11:2833
NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE
34
the glutamate receptors are coupled to sodium channels and therefore
can mediate rapid (approximately 1 millisecond) actions, whereas other
receptors are coupled to potassium channels through a G protein, and
therefore take approximately 1 second for response. Glutamate is
important for learning and plays an essential role in the hippocampus.
Hallucinogens, such as phencyclidine (PCP) act at the NMDA subtype of
glutamate receptor. In addition, it is thought that glutamate pathways play
a very important role in modulating neural responses to many other
psychoactive substances.
Dopamine
Dopamine is a neurotransmitter that is derived from the amino acid
tyrosine, and is structurally related to norepinephrine. Dopamine produces
inhibitory postsynaptic potentials. It is involved in movement, learning and
motivation. Dopamine plays a paramount role in the neurobiology of
dependence, and will be discussed in more detail in Chapters 3 and 4.
Dopamine receptor genes have also been highly implicated in substance
dependence in general, as well as in nicotine and alcohol dependence. There
are two major dopamine projections in the brain. One, the mesolimbic
pathway, projects from the VTA to the nucleus accumbens. This pathway
appears to be directly or indirectly activated by most known psychoactive
substances. Closely associated with this is the mesocortical dopamine
pathway, which projects from the VTA to regions of the cortex. The second
major dopamine pathway projects from the substantia nigra to the striatum,
which is known as the nigrostriatal pathway. In Parkinson disease, this
pathway undergoes degeneration leading to the characteristic movement
disorders. Excessive dopamine function in the mesolimbic and mesocortical
dopamine systems is thought to underlie the delusions and hallucinations
of schizophrenia. It is interesting to note here that certain substances such
as cocaine and amphetamine can, in high doses, mimic some of the features
of schizophrenia and bipolar disorders through the same basic actions on
the dopamine system.
Norepinephrine
Norepinephrine is another catecholamine that is derived from tyrosine.
Norepinephrine-synthesising cell bodies are found in the locus coeruleus,
and project widely throughout the brain. Norepinephrine is involved in
arousal and stress responses. Cocaine and amphetamine affect the
transmission of norepinephrine by increasing its concentration in the
synaptic cleft. This increase in synaptic norepinephrine contributes to the
stimulatory and rewarding effects of cocaine and amphetamine, and also to
the feelings of nervousness and anxiety that can accompany the use of these
substances.
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Serotonin
Serotonin, like dopamine and norepinephrine, is a monoamine. It is an
indoleamine that is derived from the amino acid tryptophan. It is involved in
regulation of mood, arousal, impulsivity, aggression, appetite and anxiety.
Serotonin-synthesizing cell bodies are found in the midbrain in a region called
the raphe nuclei. These neurons project to many areas of the brain such as
the cortex, hypothalamus and limbic system. There are many subtypes of
serotonin receptor. In the body, serotonin is found in the gastrointestinal tract,
platelets and spinal cord. Most antidepressant drugs work by increasing the
action of serotonin in the brain. Serotonin is also involved in the primary
actions of some psychoactive drugs such as lysergic acid diethylamide (LSD)
and ecstasy, and is also implicated in the effects of cocaine, amphetamine,
alcohol and nicotine.
Peptides
Peptides are chains of two or more amino acids linked by peptide bonds.
There are many peptides that are widely distributed throughout the nervous
system, and at least 200 identified neuropeptides to date. Some are hormones
that cause the release of other hormones, such as corticotrophin-releasing
hormone and growth hormone-releasing hormone. There are pituitary
peptides such as adrenocorticotropin, prolactin and growth hormone, and
there are a wide variety of peptides that were originally discovered in the gut,
but that also have actions in the brain, such as cholecystokinin, substance P
and vasoactive intestinal polypeptide. The endogenous opioids are also an
important class of peptide neurotransmitters. Substances such as heroin and
morphine bind to the receptors used by the endogenous opioids. Peptides
control a wide variety of functions in the body, from food intake and water
balance, to modulating anxiety, pain, reproduction and the pleasurable effects
of food and drugs. Although the opioids are widely recognized as being
involved in substance dependence, it has been shown that other peptides
also play a role (Kovacs, Sarnyai & Szabo, 1998; McLay, Pan & Kastin, 2001;
Sarnyai, Shaham & Heinrichs, 2001).
Genes
Inside the nucleus of the cell are the chromosomes, which are made up of
strands of DNA. The chromosomes are made up of distinct sets of
instructions, or genes, that “code” for proteins. Messenger ribonucleic acid
(mRNA) makes copies of sections of DNA, and transports it into the
cytoplasm. In the cytoplasm, the mRNA binds to ribosomes, which “read”
the genetic code and assemble the appropriate proteins from amino acids
in the cytoplasm (Fig. 2.9). These proteins are then used to carry out the
functions of the cell.
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Genes can be turned on or off at different times during the entire life of an
organism. Some genes are turned on or “expressed” only during development.
Others are expressed in response to certain stimuli. Eating certain foods, for
example, can increase the expression of genes that code for the enzymes that
will break down constituents of that food. Being out in the sun can stimulate
the expression of other genes that cause the skin to become more pigmented.
Similarly, drugs of all kinds can cause changes in gene expression in the brain.
Changes in gene expression cause changes in protein synthesis that can have
both short-term and long-term consequences on behaviour. This concept
will be covered in more detail below.
There are both genetic commonalities and differences among all humans.
The basic mechanisms of drug action are common to all. However, there is
considerable individual variation in the response to these drugs, the particular
forms of certain genes, and the way in which these genes interact with the
full complement of genes and with the environment in which that individual
lives. The main genetic differences currently known to be relevant to
dependence will be discussed in Chapter 5.
Cellular and neuronal effects of psychoactive substances
Cellular effects
Psychoactive substances have immediate effects on neurotransmitter release
or second messenger systems, but there are also many changes that occur at
the cellular level, both in the short-term and long-term, following single or
repeated substance use.
The primary sites of action for most psychoactive substances are the cell
membrane receptors, and their associated cascade of signal transduction
processes. The long-term effects brought about during the process of
substance dependence are usually mediated by alterations in gene
transcription, which leads to altered gene expression and subsequent changes
in the proteins synthesised. Since these proteins affect the function of the
neurons, such changes are ultimately manifested in altered behaviour of the
individual. Among the best-established molecular changes following chronic
substance use is the compensatory upregulation or superactivation of the
cyclic AMP (cAMP) pathway. Cyclic AMP is an intracellular second messenger
that can initiate a wide variety of changes in the postsynaptic cell.
The ability of chronic exposure to opioids to upregulate the cAMP
pathway has been known for decades (Sharma, Klee & Nirenberg, 1975). In
addition to opioids, upregulation of the cyclic AMP pathway has been
observed in response to chronic use of alcohol and cocaine (Unterwald et
al., 1993; Lane-Ladd et al., 1997). When a system that has been upregulated
by chronic substance use is acutely exposed to the substance, the acute
effects are diminished, representing cellular tolerance. In the absence of
the substance, the upregulated system contributes to symptoms of
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withdrawal (Nestler & Aghajanian, 1997). Effects of an upregulated cAMP
system have been demonstrated in many of the relevant brain regions, such
as the nucleus accumbens, striatum, VTA, locus coeruleus and peria-
queductal gray (Cole et al., 1995; Lane-Ladd et al., 1997; Nestler & Aghaja-
nian, 1997).
Role of cyclic AMP response element binding protein (CREB)
Cyclic AMP stimulates the expression of cAMP response element binding
protein (CREB), which is a transcription factor. Gene transcription and
expression in neurons are regulated by numerous transcription factors.
Transcription factors are proteins that bind to regions of genes to increase or
decrease their expression. It has been shown that the functions of several
transcription factors are altered by substance use and therefore are implicated
in dependence.
Alterations in the CREB-regulated pathways are among the best-
characterized adaptations related to chronic exposure to psychoactive
substances and there is evidence for upregulation and sensitization of the
cAMP/CREB-linked mechanisms (Nestler, 2001).
Role of transcriptional regulator Fos
Other transcription factors induced by exposure to psychoactive substances
belong to the Fos protein family of immediate early genes. The products of
these genes are induced very rapidly (hence the name) and play important
roles in transducing receptor-mediated signals into changes in gene
expression. These changes in gene expression affect neuronal protein
expression and function. Single administrations of a substance cause
transient increases in several members of the Fos protein family but with
chronic use, a modified variant of FosB, ∆FosB, which is more stable,
accumulates and persists in the nucleus accumbens (Hope et al., 1994).
DFosB, once generated, has an unusually prolonged half-life resulting in
persistently elevated levels (Keltz & Nestler, 2000). The accumulation of ∆FosB
has been shown to occur following chronic use of cocaine, opioids,
amphetamine, nicotine, phencyclidine and alcohol (Keltz & Nestler, 2000).
This occurs in the nucleus accumbens and dorsal striatum, and constitutes
a process specific for psychoactive drugs (Moratalla et al., 1996; Keltz
& Nestler, 2000). The elevated ∆FosB can then continue to affect the
expression of many other genes within the same neurons, which in turn by
alterations in synaptic transmission will be able to affect many neuronal
functions locally and in other areas of brain, to which these neurons project.
This provides some insight into the nature of the long-lasting changes in
neuronal composition that occur and persist well beyond the time frame of
the acute drug effects.
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Role of receptor systems targeted by drugs
Repeated stimulation of receptors by drugs can lead to alterations in receptor
number and function. For example, long-term exposure to nicotine increases
the number of nicotinic acetylcholine receptors in the brain (Wonnacott,
1990; Marks et al., 1992).
The development of tolerance and dependence to morphine and other
opioids has some unique features. When the µ-opioid receptor is activated
by endogenous opioids in the brain, the receptor is internalized into the cell,
as a means of turning off the activation signal (Pak et al., 1996; Law, Wong
& Loh, 2000). This process of receptor desensitization is a highly conserved
mechanism for G protein-coupled receptors. In contrast, activation of the
µ-opioid receptor by morphine (Matthes et al., 1996) does not induce receptor
internalization (or does so very slowly), and there is abnormal prolongation
of the cell surface activation signal without desensitization (Whistler et al.,
1999). This unique property of morphine is fundamental to its ability to induce
tolerance and withdrawal.
Neuronal effects
Since substance dependence induces long-lasting and near permanent
alterations in behaviour, the likelihood of persistent changes in neural
circuitry is high, brought about by remodelling and restructuring of neurons,
as a consequence of the molecular changes induced.
Synaptic plasticity
The reorganization of neural circuitry by psychoactive substances can occur
via changes in neurotransmitter release, the status of the neurotransmitter
receptors, receptor-mediated signalling, or the number of ion channels
regulating neuronal excitability. The mechanisms that mediate compulsive
drug-seeking and drug-taking appear to mimic the physiological mechanisms
for learning and memory (Hyman & Malenka, 2001; Nestler, 2001). There are
many parallels between the processes mediating learning and memory and
substance dependence, which will be examined in more detail in Chapter 3.
Alterations in synaptic structure
Structural changes in several brain regions as a consequence of substance
use have been shown. Neurons typically have multiply-branched processes
called dendrites, and following the activation of particular neurons, the
increase in dendritic spines is indicative of the activated state. Cocaine
administration has been associated with a marked increase in the number of
dendritic spines of the neurons of the nucleus accumbens and the prefrontal
cortex (Robinson & Kolb, 1999). In contrast, there is relative loss of the
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dendrites in some areas such as the hippocampus, in response to chronic
use of morphine (Sklair-Tavron et al., 1996; Eisch et al., 2000). Some of the
long-lasting behavioural changes seen in chronic substance use will no doubt
relate to such structural changes. Many of the synaptic changes are thought
to be mediated by processes similar to those discovered for learning and
memory (Hyman & Malenka, 2001).
Conclusion
This chapter has provided an overview of normal brain function, and of the
many distinct processes that interact to produce behaviour. Alterations in
any one of the steps in the process (generation of action potentials, changes
in electrical activity or chemical conductance, neurotransmitter release,
neurotransmitter reuptake, changes in second messenger function, altered
gene expression, altered synaptic connectivity) can alter the function of other
interacting processes, which ultimately can affect behaviour. As will be seen
in the following chapters, psychoactive substances can profoundly alter
neuronal processes, leading to the behaviours characteristic of dependence.
The immediate psychoactive and rewarding effects of substance use can
be explained by understanding the mechanism of action of these substances
at the pharmacological level. Further, the development of tolerance and
withdrawal, and the long-term effects of substance use can also be
understood through knowledge of a drug’s mechanism of action. The effects
of psychoactive substances on more complex processes such as motivation
can also be understood through the knowledge of their effects on the brain.
Their effects on motivational systems in the brain will be discussed further
in Chapter 3. The specific effects of the major psychoactive substances will
be explored in Chapter 4.
BOX 2.1
Neuroimaging techniques
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) uses magnetic fields and radio waves to produce
high-quality two- or three-dimensional images of brain structures without injecting
radioactive tracers. The brain can be imaged with a high degree of detail. Although
MRI gives only static pictures of brain anatomy, functional MRI (fMRI) can provide
functional information by comparing oxygenated and deoxygenated blood, which
provides information on changes in brain activity in specific brain regions in response
to various stimuli such as drugs, sounds, pictures, etc. An fMRI scan can produce
images of brain activity as fast as every second, whereas positron emission
tomography (PET) usually takes 40 seconds or much longer to produce images of
brain activity. Thus, with fMRI, there is greater temporal precision. fMRI has the
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advantages of having the highest spatial resolution among imaging techniques,
and does not require the use of ionizing radiation, thus it provides increased
experimental safety and the ability to retest subjects multiple times. Magnetic
resonance spectroscopy is used to gather information on the chemical composition
of a discrete brain region.
Positron emission tomography
Positron emission tomography (PET) is a technique for viewing the activity in different
regions in the brain. PET scans provide information about the metabolic activity in
a certain brain region. Most commonly, the person is injected with a radioactive
compound that can be followed through the bloodstream in the brain. This is usually
labelled 2-deoxyglucose (2-DG), which is taken up by active neurons due to its
similarity in structure to glucose. Thus, areas that are more metabolically active
will take up more glucose and 2-DG. Unlike glucose, 2-DG is not metabolized, and
therefore accumulates in the neurons. This can be visualized as two- or three-
dimensional images, with different colours on a PET scan indicating different levels
of radioactivity (blues and greens indicating areas of lower activity, and yellows
and reds indicating areas of higher activity). Using different compounds, PET scans
can be used to show blood flow, oxygen and glucose metabolism, and drug
concentrations in the tissues of the living brain. Regional cerebral blood flow can
be measured using PET imaging using a “flow tracer” such as [15 O] water to look
at blood flow in a given area. Selective labelling of radiotracers allows highly selective
biochemical specificities at low concentrations of tracers.
Single photon emission computed tomography
Similar to PET, single photon emission computed tomography (SPECT) uses
radioactive tracers and a scanner to record data that a computer uses to construct
two- or three-dimensional images of active brain regions. However, SPECT tracers
are more limited than PET tracers in the kinds of brain activity they can monitor,
and the SPECT tracers also deteriorate more slowly than many PET tracers, which
means that SPECT studies require longer test and retest periods than PET studies.
However, because SPECT tracers are longer lasting, they do not require an onsite
cyclotron to produce them. SPECT studies also require less technical and medical
staff support than PET studies do. While PET is more versatile than SPECT and
produces more detailed images with a higher degree of resolution, particularly of
deeper brain structures, SPECT is considerably less expensive than PET and can
address many of the same drug dependence research questions that PET can.
Electroencephalography
Electroencephalography (EEG) uses electrodes placed on the scalp to detect
and measure patterns of electrical activity emanating from the brain due to the
communication between neurons. EEG can determine the relative strengths and
positions of electrical activity in different brain regions within fractions of a second
after a stimulus has been administered. However, the spatial resolution of EEG is
not as good as with other imaging techniques. As a result, EEG images of brain
electrical activity are often used in combination with other techniques such as
MRI scans to better pinpoint the location of the activity within the brain.
Sources: Aine CJ, 1995; National Institute on Drug Abuse , 1996; Volkow et al., 1997;
Gatley & Volkow, 1998.
Chapter_2 19.1.2004, 11:2940
41
2. BRAIN MECHANISMS: NEUROBIOLOGY AND NEUROANATOMY
References
Aine CJ (1995) A conceptual overview and critique of functional neuro-imaging
techniques in humans. I. MRI/fMRI and PET. Critical Reviews in Neurobiology,
9:229–309.
Cardinal RN et al. (2002) Emotion and motivation: the role of the amygdala,
ventral striatum, and prefrontal cortex. Neuroscience and Biobehavioral Reviews,
26:321–352.
Carlson NR (1988) Foundations of physiological psychology. Boston, MA, Allyn
& Bacon.
Cole RL et al. (1995) Neuronal adaptation to amphetamine and dopamine:
molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron,
14:813–823.
Eisch AJ et al. (2000) Opiates inhibit neurogenesis in the adult rat hippocampus.
Proceedings of the National Academy of Science of the United States of America,
97:7579–7584.
Gatley SJ, Volkow ND (1998) Addiction and imaging of the living human brain.
Drug and Alcohol Dependence, 51:97–108.
Hope BT et al. (1994) Induction of a long-lasting AP-1 complex composed of
altered Fos-like proteins in brain by chronic cocaine and other chronic
treatments. Neuron, 13:1235–1244.
Hyman SE, Malenka RC (2001) Addiction and the brain: the neurobiology of
compulsion and its persistence. Nature Reviews: Neuroscience, 2:695–703.
Kandel ER, Schwartz JH, eds (1985) Principles of neural science, 2nd ed. New York,
NY, Elsevier.
Kandel ER, Schwartz JH, Jessell TM, eds (1995) Essentials of neural science and
behavior. Norwalk, CT, Appleton & Lange.
Keltz MB, Nestler EJ (2000) ∆FosB: a molecular switch underlying long-term neural
plasticity. Current Opinion in Neurology, 13:715–720.
Kolb B, Whishaw IQ (1996) Fundamentals of human neuropsychology, 4th ed. San
Francisco, CA, WH Freeman.
Kovacs GL, Sarnyai Z, Szabo G (1998) Oxytocin and addiction: a review.
Psychoneuroendocrinology, 23:945–962.
Lane-Ladd SB et al. (1997) CREB in the locus coeruleus: biochemical, physio-
logical and behavioral evidence for a role in opiate dependence. Journal of
Neuroscience, 17:7890–7901.
Law PY, Wong YH, Loh HH (2000) Molecular mechanisms and regulation of opioid
receptor signaling. Annual Review of Pharmacology and Toxicology, 40:389–430.
Marks MJ et al. (1992) Nicotine binding and nicotinic receptor subunit RNA after
chronic nicotine treatment. Journal of Neuroscience, 12:2765–2784.
Matthes HW et al. (1996) Loss of morphine-induced analgesia, reward effect and
withdrawal symptoms in mice lacking the µ-opioid receptor gene. Nature,
383:819–823.
Chapter_2 19.1.2004, 11:2941
NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE
42
McLay RN, Pan W, Kastin AJ (2001) Effects of peptides on animal and human
behavior: a review of studies published in the first twenty years of the journal
Peptides. Peptides, 22:2181–2255.
Moratalla R et al. (1996) D1-class dopamine receptors influence cocaine-induced
persistent expression of Fos-related proteins in striatum. Neuroreport, 8:1–5.
Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction.
Nature Reviews: Neuroscience, 2:119–128.
Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction.
Science, 278:58–63.
National Institute on Drug Abuse (1996) Special report: brain imaging research.
NIDA Notes, November/December. http://165.112.78.61/NIDA_Notes/
NN96Index.html#Number5.
Pak Y et al. (1996) Agonist-induced functional desensitization of the mu-opioid
receptor is mediated by loss of membrane receptors rather than uncoupling from
G protein. Molecular Pharmacology, 50:1214–1222.
Pinel JPJ (1990) Biopsychology. Boston, MA Allyn & Bacon.
Robbins TW, Everitt BJ (1996) Neurobehavioural mechanisms of reward and
motivation. Current Opinion in Neurobiology, 6:228–236.
Robinson TE, Kolb B (1999) Alterations in the morphology of dendrites and
dendritic spines in the nucleus accumbens and prefrontal cortex following
repeated treatment with amphetamine or cocaine. European Journal of
Neuroscience, 11:1598–1604.
Rosenzweig MR, Leiman AL, Breedlove SM (1999) Biological psychology, 2nd ed.
Sunderland, MA, Sinauer Associates.
Sarnyai Z, Shaham Y, Heinrichs SC (2001) The role of corticotropin-releasing factor
in drug addiction. Pharmacological Reviews, 53:209–293.
Sharma SK, Klee WA, Nirenberg N (1975) Dual regulation of adenylate cyclase
accounts for narcotic dependence and tolerance. Proceedings of the National
Academy of Science of the United States of America, 72:3092–3096.
Shepherd GM (1994) Neurobiology. New York, NY, Oxford University Press.
Sklair-Tavron L et al. (1996) Chronic morphine induces visible changes in the
morphology of mesolimbic dopamine neurons. Proceedings of the National
Academy of Science of the United States of America, 93:11202–11207.
Unterwald EM et al. (1993) Chronic repeated cocaine administration alters basal
and opioid-regulated adenylyl cyclase activity. Synapse, 15:33–38.
Volkow ND, Rosen B, Farde L (1997) Imaging the living human brain: magnetic
resonance imaging and positron emission tomography. Proceedings of the
National Academy of Sciences of the United States of America, 94:2787–2788.
Whistler J et al. (1999) Functional dissociation of µ-opioid receptor signaling and
endocytosis: implications for the biology of opiate tolerance and addiction.
Neuron, 23:737–746.
Wise RA (1998) Drug-activation of brain reward pathways. Drug and Alcohol
Dependence, 51:13–22.
Wonnacott S (1990) The paradox of nicotinic acetylcholine receptor upregulation
by nicotine. Trends in Neuroscience, 11:216–218.
Chapter_2 19.1.2004, 11:2942
43
3. BIOBEHAVIOURAL PROCESSES UNDERLYING DEPENDENCE
CHAPTER 3
Biobehavioural Processes Underlying
Dependence
Introduction
This chapter focuses on specific brain processes that are involved in the
rewarding effects of psychoactive substance use, reinforcement and the
development of dependence. Biological systems that have evolved to guide
and direct behaviour towards stimuli that are critical to survival are recruited
and abnormally strengthened by repeated use of psychoactive substances,
leading to the cycle of behaviours characteristic of dependence.
The chapter also describes the current hypotheses and evidence on the
biological basis of the behavioural and psychological factors that contribute
to substance dependence. Dependence is the result of a complex interaction
of the physiological effects of drugs on brain areas associated with motivation
and emotion, combined with “learning” about the relationship between drugs
and drug-related cues, all of which have a biological basis. These learning
processes are critically dependent upon the same motivational and emotional
systems in the brain that are acted upon by psychoactive substances (Hyman
& Malenka, 2001).
Although each class of psychoactive substances has its own unique
pharmacological mechanism of action (see Chapter 4), all psychoactive
substances activate the mesolimbic dopamine system (Fig. 3.1). The current
chapter focuses on mechanisms that are common to all psychoactive
substances and that are responsible for the cluster of symptoms
characteristic of substance dependence. The mesolimbic dopamine system,
in particular, will be highlighted because of its key role in learning and
motivational processes. In all cases, individual differences in biology and
environment will affect the neurobiological effects of psychoactive
substances; however, this chapter presents basic mechanisms that may
underlie the development of dependence from a biobehavioural
perspective.
The first section of this chapter provides an overview of learning theory
and terminology as it relates to dependence. The next section explains how
the unique properties of psychoactive substances can lead to dependence
through sensitization of the incentive value of drugs. The processes of
withdrawal and tolerance are also considered. Finally, individual differences
in responses to psychoactive substances are discussed.
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Defining terms
Behavioural science is concerned with studying those aspects of behaviour
that can be objectively viewed and verified, and describing behaviour in terms
of stimuli and responses to those stimuli. The development of dependence
can be seen as part of a learning process, in the sense that enduring changes in
behaviour result from interactions with drugs and drug-related environments.
Psychoactive substances cause profound activation of specific areas of the brain
involved in motivation, namely the mesolimbic dopamine system (see Fig. 3.1).
Through associative learning processes, this may eventually lead to the classic
symptoms of dependence following repeated exposure.
Basic principles of learning have been studied for decades, and have been
applied to the field of drug dependence. Two major theories of learning and
behaviour are relevant: (a) classical or Pavlovian conditioning and (b)
instrumental or operant conditioning.
Classical or Pavlovian conditioning
Classical or Pavlovian conditioning is based on simple stimulus–response
relationships as illustrated in Figure 3.2.
Fig. 3.1 Mesolimbic dopamine pathway
Source: National Institute on Drug Abuse (NIDA) website http://www.drugabuse.gov/pubs/
teaching/largegifs/slide-9.gif
Chapter_3 19.1.2004, 11:3744
45
3. BIOBEHAVIOURAL PROCESSES UNDERLYING DEPENDENCE
(a) A stimulus, such as the appearance of a light, normally elicits no
particular response, i.e. it is a neutral stimulus.
(b) When a puff of air is blown into the eye, it reliably elicits a response:
the eye blinks. The puff of air is the unconditioned stimulus and the
eye blink is the unconditioned response. The unconditioned response
occurs in response to the unconditioned stimulus.
(c) The unconditioned stimulus (puff of air) is repeatedly paired with the
neutral stimulus (light).
(d) Eventually the light alone is able to elicit the same response (eye blink)
as the puff of air on the assumption that a puff of air will follow. The
light is now known as a conditioned stimulus and the response to it is
the conditioned response.
This type of conditioning can occur for even complex behaviours such as
emotional responses and drug craving. Advertisements for alcohol and
tobacco products generally try to pair their products with images that create
a positive emotional response. This leads to an association being formed in
the brain between the product and the emotional response evoked by the
advertisement. To an individual with substance dependence, the sight of drug
paraphernalia (e.g. syringes, smoking devices) or exposure to environments
in which drugs have previously been used can induce craving for drugs and
relapse to substance use through classical conditioning processes. As
discussed later in this chapter, the neurobiological basis of these associations
with respect to psychoactive substance dependence appears to be dopamine
signals in the nucleus accumbens.
Fig. 3.2 Classical or Pavlovian conditioning (see text)
No response
Unconditioned
 response
Conditioned
response
Unconditioned
 response
Neutral
stimulus
Conditioned
stimulus
Neutral
stimulus
Unconditioned
stimulus
Unconditioned
stimulus
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Instrumental or operant conditioning
Instrumental or operant conditioning is different from classical or Pavlovian
conditioning in that in the latter the organism has no control over the
presentation of the stimulus. For example, when the conditioned stimulus
(light) appears, the conditioned response (eye blink) occurs. In contrast, in
instrumental conditioning, the organism’s behaviour produces the stimulus.
That is, the behaviour occurs because of the consequences that it produces;
it is instrumental in producing the consequences. This is often referred to as
“goal-directed behaviour”. There are three main categories of instrumental
conditioning as illustrated in Figure 3.3: positive reinforcement, negative
reinforcement and punishment. In positive reinforcement, a behaviour brings
about a pleasurable stimulus, which reinforces the repetition of the behaviour.
For example, animals can be trained to press a lever to obtain a food pellet.
Thus, the behaviour produces the food, which is the stimulus. If the animal
wants food, it learns to press the lever to obtain it. In negative reinforcement,
a behaviour eliminates or prevents an aversive stimulus, which again
reinforces the behaviour, or increases the likelihood of that behaviour
occurring again. In punishment, the behaviour elicits an aversive stimulus.
In this case, the behaviour is less likely to occur again. Instrumental
Fig. 3.3 Examples of instrumental conditioning (see text)
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conditioning is important in substance use and dependence, since a person
performs an operant response when choosing to acquire and use a
psychoactive substances to experience its effects. Mesolimbic dopamine
systems are also thought to be important in instrumental learning about the
effects of psychoactive substances.
The following sections will examine aspects of learning theory as they relate
to dependence.
Reinforcer
A reinforcer is commonly defined as a stimulus that strengthens responses
upon which it is contingent (i.e. which it reliably follows). Thus, if one puts
money in a vending machine to obtain a bar of chocolate, the chocolate acts
as a reinforcer for the behaviour of putting money into the machine.
Reward
Reward is a term frequently used in the psychobiology of substance
dependence, to describe the pleasurable or enjoyable effects of a drug. In
general, rewards are stimuli that provide positive motivation for behaviour.
A fundamental feature of rewards is that of transferring their motivational
properties to stimuli that predict their occurrence, and of strengthening
responses upon which they are contingent. For this reason, rewards are
reinforcers. Although many drugs are taken for their pleasure-producing or
“rewarding” properties, this alone cannot account for the entire range of
behavioural processes involved in substance dependence (Robinson
& Berridge, 2000). Many stimuli can serve as rewards, but few take on the
profound, all-consuming value that psychoactive substances do, such that
they can lead to the symptoms and behaviours characteristic of dependence
(see Chapter 1).
Incentive
The term incentive was originally used to refer to the ability of certain stimuli
to elicit species-specific response patterns such as orienting, approaching
or exploring (Bindra, 1974). This term implies that responding is a
consequence of the stimuli (incentives). Accordingly, while reinforcers act as
consequences of responding, incentives act as premises. An example of an
incentive is a stimulus associated with food, such as smell, the sight of a
restaurant, or an advertisement for food. These stimuli may elicit certain
responses that direct attention and behaviour towards the acquisition of the
food, and activate the motivational circuits in the brain in order to acquire
the food. This example illustrates that incentives have two properties. One is
a directional property that promotes responses directed towards the
incentive, and towards the reward to which the incentive has been
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conditioned. The second is an activational property that promotes a state of
motivational arousal. These two properties have their biological roots in the
mesolimbic dopamine system, and act together to direct behaviour towards
goals.
Motivation
Motivation is the allotment of attentional and behavioural resources to stimuli
in relation to their predicted consequences. Motivation therefore involves
learning of predictive relationships (contingencies) between neutral stimuli
and biologically meaningful ones, and between responses and their
outcomes. Learning of these contingencies enables the subject to act in ways
that lead to the most desirable outcomes.
Incentive-motivational responding
Incentive-motivational responding is responding based on the motivation
aroused by an external stimulus. Responding is a function of the perceived
value of the stimulus to the organism. The basis for this form of motivated
responding is hard-wired by evolution in the brain of organisms, including
humans. Thus, certain stimuli such as the taste of a sweet or the cry of a
predator, evoke responses that, depending on the stimulus, involve
approaching or avoiding the object or organism from which they originate.
Incentive-motivational responding is, however, subject to conditioning
principles, and therefore stimuli associated with the primary unconditioned
stimuli can take on incentive-motivational properties. Thus, individuals with
substance dependence may seek out people or environments previously
associated with drug use.
As an example of incentive-motivational responding, consider the earlier
example of the sight or smell of food. If a person is not hungry, this may have
little incentive-motivational value and hardly any attention will be paid to
the food, with no attempt to obtain it. If the person is hungry, the incentive
of food may cause him or her to orient towards the food, to begin to salivate,
and prepare to eat. If extremely hungry, the incentive-motivational value of
the food will be very high, and may cause the person to focus specifically on
the food to the exclusion of other stimuli, to become preoccupied with the
food, and possibly to engage in risky behaviour in order to obtain it. Similarly,
as described in the following sections, once drugs become conditioned
reinforcers, their incentive-motivational value can become higher than all
other competing motivations.
Drug reward alone does not explain drug dependence
The self-administration of drugs for non-therapeutic and non-medical use
is probably as old as human culture and civilization, and testifies that drugs
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serve as positive reinforcers (Johanson & Uhlenhuth, 1978). Additionally, the
property of eliciting pleasurable feelings also indicates that drugs are indeed
rewarding. Rewarding properties of drugs do not necessarily consist of sheer
sensations of pleasure like the “high” or the “rush” typical of amphetamine
and heroin or of inhaled crack (cocaine base) but can take milder forms of
hedonia, such as relief of tension, reduction of fatigue, increased arousal, or
improvement of performance. These positive sensations can explain why
drugs are used, but not necessarily why they can produce the behavioural
repertoire characteristic of dependence. In particular, drug reward alone
cannot account for drug dependence, a condition characterized by
compulsive, relapsing drug use and focusing of motivated behaviour on drugs
to the exclusion of alternative goals and in the face of familiar, social and
medical problems.
Clearly, the rewarding properties of drugs, at least as we understand them
from their comparison with conventional rewards, do not fully explain the
behavioural abnormalities associated with their use.
In the context of dependence, it is important to remember that over a
lifespan many people experiment with a variety of potentially dependence-
producing drugs, but most do not become dependent. Therefore, the question
specifically becomes:
— what is the process by which drug-taking behaviour, in certain
individuals, evolves into compulsive patterns of drug-seeking and
drug-taking behaviour that take place at the expense of most other
activities?
— what accounts for the inability of some compulsive drug users to stop
using drugs?
A complex interplay of psychological, neurobiological and individual
factors appears to be responsible. This section will cover some of the general
principles concerning effects of psychoactive substances on learning and
motivational processes that may come into effect during the development of
dependence. Clearly, an individual’s genetic and environmental background
will influence the ultimate behavioural expression of these influences. These
factors will be considered separately in other sections of this report. The
following discussion is intended to provide information on how substance
use interacts with motivational systems in the brain to contribute to the
development of dependence.
Drug dependence as a response to incentive-motivation
While not sufficient, the rewarding properties of drugs are nonetheless
necessary for their dependence-producing effects for at least two reasons.
First, drug reward, by promoting drug self-administration, is necessary for
repeated drug exposure. Secondly, the rewarding properties of drugs are
necessary for attributing – by an associative learning mechanism – positive
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motivational value to stimuli that predict drug availability and act as powerful
incentives of drug-seeking behaviour.
Because psychoactive drugs have strongly reinforcing properties, and
because these reinforcing properties can increase the motivational value of
drugs and drug-associated stimuli (e.g. environments where drugs are taken,
the presence of drug dealers or drug users, the sight of drug paraphernalia)
through repeated pairings, the incentive-motivational responding towards
drugs and drug-associated stimuli is increased. (Wikler, 1973; Goldberg, 1976;
Stewart, de Wit & Eikelboom, 1984; Childress et al., 1988; O’Brien et al., 1992;
Robinson & Berridge, 1993; Di Chiara, 1998). Thus, the drug is used, it has
rewarding effects, and this reinforces the drug-using behaviour and associated
stimuli. The question is then: why are psychoactive substances such powerful
reinforcers that they can lead to the development of dependence?
Drug dependence as a response to drug withdrawal
In addition to understanding drug dependence in terms of incentive theories,
it can also be seen as a response to withdrawal reactions. Early theories of
drug dependence, for example, placed major emphasis on the physical effects
of withdrawal as a factor of drug dependence (Himmelsbach, 1943). In this
regard, the adverse physical consequences of withdrawing from a drug’s
effects are viewed as a key motivational determinant of sustained drug taking
through negative reinforcement mechanisms (see Fig. 3.3). However, it is
possible to have dependence without withdrawal and withdrawal without
dependence. For example, it is possible to have cocaine or alcohol
dependence, but not to experience withdrawal symptoms between episodes
of use. There can also be withdrawal symptoms in the absence of dependence,
such as following long-term medical use of benzodiazepines or morphine.
These factors are recognized in diagnostic criteria, where withdrawal is not
necessary or sufficient for a diagnosis of dependence (see Chapter 1). For
these reasons, more recent theories of dependence have moved the emphasis
away from physical withdrawal, and towards motivational dependence
produced in part by withdrawal-induced negative moods such as anhedonia
and dysphoria. This state, by a negative reinforcing mechanism, would
maintain drug self-administration because the drug removes the negative
emotional state of withdrawal (Koob et al., 1989, 1997). The advantage of this
modern version over early physical dependence theories is that motivational
dependence has properties that are common to different classes of
psychoactive substances while the properties of physical dependence differ
widely from one class to another.
Dopamine and reinforcement learning
The role of dopamine in response-reinforcement learning is at the root of
current models of instrumental responding (Montague, Dayan & Sejnowski,
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1996; Schultz, Dayan & Montague, 1997). This is why, although different
classes of psychoactive substances have different primary pharmacological
mechanisms of action, dopamine is important to the development of
dependence for all classes because of its critical role in response-
reinforcement learning. Almost all psychoactive substances with reinforcing
properties activate mesolimbic dopamine, either directly or indirectly.
According to these models, dopamine is released in response to an
unexpected reward. This leads to a strengthening of the synaptic connections
in neural pathways that led to the behaviour that was associated with the
reward. Although psychoactive substances act through a wide variety of
primary pharmacological mechanisms, almost all eventually influence
mesolimbic dopamine function, which is why dopamine is such an important
neurochemical in the neuroscience of dependence. Dopamine is released in
response to all unexpected rewards, thus reinforcing the behaviours that led
to the occurrence of that reward.
Dependence-producing drugs as surrogates of conventional reinforcers
Drug and non-drug (e.g. stimuli associated with food, water, sex) reinforcers
share behavioural and neurochemical similarities. For example, drug and
non-drug reinforcers share the property of activating dopamine transmission
preferentially in a region of the nucleus accumbens known as the “shell”
(Pontieri, Tanda & Di Chiara, 1995; Robbins & Everitt, 1996; Bassareo & Di
Chiara, 1997; Tanda, Pontieri & Di Chiara, 1997; Bassareo & Di Chiara, 1999).
Therefore, dependence-producing drugs reproduce certain central
neurochemical effects of conventional reinforcers (Di Chiara et al., 1993),
thereby obtaining motivational significance in the brain.
Dependence-producing drugs, however, differ from conventional
reinforcers in that their stimulant effects on dopamine release in the nucleus
accumbens are significantly greater than natural reinforcers such as food.
Whereas food increased dopamine levels in the nucleus accumbens by 45%,
amphetamine and cocaine increased dopamine levels by 500% (Hernandez
and Hoebel, 1988). The mesolimbic dopamine system reinforces behaviours
and signals that are associated with stimuli that are critical to survival, such
as feeding and reproduction. Because psychoactive substances also activate
this circuit so powerfully and reliably, the drug-taking behaviour and stimuli
associated with it are registered in the brain as being critically important.
The repetitive, profound stimulation of dopamine transmission induced by
drugs in the nucleus accumbens abnormally strengthens stimulus–drug
associations (Pavlovian incentive learning). By this mechanism stimuli that
are associated with or predictive of drugs are attributed great motivational
value, thus becoming capable of facilitating behaviour that is instrumental
to the self-administration of the drug.
Relapse to substance use is known to be triggered by cues previously paired
with substance use, by stress, or by the presence of the drug itself (Stewart,
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2000). All of these phenomena are mediated by increased mesolimbic
dopamine. Thus, activity in these circuits can mediate not only the primary
rewarding effects of the drugs, but also the conditioning of secondary stimuli,
and the subsequent ability of these stimuli to trigger cravings and relapse.
Functional brain imaging techniques (see Chapter 2) are beginning to
revolutionize the study of previously obscure concepts such as craving, which
can now be “visualized” in discrete brain regions. For example, activation of
the mesolimbic dopamine system and other brain regions by cocaine (Breiter
et al., 1997), heroin (Sell et al., 1999), alcohol (Wang et al., 2000), nicotine
(Volkow et al., 1999), or any other psychoactive substance, can be observed
using functional imaging techniques. Moreover, brain responses to predictors
of the drugs, or cues associated with drug use can also be measured. This is
very important in terms of studying craving and relapse. When visual or verbal
cues associated with heroin and cocaine are presented to people who use
these substances, they result in metabolic activation in brain regions
associated with expectancy of reward and learning (Childress et al., 1999;
Sell et al., 1999; Wang et al., 1999; Sell et al., 2000). These studies also found
that self-reports of “craving” and “urge to use” strongly correlated with
metabolic changes in specific brain regions. This indicates that previously
unmeasurable concepts such as craving are now beginning to be quantifiable,
measurable phenomena associated with specific brain regions. In addition,
the conditioning of secondary stimuli with drug effects can also be measured.
Dopamine and incentive sensitization
Dopamine was originally thought to mediate the rewarding or hedonic
properties of drug and non-drug reinforcers (Wise, 1982). However, evidence
obtained subsequently suggested that dopamine was affecting the motivation
to respond for reward, rather than the experience of reward itself (Phillips
& Fibiger, 1979; Gray & Wise, 1980). On this basis it was hypothesized that
dopamine mediates the incentive-motivational properties of both primary
reinforcers (rewards) and secondary reinforcers (Gray & Wise, 1980).
The above hypothesis has been further modified to distinguish between
the rewarding properties of drugs, and the response-eliciting properties of
drugs. Mesolimbic dopamine has been assigned a role in response-eliciting
but not in rewarding (Robinson and Berridge 1993; Berridge 1996; Berridge
& Robinson 1998; Robinson & Berridge, 2000). In other words, the reasons
that people enjoy the primary effects of psychoactive substances may have
to do with their effects on several different neurotransmitter systems, but
the desire to repeat using the drugs comes from the activation of the brain
mesolimbic dopamine system that guides motivated behaviour. Because
psychoactive substances activate the mesolimbic dopamine system, and
because the mesolimbic dopamine system has a primary role in guiding
motivated behaviour, the repeated exposure of the brain to psychoactive
substances leads to strong associations being formed. The mechanism by
Chapter_3 19.1.2004, 11:3752
53
3. BIOBEHAVIOURAL PROCESSES UNDERLYING DEPENDENCE
which dopamine exerts this function has been termed “incentive
sensitization”. Thus, the brain becomes more sensitive, or “sensitized” to the
motivational and rewarding effects of psychoactive substances.
It is hypothesized that this process of incentive sensitization produces
compulsive patterns of drug-seeking behaviour. Through associative learning,
the enhanced incentive value becomes focused specifically on drug-related
stimuli, leading to more and more compulsive patterns of drug-seeking and
drug-taking behaviour.
Psychomotor sensitization
Most laboratory studies showing that the repeated administration of
psychoactive substances can produce sensitization of the mesolimbic
dopamine system involve two measures: measures of levels of dopamine and
its metabolites in the nucleus accumbens, and measures of the psychomotor-
activating effects of drugs, such as their ability to enhance locomotor activity
in laboratory animals. Studies on the psychomotor-activating effects of drugs
are relevant to dependence because the mesolimbic dopamine system
controls both locomotion and behaviour, and locomotion is an easily
observable behavioural assay of nucleus accumbens function (Wise &
Bozarth, 1987).
There is now considerable evidence that the repeated intermittent
administration of psychomotor-stimulant substances results in a progressive
increase in their psychomotor- activating effects. Psychomotor sensitization
has been shown for amphetamine, cocaine, methylphenidate, fencamfamin,
morphine, phencyclidine, ecstasy, nicotine and ethanol (Robinson & Berridge,
1993).
Sensitization is remarkably persistent, and animals that have been
sensitized may remain hypersensitive to the psychomotor-activating effects
of drugs for months or years (Robinson & Becker, 1986; Paulson, Camp &
Robinson, 1991). It is important to note that sensitization can develop even
after a drug has been self-administered (Hooks et al., 1994; Phillips & DiCiano,
1996; Marinelli, Le Moal & Piazza, 1998), and therefore, that the experimental
models of sensitization are valid models of human substance use.
Sensitization and drug reward
Studies show that sensitization results from the psychomotor-activating
effects as well as the rewarding effects of psychoactive drugs (Schenk
& Partridge, 1997). Thus, upon repeated exposure to drugs over time, their
subjective rewarding effects are increased. (Note that this is in contrast to
the short-term tolerance that may occur within a single session of drug intake.
Sensitization develops over days to weeks to months). It is thought that the
shift from substance use to substance dependence may be closely related to
the phenomenon of sensitization (Deroche, Le Moal & Piazza, 1999).
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There is a large body of data showing that sensitization is associated with
marked changes in the mesolimbic dopamine system. There are both
presynaptic changes (increased dopamine release) and postsynaptic changes
(changes in receptor sensitivity). In addition, structural changes in output
neurons in the nucleus accumbens and prefrontal cortex have also been seen
following sensitization to amphetamine and cocaine (Robinson & Kolb, 1997;
1999).
Sensitization and tolerance
It is important at this point to emphasize again that this discussion focuses
on sensitization of the mesolimbic dopamine system, i.e. the increase in
dopamine in the nucleus accumbens that is observed on repeated drug
presentations, and that has been reported for psychoactive substances of all
classes.
Tolerance can be defined as a given drug producing a decreasing effect
with repeated dosing, or when larger doses must be administered to produce
the same effect ( Jaffe, 1985, 1990). There is differential tolerance to
psychomotor stimulants, meaning that tolerance develops to some of the
drug effects, but not to others. Indeed, as will be discussed, some drug effects
are increased upon repeated drug use. In humans, rapid tolerance develops
to the anorexic effects and the lethal effects of amphetamine and cocaine
(Angrist & Sudilovsky, 1978; Hoffman & Lefkowitz, 1990). However, no
tolerance or change in sensitivity of behavioural responses was observed after
repeated daily oral doses of 10 mg of D-amphetamine (Johanson, Kilgore
& Uhlenhuth, 1983). Similarly, no tolerance developed to the subjective “high”
after repeated daily oral doses of 10 mg of methamphetamin, but tolerance
did develop to the cardiovascular effects with repeated daily dosing (Perez-
Reyes et al., 1991). Some acute tolerance appears to develop to the
cardiovascular effects of cocaine even over a 4-hour infusion period (Ambre
et al., 1988). Subjective, behavioural and cardiovascular effects also decline
after sequential oral doses of D-amphetamine, despite substantial plasma
levels, also suggesting acute tolerance (Angrist et al., 1987). Tolerance does
not develop to the stereotyped behaviour and psychosis induced by
stimulants, and in fact these behavioural effects appear to show sensitization
or an increase with repeated administration (Post et al., 1992). Similar results
have been observed in animal studies, with tolerance developing to the
anorexic and lethal effects of amphetamine but not to stereotyped behaviour
(Lewander, 1974). The same is also true of tolerance to nicotine, alcohol and
benzodiazepines, which develops to some drug effects but not others.
Tolerance to specific classes of psychoactive substances will be discussed
further in Chapter 4.
Tolerance can also develop as a result of metabolic enzyme induction, i.e.
enzymes that are involved in the metabolism of a drug can increase their
activity in the presence of increasing concentrations of the drug. The
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metabolism of alcohol and nicotine by the cytochrome P450 enzymes in the
liver can be increased in this way, thus larger doses are needed for the drug
to achieve the same effects as it had prior to enzyme induction. Tolerance
can also develop due to changes in receptor number or sensitivity. These
concepts will be further discussed in Chapter 4.
Although tolerance and sensitization to different aspects of a drug’s effects
can coexist (Hyman & Malenka, 2001), sensitization and tolerance are
essentially separate phenomena.
Sensitization occurs in connection with the rewarding effects of psycho-
active substances, and appears to be very important in the acquisition of
persistent substance use (Schenk & Partridge, 1997). Pre-exposure to a drug
can reduce the latency period for experimental animals to acquire self-
administration, and also can result in lower than expected doses of a drug
having reinforcing effects (Schenk & Partridge, 1997). This sensitization can
occur either through pre-exposure or from environmental factors such as
stress (Antelman et al., 1980; Cador et al., 1992; Deroche et al., 1992; Henry et
al., 1995; Badiani, Oates & Robinson, 2000). A key feature of sensitization is
that it is long-lasting (Robinson & Becker, 1986). Conversely, tolerance to the
behavioural effects of a drug appears to be more transient, and associated
with high frequency of drug use in a short period of time (Schenk & Partridge,
1997). Again, it is important to emphasize that tolerance and sensitization
can coexist in respect to different aspects of the drug’s effects (Hyman
& Malenka, 2001), and that tolerance can have both acute and chronic aspects.
Individual differences
There are individual differences in biology and environmental factors that
mediate the reinforcing effects of psychoactive substances. Individual
differences in response to first drug use can determine who will be more likely
to use the drug again (Davidson, Finch & Schenk, 1993). In animal models,
there are clear behavioural differences that can predict which animals are
more likely to develop sensitization and learn to self-administer drugs more
quickly (Piazza et al., 1990; Hooks et al. 1992; De Sousa, Bush & Vaccarino,
2000; Sutton, Karanian & Self, 2000). These behavioural factors are related to
increased mesolimbic dopamine in susceptible animals, both at baseline and
following food and drug rewards (Sills & Crawley, 1996; Sills, Onalaja
& Crawley, 1998). These findings have led to suggestions that there may be a
behavioural phenotype associated with mesolimbic dopamine function in
humans that can predict those who are more susceptible to developing
substance dependence (Zuckerman, 1984; Bardo, Donohew & Harrington,
1996; Dellu et al., 1996; Depue & Collins, 1999).
To summarize, dependence-producing substances share the ability to
produce persistent changes in brain regions that are involved in the process
of incentive- motivation and reward, and such changes make these regions
hypersensitive (sensitized). There is a wealth of evidence to support this claim.
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BOX 3.1
Definitions
Classical conditioning
Also called Pavlovian conditioning after Pavlov’s experiments with dogs, in which
stimuli such as the sound of a bell, repeatedly paired with food presentation,
eventually came to elicit salivation in the dogs in the absence of the food. Classical
conditioning is the simplest form of learning to make new responses to stimuli
and to learn about relationships between stimuli. It is a form of learning in which
a previously neutral stimulus (conditioned stimulus) gains power over behaviour
through association with a biologically relevant stimulus (unconditioned stimulus),
and can elicit the same behavioural or physiological response (unconditioned
response) as the unconditioned stimulus. The response to the conditioned stimulus
is called the conditioned response.
Conditioned response
In classical (or Pavlovian) conditioning, a response elicited by a previously neutral
stimulus, which occurs as a result of pairing the neutral stimulus with an
unconditioned stimulus.
Conditioned stimulus
In classical conditioning, the previously neutral stimulus which comes to elicit a
conditioned response.
Cognition
The process of knowing, including attending, remembering, reasoning etc., as
well as the content of these processes, such as concepts and memories.
Craving
Drug craving is the desire for the previously-experienced effects of a psychoactive
substance. This desire can become compelling and can increase in the presence
of both internal and external cues, particularly with perceived substance availability.
It is characterized by an increased likelihood of drug-seeking behaviour and, in
humans, of drug-related thoughts.
Dependence
A cluster of cognitive, behavioural, and physiological symptoms indicating that
the individual continues the use of the substance despite significant substance-
related problems.
Emotion
A complex phenomenon, including physiological arousal, feelings, cognitive
processes, and behavioural reactions, made in response to a situation perceived
to be personally significant.
Habit
A behaviour performed automatically in response to specific stimuli, independently
from its outcome.
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Habituation
A decrease in the ability of a stimulus to elicit a response.
Incentive-motivation
Motivation due to stimuli that elicit responses on the basis of their contingency
with other stimuli (Pavlovian principle).
Learning
A process that results in a relatively permanent change in behaviour or behavioural
potential based on experience.
Memory
The mental capacity to store and later recognize or recall events that were
previously experienced.
Reinforcement
The increase in the probability that a behaviour will occur because of the
consequences of that behaviour.
Reinforcer
A stimulus that strengthens responses upon which it is contingent (i.e. which it
reliably follows).
Reward
A primary, unconditioned stimulus that utilizes sensory modalities (e.g. gustatory,
tactile, thermic), and provides feelings of pleasure or well-being.
Sensitization
An increase in the effect of a drug following repeated use. It may be expressed
as behavioural sensitization, and is presumably the result of neural sensitization.
(An increase in the ability of a stimulus to elicit a response).
Stimulus
Any event in the environment that is detected by the sense organs could be a
stimulus.
Tolerance
A decrease in the effect of the same dose of a drug following repeated use.
Withdrawal
A maladaptive behavioural change, with physiological and cognitive concomitants,
that occurs when blood or tissue concentrations of a substance decline in an
individual who had maintained prolonged heavy use of the substance.
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Persistence of neural sensitization may leave dependent individuals
susceptible to relapse long after discontinuation of substance use. Relapse
can occur following stress, exposure to the drug or a similar drug or to drug
cues. Individual differences in genetics and environmental factors, however,
will have mitigating effects on the primary rewarding effects of psychoactive
substances.
Summary
Substance dependence may be viewed as the result of the action of various
factors. In the early stages of substance use, as a result of curiosity, peer
pressure, social marketing factors, ubiquity of exposure, personality traits,
and other related factors, the subject comes into contact with a drug with
dependence-producing effects. The reinforcing properties of the drug,
together with the individual’s own biological make-up and environmental
background, may facilitate further exposure to the drug. Associative learning
properties related to release of dopamine in the nucleus accumbens also
strengthen the reinforcing effects of the drug and of the environment and
emotions associated with its use. In this stage the subject responds to the drug
and to drug-related stimuli in a manner not dissimilar from normal motivated
responding. Through activation of emotional and motivational centres of the
brain, learning processes are invoked. It is important to note here that exposure
to psychoactive substances and substance use in everyday life and through
the media, particularly when presented in a positive environment, can create
pleasurable emotions. An individual can easily become conditioned to
associate these emotions with substance use, resulting in learning, focused
attention, facilitated memory, and the development of attitudes surrounding
substance use that guide motivation. These factors all interact with individual,
biological, social, and cultural factors to determine whether or not substance
use is repeated, and whether that repeated substance use results in the cluster
of symptoms known as dependence.
With repeated drug exposure, there is the repeated association of drug
reward and drug-related stimuli parallel to the stimulation of dopamine
transmission in the nucleus accumbens, resulting in the attribution of
motivational value to drug-associated stimuli. This is the stage of incentive
sensitization. In this stage the person can still control drug intake in the
absence of drug-related stimuli and is not dependent, but can experience
health and social consequences of his or her substance use. This stage is often
called hazardous substance use.
The stage of dependence is clinically defined by at least three of the
following:
— a strong desire or sense of compulsion to take the substance;
— difficulties in controlling substance-taking behaviour in terms of its
onset, termination or levels of use;
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— a physiological state of withdrawal;
— evidence of tolerance;
— progressive neglect of alternative pleasures or interests;
— persistent use despite clear evidence of overtly harmful consequences.
Compulsive drug-seeking and craving are elicited by the presence of drugs
or associated stimuli (see Chapter 1).
Neuroscience focuses on the events that occur to bring about each of these
symptoms. However, some behaviours are more easily studied than others.
Tolerance and withdrawal have been relatively easier to define and measure
in laboratory animals, which has led to a greater understanding of the effects
of drugs on health and the long-term consequences of substance use.
Concepts such as craving, loss of control and persistent use have been harder
to study in the laboratory. However, modern neuroimaging studies of the
human brain are helping researchers to understand these processes in greater
detail than ever before, and are for the first time giving objective, measurable
images of previously uncharacterizable phenomena such as “craving”.
It is also interesting to relate these biobehavioural learning processes to
the behavioural therapies that are sometimes employed in treating substance
dependence (see Box 3.2). Motivational and cognitive therapies are designed
to work on the same motivational systems in the brain as those that are
affected by substance dependence. These therapies try to replace the
motivation to use drugs with the motivation to engage in other behaviours.
Note that these therapies rely on the same principles of learning and
motivation that are used to describe the development of dependence.
Contingency management, for example, uses the principles of positive
reinforcement and punishment to manage behaviour. Cognitive behavioural
therapies and relapse prevention help the person develop new stimulus–
response associations that do not involve substance use or craving. These
principles are employed in an attempt to “unlearn” the dependence-related
behaviour and to learn more adaptive responses. Similar neurobiological
mechanisms are involved in the development of dependence, as are involved
in learning to overcome dependence.
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BOX 3.2
Types of psychotherapies/behavioural interventions
Cognitive behavioural therapies
Cognitive behavioural therapies focus on (a) altering the cognitive processes
that lead to maladaptive behaviours of substance users, (b) intervening in the
behavioural chain of events that lead to substance use, (c) helping patients deal
successfully with acute or chronic drug craving, and (d) promoting and reinforcing
the development of social skills and behaviours compatible with remaining drug
free. The foundation of cognitive therapy is the belief that by identifying and
subsequently modifying maladaptive thinking patterns, patients can reduce or
eliminate negative feelings and behaviour (e.g. substance use).
Relapse prevention
An approach to treatment in which cognitive behavioural techniques are used in
an attempt to help patients develop greater self-control in order to avoid relapse.
Specific relapse prevention strategies include discussing ambivalence, identifying
emotional and environmental triggers of craving and substance use, and
developing and reviewing specific coping strategies to deal with internal or external
stressors.
Contingency management
A behavioural treatment based on the use of predetermined positive or negative
consequences to reward abstinence or punish (and thus deter) drug-related
behaviours. Rewards have included vouchers – awarded for producing drug-free
urine samples – that can be exchanged for mutually agreed-upon on items (e.g.
cinema tickets) or ‘community reinforcement,’ in which family members or peers
reinforce behaviours that demonstrate or facilitate abstinence (e.g. participation
in positive activities). Negative consequences for returning to substance use
may include notification of courts, employers or family members.
Motivational enhancement therapy (MET)
This brief treatment modality is characterized by an empathetic approach in which
the therapist helps to motivate the patient by asking about the pros and cons of
specific behaviours, by exploring the patient’s goals and associated ambivalence
about reaching these goals, and by listening reflectively. Motivational enhancement
therapy has demonstrated substantial efficacy in the treatment of substance
dependence.
Source: The American Journal of Psychiatry, 1995.
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CHAPTER 4
Psychopharmacology of Dependence
for Different Drug Classes
Introduction
The purpose of this chapter is to provide an overview of the major classes of
psychoactive substances, and their individual and common effects in the
brain. The previous chapter introduced the biobehavioural concepts that
explain how a substance1 with rewarding properties can be reinforcing,
causing the self-administration of that substance to be repeated, and how
this can lead to sensitization of motivational circuits in the brain, and
ultimately to dependence. This chapter will discuss each class of psychoactive
substances, its mechanism of action, behavioural effects, development of
tolerance and withdrawal, long-term neuropsychological consequences, and
potential pharmacological treatments (see Tables 4.1 and 4.2). Finally,
common neurobiological and cellular effects of psychoactive substances will
be presented. By understanding the acute and chronic effects of drug action,
targeted therapies can be developed, and questions concerning how and why
some drugs can be used by certain individuals without leading to dependence,
whereas others lead to chronic dependence and relapse, can be better
understood.
At all times, it is important to remember that individual differences in
genetics, biology, and social and cultural factors influence the effects of a
substance on a person and the outcome of substance use. This chapter
presents the commonly known effects of drugs from research on large groups
of people and on experimental animals.
The pharmacology of the common psychoactive substances is considered:
alcohol, sedative/hypnotics, nicotine, opioids, cannabis, cocaine,
amphetamines, ecstasy, volatile solvents, and hallucinogens. For each one
of those, a brief review is provided of:
— behavioural manifestations of acute and chronic use of a drug in
humans and in  animal models;
— molecular and biochemical mechanism of action in the main brain
areas involved with acute effects;
1 The terms substance, drug, psychoactive substance or psychoactive drug, are
used interchangeably in this report, and may refer to nicotine, alcohol or other drugs.
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— development of tolerance and withdrawal;
— neurological adaptations (direct effects and indirect effects) due to
prolonged use;
— information on pharmacological treatment approaches for each drug
class where available.
Animal models are frequently employed in order to better understand the
biological basis of drug use and drug action. The following animal models
show reliability when used to study selective aspects of human dependence
and substance use:
— self-administration;
— intracerebral self-stimulation;
— place preference;
— drug discrimination.
There are several different procedures within each one of these models, as
extensively reviewed by Koob (1995). The reinforcing properties of the drugs
will cause animals from different species to perform operant tasks to self-
administer drugs. This is considered to model the dependence-producing
potential of the drugs, and is also widely used for preclinical assessment of
new therapies. Self-stimulation of certain brain areas activates brain circuits
that are probably activated by natural reinforcers. Psychoactive substances
are tested in this paradigm to verify whether they decrease the reward
threshold and if they influence in the reward and reinforcement processes.
Place preference uses a Pavlovian conditioning procedure to evaluate
reinforcement by a drug. One assumes that an animal that chooses to spend
more time in an area that has been paired with a certain drug state expresses
the positive reinforcement experience in that location. The last model, i.e.
drug discrimination, relies on the assumption that the discriminative
stimulus of a drug in animals is a reflection of the subjective effects of the
drug in humans. These drug effects would serve as an internal cue that
induces effects similar to the effects of a well-known psychoactive drug.
Research into dependence has been difficult for neuroscientists for the
reason that dependence is made up of many behavioural and physiological
components, some of which can be readily measured, such as withdrawal
symptoms, while others are more difficult to study experimentally, such as
craving and loss of control.
Animal models have been very useful for studying substance use, and the
short-term and long-term physical effects of substance use. Other
components of dependence are more difficult to study, or are uniquely
human, such as craving, social consequences of substance use, and feelings
of loss of control over substance use. However, developments in neuroscience
over the past several years have greatly enhanced the ability to study changes
in human brain function and composition, using functional magnetic
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resonance imaging (MRI), regional cerebral blood flow, and positron emission
tomography (PET).
Major advances in the understanding and treatment of dependence have
come from understanding the basic mechanisms of drug action and long-
term health consequences. There have been some successful treatments,
such as methadone for heroin dependence, nicotine patches for nicotine
dependence, and various pharmacotherapies for alcohol dependence.
The development of treatments and medications is promising, but brings
with it a host of ethical issues which need to be addressed (see Chapter 7).
However, it is important to first understand the biology behind these new
approaches to treatment, as well as the research and animal models used to
gain insight into the effects of psychoactive substance use.
Alcohol (ethanol)
Introduction
Beverage alcohol (ethyl alcohol or ethanol) is consumed throughout the world
for recreational and religious purposes (Jacobs & Fehr, 1987). It is produced
by fermentation and distillation of agricultural products.
Ethanol is almost always taken orally, and absorbed quickly from the small
intestine into the bloodstream. Delays in gastric emptying, caused by, for
example, the presence of food, will slow its absorption. First-pass metabolism
by gastric, and consequently hepatic alcohol dehydrogenase, decreases the
bioavailability of ethanol while gender and genetic diversity may account for
individual differences in blood alcohol levels. Very small amounts of ethanol
may be excreted unchanged in urine, sweat and breath while most of it is
metabolized to acetyldehyde by alcohol dehydrogenase, catalase and
microsomal P450 enzymes largely in the liver. Subsequently, acetaldehyde is
converted to acetate by hepatic aldehyde dehydrogenase. As discussed in
Chapter 5 the effects of ethanol differ widely between individuals because of
genetic variation in these metabolic enzymes. This may contribute to the fact
that some people are more prone than others to the development of alcohol
dependence.
Behavioural effects
In humans, the acute behavioural effects of ethanol vary between individuals
according to many factors such as dose, rate of drinking, gender, body weight,
blood alcohol level and the time since the previous dose. Ethanol has biphasic
behavioural effects. At low doses, the first effects that are observed are
heightened activity and disinhibition. At higher doses, cognitive, perceptual
and motor functions become impaired. Effects on mood and emotions vary
greatly from person to person (Jacobs & Fehr, 1987).
 Ethanol is self-administered orally by animals. Rats selectively bred for
high preference for ethanol will reliably self-administer ethanol by free-choice
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drinking and will operantly respond to oral ethanol in amounts that produce
pharmacologically meaningful blood alcohol concentrations. Compared with
non-preferring rats, alcohol-preferring rats are less sensitive to the sedative/
hypnotic effects of ethanol, develop tolerance more quickly to high doses of
ethanol, and show signs of physical dependence after withdrawal (McBride
& Li, 1998). Ethanol increases the sensitivity of animals to brain stimulation
reward, (Kornetsky et al., 1988), place preference conditioning (Grahame et
al., 2001), and drug discrimination (Hodge et al., 2001).
Mechanism of action
Ethanol increases the inhibitory activity mediated by GABA-A receptors and
decreases the excitatory activity mediated by glutamate receptors, especially
the NMDA receptors. These two mechanisms of action may be related to the
general sedative effect of alcohol and impairment of memory during periods
of intoxication. GABA-A receptors are sensitive to ethanol in distinct brain
regions and are clearly involved in the acute effects of ethanol, ethanol
tolerance and dependence, and ethanol self-administration (Samson &
Chappell, 2001; McBride, 2002). GABA-A receptor activation mediates many
of the behavioural effects of ethanol including motor incoordination,
anxiolysis and sedation (Grobin et al., 1998).
The reinforcing effects produced by ethanol are probably related to
increased firing rate of ventral tegmental area (VTA) dopamine neurons
(Gessa et al., 1985), and dopamine release in the nucleus accumbens (Di
Chiara & Imperato, 1988a), probably as a secondary consequence of activation
of the GABA system or stimulation of endogenous opioids (O´Brien, 2001).
The increase in dopamine activity occurs only while blood concentration of
ethanol is rising. The increase in mesolimbic dopamine is critical to the
reinforcing effects of psychoactive substances (see Chapter 3).
Imaging studies of brain metabolism show that alcohol decreases
metabolic activity in occipital brain regions and increases metabolism in the
left temporal cortex (Wang et al., 2000; Fig. 4.1)
Tolerance and withdrawal
Ethanol induces diverse types of tolerance. Among them is behavioural
tolerance which refers to adaptive learning to overcome some of the effects
of ethanol (Vogel-Sprott & Sdao-Jarvie, 1989). Both operant and associative
learning can play a major role in the development of tolerance to alcohol
and cross-tolerance to other drugs. Most of the neural mechanisms related
to learning and memory are now known to be involved in the development
and retention of tolerance (Kalant, 1998). Metabolic tolerance also occurs,
and is a function of the upregulation of metabolic enzymes in the liver, with
the result that an increased dose or more frequent use of alcohol is required
to obtain the desired psychopharmacological effects.
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Of particular clinical importance is the development of adaptive changes
in synaptic function in response to ethanol’s action on ion channels (see
Chapter 2), which also contribute to tolerance. Ethanol tolerance and
dependence may be explained, in part, by changes in the function of GABA(A)
receptors. Cross-tolerance and sensitization (see Chapter 3) have also been
intensely researched during the past few years. Sensitization to the
neuroactive steroids – endogenous modulators of the GABA-A receptors –
influences ethanol dependence and withdrawal and may explain gender
differences in the molecular effects of ethanol (Grobin et al., 1998). Animal
models of ethanol dependence have identified GABA-A receptor genes as
likely mediators of the behavioural adaptations associated with ethanol
dependence and withdrawal (Grobin et al., 1998).
A withdrawal syndrome that may be severe enough to be fatal
characterizes ethanol withdrawal. The severity of this syndrome is a function
of the amount of ethanol consumed, frequency of use, and the duration of
drinking history. Early signs of withdrawal are severe shaking, sweating,
weakness, agitation, headache, nausea and vomiting, and rapid heart rate.
Within 24 hours after stopping drinking, seizures may start to appear (Jacobs
& Fehr, 1987). The alcohol withdrawal can be complicated by the state that
is known as delirium tremens, and is characterized by severe agitation,
autonomic hyperactivity, hallucinations and delusions. Untreated, the
Fig. 4.1 Fluorodeoxyglucose (FDG)-PET images of normal subject after
placebo (diet soda) and ethanol (0.75 g/kg)
Source: Wang et al., 2000. Reproduced with permission of the publisher.
Placebo
Ethanol (0.75 gm/kg, p.o.)
80
0
µmol/100g/min
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withdrawal syndrome lasts 5 to 7 days. Benzodiazepines are usually used
to lessen the severity of alcohol withdrawal, because of their actions on the
GABA-A receptors.
Neurobiological adaptations to prolonged use
Chronic alcohol consumption can induce alterations in most if not all brain
systems and structures. In animals and humans, specific alterations occur in
the function and morphology of the diencephalon, medial temporal lobe
structures, basal forebrain, frontal cortex and cerebellum, while other
subcortical structures, such as the caudate nucleus, seem to be relatively
unaffected (see Chapter 2). The neuropathological alterations in
mesencephalic and cortical structures are correlated with impairments in
cognitive processes. In people who are dependent on alcohol, the prefrontal
cortex seems particularly vulnerable to the effects of ethanol. Due to the role
of these cortical structures in cognitive functions and in the control of
motivated behaviour, functional alterations in this area of the brain may have
an important part to play in the onset and development of alcohol
dependence (Fadda & Rossetti, 1998). There is a loss in brain volume and
impairment of function that worsens with continued alcohol consumption,
but may be partially reversed after a period of complete abstinence. After
prolonged use of alcohol, impairment of pre-frontal cortex functions, due to
neuronal lesion, may compromise decision-making and emotion, inducing
a lack of judgement and loss of control in reducing alcohol use (Pfefferbaum
et al., 1998). These cognitive impairments need to be readdressed during
alcohol dependence treatment.
Pharmacological treatment of alcohol dependence
Acamprosate (calcium acetyl-homotaurine) is a synthetic drug with structural
similarity to a naturally occurring amino acid. Acamprosate acts centrally
and appears to restore the normal activity of glutaminergic neurons, which
become hyperexcited as a result of chronic exposure to alcohol. Acamprosate
has been available on prescription in France since 1989 and is now available
in many other countries throughout the world. Overall, patients treated with
acamprosate exhibit a significant increase in rate of completion of treatment,
time to first drink, abstinence rate and/or cumulative duration of abstinence,
than patients treated with placebo (Mason, 2001).
The opioid antagonist naltrexone is also effective in reducing relapse and
in helping people to remain abstinent and to decrease alcohol consumption
(Streeton & Whelan, 2001).
Disulfiram is known as a “deterrent” medication because it makes the
ingestion of alcohol unpleasant by altering the body’s normal metabolism of
alcohol. Disulfiram inhibits aldehyde dehydrogenase, the enzyme that
converts acetaldehyde to acetate, thus reducing the clearance of acetaldehyde
from the body. High acetaldehyde levels produce an unpleasant reaction (see
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Chapter 5) that is intended to render the consumption of alcohol aversive
(Kranzler, 2000). The efficacy of disulfiram is not clear, and is confounded by
the need to carefully titrate the dose, and by the need for a high degree of
compliance (Kranzler, 2000). Some people are thought to be naturally
protected from alcohol dependence because, due to a genetic alteration, they
lack a functional enzyme that metabolizes acetaldehyde (see Chapter 5) and,
therefore, have an aversive reaction (known as “flushing reaction”) when they
drink.
Sedatives and hypnotics
Introduction
Although alcohol falls under the category of sedatives and hypnotics, it has
been considered separately in this report since there is such a large body of
research on alcohol, and since its use is so prevalent. In this section, other
sedatives/hypnotics and minor tranquillizers will be discussed.
The most common minor tranquillizers are sleeping pills (benzodiazepines
and barbiturates) (Jacobs & Fehr, 1987). Many solvents produce similar effects
to sedatives/hypnotics when inhaled, but they will be considered separately
in the section on volatile solvents. The sedatives/hypnotics cause a slowing
of the functions of the brain and other parts of the nervous system.
Behavioural effects
The effects of sedatives/hypnotics range from mild sedation to general
anaesthesia, and, in the case of severe overdose, death. These drugs are
generally used for their intoxicating and inhibition-releasing properties.
Sleeping pills also become habit-forming, and tolerance readily develops to
these drugs (Jacobs & Fehr, 1987). The most common symptoms of sedative/
hypnotic use are drowsiness, mild to moderate motor incoordination, and
some clouding of mental functions (Jacobs & Fehr, 1987). These effects are
related to the role of the GABA-A receptor, discussed below. With higher doses,
these effects become more pronounced and lead to general impairment of
motor function, increased reaction times, and impairments in cognitive
function and memory. Eventually, sleep is induced in severe cases, and death
can occur from respiratory depression. Hangover effects of fatigue, headache
and nausea also occur.
Benzodiazepines and barbiturates show strong reinforcing properties in
animal models, and are self-administered by monkeys (Meisch, 2001; Munzar
et al., 2001; Gomez, Roach & Meisch, 2002) and rodents (Davis, Smith & Smith,
1987; Szostak, Finlay & Fibiger, 1987; Naruse & Asami, 1990). Benzodiazepines
have reward-consistent effects on brain self-stimulation (Carden & Coons,
1990), induce conditioned place preferences (Spyraki, Kazandjian & Varonos,
1985), and show discriminative stimulus effects (Wettstein & Gauthier, 1992).
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Mechanism of action
Benzodiazepines act by binding to a specific binding site on the GABA-A
receptor complex, which facilitates the effects of GABA on the opening of
the chloride channel (Haefely, 1978). Barbiturates also bind to a separate
specific site on the GABA-A receptor and directly open the chloride channel
(Nutt & Malizia, 2001). Benzodiazepines do not directly open the channel,
but they modulate the ability of GABA to do so, thus less GABA than usual
is required to open the channel (Barnard et al., 1998). The effects of
benzodiazepines on endogenous GABA function makes them safer in large
doses than the barbiturates and alcohol. The latter directly open the chloride
channel and therefore can have effects in excess of the naturally occurring
effects of GABA.
The increase in chloride conductance following opening of the chloride
channel hyperpolarizes the cell, making it less likely to fire an action potential
(see Chapter 2). Because GABA controls neuronal excitability in all brain
regions, increasing GABA function is the mechanism by which sedatives and
hypnotics have their characteristic effects of sedation, amnesia and motor
incoordination (Nutt & Malizia, 2001).
Like other dependence-producing drugs, there is also evidence that
sedatives and hypnotics affect the mesolimbic dopamine system
(Feigenbaum & Yanai, 1983), leading to their reinforcing effects and enhancing
the motivation to repeat their use.
Similarly to alcohol, the benzodiazepine lorazepam decreases metabolic
activity in the occipital cortex, increases activity in the temporal cortex, and
also decreases thalamic metabolism, as measured by positron emission
tomography (Wang et al., 2000).
Tolerance and withdrawal
Tolerance to the effects of sedatives/hypnotics develops rapidly, and increased
doses are required to maintain the same level of effect. Tolerance develops to
the pleasurable and sedative effects, as well as to the effects of benzodiazepines
and barbiturates on motor coordination. Tolerance to the anticonvulsant effects
does not appear to occur (Jacobs & Fehr, 1987). There is also a high degree of
cross-tolerance between sedatives/hypnotics, including alcohol.
Upon withdrawal of sedatives and hypnotics, certain effects are observed
which are opposite to those of the drug. Thus, increased arousal, anxiety,
restlessness, insomnia and excitability are characteristic withdrawal
symptoms (Nutt & Malizia, 2001). In severe cases, seizures can occur.
There is evidence that chronic treatment with benzodiazepines alters the
composition of GABA-A receptor subunits (Holt, Bateson & Martin, 1996),
which may also be due to changes in receptor coupling and function. This
results in tolerance in the presence of benzodiazepines, and withdrawal
symptoms when benzodiazepines are removed.
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Neurobiological adaptations to prolonged use
Dependence on sedatives and hypnotics may develop with chronic use,
regardless of how often these drugs are used, or their doses. For example,
people may feel an overwhelming urge or craving for the drug only under
specific circumstances, such as social gatherings or times of increased stress
(Jacobs & Fehr, 1987).
It is important to note that many individuals require long-term therapy with
benzodiazepines or barbiturates for epilepsy, brain injuries or other disorders.
This use may lead to tolerance to some of the effects of the drugs, and
withdrawal effects upon cessation of their use. The use of benzodiazepines or
barbiturates for medical purposes may or may not lead to dependence, even if
tolerance and withdrawal are present (see Table 4.1). Problems are more often
related to the non-medical use of benzodiazepines by polydrug users, and their
chronic use by some patients. These include impairment of memory, risk of
accidents, falls and hip fractures in the elderly, a withdrawal syndrome, brain
damage, and oversedation when combined with alcohol or other drugs (which
can lead to coma, overdose and death) (Griffiths & Weerts, 1997). Treatment of
sedative dependence involves slowly tapering off drug use, together with
behavioural therapy (see Chapter 3 for types of behavioural therapies).
Tobacco
Introduction
Although tobacco contains thousands of substances, nicotine is the one most
frequently associated with dependence because it is the component that is
psychoactive and causes observable behavioural effects, such as mood
changes, stress reduction and enhancement of performance. The behavioural
effects associated with nicotine delivered during smoking include arousal,
increased attention and concentration, enhancement of memory, reduction
of anxiety and suppression of appetite.
The average half-life of nicotine is approximately 2 hours but is about 35%
longer in persons with a particular form of a gene (i.e. an allele) for the enzyme
(CYP2A6) that inhibits the primary metabolic pathway of nicotine (Benowitz
et al., 2002). Preliminary studies suggest that the CYP2A6 allele frequency is
more common in Asians than in Africans or Caucasians, and that this
difference partially accounts for the lower daily consumption of cigarettes
and lower risk of lung cancer in Asians as compared to Africans and
Caucasians (Ahijevych, 1999; Tyndale & Sellers, 2001; Benowitz et al., 2002).
This is discussed further in Chapter 5.
Behavioural effects
Nicotine is a potent and powerful agonist of several subpopulations of
nicotinic receptors of the cholinergic nervous system (Henningfield, Keenan
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& Clarke, 1996; Vidal, 1996; Paterson & Nordberg, 2000). Acute doses can
produce alteration of mood, although daily users are substantially less
sensitive to such effects than non-users, suggesting that tolerance develops
to some of the effects (Soria et al., 1996; Taylor, 1996; Foulds et al., 1997; US
DHHS, 1988). In brief, nicotine produces dose-related psychoactive effects
in humans that are similar to those of stimulants, and it elevates scores on
standardized tests for liking and euphoria that are relied upon by WHO for
assessing dependence potential (Henningfield, Mizasato & Jasinsk, 1985; US
DHHS, 1988; Jones, Garrett & Griffiths, 1999; Royal College of Physicians,
2000).
The potential for dependence associated with smoking seems to equal or
surpass that of other psychoactive substances. In animal models, nicotine
can serve as a potent and powerful reinforcer, it induces intravenous self-
administration, facilitates intracranial self-stimulation and conditioned place
preference and has discriminative stimulus properties (Goldberg et al., 1983;
Goldberg & Henningfield, 1988; Corrigall, 1999; Di Chiara, 2000). Patterns of
self-administration are more similar to those of stimulants than of other drug
classes (Griffiths, Bigelow & Henningfield, 1980).
Mechanism of action
At the cellular level, nicotine binds to nicotinic acetylcholine receptors
(nAChRs). There are a variety of subtypes of neuronal nAChRs. Cloning
techniques have revealed several different neuronal nAChR subunits in
mammals (Lukas et al., 1999). The receptors are composed of five subunits
around an ion channel. Agonist (e.g. nicotine) binding causes the resting
conformation of the subunits to change to the open conformation and allows
sodium ion inflow, which causes cell depolarization (Miyazawa et al., 1999;
Corringer, Le Novere & Changeux, 2000).
In the brain, nicotinic receptors are situated mainly in presynaptic
terminals and modulate neurotransmitter release; therefore, nicotine effects
may be related to various neurotransmitter systems (reviewed in Dani & De
Biasi, 2001; Kenny & Markou, 2001; Malin, 2001). Nicotine is known to
promote dopamine synthesis by increasing tyrosine hydroxylase expression
and release through activation of somatodendritic nAChRs in both
nigrostriatal and mesolimbic dopamine pathways (Clarke & Pert , 1985;
Panagis et al., 2000).
Nicotine increases dopamine output in the nucleus accumbens, and
blocking dopamine release reduces nicotine self-administration in rats
(Schilstrom et al., 1998; Dani & De Biasi, 2001). Nicotine stimulates dopamine
transmission in specific brain areas and in particular, in the shell of the
nucleus accumbens and in areas of the extended amygdala, which have been
related to drug dependence for most drugs (see Chapter 3). Therefore,
nicotine depends on dopamine for the behavioural effects that are most
relevant for its reinforcing properties; this is likely to be the basis of the
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dependence-producing ability of tobacco. However, other neuronal systems
related to substance dependence, such as opioid, glutamate, serotonin and
glucocorticoid systems may also be modulated by nicotine (Dani & De Biasi,
2001; Kenny & Markou, 2001; Malin, 2001) and may be of importance to
specific aspects of substance dependence.
Tolerance and withdrawal
Exposure to nicotine results in a high degree of tolerance, which appears to
be mediated by several mechanisms, and which includes acute and long-
term components (Swedberg, Henningfield & Goldberg, 1990; Perkins et al.,
1993). Tolerance to some effects may be related to the upregulation of nicotine
receptors in the central nervous system, but genetic factors also modulate
the effects of nicotine including the development of tolerance (Collins
& Marks, 1989). This may account for some individual differences in nicotine
dependence (see Chapter 5).
Tolerance rapidly develops to the subjective effects of nicotine during the
course of the day. Smokers generally consider that the first cigarette in the
morning is more rewarding, which may be due to tolerance or to the relief
from the withdrawal that develops overnight. Receptor desensitization (loss
of sensitivity) may explain some of the behavioural effects of nicotine, acute
and/or chronic tolerance, and relapse (Rosecrans & Karan, 1993).
Withdrawal from smoking may be accompanied by symptoms such as
irritability, hostility, anxiety, dysphoric and depressed mood, decreased
heart rate and increased appetite. The urge to smoke correlates with low
blood nicotine levels (Russell, 1987), suggesting that smoking occurs to
maintain a certain concentration of nicotine in the blood in order to avoid
withdrawal symptoms. Thus, the continuity of tobacco use would be
explained by both the positive and negative reinforcement of nicotine.
Termination of prolonged nicotine administration to animals induces
behaviours that suggest depression and increased anxiety, changes in
trained behaviours, as well as weight gain. Reduction of locomotion, and
decreased dopamine content and release in limbic structures, nucleus
accumbens and striatum during nicotine withdrawal have been described
in animal models, and may be correlated with behavioural changes due
to nicotine withdrawal (Malin, 2001). Therefore, animal models for
nicotine withdrawal have some external validity and are used in preclinical
studies, mainly to describe possible future treatments for nicotine
dependence.
The signs and symptoms of tobacco withdrawal, including effects on
electrical activity of the brain, cognitive performance, anxiety, and response
to stressful stimuli, can be largely mitigated by administration of pure nicotine
in a variety of forms (e.g. gum, patch, nasal delivery) (Hughes, Higgins &
Hatsukami, 1990; Heishman, Taylor & Henningfield, 1994; Pickworth,
Heishman & Henningfield, 1995; Shiffman, Mason & Henningfield, 1998).
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Humans report similar subjective effects from intravenous nicotine as from
smoked tobacco (Henningfield, Miyasato & Jasinski, 1985; Jones, Garrett
& Griffiths, 1999). Craving for tobacco is generally only partially relieved by
the administration of pure forms of nicotine, since it can be elicited by factors
that are not mediated by nicotine (e.g. the smell of smoke, the sight of other
people smoking, and tobacco advertisements), through the process of
conditioning and it can be reduced by constituents in tobacco smoke other
than nicotine, such as “tar” (Butschky et al., 1995). These additional factors
may have synergistic effects with nicotine in cigarettes to provide more
effective relief from craving than nicotine delivered in cigarette smoke (Rose,
Behm & Levin, 1993).
Pharmacological treatment of nicotine dependence
An improved understanding of dependence, and the identification and
acceptance of nicotine as a dependence-producing drug, have been
fundamental to the development of medications and behavioural
treatments for nicotine dependence. There are currently many readily
available treatments to help people reduce their smoking. Estimates are
that over one million people have been successfully treated for nicotine
dependence since the introduction of nicotine gum and the transdermal
patch. All nicotine-replacement therapies are equally effective in helping
people to quit smoking, and, combined with increased public service
announcements in the media about the dangers of smoking, have produced
a marked increase in successful quitting. However, treating dependence
with medication alone is far less effective than when the medication is
coupled with a behavioural treatment. In this case nicotine can prevent the
physical withdrawal effects, while the individual attempts to deal with the
craving and drug-seeking behaviour that have become habitual (see
Chapter 3, section on behavioural therapies). The use of nicotine-based
therapy is not intended for long-term use, but rather only at the beginning
of treatment.
Although the major focus of pharmacological treatments of nicotine
dependence has been nicotine-based, other treatments are being developed
for the relief of symptoms of nicotine withdrawal. For example, the first non-
nicotine prescription drug, the antidepressant bupropion, is currently used
as a pharmacological treatment for nicotine dependence (Sutherland, 2002).
Bupropion improves the abstinence rates of smokers, especially if combined
with nicotine replacement therapy (O´Brien, 2001). Because depression is
frequently associated with nicotine dependence – either by predisposing the
individual to use tobacco, or on account of its development during nicotine
dependence, or as a consequence of nicotine withdrawal – antidepressant
agents have been tested for the treatment of nicotine dependence. This
concept is explored more fully in Chapter 6 where comorbidity of substance
use and mental illness are discussed.
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Opioids
Introduction
Opiate drugs are compounds that are extracted from the poppy seed. These
drugs opened the way to the discovery of the endogenous opioid system in
the brain (Brownstein, 1993). The term “opioids” includes “opiates” as well
as semisynthetic and synthetic compounds with similar properties. Evidence
for the existence of opioid receptors was based on the observation that opiates
(e.g. heroin and morphine) interact with specific binding sites in the brain.
In 1976, the first evidence for the existence of multiple opioid receptors was
reported (Martin et al., 1976) and pharmacological studies led to the
classification of opioid binding sites into three receptor classes referred to as
mu, delta and kappa receptors. Later, studies revealed that several subtypes
of each receptor class exists (Pasternak, 1993).
The existence of opioid receptors suggested that these receptor sites might
be the targets for opiate-like molecules that exist naturally in the brain. In
1975, two peptides that act at opiate receptors were discovered, Leu-
enkephalin and Met-enkephalin (Hughes et al., 1975). Shortly after, other
endogenous peptides were identified and more than 20 distinct opiate
peptides are known today (Akil et al., 1997).
Behavioural effects
Intravenous injection of opioids produces a warm flushing of the skin and
sensations described by users as a “rush”; however, the first experience with
opiates can also be unpleasant, and can involve nausea and vomiting (Jaffe,
1990). Opioids have euphorogenic, analgesic, sedative, and respiratory
depressant effects.
Numerous animal experiments using selective opioid compounds have
shown that agonists of the mu receptor subtype, injected either peripherally
or directly into the brain, have reinforcing properties. Delta agonists, as
well as endogenous enkephalins, seem to produce reward, although to a
lesser extent than mu agonists. Reinforcement by mu and delta agonists
has been shown in several behavioural models, including drug self-
administration, intracranial self-stimulation and conditioned place
preference paradigms, and has been reviewed extensively (Van Ree, Gerrits
& Vanderschuren, 1999). Pharmacological studies, therefore, have proposed
that activation of both mu and delta receptors is reinforcing. It is also
significant that the genetic inactivation of mu receptors abolished both the
dependence-producing and analgesic effects of morphine, as well as actions
of other clinically used opioid drugs. This demonstrated that mu receptors
are critical for all the beneficial as well as detrimental effects of clinically
relevant opiate drugs (Kieffer, 1999). Molecular studies, therefore, have
highlighted mu receptors as the gate for opioid analgesia, tolerance and
dependence.
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Kappa receptors, however, appear to have an opposing effect on reward.
The hypothesis of a mu/kappa control of mesolimbic dopaminergic neurons
is best documented. It is important to note the observation that heroin is
also self-administered in animals in the absence of these neurons, suggesting
the existence of dopamine-independent mechanisms in opioid reinforce-
ment (Leshner & Koob, 1999).
Mechanism of action
The three opioid receptors (mu, delta and kappa receptors) mediate activities
of both exogenous opioids (drugs) and endogenous opioid peptides, and
therefore represent the key players in the understanding of opioid-controlled
behaviours. Opioid receptors belong to the superfamily of G protein-coupled
receptors. Agonist binding to these receptors ultimately causes inhibition of
neuronal activity.
Opioid receptors and peptides are strongly expressed in the central nervous
system (Mansour et al., 1995; Mansour & Watson, 1993). In addition to its
involvement in pain pathways, the opioid system is largely represented in brain
areas involved in responses to psychoactive substances, such as the VTA and
nucleus accumbens shell (Akil et al., 1997). Opioid peptides are involved in a
wide variety of functions regulating stress responses, feeding, mood, learning,
memory, and immune functions (for review, see Vaccarino & Kastin, 2001).
Tolerance and withdrawal
With repeated administration of opioid drugs, adaptive mechanisms change
the functioning of opioid-sensitive neurons and neural networks. Tolerance
develops, and higher doses of the drugs are required to gain the desired effect.
Humans and experimental animals develop profound tolerance to opioids
over periods of several weeks of escalating chronic administration. Tolerance
involves distinct cellular and neural processes. Acute desensitization or
tolerance of the opioid receptor develops in minutes during opioid use and
abates in minutes to hours after exposure. There is also a long-term
desensitization of the receptor that slowly develops and persists for hours to
days after removal of opioid agonists. There are also counteradaptations to
opioid effects of intracellular signalling mechanisms and in neuronal circuitry
that contribute to tolerance. These processes have been recently reviewed
(Williams, Christie & Manzoni, 2001).
Cessation of chronic opioid use is associated with an intensely dysphoric
withdrawal syndrome, which may be a negative drive to reinstate substance
use. The withdrawal is characterized by watering eyes, runny nose, yawning,
sweating, restlessness, irritability, tremor, nausea, vomiting, diarrhoea,
increased blood pressure and heart rate, chills, cramps and muscle aches,
which can last 7–10 days (Jaffe, 1990). This was once thought to be sufficient
to explain the persistence of opioid dependence (Collier, 1980). There is no
Chapter_4 19.1.2004, 11:4280
81
4. PSYCHOPHARMACOLOGY OF DEPENDENCE FOR DIFFERENT DRUG CLASSES
doubt that the intensely dysphoric withdrawal syndrome plays an important
role in maintaining episodes of opioid use, but opioid dependence, and
relapse that occurs long after withdrawal cannot be explained solely on this
basis (Koob & Bloom, 1988). Currently, long-term adaptations in neural
systems are also thought to play an important role in dependence and relapse.
In conclusion, the data show complex and broad changes of the
endogenous opioid system following repeated stimulation of mu receptors
by opioids. The precise consequences of those changes remain unclear, but
it is likely that the long-term dysregulation of the opioid system influences
stress responses and drug-taking behaviour.
Neurobiological adaptations to prolonged use
Adaptations following chronic drug exposure extend well beyond reward
circuits to other brain areas, notably those involved in learning and stress
responses. Important regions are the amygdala, hippocampus and cerebral
cortex, which are all connected to the nucleus accumbens. All these areas
express opioid receptors and peptides, and the overall distribution of opioid
peptide-expressing cells in neural circuits of dependence has been reviewed
(Nestler, 2001; Koob & Nestler, 1997).
Repeated exposure to opioids induces drastic and perhaps irreversible
modifications in the brain. Hallmarks of adaptations to chronic opioid use
are tolerance, defined as a reduced sensitivity to the drug effects and generally
referring to attenuation of analgesic efficacy. Drug craving and the
physiological manifestations of drug withdrawal are also indications of long-
term neuroadaptations. These phenomena are a consequence of sustained
mu receptor stimulation by opiate drugs inducing neurochemical adaptations
in opioid receptor-bearing neurons (Kieffer & Evans, 2002).
Pharmacological treatment of opioid dependence
Treatment of heroin dependence has been quite successful because of
substitution therapy and methadone maintenance treatment in particular
(see Box 4.1). Methadone is a synthetic opioid agonist that acts on the same
receptors as opiate drugs, and therefore blocks the effects of heroin,
eliminates withdrawal symptoms, and reduces craving. When properly used,
methadone is non-sedating, non-intoxicating and does not interfere with
regular activities. The medication is taken orally, and it suppresses opioid
withdrawal for 24 hours. There is no cognitive blunting. Its most important
feature is to relieve the craving associated with heroin dependence, thereby
reducing relapse. Methadone maintenance treatment is safe, and very
effective in helping people to stop taking heroin, especially when combined
with behavioural therapies or counselling and other supportive services.
Methadone maintenance treatment can also reduce the risk of contracting
and transmitting HIV, tuberculosis and hepatitis (Krambeer et al., 2001).
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A newer drug, Levo-alpha-acetyl-methadol (LAAM) resembles methadone:
it is a synthetic opioid that can be used to treat heroin dependence, but it
needs only to be taken three times per week, thus making it even easier for
people to use this therapy.
Buprenorphine is another prescribed drug for management of opioid
dependence that has the potential of improving access to drug treatment by
bringing more people into treatment in primary health care settings (see
Box 4.2). It has been widely used in France and is now being trialed in the USA.
BOX 4.1
Substitution therapy
Substitution therapy is defined as the administration under medical supervision of
a prescribed psychoactive substance – pharmacologically related to the one
producing dependence – to people with substance dependence, for achieving
defined treatment aims (usually improved health and well-being). Substitution therapy
is widely used in the management of opioid dependence and is often referred to as
“opioid substitution treatment,” “opioid replacement therapy”, or “opioid
pharmacotherapy”. Agents suitable for substitution therapy of opioid dependence
are those with some opioid properties, so that they have the capacity to prevent
the emergence of withdrawal symptoms and reduce craving. At the same time
they diminish the effects of heroin or other opioid drugs because they bind to
opioid receptors in the brain. In general, it is desirable for opioid substitution drugs
to have a longer duration of action than the drug they are replacing so as to delay
the emergence of withdrawal and reduce the frequency of administration. As a
result there is less disruption of normal life activities from the need to obtain and
administer drugs, thereby facilitating rehabilitation efforts. Whereas non-prescribed
opioids are usually injected or inhaled by drug users, these prescribed medicines
are usually administered orally in the form of a solution or a tablet. Agents used in
substitution therapy can also be prescribed in decreasing doses over short periods
of time (usually less than one month) for detoxification purposes. Substitution
maintenance treatment is associated with prescription of relatively stable doses of
opioid agonists (e.g. methadone and buprenorphine) over a long period of time
(usually more than 6 months). The mechanisms of action of opioid substitution
maintenance therapy include prevention of disruption of molecular, cellular and
physiological events and, in fact, normalization of those functions already disrupted
by chronic use of usually short-acting opiates such as heroin. The context of delivery
of substitution therapy has important implications for the quality of the interventions,
both to maintain adequate control and to ensure responsible prescribing.
Since 1970, methadone maintenance treatment has grown substantially to
become the dominant form of opioid substitution treatment globally. Because
the treatment was initially controversial, it has been more rigorously evaluated
than any other treatment for opioid dependence. The weight of evidence for
benefits is substantial.
Source: WHO, 1998; Kreek, 2000.
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Heroin-assisted treatment of heroin dependence (see Box 4.3) has also
been proposed.
Naloxone and naltrexone are medications that also block the effects of
morphine, heroin and other opiates by acting as antagonists at the opioid
receptors. They are especially useful in preventing relapse because they block
BOX 4.2
Use of buprenorphine in treatment of opioid dependence
Whilst much of the work on substitution therapy has focused on methadone,
several new synthetic oral opioids such as LAAM (L-alpha-acetyl-methadol), slow-
release morphine and buprenorphine have been investigated as potential
therapeutic agents in the treatment of opioid dependence. Buprenorphine in
particular has been undergoing extensive clinical testing for treatment of opioid
dependence and is likely to become the medication used in the management of
opioid dependence not only in specialized clinics, but also in primary health care.
Its pharmacological properties and resultant clinical characteristics – especially
its relatively long duration of action and high safety profile – appear certain to
ensure buprenorphine an important place in the overall treatment of opioid
dependence.
Pharmacologically, buprenorphine is a partial agonist at the mu receptor and a
weak antagonist at the kappa receptor. Because it binds tightly to, and dissociates
slowly from these receptors, buprenorphine exhibits an agonist ‘ceiling effect’,
most noticeably in its respiratory depression effect, which accords the medication
a high degree of clinical safety. Its tight binding with slow dissociation from
receptors also provides a blockade for the effects of subsequently-administered
agonists, precipitates withdrawal in patients maintained on a sufficient dose of
full agonist, and provides prolonged duration of action with poor reversibility by
naloxone. Furthermore, buprenorphine’s weak antagonist effect at the kappa
receptor renders it devoid of psychotomimetic effects. Further research has
demonstrated buprenorphine’s limited levels of reinforcing efficacy in comparison
to opioids, and established its ability to suppress heroin self-administration in
opioid-dependent primates and humans.
The formulation containing both buprenorphine and the opioid antagonist naloxone
has been recently introduced for maintenance therapy of opioid dependence.
Adding naloxone to buprenorphine aims at reducing a risk of diversion and injecting
use of prescribed buprenorphine. Over the past decade a series of controlled
clinical trials, using such outcome measures as illicit opiate use, retention in
treatment, craving and global rating of improvement, have substantiated
buprenorphine’s clinical safety and efficacy. When used in opioid substitution
treatment for dependent pregnant women, it appears to be associated with a low
incidence of neonatal withdrawal syndrome. Due to the above features,
buprenorphine is a useful drug in the facilitation of withdrawal from opioids.
Sources: Barnett, Rodgers & Bloch, 2001; Fischer et al., 2000; Ling et al., 1998.
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BOX 4.3
Heroin-assisted treatment of heroin dependence
Heroin prescription for treatment of opioid dependence, practised on a limited
scale in the United Kingdom for many years, gained increased international interest
in the early 1990s, with feasibility studies in Australia and a first national study of
heroin-assisted treatment in Switzerland that started in 1994. This study led to
the establishment of heroin-assisted treatment as one of the treatment options in
Switzerland. The findings of the study showed that there were significant reductions
in illicit drug use, improvement in health status and social integration (Uchtenhagen
et al., 1999). Follow-up results at 18 months documented stability of improvements
also after discharge from the programme (Rehm, 2001).
A review by a WHO expert group supported the main conclusions of the Swiss
study, but also recommended further research in order to better identify the
specific benefits of prescribed heroin (Ali et al., 1999). These recommendations
have been respected in randomised controlled trials: one implemented in 1998-
2001 in the Netherlands (van den Brink et al., 2002), one started in 2002 in
Germany (Krausz, 2002). Other similar research projects are in preparation
(Fischer et al., 2002). The shared objective of the trials is to test an additional
therapeutic option for those heroin addicts for whom other treatments have failed
and who are out of contact with the treatment system. An international network
of scientists, engaged in the projects mentioned above, has emerged and
organised three conferences for an exchange of methodological, therapeutic
and practical problems and experience. The international debate on heroin-assisted
treatment of opioid dependence, initially mainly political and controversial, tends
to become more scientific and evidence-oriented (Bammer et al., 1999).
Sources: Ali et al., 1999; Bammer et al., 1999; Uctenhagen et al., 1999; Rehm et al.,
2001; van den Brink et al., 2002; Krausz, 2002; Fischer et al. (2002).
all of the effects of opiates. The effects are relatively long-lasting, ranging from
1–3 days. This therapy begins after medically supervised detoxification,
because naloxone and naltrexone do not protect against the effects of
withdrawal, and can in fact precipitate withdrawal symptoms in dependent
people. Naltrexone itself has no subjective effects or potential for the
development of dependence. Patient noncompliance is a common problem.
Therefore, a favourable treatment outcome requires that there also be a
positive therapeutic relationship, effective counselling or therapy, and careful
monitoring of medication compliance.
Cannabinoids
Introduction
Among all the cannabinoids contained in Cannabis sativa, delta-9-
tetrahydrocannabinol (THC) is the major chemical with psychoactive effects
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and is metabolized to another active compound, 11-OH-delta-9-THC.
Cannabinoids are generally inhaled by smoking, but may also be ingested.
Peak intoxication through smoking is reached within 15–30 minutes and the
effects last for 2–6 hours. Cannabinoids remain in the body for long periods
and accumulate after repeated use. Cannabinoids may be found in the urine
for 2–3 days after smoking a single cigarette and for up to 6 weeks after the
last use in heavy users.
Several studies (e.g. Tramer et al. 2001) have demonstrated therapeutic
effects of cannabinoids, e.g. in controlling nausea and vomiting in some cancer
and AIDS patients. This has led to controversial discussion regarding the
potential beneficial effects of cannabis itself in certain conditions (see Box 4.4).
Behavioural effects
The perception of time is slowed and there are feelings of relaxation and of
sharpened sensory awareness. The perception of increased self-confidence
and heightened creativity is not accompanied by better performance and
there is impairment of short-term memory and of motor coordination.
Analgesia, antiemetic and antiepileptic action, and increased appetite are
BOX 4.4
Therapeutic potential for cannabis
Therapeutic uses of D-9-tetrahydrocannabinol (THC) have led to discussions about
the therapeutic potential of cannabis itself, although little research exists in this
area and satisfactory clinical studies have not been conducted. In order to explore
possible therapeutic uses of cannabis, several scientific issues need to be
considered, including:
— the standardization of cannabis preparations required for some types of clinical
and preclinical studies
— the difficulties inherent in the study of smoking as the mode of administration
of a substance
— the need for a comparable placebo “cigarette” which would not be easily
identified by experimental subjects and patients in controlled trials.
— the large number of patients which would be needed to study the comparative
efficacy of smoking cannabis compared with other cannabinoids and other
therapeutic agents.
— the possibility of using alternative delivery systems which could avoid smoking
cannabis as well as the other components contained in its smokable form.In
addition, the broader implications of such research on cannabis control policies
would need to be carefully considered.
Source: WHO, 1997a.
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central effects sometimes described to be of clinical relevance (O´Brien,
2001).
Cannabis derivatives produce clear subjective motivational responses in
humans, leading to drug-seeking behaviour and repeated drug use. Indeed,
cannabis derivatives are the most widely used illicit drugs in the world (Adams
& Martin, 1996).
Animal studies have demonstrated that cannabinoids fulfil most of the
common features attributed to substances with reinforcing properties
(reviewed in Maldonado & Rodriguez de Fonseca, 2002). Thus, subjective
effects have been demonstrated in animals by using a large range of doses of
cannabinoids in the drug discrimination paradigm. The rewarding
characteristics of these subjective effects have also been defined in animals
by using the conditioned place preference and the intracranial self-
stimulation paradigm. Animal studies have also revealed that cannabinoids
interact with brain reward circuits and share with other psychoactive
substances some biochemical features (e.g. changes in dopamine and opioid
activity) that have been directly related to their reinforcing properties (Koob,
1992). These biochemical findings clearly support the dependence-producing
ability of cannabinoids that has been reported in humans.
Mechanism of action
Cannabinoid receptors and their endogenous ligands together constitute
what is now referred to as the ‘endocannabinoid system’. Plant-derived
cannabinoids or their synthetic analogues are classical cannabinoid receptor
agonists (reviewed in Pertwee, 1999; Reggio & Traore, 2000; Khanolkar, Palmer
& Makriyannis, 2000).
Cannabinoid compounds induce their pharmacological effects by
activating two different receptors that have been identified and cloned: the
CB-1 cannabinoid receptor, which is highly expressed in the central nervous
system (Devane et al., 1988; Matsuda et al., 1990), and the CB-2 cannabinoid
receptor, which is localized in the peripheral tissues mainly at the level of
the immune system (Munro, Thomas & Abu-Shaar, 1993). THC and its
analogues show good correlation between their affinity for these receptors
and their effects, denoting that these receptors are the targets for these
compounds. After the identification of the first cannabinoid receptor, the
search for an endogenous ligand for this receptor was started. The discovery
of the first endogenous cannabinoid (endocannabinoid) ligand took place
in 1992 when the anandamide, arachidonoyl ethanolamide, was isolated
from pig brain (Devane et al., 1992). A second type of endocannabinoid
was discovered in 1995, also a derivative of arachidonic acid (Mechoulam
et al., 1995; Sugiura et al., 1995). Recently, a third endocannabinoid ligand
has been identified (Hanus et al., 2001). The identification of these
endocannabinoid compounds and the development of potent and selective
synthetic cannabinoid agonists, as well as selective cannabinoid antagonists
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has played a major role in the recent advances in cannabinoid pharma-
cology.
The endogenous ligands undergo depolarization-induced synthesis and
release from neurons and are removed from the extracellular space by a
carrier-mediated uptake process that is present in the membranes of neurons
and astrocytes (Di Marzo et al., 1998; Maccarrone et al., 1998; Di Marzo, 1999;
Piomelli et al., 1999; Hillard & Jarrahian, 2000). This is taken as evidence that
these endogenous cannabinoids behave as transmitters in the brain.
Although cannabis is widely used, the mechanisms of its euphoriant and
dependence-producing effects are largely unknown. There is a compelling
body of evidence that delta-9-THC increases dopamine activity in the
mesolimbic pathway projecting from the VTA to the nucleus accumbens, a
key region in the development of dependence (see Chapter 3). In vivo studies
have shown that delta-9-THC increases extracellular concentrations of
dopamine in the nucleus accumbens (Chen et al., 1990). More recently, it
has been shown by brain microdialysis that delta-9-THC increases
extracellular dopamine concentration preferentially in the shell of the nucleus
accumbens, similar to the action of many psychoactive substances (Tanda,
Pontieri & Di Chiara, 1997). Systemic administration of delta 9-THC or
synthetic cannabinoids also increases spontaneous firing of dopamine
neurons within the VTA (French, 1997; Gessa et al., 1998).
The brain distribution of CB1 binding sites correlates with the effects of
cannabinoids on memory, perception, motor control and anticonvulsant
effects (Ameri, 1999). CB1 receptor agonists impair cognition and memory
and alter motor function control. Thus, the cerebral cortex, hippocampus,
lateral caudate-putamen, substantia nigra, pars reticulata, globus pallidus,
entopeduncular nucleus and the molecular layer of the cerebellum are all
populated with particularly high concentrations of CB1 receptors (Pertwee,
1997). Intermediate levels of binding are found in the nucleus accumbens.
CB1 receptors are also found on pain pathways in the brain and spinal cord
and at the peripheral terminals of primary sensory neurons (Pertwee, 2001)
thus explaining the analgesic properties of cannabinoid receptor agonists.
CB1 receptors are expressed on neurons of the heart, vas deferens, urinary
bladder and small intestine (Pertwee, 1997).
The CB1 receptors located at nerve terminals (Pertwee, 1997; Ong & Mackie,
1999; Pertwee, 2001) suppress the neuronal release of transmitters that include
acetylcholine, noradrenaline, dopamine, 5-hydroxy-tryptamine, GABA,
glutamate and aspartate (Pertwee, 2001). CB2 receptors found in immune
cells, with particularly high levels in B-cells and natural killer cells (Galiegue
et al., 1995), are immunomodulatory (Molina-Holgado, Lledo & Guaza, 1997).
Tolerance and withdrawal
Tolerance rapidly develops to most effects of cannabis, cannabinoids, and
related drugs acting at the CB1 cannabinoid receptor. The development of
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tolerance to antinociception, and to anticonvulsant and locomotor effects
follow different time spans and occur to differing extents.
There is little evidence of withdrawal associated with cannabinoid use.
In fact, withdrawal reactions after prolonged use of cannabinoids are rarely
reported, probably because of the long half-life of cannabinoids, which
prevents the emergence of withdrawal symptoms. Increased release of
corticotrophin-releasing factor is a biochemical marker of stress that is
increased during cannabinoid withdrawal (Rodriguez de Fonseca et al.,
1997).
Neurobiological adaptations to prolonged use
Cannabis is sometimes regarded as an “innocuous” drug and the prevalence
of lifetime and regular use has increased. However, people with schizophrenia
who use cannabis are vulnerable to relapse and exacerbation of existing
symptoms, while users report short-lived adverse effects, and regular use is
related to the risk of dependence (Johns, 2001). Evidence linking cannabis to
irreversible brain lesions and the induction of toxic encephalopathy in
children is inconclusive.
It has been shown in several studies (as reviewed in Ameri, 1999) that
long-term exposure to cannabis can produce long-lasting cognitive
impairment, which may be due to residue drug in the brain, withdrawal
reaction or direct neurotoxicity of cannabinoids, tar, carboxyhaemoglobin
or benzopyrene. There is some evidence of impaired ability to focus
attention and filter out irrelevant information, which increases with the
number of years of use but is unrelated to frequency of use. The speed of
information processing is delayed significantly with increasing frequency
of use but is unaffected by duration of use. The results suggest that a chronic
build-up of cannabinoids produces both short-term and long-term
cognitive impairments (Solowij, Michie & Fox, 1995). In general, the data
support a drug residue effect on attention, psychomotor tasks, and short-
term memory during the 12–24 hour period immediately after cannabis use,
but evidence is as yet insufficient to support or refute either a more
prolonged drug residue effect, or a toxic effect on the central nervous system
that persists even after drug residues have left the body (Pope, Gruber
& Yurgelun-Todd, 1995).
A review of the preclinical literature suggests that both age during
exposure and duration of exposure may be critical determinants of
neurotoxicity. Cannabinoid administration for at least 3 months (8–10% of
a rat’s lifespan) was required to produce neurotoxic effects in peripubertal
rodents, which would be comparable to about 3 years of exposure in rhesus
monkeys and 7–10 years in humans. Studies of monkeys after having been
exposed daily for up to 12 months have not consistently reported
neurotoxicity, and the results of longer exposures have not yet been
published (Scallet, 1991).
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Cocaine (hydrochloride and crack)
Introduction
Cocaine is a powerful nervous system stimulant that can be taken
intranasally, injected intravenously or smoked. The use of cocaine by many
different cultures dates back for centuries. Cocaine is found in the leaves of
Erythroxylon coca, trees that are indigenous to Bolivia and Peru.
Behavioural effects
Cocaine increases alertness, feelings of well-being and euphoria, energy
and motor activity, feelings of competence and sexuality. Anxiety, paranoia
and restlessness are also frequent. Athletic performance may be enhanced
in sports where sustained attention and endurance is required. With
excessive dosage, tremors, convulsions and increased body temperature are
detected. Activation of the sympathetic nervous system occurs
concomitantly with the behavioural effects. Tachycardia, hypertension,
myocardial infarct and cerebrovascular haemorrhages may occur during
cocaine overdose. As the effects of the drugs subside, the user feels
dysphoric, tired, irritable and mildly depressed, which may lead to
subsequent drug use to regain the previous experience (O´Brien, 2001).
There have been numerous papers reporting that cocaine can be self-
administered by animals via the intravenous and oral routes (Caine & Koob
1994; Barros & Miczek, 1996; Rocha et al., 1998; Platt, Rowlett & Spealman,
2001). Cocaine’s augmentative effect on intracranial self-stimulation requires
activation of both D
1
 and D
2
 dopamine receptors (Kita et al., 1999).
Conditioned place preference can be induced in rodents by administration
of cocaine (Itzhak & Martin, 2002).
Mechanism of action
In the brain, cocaine acts as a monoamine transporter blocker, with similar
affinities for dopamine, serotonin, and norepinephrine transporters (Ritz,
Cone & Kuhar, 1990). Cocaine, and the dopamine transporter to which it
binds, can be visualized in the human brain using positron emission
tomography (PET) imaging (Fig. 4.2). The antagonism of the transporter
proteins leaves more monoaminergic neurotransmitters available in the
synaptic cleft to act upon presynaptic and postsynaptic receptors. It is widely
accepted that the ability of cocaine to act as a reinforcer is due largely to its
ability to block dopamine reuptake (Wise & Bozarth 1987; Woolverton &
Johnson 1992; Sora et al., 2001). The reinforcing effects of psychostimulants
are associated with increases in brain dopamine and D
2
 receptor occupancy
in humans as noted in PET studies (Volkow et al., 1999). However, both D
1
and D
2
 receptors have been implicated in the reinforcing effects of cocaine.
It has been demonstrated in animal studies that D
1
 and D
2
-like receptor
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antagonists attenuate cocaine self-administration (Caine & Koob 1994) while
D
1
 and D
2
-like receptor agonists maintain cocaine self-administration (as
reviewed in Platt, Rowlett & Spealman, 2001). Using PET to investigate the
role of dopamine in the reinforcing effects of cocaine in humans it has been
shown that the rate at which cocaine enters the brain and blocks the
dopamine transporter is associated with the “high”, and not merely with the
presence of the drug in the brain (Volkow et al., 1999).
Despite the evidence pointing to a dopaminergic mechanism for cocaine
reward, dopamine may not be the sole mediator of the reinforcing properties
of cocaine, since dopamine transporter knock-out mice – mice that have had
the dopamine transporter gene silenced so that the transporter is not
expressed, (see Chapter 5) – continue to self-administer cocaine (Rocha et
al., 1998). The serotonergic system may influence the reinforcing properties
of cocaine, because cocaine also facilitates serotonin transmission in the
nucleus accumbens (Andrews & Lucki, 2001).
Fig. 4.2 Images of [(11)C] cocaine distribution in human brain at different
time points after injection
Source: Fowler et al., 2001. Reproduced with permission of the publisher.
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Tolerance and withdrawal
In general, there appears to be little tolerance to the effects of cocaine,
although there may be acute tolerance within a single session of repeated
substance use (Brown, 1989).
Cocaine withdrawal does not result in the severe symptoms that
characterize opioid withdrawal, but it does induce a “post-high down” (Brown,
1989), which can contribute to further cocaine use or use of another drug.
During protracted withdrawal, the orbitofrontal cortex of people with cocaine
dependence is hypoactive in proportion to the levels of dopamine D
2
receptors in the striatum. It is now proposed that the dependent state involves
disruption of orbitofrontal cortex circuits related to compulsive repetitive
behaviours (Volkow & Fowler, 2000).
Neurobiological adaptations to prolonged use
Cognitive deficits associated with chronic use of cocaine have been noted,
and such deficits reflect changes to the underlying cortical, subcortical and
neuromodulatory mechanisms that underpin cognition – and also interfere
directly with rehabilitative programmes (Rogers & Robbins, 2001). Individuals
who are dependent on cocaine have specific defects of executive functions,
e.g. decision-making and judgement, and this behaviour is associated with
dysfunction of specific prefrontal brain regions. PET studies suggest that
stimulation of the dopaminergic system secondary to chronic use of cocaine
activates a circuit that involves the orbitofrontal cortex, cingulate gyrus,
thalamus and striatum. This circuit is abnormal in people with cocaine
dependence and it is hypothesized that this abnormality contributes to the
intense desire to use cocaine, resulting in the loss of control over the drive to
take more cocaine (Volkow et al., 1996).
There appears to be strong evidence supporting the existence of a
neurological syndrome following long-term use of cocaine. People with
cocaine dependence exhibit impaired performance in tests of motor system
functioning and have slower reaction times than non-dependent individuals.
Evidence for EEG abnormalities among people recovering from cocaine
dependence have also been found (Bauer, 1996).
Clinical and preclinical studies provide convincing evidence for persistent
neurological and psychiatric impairments and possible neuronal
degeneration associated with chronic use of cocaine or other stimulants.
These impairments include multifocal and global cerebral ischaemia, cerebral
haemorrhages, infarctions, optic neuropathy, cerebral atrophy, cognitive
impairments, and mood and movement disorders. These may include a broad
spectrum of deficits in cognition, motivation and insight, behavioural
disinhibition, attention deficits, emotional instability, impulsiveness,
aggressiveness, depression, anhedonia, and persistent movement disorders.
The neuropsychiatric impairments accompanying stimulant use may
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contribute to the very high rate of relapse in individuals that can take place
after years of abstinence.
Pharmacological treatment of cocaine dependence
Various approaches are being examined in the treatment of cocaine
dependence. Because cocaine has potent effects on the dopamine
transporter, medications that bind to the dopamine transporter have been
tested. GBR 12909 is a selective and potent inhibitor of dopamine uptake
that antagonizes the effects of cocaine on mesolimbic dopamine neurons in
rats (Baumann et al., 1994), and blocks self-administration of cocaine
in rhesus monkeys (Rothman & Glowa, 1995). Clinical trials of this drug are
in the planning stage.
A novel strategy for treating cocaine dependence is the development of
anti-cocaine antibodies, or immunotherapies to prevent cocaine from
entering the brain. This approach differs significantly from traditional types
of pharmacotherapies in that after cocaine is consumed, it is sequestered in
the bloodstream by cocaine-specific antibodies that prevent its entry into
the brain. One benefit from using a peripheral cocaine-blocking agent is that
side effects typically associated with penetration of therapeutic drugs into
the central nervous system are avoided.
The cocaine vaccine IPC-1010 has been tested in preclinical studies that
were initiated by ImmuLogic Pharmaceutical Corporation in collaboration
with Boston University and then continued under the name TA-CD in clinical
studies conducted by Cantab Pharmaceuticals plc and Xenova Group plc in
collaboration with Yale University, and support from The National Institute
on Drug Abuse.
A series of studies assessed the preclinical effectiveness of anti-cocaine
antibodies and the cocaine vaccine IPC-1010 on cocaine self-administration
behaviour in rats. Active immunization with IPC-1010 significantly reduced
both drug-seeking behaviour and the number of drug infusions earned
compared to pre-immunization levels. Only rats having serum antibody levels
greater than 0.05 mg/ml displayed attenuated drug-seeking behaviour and
number of drug infusions across the range of doses examined. Active
immunization with IPC-1010 with access to cocaine during immunization
suggested that daily exposure to cocaine during the immunization period
does not interfere with the ability of the immunotherapy to induce antibody
formation and reduce cocaine self-administration behaviour. Studies also
showed that immunization with IPC-1010 specifically decreased cocaine-
seeking, and did not affect responding for another reward of food pellets.
In a phase I study, the safety and immunogenicity of TA-CD were evaluated
in three groups of abstinent cocaine abusers (Kosten et al., 2002).
Immunization with TA-CD induced cocaine-specific antibodies in the three
groups of human subjects. The first clearly detectable anti-cocaine antibodies
appeared on day 28 (14 days after the second immunization) which
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corresponded with the initial appearance of a decrease in cocaine self-
administration behaviour in rats (Kantak et al., 2001). The antibody response
was maximal after the third immunization and remained at this level for
4 months. As with rats, there was substantial variability between individuals
in the magnitude of the antibody response. By one year after immunization,
antibody levels in all three groups declined to baseline values. Adverse effects
were minor and included small temperature elevations, mild pain and
tenderness at the site of injection, and muscle twitch at the highest dose.
Phase II clinical trials with TA-CD are currently underway; however, press
releases describing preliminary findings are available on the Internet. In the
initial phase II study, an improved dosing regimen was initiated to boost anti-
cocaine antibody levels. The immunotherapy produced high levels of
antibodies against cocaine which approached levels produced in the rodent
self-administration model.
In terms of clinical treatment with the cocaine immunotherapy, it is likely
to work best with individuals who are highly motivated to quit using drugs
altogether, since anti-cocaine antibodies are liable to have pharmacological
specificity in addition to their behavioural specificity. The cocaine
immunotherapy induces antibodies that are highly specific for recognizing
cocaine and its active metabolite norcocaine and active derivative
cocaethylene (Fox et al., 1996), and therefore they would not recognize
structurally dissimilar stimulants.
It is clear from the present series of studies that the anti-cocaine actions
of the cocaine immunotherapy emerge gradually over time once
immunization begins. Therefore, the immunotherapy is not expected to
immediately target craving for cocaine. Craving is significantly more common
among inpatients than outpatients, but cocaine-abstinent individuals report
less craving across outpatient treatment and follow-up compared to moderate
and heavy cocaine users (Bordnick & Schmitz, 1998). On the basis of these
considerations, it is hypothesized that treatment with the cocaine
immunotherapy may eventually help ease craving and prevent relapse if it
extinguishes cocaine use. Adjunct treatment with an anti-craving medication
may help in this regard, particularly during the immunization process. How
anti-cocaine antibodies interact with anti-craving medications deserves
serious attention (e.g. Kuhar et al., 2001) as the development of these
medications continues and the ability of the immunotherapy to block the
reinforcing effects of cocaine in human clinical trials unfolds.
The ethical implications of this new type of therapy are considered in
Chapter 7.
Amphetamines
Introduction
Amphetamines include ∆-amphetamine, L-amphetamine, ephedrine,
methamphetamine, methylphenidate, and pemoline. Another member of this
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group is (-)cathinone, the active ingredient in freshly gathered leaves of the
Khat shrub (Catha edulis), whose actions are very similar to that of
amphetamine (Jaffe, 1990) (see Box 4.5). Amphetamines are used not only for
the subjective “high” that they produce, but also to extend periods of
wakefulness, as used by lorry drivers and students studying for exams. In
addition, they are used as appetite suppressants, although this effect is short-
lived. Medically, amphetamines are currently used only in the treatment of
narcolepsy, and in treating the symptoms of attention deficit hyperactivity
disorder (ADHD) in children. This condition is thought to be partly due to low
cortical norepinephrine, which permits subcortical emotional systems to
govern behaviour impulsively. When cortical arousal is facilitated with
psychostimulants, children with ADHD are able to pay attention to the tasks
they are engaged in (Panksepp, 1998) (see Box 4.6). Non-medical use of amphe-
tamines and related stimulants is a growing problem worldwide (see Box 4.7).
Behavioural effects
Amphetamines are stimulants of the central nervous system that produce
increased alertness, arousal, energy, motor and speech activity, increased self-
confidence and ability to concentrate, an overall feeling of well-being and
reduced hunger (Jacobs & Fehr, 1987; Hoffman & Lefkowitz, 1990). The short-
term effects of low doses of amphetamine include restlessness, dizziness,
insomnia, euphoria, mild confusion, tremor, and may induce panic or
psychotic episodes. There is a general increase in alertness, energy and activity,
and a reduction of fatigue and drowsiness. There may be heart palpitations,
irregular heartbeat, increased respiration, dry mouth and suppression of
appetite. With higher doses, these effects are intensified, leading to exhilaration
and euphoria, rapid flow of ideas, feelings of increased mental and physical
ability, excitation, agitation, fever and sweating. Paranoid thinking, confusion
and hallucinations have been observed. Severe overdose may lead to high fever,
convulsions, coma, cerebral haemorrhage and death (Jacobs & Fehr, 1987).
BOX 4.5
Khat
The leaves and buds of an East African plant, Catha edulis, which are chewed or
brewed as a beverage. Used also in parts of the eastern Mediterranean and
North Africa, khat is a stimulant with effects similar to those of amphetamine –
the reason being that the main active ingredient in khat is cathinone, an
amphetamine-like substance. Consumption of khat produces euphoria and
increased alertness, although concentration and judgement are impaired. Heavy
use can result in dependence and physical and mental problems resembling
those produced by other stimulants.
Source: WHO, 1994.
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Amphetamine is a potent psychotomimetic, and can intensify symptoms
or precipitate a psychotic episode in vulnerable individuals (Ujike, 2002).
People who use amphetamine chronically often develop a psychosis very
similar to schizophrenia (Robinson & Becker, 1986; Yui et al., 1999).
Amphetamine is readily self-administered by animals (Hoebel et al., 1983),
shows robust place preference conditioning (Bardo, Valone & Bevins, 1999),
discriminative stimulus effects (Bevins, Klebaur & Bardo, 1997), and brain
stimulation reward effects (Phillips, Brooke & Fibiger, 1975; Glick, Weaver &
Meibach, 1980).
Mechanism of action
The primary mechanism of action of amphetamine is to stimulate the release
of dopamine from nerve terminals via the dopamine transporter. Thus,
dopamine can be released independently of neuronal excitation. This
contrasts with the effects of cocaine, which blocks the reuptake of
monoamines in the nerve terminal, and thus only affects active neurons. Like
cocaine, amphetamine also inhibits, to a certain extent, the reuptake of the
catecholamines, thereby increasing their ability to activate receptors.
Amphetamine may also directly activate catecholamine receptors, further
contributing to monoaminergic activity.
Tolerance and withdrawal
Tolerance develops rapidly to many of the behavioural and physiological
effects of amphetamines, such as suppression of appetite, insomnia,
euphoria, and cardiovascular effects (Jacobs & Fehr, 1987). Interestingly, the
BOX 4.6
Use of stimulant drugs to treat attention deficit hyperactivity
disorder
Attention deficit hyperactivity disorder (ADHD) is characterized by hyperactivity,
impulsivity and deficits in attention that are not appropriate for a child’s
developmental age. Psychostimulants, such as methylphenidate, are used in the
treatment of ADHD. This use may seem paradoxical, however, it is believed that
individuals with ADHD have low norepinephrine and dopamine activity and therefore
have poor attention and difficulty in regulating behaviour based on external stimuli.
The neurotransmitters norepinephrine and dopamine promote sensory and motor
arousal. With too little cortical arousal, it is thought that subcortical emotional
systems govern behaviour impulsively. When cortical arousal is facilitated with
psychostimulants, the attention of children with ADHD improves and they are
more able to concentrate on a task. Thus, with improved attention, individuals
with ADHD can better regulate their own behaviour.
Source: Panksepp, 1998.
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effects of amphetamines on behaviour in children with ADHD and in people
with narcolepsy do not show signs of tolerance. It is important to note that
even though methamphetamine is used to treat ADHD in children, the
therapeutic doses for ADHD and other disorders such as narcolepsy are much
lower than the daily amounts taken for non-medical use.
Although tolerance develops to some aspects of psychostimulant use,
sensitization, or an increase in the hyperactivity or stereotypy induced by
amphetamine also occurs, even if the doses are spread out over days or weeks.
Cross-sensitization with cocaine occurs, and is thought to be the result of
increased dopamine in the striatum (Kalivas & Weber, 1988). Sensitization is
thought to play a critical role in dependence (see Chapter 3).
Neurobiological adaptations to prolonged use
Long-term use of amphetamine may result in sleeping problems, anxiety,
suppression of appetite, and high blood pressure. People who use
amphetamine often take sedative/hypnotic drugs to counteract these effects,
and thus the incidence of polydrug use is high (Jacobs & Fehr, 1987).
Amphetamine users sometimes ingest increasing quantities of
amphetamine in “runs” that last 3–6 days. This continuous use has been
modelled in animals, and changes in behaviour are observed consistent with
hallucinatory-like effects. This pattern of use is neurotoxic and produces brain
damage. Continuous infusion of low doses of amphetamine into rats produces
a depletion of nigrostriatal dopamine, its precursors and metabolites, and
receptors (Robinson & Becker 1986).
With long-term use of methamphetamine there is a decrease in dopa-
mine D
2
 receptor availability in the caudate and putamen, and a decrease in
metabolic rate in the orbitofrontal cortex (Volkow et al., 2001a) (see Fig. 4.3),
and loss of dopamine transporters that is associated with motor and cognitive
impairment (Volkow et al., 2001b).
There are limited data available on the proportion of current amphetamine
users who are dependent (see Box 4.7). A review of the medical literature
indicates that some antidepressant drugs may decrease craving for
amphetamines (Srisurapanont, Jarusuraisin & Kittirattanapaiboon, 2001).
However, this may also be related to the comorbidity of psychostimulant
dependence and depression (see Chapter 6).
Ecstasy
Introduction
Ecstasy or 3,4-methylenedioxymethamphetamine (MDMA) is a synthetic
amphetamine, also known as XTC, E, Adam, MDM or “love drug” (Shaper,
1996). Ecstasy can be classified as a psychostimulant, belonging to the same
group as cocaine and the amphetamines, since many of its acute effects are
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similar to these substances. Ecstasy is classifiable as a hallucinogen, due to
the potential induction of hallucinations if used in extremely high doses
(American Psychiatric Association, 1994; WHO, 2001). As the subjective effects
of MDMA in humans are not the same as those produced by LSD and because
the drug does not present similar structure or pharmacological activity to
hallucinogens, the term “entactogens”, meaning “entering in contact with
yourself ” (Nichols, 1986; Morgan, 2000) was proposed to define a new
pharmacological class. As the understanding of the drug effects increases,
its classification will be more accurate. Use of ecstasy has recently been
associated with the global trend of dance parties (or “raves”) and “techno”
music (WHO, 2001).
Psychostimulant effects of MDMA are observed 20–60 minutes after oral
ingestion of moderate doses (50–125 mg) of ecstasy and last from 2–4 hours
(Grispoon & Bakalar, 1986). Peak plasma levels of ecstasy occur 2 hours after
oral administration, and only residual levels are found 24 hours after the last
dose (Verebey, Alrazi & Jafre, 1988; Cami et al., 1997). MDMA has a non-linear
pharmacokinetic profile: consumption of elevated doses of the substance
may produce disproportional elevation of plasma levels of ecstasy (Cami et
al., 1997; de la Torre et al., 2000).
Fig.4.3 Comparison of dopamine D2 receptor binding in the brains of a
control subject and a person with methamphetamine
dependence
Source: Volkow et al., 2001a. Reproduced with permission from the publisher.
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BOX 4.7
Growing epidemic of amphetamine-type stimulants (ATS) use
Amphetamine-type stimulants (ATS) refer to a group of drugs whose principal
members include amphetamine and methamphetamine. However, a range of other
substances also fall into this group, such as methcathinone, fenetylline, ephedrine,
pseudoephedrine, methylphenidate and 3,4-methylenedioxymethamphetamine
(MDMA) or ‘Ecstasy’ – an amphetamine-type derivative with hallucinogenic
properties. The use of ATS is a global and growing phenomenon and in recent
years, there has been a pronounced increase in the production and use of ATS
worldwide.
Over the past decade, use of ATS has infiltrated its way into the mainstream
culture in certain countries. Younger people in particular seem to possess a
skewed sense of safety about these substances, believing rather erroneously
that they are safe and benign. Meanwhile, ATS are posing a serious threat to the
health, social and economic fabric of families, communities and countries. For
many countries, the problem of ATS is relatively new, growing quickly and unlikely
to go away. Geographically, its occurrence is spreading, but awareness of ATS is
limited and responses are neither integrated nor consistent.
Recent data have shown a stabilization in ATS use in north America and western
Europe, while the highest levels of abuse worldwide have emerged in East Asia
and Oceania. According to a review conducted by UNDCP in 1996, there are
about 20 countries in this region in which the abuse of ATS is more widespread
than that of heroin and cocaine combined. In Japan, the Republic of Korea and
the Philippines use of ATS is 5–7 times that of heroin and cocaine use.
Smoking, sniffing and inhaling are the most popular methods of ATS use, but
ways to take the drug vary widely across the region. In countries such as Australia,
where over 90% of those who report using ATS (mostly methamphetamine) inject,
the drug represents a significant risk factor in the transmission of blood-borne
viruses. The Philippines and Viet Nam are also reporting signs that injecting
methamphetamine is increasing while in Thailand, the number of methamphetamine
users now represents the majority of all new drug treatment cases. There are
currently very limited data to indicate what proportion of current users are
dependent. Researchers have pointed out that it is likely that dependence and
chronic usage is associated with methamphetamine psychosis and related adverse
consequences, and that because of the high rates of usage, levels of presentation
of methamphetamine psychosis to mental health services are dramatically
escalating.
In short, the present situation warrants immediate attention, with a major epidemic
of methamphetamine use in Thailand that appears to be spreading across the
entire Asia Pacific Region. Researchers have stressed an urgent need to map out
this epidemic to assess the spread and scale of the problems, consequences
and responses.
Sources: WHO, 1997b; Farrell et al., 2002; UNODCCP, 2002.
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MDMA is widely distributed, easily crossing membranes and the blood-
brain barrier. Its clearance depends partially on metabolism by the liver,
between 3–7% is converted to the active substance methylenedioxyam-
phetamine (MDA), 28% is biotransformed to other metabolites, and around
65% is eliminated, unchanged, via the kidneys (Verebey, Alrazi & Jafre, 1988;
Cami et al., 1997).
The half-life of ecstasy in plasma is 7.6 hours. This information is relevant
when treating intoxication: 6–8 half-lives are necessary for complete
elimination of ecstasy, giving a total time of around 48 hours for the drug to be
completely eliminated. It can also be seen that at a plasma level of 8 mg/l –
considered to be the level of severe intoxication – more than 24 hours would
be necessary to decrease this to a plasma level lower than 1 mg/l, which
produces less clinical effects. Therefore, 24 hours would be the estimated time
of intensive care needed by intoxicated patients who had taken a few ecstasy
capsules.
Behavioural effects
MDMA may produce subjective effects in humans that are similar to, but
distinguishable from, those of the psychostimulants ∆-amphetamine and
cocaine. Increased self-confidence, understanding and empathy together
with enhanced sensation of proximity and intimacy with other people, and
improvement of communication and relationship skills are described in
uncontrolled studies. Euphoria and increased emotional and physical energy
are presumed to occur with this psychostimulant (Downing, 1986; Nichols,
1986; WHO, 2001). Negative psychological effects of anxiety, paranoia, and
depression can also occur (WHO, 2001).
Intravenous self-administration behaviour in primates (Beardsley, Balster
& Harris, 1986) and in rats (Acquas et al., 2001) is maintained across a range
of doses of ecstasy.
Mechanism of action
Similar to other amphetamines (McKenna & Peroutka, 1990), the effects of
ecstasy may be related to several neurotransmitters including serotonin,
dopamine, and norepinephrine (Downing, 1986; Nichols, 1986; Kalant, 2001;
Montoya et al., 2002). However, serotonin plays the main role in mediating
the effects of ecstasy (Shulgin, 1986; Mascaro et al, 1991; Marona-Lewicka
et al., 1996; Kalant, 2001; Montoya et al., 2002). There is increased net
serotonin release because MDMA binds to and blocks the serotonin
transporter, thus blocking serotonin reuptake (Kalant, 2001). Eventually this
leads to long-term depletion of serotonin and metabolite concentrations
in the brain (WHO, 2001). MDMA also increases the release of dopamine
(WHO, 2001).
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Tolerance and withdrawal
Tolerance develops rapidly with use of ecstasy, and some individuals use
progressively larger amounts of ecstasy to reinforce its psychoactive effect
(McCann & Ricaurte, 1991; WHO, 2001). In some individuals, tolerance occurs
to the pleasant psychoactive effects of ecstasy but not to the physical collateral
effects, therefore any dose increase to augment the psychoactive effects may
produce dysphoria (Grispoon & Bakalar, 1986). In this group of individuals,
MDMA will not cause dependence, and thus the use of large amounts of
ecstasy for long periods is rare (Peroutka, 1989). It is still necessary to define
which are the social, genetic, cultural, environmental and hormonal factors
involved in these long-term individual differences in the effects of ecstasy.
For 2–3 days following MDMA use, there may be residual effects associated
with the acute withdrawal of the drug, including muscle stiffness and pain,
headache, nausea, loss of appetite, blurred vision, dry mouth and insomnia
(Kalant, 2001). Psychological effects may also be observed, most commonly
depression, anxiety, fatigue, and difficulty in concentrating (Kalant, 2001).
This is typical of the “crash” that is also seen following the use of ampheta-
mines and cocaine.
Neurobiological adaptations to prolonged use
Neurotoxicity induced by MDMA is cumulative and is related to the dose and
frequency of drug use (McKenna & Peroutka, 1990; Kalant, 2001). In animals,
acute neurochemical effects are observed after doses of around 5–10 mg/kg
of ecstasy and long-term effects occur after doses 4 times higher, or after
frequent administration of smaller doses. A neurotoxic schedule of ecstasy
reduces rat brain serotonin concentrations by 45%. Damage or
neuroadaptation to the brain has been clearly demonstrated in both humans
and in animal models, which show reduced serotonin concentrations,
neurons, transporters and terminals (Kalant, 2001).
 There are also long-term psychiatric and physical problems associated with
MDMA use. Impairments of memory, decision-making and self-control are
observed, as are paranoia, depression and panic attacks (Kalant, 2001; Montoya
et al., 2002). There can also be major hepatic, cardiovascular and cerebral toxic
effects (Kalant, 2001; Montoya et al., 2002). The long-term depletion of brain
serotonin by ecstasy is also accompanied by impairment of body temperature
control and behavioural responses (Shankaran & Gudelsky, 1999). The public
health implications of these findings are apparent.
Volatile Solvents
Introduction
Several volatile chemicals (including gases such as nitric oxide, volatile
solvents such as toluene, and aliphatic nitrites) produce effects on the central
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nervous system and are used mainly by children and adolescents due to their
ready availability (see Box 4.8). The term inhalant applies to a diverse group
of substances that can be found in products such as gasoline, nail-polish
remover, paint stripper and adhesive glue (Weir, 2001). These compounds
are intentionally sniffed either directly or from a solvent-soaked rag placed
in the person’s mouth or in a plastic bag. The volatile solvent compounds
have few characteristics in common other than their toxicity and the
behavioural effects they produce.
Behavioural effects
The intoxication induced by inhalation of solvent vapour produces some
behavioural effects similar to those due to alcohol. Minutes after inhalation
dizziness, disorientation and a short period of excitation with euphoria are
observed, followed by a feeling of light-headedness and a longer period of
depression of consciousness. In addition, marked changes in mental state
are induced in people who misuse toluene and other solvents. Most users
report elevation of mood and hallucinations. Potentially dangerous delusions
such as believing one can fly or swim also occur, thoughts are likely to be
slowed, time appears to pass more quickly, and tactile hallucinations are
common (Evans & Raistrick, 1987). These behavioural effects are
accompanied by visual disturbances, nystagmus, incoordination and
unsteady gait, slurred speech, abdominal pain and flushing of the skin.
BOX 4.8
Use of volatile solvents
The term volatile solvent use describes the intentional inhalation of a variety of
volatile substances (mostly organic solvents), for psychoactive effects. The term
inhalants has come to encompass a group of psychoactive chemicals that are
defined by the route of administration rather than by their effects on the central
nervous system. Thus, such diverse substances as toluene, ether, and nitrites
have been classified as inhalants because they are all taken in through the nose
and mouth by inhalation.
Volatile solvent use (including glue sniffing, inhalant and solvent use) has now
been reported in various parts of the world, mainly among adolescents, individuals
living in remote communities and those whose occupations provide easy access
to these substances. In certain countries volatile solvent use is associated with
particular groups of young people such as street children and children from
indigenous populations. Many products that can be used to achieve intoxication
are readily available in the home and in a range of shops.
Sources: WHO, 1999; Brouette & Anton, 2001.
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Animal studies have shown that, in common with classical depressant
drugs, volatile solvents have biphasic effects on motor activity, disrupt
psychomotor performance, have anticonvulsant effects, produce biphasic
drug-like effects on rates of schedule-controlled operant behaviour, increase
rates of punished responding, serve as reinforcers in self-administration
studies and share discriminative stimulus effects with barbiturates and
ethanol (Evans & Balster, 1991). Toluene is self-administered in primates
(Weiss, Wood & Macys, 1979), and has biphasic effects on intracranial self-
stimulation, increasing the frequency of self-stimulation at lower
concentrations and decreasing it at higher concentrations. Several solvents
contained in glue vapours, including toluene, induce conditioned place
preference and activate the brain reward system in intracranial self-
stimulation in rats, predicting the dependence-producing potential of volatile
solvents (Yavich & Patkina, 1994; Yavich & Zvartau, 1994).
Mechanism of action
Little is known about the mechanism of action of the solvents, and they have
received far less attention in research than other psychoactive substances. Most
reviews consider the nature of the acute effects of volatile organic solvents by
comparing their actions to those of classical depressant drugs such as the
barbiturates, benzodiazepines and ethanol. Based on their physical effects it
is assumed that solvents induce similar biochemical changes as ethanol and
anaesthetics, and therefore the search for a GABAergic mechanism of action
has been pursued. In mice, the discriminative stimulus effects of ethanol may
be substituted for several volatile anaesthetics, toluene and other volatile
solvents (Bowen & Balster, 1997). Acquisition of toluene discrimination by rats
and mice, generalizes for GABAergic agents such as barbiturates and
benzodiazepines, suggesting that toluene may have drug dependence potential
of the CNS-depressant type (Knisely, Rees & Balster, 1990).
The commonly used solvents, including toluene, also affect ligand-gated
ion channel activity. Toluene, similar to ethanol, reversibly enhances GABA(A)
receptor-mediated synaptic currents. Therefore, the molecular sites of action
of these compounds may overlap with those of ethanol and the volatile
anaesthetics (Beckstead et al., 2000). Toluene has excitatory and inhibitory
biphasic effects on neurotransmission that are related to GABAergic neuro-
transmission.
Dopamine in the nucleus accumbens is closely related to substance
dependence for all psychoactive substances (Chapter 3). Acute inhalation of
toluene by rats results in an increase in extracellular dopamine levels in the
striatum (Stengard, Hoglund & Ungerstedt, 1994), and changes in neuronal
firing of dopamine neurons of the VTA (Riegel & French, 1999). Therefore,
this electrophysiological study suggests that mesolimbic dopamine
neurotransmission can be changed by toluene exposure, pointing towards
the same conclusion as the neurochemical studies.
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Other evidence of dopamine involvement following toluene inhalation
comes from studies on occupational toxicology. Subchronic inhalation
exposure to concentrations of toluene likely to be found in occupational
settings induces persistent changes in locomotor activity and the number of
dopamine D
2
 receptors in rat caudate (von Euler et al., 1993; Hillefors-
Berglund, Liu & von Euler, 1995). Toluene-induced locomotor hyperactivity
may be blocked by D
2
 receptor antagonists (Riegel & French, 1999).
Tolerance and withdrawal
The acute neurobehavioural effects of volatile solvents, including anxiolysis
and sedation, are those typically associated with central nervous system
depressants, and these effects may lead to continued use, tolerance and
withdrawal (Beckstead et al., 2000).
Tolerance may occur but it is considered difficult to estimate in humans.
It seems to be established after 1–2 months of repetitive exposure to volatile
solvents (American Psychiatric Association, 1994). Rats exposed to high
environmental concentrations of toluene vapours for long periods of time,
present tolerance to motor abnormalities (Himnan, 1984).
Withdrawal from volatile solvents in mice is characterized by increased
susceptibility to convulsions and may be reversed or diminished by other
solvent vapours, as well as by ethanol, midazolam and pentobarbital. These
data support the hypothesis that the basis for volatile solvent use may be its
ability to produce ethanol-like and depressant drug-like effects (Evans
& Balster, 1991).
Neurobiological adaptations to prolonged use
Persistent changes in dopamine receptor binding and function have been
found in rats exposed to low concentrations of toluene. In addition, acute
inhalation exposure to toluene is accompanied by an increase in extracellular
dopamine levels within the striatum (Stengard, Hoglund & Ungerstedt, 1994),
while prolonged exposure does not significantly change extracellular
dopamine levels in rat accumbens (Beyer et al., 2001).
Repeated exposure to toluene increased the acute motor-stimulant
response to cocaine and potentiated and prolonged cocaine-induced
increases in dopamine outflow in the nucleus accumbens, showing that
repeated exposure to toluene enhances behavioural and neurochemical
responses to subsequent cocaine administration in rats. This is evidence of
the development of sensitization and cross-sensitization, which are key
features in the development of dependence (see Chapter 3). These findings
suggest that exposure to toluene alters neuronal function in an area known
to be critically involved in substance dependence, by increasing sensitivity
to other psychoactive substances and may, therefore, increase the probability
of substance dependence (Beyer et al., 2001).
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Organic solvent inhalation is the cause of several neuropathological
changes that are associated with decreased cognitive functioning. Workers
chronically exposed to mixtures of organic solvents in the environment at
concentrations within or slightly exceeding the acceptable values, present
with subtle cognitive deficits, detected through visual evoked potentials
(Indulski et al., 1996). Chronic inhalation of primarily toluene-based solvents
can produce a persistent paranoid psychosis, temporal lobe epilepsy and a
decrease in IQ. These psychiatric and neurological sequelae of chronic solvent
use are serious and potentially irreversible (Byrne et al., 1991). The degree to
which these chronic neuropsychiatric effects modulate the persistent use of
solvents or other substances needs clarification.
Hallucinogens
Introduction
The hallucinogens are a chemically diverse class, but are characterized by
their ability to produce distortions in sensations, and to markedly alter mood
and thought processes. They include substances from a wide variety of natural
and synthetic sources, and are structurally dissimilar (Jacobs & Fehr, 1987).
The name hallucinogen refers to hallucination-producing properties of these
drugs. However, hallucinations are not the only effects caused by these drugs,
and often occur only at very high doses. The hallucinations are most often
visual, but can affect any of the senses, as well as the individual’s perception
of time, the world, and the self. The subjective effects vary greatly between
individuals, and from one use to the next within the same person.
The hallucinogens are divided into classes based on structural similarity of
the drugs. One class is related to lysergic acid diethylamide (LSD). These are
the indolealkylamines, which are structurally similar to the neurotransmitter
serotonin. This group includes LSA (d-lysergic acid amine, found in the seeds
of several varieties of morning glory), psilocybin, and dimethyltryptamine
(DMT). These latter three compounds are all naturally occurring.
The next group of hallucinogens consists of phenylethylamine drugs, of
which mescaline, methylenedioxyamphetamine (MDA), and methylenedioxy-
methamphetamine (MDMA) are the most popular members. MDMA, or
ecstasy, is considered separately in this chapter due to its widespread use and
current popularity. Paramethoxyamphetamine (PMA), dimethoxy-4-
methylamphetamine (DOM) and trimethoxyamphetamine (TMA) are other
members of this group. These drugs bear a close structural relationship with
amphetamine.
Phencyclidine (PCP) and ketamine are dissociative anaesthetics that
belong to the arylcycloalkylamine family of drugs, and act on glutamate
receptors.
Finally, there is the atropinic family, which includes atropine, scopolamine
and hyoscyamine. They are found naturally in many species of potato plants.
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They are also found in Atropa belladonna (deadly nightshade), Datura
stramonium (jimsonweed), and several related species throughout the world.
Cannabis is also classified as a hallucinogen, but is considered separately
in this chapter.
Behavioural effects
These drugs produce increased heart rate and blood pressure, elevated body
temperature, reduced appetite, nausea, vomiting, abdominal discomfort, rapid
reflexes, motor incoordination and pupillary dilatation (Jacobs & Fehr, 1987).
The hallucinatory effects are related to dose, and distortions of any of the
sensory modalities can occur. The melding of two sensory modalities is also
possible (e.g. music being “seen”), and is called synaesthesia (Jacobs & Fehr,
1987). These drugs also affect thought processes and memory.
The intensity of the effects, and the emotional reaction to them, differ from
person to person. Reactions can range from joy and euphoria to fear and
panic. There can be a sense of deep insight, as well as psychotic episodes.
The effects of hallucinogens are quite similar between classes of drugs
within this category, and range from excitation or depressant effects, analgesic
and anaesthetic effects, depending on the dose taken and the situation. PCP
and ketamine can produce hallucinations at very low doses.
Mechanism of action
LSD acts on the serotonin system, and is an autoreceptor agonist in the raphe
nucleus. An autoreceptor is a receptor on a neuron for the transmitter that
neuron releases. Activation of an autoreceptor acts as a negative feedback
mechanism to turn down the firing of the neuron. This helps to regulate
neuronal firing and to prevent overactivation of neurons. LSD also acts as a
serotonin-2 agonist, or partial agonist (Jaffe, 1990). It is taken orally, and doses
as low as 20–25 µg can produce effects.
PCP is a non-competitive antagonist at the N-methyl-D-aspartate (NMDA)
receptor (Lodge & Johnson 1990). PCP-induced psychosis can last for weeks
despite abstinence from substance use (Allen & Young 1978; Luisada 1978).
Similarly to PCP, ketamine, a PCP analogue that is also a non-competitive
NMDA receptor antagonist that exhibits higher selectivity than PCP for the
NMDA receptor (Lodge & Johnson 1990), also induces psychotomimetic
effects in healthy volunteers (Newcomer et al., 1999), and exacerbates
symptoms in patients with schizophrenia (Lahti et al., 1995).
The atropinic class of hallucinogens are antagonists of muscarinic
cholinergic receptors.
Tolerance and withdrawal
Tolerance develops rapidly to both the physical and psychological effects of
the hallucinogens. The psychoactive effects will no longer occur after 3–4 days
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of repeated use, and will not recur unless a period of several days of abstinence
occurs. There is no evidence of withdrawal occurring to any of the hallucinogens
(Jacobs & Fehr, 1987).
Neurobiological adaptations to prolonged use
Few data are available on the long-term neurological effects of
hallucinogens. “Flashbacks” may occur either shortly after using the drugs,
or up to 5 years later (Jacob & Fehr, 1987). Flashbacks are spontaneous
recurrences of experiences which occurred during a previous LSD episode.
Other effects of long-term use include increased apathy, decreased interest,
passivity, and failure to plan ahead, and there may also be disregard for
social norms. However, it is difficult to ascribe these effects entirely to
hallucinogens, as they are often used with other drugs as well. Finally,
chronic use of hallucinogens can result in acute or long-term psychotic
episodes.
Summary
It is evident that almost all psychoactive substances share the common
property of increasing mesolimbic dopamine function. Not only
psychostimulants such as cocaine (Kuczenski & Segal, 1992) and
amphetamine (Carboni et al., 1989) but also narcotic analgesics (Di Chiara &
Imperato, 1988b), nicotine (Imperato, Mulas & Di Chiara, 1986), ethanol
(Imperato & Di Chiara, 1986) and phencyclidine (Carboni et al., 1989)
stimulate dopamine transmission in the nucleus accumbens (Di Chiara
& Imperato, 1988a), the main area of the ventral striatum. The implications
of this with respect to dependence were discussed in Chapter 3.
The understanding of the acute and chronic effects of psychoactive
substances on the brain has expanded greatly in recent years to begin to
provide a substantial molecular and cellular fingerprint of the extensive
changes in neuronal systems. The major realization has been that the use of
psychoactive substances usurps the normal physiological mechanisms that
mediate reward, learning and memory, and eventually results in remodelling
of neuronal contacts and pathways, producing long-lasting, near-permanent
changes. Furthering our understanding of the mechanisms involved still
requires intensive research effort, and the availability of sophisticated
molecular and biochemical tools should greatly facilitate this process.
Although psychoactive substances have these common effects, there
is still considerable variability between drug classes in terms of primary
physical and psychological effects, mechanisms of action, development of
tolerance and withdrawal, and long-term effects (see Tables 4.1 and 4.2).
Differences in the availability, cost, legality, marketing and cultural attitudes
towards psychoactive substances and their use also affect which substances
are used, and the development of dependence upon them. Thus, the study
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of substance dependence must take these factors into account, while at the
same time noting the similarities across drug classes. The next chapter
examines genetic effects on substance use, both across and between
substance groups. Chapter 6 discusses how substance use interacts with,
precipitates, or may be a result of psychiatric illness. It is important to keep
in mind that substance dependence is the result of not only the primary
pharmacological properties of the psychoactive substance, but also the
complex interplay of biological and environmental factors that surround its
use.
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CHAPTER 5
Genetic Basis of Substance Dependence
Introduction
The aim of this chapter is to critically assess the evidence for a genetic
contribution to the risk of developing psychoactive substance use and
dependence in humans. While individual genetic differences contribute to
the development of substance dependence, genetic factors are but one
contributor to the complex interplay of physiological, social, cultural and
personal factors that are involved. A list of commonly used genetic terms is
provided in Box 5.1.
The classical (and popular) view of human genetics is one in which genetic
mutation is the direct and usually only cause of a particular illness, for
example, the single gene – or Mendelian – disorders such as Huntington’s
disease. Single gene diseases are caused by a specific mutated gene, and the
mutation is both necessary and sufficient to cause the illness. Unlike single
gene disorders, which are rare and might affect 1 in 10 000 people, complex
disorders, such as substance dependence, are common in the population,
often affecting 1 in 100 or more people. Complex disorders are clearly not
caused by genes alone, but by the interaction between genes and the
environment. Thus exposure to psychoactive substances could have a much
greater effect on somebody who carries a genetic vulnerability to substance
dependence, than on someone who does not.
Genetic vulnerability, or predisposition, to substance dependence is likely
to be tied to several distinct genes (or multiple alleles), each producing a
small effect, which might increase risk of developing substance dependence
by 2–3 fold. Any one of the genes on its own will be insufficient to cause
dependence, but several different genes may all contribute to the
vulnerability. It is hypothesised that not everyone who carries a “risk gene”
for substance use or dependence will become dependent, and likewise some
of those who become dependent will not carry that particular genetic risk
factor.  It is the combination of the presence of several distinct genes or alleles
which may be important, rather than a single gene. These genetic
contributions to vulnerability seem likely to be distributed over several
distinct regions (loci) on the chromosomes.
This chapter will address the genetics of substance use disorders in general,
but will also specifically examine the data for opioid, alcohol and tobacco
dependence, as these substances have received a substantial amount of
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BOX 5.1
Commonly used genetic terms
Allele: One member of a pair of homologous genes in a diploid cell. An individual
with identical alleles at a genetic locus is a homozygote; one with non-identical
alleles is a heterozygote. In a case in which one allele leads to an observable
gene product and the other has no phenotype, the functional allele is said to
be dominant and the non-functional allele recessive.
Candidate genes: Genes with perceived relevance to the trait in question, which
can be used to compare allele frequencies between affected and non-affected
groups.
Gene: In genetics, a unit inferred from the pattern of inheritance; in molecular
biology, defined narrowly as a section of DNA that is expressed as RNA or,
more widely, as a coding sequence of DNA and associated regulatory
sequences.
Gene locus: The specific place on a chromosome where a gene is located.
Heritability: The proportion of phenotypic variance that can be attributed to
additive genetic variance.
Genotype: The genetic make-up of any organism.
Linkage: The more-frequent-than-random occurrence of two traits together due
to the proximity of their corresponding genes on the same chromosome. The
likelihood of a recombination event separating the two genes decreases with
their increasing proximity on the chromosome.
Linkage studies: These studies use multiply-affected families to examine traits
that are inherited together. The concept is based on the fact that genes that
are located close to one another will be more likely to be inherited together
from one parent than two genes located further apart.
Phenotype: The outward physical manifestation of the cell or individual due to
actual expression of the alleles that are present.
Polygenic: A trait arising from more than one gene.
Polymorphism: The occurrence of something in several forms, e.g. the
occurrence in a population of two or more alleles of a gene at a single genetic
locus.
genetic research attention. However, one overwhelming finding from genetic
studies of psychoactive substances is that the heritability (i.e. genetic
contribution) of dependence for one substance correlates highly with
dependence for other substances.  Thus, there may be some common genetic
components to substance dependence in general, as well as to dependence
for specific psychoactive substances. There is also a high degree of association
of substance dependence with mental illness (see Chapter 6). The most
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common types of genetic studies in humans and the types of information
these studies provide are summarized below. Animal studies are also briefly
presented.
Family, twin and adoption studies: estimations of heritability
Family, twin and adoption studies can be used to determine whether or not
there is a genetic contribution to psychoactive substance use and
dependence, but they do not provide evidence to determine which particular
gene is involved. Twin and adoption studies also help to dissociate
environmental factors from genetic factors.
Family studies examine the inheritance of traits through a family, in order
to find out about patterns of inheritance and the relative risk of inheriting a
disorder.
Twin studies are based on the fact that monozygotic (identical) twins share
identical genetic material, while dizygotic (fraternal) twins share the same
degree of genetic similarity as non-twin siblings.  Presumably, twins raised
together share very similar environments. If genetic effects are present, then
monozygotic twins should be more alike, with respect to those effects, than
dizygotic twins. This allows an estimation of the genetic contribution to
psychoactive substance dependence. These types of studies provide evidence
that variation in the vulnerability to substance dependence in populations is
influenced by both individual genotypes and environmental differences
(Heath et al., 1999a; Vanyukov & Tarter, 2000).
Adoption studies are capable of almost completely separating genetic and
environmental influences on the variation in the vulnerability to a disorder
(except contributions of antenatal and early postnatal environmental factors)
(Heath et al., 1999a; Vanyukov & Tarter, 2000); in this way they complement
the more traditional twin studies. Using adoption studies, environmental
factors can be separated from genetic factors, since children adopted at birth
are raised in an environment that is different from that of their genetic family.
In this way, environmental factors such as socioeconomic status, learning
about substance use, exposure to psychoactive drugs, etc., are randomized.
For example, if a particular family shows a high level of substance dependence
from generation to generation, it is difficult to know how much of this is
attributable to shared genes, and how much is attributable to the shared
environment. With adoption studies, the effect of the environment is factored
out, and thus, it is easier to determine more clearly the contribution of
genetics.
Identifying chromosomal locations of interest: linkage studies
Twin and adoption studies give an estimation of the proportion of variation
in a trait that is due to genetics; however, they do not provide any information
about which genes or chromosomes are involved.  Linkage and association
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studies are used to identify regions of DNA that may be involved in the
expression of a trait such as substance dependence. Linkage studies examine
inheritance within related individuals, whereas association studies examine
inheritance in unrelated individuals. The concept of linkage is based on the
fact that genes located close to one another on a chromosome are more likely
to be inherited together from one parent, than are two genes located further
apart, due to the reassortment of genes that occurs during the process of
recombination. The genes are said to be “linked” since there is a greater
probability of the genes being inherited together. Linkage studies have been
an important tool for the localization of chromosomal regions contributing
to substance dependence; they support candidate gene studies and provide
potential identities of unknown phenotype-related genes (Arinami, Ishiguro
& Onaivi, 2000).  The studies examine chromosomal locations that are
inherited together in people who have the phenotype in question (e.g. who
have nicotine dependence) in order to find areas of the chromosome
important for the condition.
Candidate gene approach
The candidate gene approach requires the selection of genes that may have
relevance to the phenotype in question. For example, it would be appropriate
to investigate nicotinic receptor genes when examining the genetics of
nicotine dependence. These studies examine candidate genes in people with
or without dependence, to look for differences between these groups.
Animal studies
Many genetic studies on substance dependence employ animal models.
Animal models have a great advantage in that the history of exposure to
psychoactive substances and most other environmental factors can be
controlled and manipulated allowing the use of powerful statistical analysis.
In addition, genetic studies in animals allow for specific breeding studies that
cannot be done with humans, and the results of these studies can be obtained
in a relatively short period of time.  Moreover, while early studies could only
control the genetic make-up of experimental animals by in-breeding, modern
transgenic and knockout methodology allows the genotype of these animals
to be manipulated in a specified manner so that the role of specific genes in
the behaviours of interest can be investigated.
Transgenic animals (usually mice) are created by injecting a foreign gene
(transgene) into fertilized mouse eggs.  The transgene integrates into the
mouse chromosome in one or several copies in a random location.  The eggs
are then implanted into foster mothers. When the embryos develop to term,
a proportion of them will have the transgene integrated into the mouse
genome.  The resulting transgenic founder animals are then bred to create
transgenic lines of mice (Picciotto & Wickman, 1998; Bowers, 2000).  The
Chapter_5 19.1.2004, 11:45128
129
5. GENETIC BASIS OF SUBSTANCE DEPENDENCE
application of the transgenic approach depends on the understanding of
mechanisms regulating gene expression in the mouse, which is currently
relatively limited (Quinn, 1996; Spergel et al., 2001).
The gene knockout methodology allows the deletion of a gene – or a
fragment of the gene – from the animal chromosomes.  In this methodology
a mutated copy of the gene of interest is introduced into cultured mouse
embryonic stem cells.  Through homologous recombination the mutated gene
becomes integrated into the genome of the stem cell, and disrupts (or
modifies, in the so-called knock-in technology) its function.  Stem cells in
which the gene is disrupted are injected into blastocysts, which are then
implanted into foster mothers.   Resulting mice have the gene disrupted in
some but not all cells, and are further bred to create knockout lines of mice
(Capecchi, 1994; Picciotto & Wickman, 1998).
Transgenic and knockout mice can serve as powerful research tools to
observe the effects of gene modifications.  However, results from transgenic
and knockout studies need to be interpreted with caution for several reasons.
The site of integration for the transgene into the mouse chromosome is
random, and is as yet impossible to control.  Therefore, some of the
phenotypes observed in transgenic mice can be due to the functions of the
transgene, but some can also be due to the disruption of the gene in which
the transgene has been integrated. Creation of several transgenic lines is
therefore necessary to verify that the observed phenotype is indeed due to
the transgene (Bowers, 2000). The knockout technology does not have the
problem of random transgene integration because the mutation in these mice
is targeted to a specific gene.  However, it has other problems, for example,
the problem with background genotype (Crawley et al., 1997).
Both transgenic and knockout approaches are also faced with a problem
of developmental compensation.  That is, while the gene that is modified or
over-expressed in the mutant animal could be important in the investigated
phenotype, compensatory mechanisms could also occur during development
(e.g. when a subunit of a receptor is knocked-out, another subunit could be
over-expressed and compensate for the absence of the knocked-out subunit).
If such compensation is occurring, the predicted change in the phenotype of
the mutant mice will not occur.  New methodologies, including inducible
and brain region-specific transgenic and knockout approaches, are being
developed, and should in future alleviate many such problems (Sauer, 1998;
Le & Sauer, 2000).
Another approach used in animal studies is the quantitative trait loci (QTL)
analysis. Substance dependence is considered to be a quantitative trait in
which a combined action of multiple alleles leads to predisposition to
dependence.  This approach does not assume any prior knowledge of genes
involved in substance-related disorders, and seeks to find them based on
related phenotypes. QTL analysis is analogous to linkage studies in humans.
As an example, inbred strains of mice that are genetically identical can be
crossed with other inbred strains, and the absence or presence of a mapped
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sequence of DNA (marker) in each strain can be correlated with a quantitative
measure of a phenotype (e.g. amount of psychoactive substance self-
administered).  Strong correlation of a phenotype with the presence of a
genetic marker suggests that the genetic sequence in the proximity of this
marker is involved in the regulation of this measure.  Since the location of
the marker sequence is mapped on mouse chromosomes, such analysis
allows researchers to create genetic maps of loci important for the traits (Gora-
Maslak et al., 1991; Grisel, 2000).
Genetics of tobacco dependence
Heritability of tobacco dependence
There is evidence of significant heritability of tobacco use among different
populations, sexes and ages, as reported in a number of large-scale twin studies.
Family and twin studies have demonstrated a genetic effect on “ever” smoking
(or lifetime smoking, i.e. having smoked a cigarette at least once) (Cheng, Swan
& Carmelli, 2000; McGue, Elkins & Iacono, 2000). A major genetic influence on
the probability that an individual will become a smoker (“initiation”) of about
60% has been observed, and continuation of the smoking habit once smoking
has started (“persistence”) of about 70% (Kaprio et al., 1982; Carmelli et al.,
1992; Heath et al., 1995; Heath et al., 1999a; Koopmans et al., 1999; Sullivan
& Kendler, 1999; Kendler, Thornton & Pedersen, 2000).
The initiation of smoking is separate from the development of nicotine
dependence. One set of genetic factors was found to play a significant etiological
role in both initiation and dependence, while another set of familial factors,
probably in part genetic, solely influenced dependence (Kendler et al., 1999).
In other words, genetic factors that contribute to variation in smoking initiation
and dependence only partly overlap (Heath & Martin, 1993; Kendler et al., 1999;
Madden et al., 1999; Sullivan & Kendler, 1999; Heath et al., 2002).
Other aspects of smoking, such as the age when the onset of smoking
occurs, are also influenced by genetic effects in both sexes (Heath et al., 1999a;
Koopmans et al., 1999). Once smoking is initiated, genetic factors determine
to a large extent (86%) the quantity that is smoked (Kaprio et al., 1982;
Koopmans et al., 1999). In addition some aspects of smoking, such as “never”
smoking or intensity of smoking, showed a genetic contribution in males,
which was not clear in females (Edwards et al., 1995). A study in adolescents
demonstrated heritability estimates of over 80% for susceptibility to lifetime
smoking and current use (Maes et al., 1999). Other aspects of smoking are
also influenced by genetics, such as weight gain following cessation (Swan &
Carmelli, 1995).
It is evident that there are different genetic contributions to different
aspects of smoking behaviour, such as initiation, amount used, development
of compulsive use, withdrawal symptoms, and development of tolerance.
These factors individually contribute to the ICD-10 criteria for dependence
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(Box 1.2).  Thus, it can be seen that there are multiple genetic factors (as well
as environmental factors such as availability and marketing) that contribute
at different stages in the development of dependence.
Tobacco dependence and linkage studies
There is some evidence that smoking behaviour is associated with at least
14 different chromosomal locations (Bergen et al., 1999; Duggirala, Almasy
& Blangero, 1999; Straub et al., 1999;).  These studies suggest that the effect of
any one gene on smoking behaviour is likely to be weak (Bergen et al., 1999;
Arinami et al., 2000; Duggirala, Almasy & Blangero, 1999).  One of the loci of
interest is located on chromosome 5q near the locus for the dopamine D1
receptor, and this receptor has been associated with smoking (Comings et
al., 1997; Duggirala, Almasy & Blangero, 1999).
Candidate genes for tobacco dependence
Nicotine is the primary compound in tobacco that establishes and maintains
tobacco dependence (Henningfield, Miyasato & Jasinski, 1985). Smokers who
are dependent on tobacco adjust their smoking to maintain their nicotine
levels (Russell, 1987). Studies have been carried out to examine if genetic
variation in the specific receptors for nicotine (Mihailescu & Drucker-Colin,
2000) as well as in pathways of nicotine elimination (Tyndale & Sellers, 2002)
alter aspects of smoking behaviour.
Nicotinic receptors
Several types of evidence have suggested that a nicotinic receptor containing
the β2-subunit is necessary for at least some of the reinforcing properties of
nicotine (Mihailescu & Druker-Colin, 2000). However, no associations with
changes in these receptors have been found (Silverman et al., 2000).
Recent studies of ethanol and tobacco use by humans suggest that
common genes may influence the dependence on tobacco and ethanol. The
results of one study of inbred mouse strains, selected on the basis of their
response to ethanol, suggest that the α4 nicotinic receptor gene should be
evaluated for its potential role in regulating ethanol and tobacco use in
humans (Tritto et al., 2001).
Nicotine metabolism
Variation in the metabolic inactivation of nicotine is important because of
the role of nicotine in producing tobacco dependence and regulating smoking
patterns (Henningfield, Miyasato & Jasinski, 1985; Russel, 1987). Smoking is
increased if the nicotine content in cigarettes is decreased or if nicotine
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excretion is increased, and smoking is decreased if nicotine is administered
concurrently either intravenously or with a patch. The genes involved in
nicotine metabolism may be important risk factors for smoking; the extent
of variation is likely to be a major determinant of levels and accumulation of
nicotine in the brain.
The metabolic enzyme CYP2A6 is genetically polymorphic (i.e. exists in
more than one form). It is responsible for about 90% of the metabolic
inactivation of nicotine to cotinine (Nakajima et al., 1996; Messina, Tyndale
& Sellers, 1997). A significant impact of CYP2A6 genetic variance has been
found on the risk for tobacco dependence, age of starting smoking, the
amount and patterns of cigarette smoking, duration of smoking, probability
of quitting, and some aspects of risk of developing lung cancer (Miyamoto et
al., 1999; Gu et al., 2000; Rao et al., 2000; Tyndale et al., 2002; Tyndale & Sellers,
2002). However, not all studies agree with these findings (Loriot et al., 2001;
Tiihonen et al., 2000; Zhang et al., 2001).
Among Caucasian smokers those with genetically slow nicotine metabolism
required fewer cigarettes per day, reflected in lower carbon monoxide levels,
to maintain equal plasma nicotine levels, while those with the CYP2A6 gene
duplication (fast metabolizers) smoked more, and with greater intensity (Rao
et al., 2000). In Caucasians, frequencies of genotypes with at least one decreased
or inactive allele were higher in non-smokers than in smokers (Tyndale et al.,
2002) indicating that slow nicotine inactivation modestly protects people from
becoming smokers. It has also been shown that inhibiting CYP2A6 (mimicking
the genetic defect) in smokers results in decreased smoking and rerouting of
procarcinogens to other detoxifying pathways (Sellers, Kaplan & Tyndale, 2000;
Sellers et al., 2002). Substantial variation in CYP2A6 allele and genotype
frequencies exists among ethnic groups (Oscarson et al., 1999; Tyndale et al.,
2002). These data suggest that the CYP2A6 genotype is likely to alter the risk for
smoking and may alter the risk for smoking-related disease (Bartsch et al., 2000)
among ethnic groups.
Genetics of alcohol dependence
Heritability of alcohol dependence
Heritability estimates of alcohol dependence depending on the diagnostic
criteria used (e.g. DSM-IV, ICD-10; see Boxes 1.2 and 1.3) range from 52% to
63% (van den Bree et al., 1998a). It seems that some diagnostic systems are
more sensitive in detecting genetic influences and may be more appropriate
for studies attempting to find genes for alcohol dependence (van den Bree et
al., 1998a).
Twin studies provide estimations of the heritability of predisposition to
alcohol dependence of 51–65% in females and 48–73% in males (Carmelli et
al., 1992; Kendler et al., 1994; Heath et al., 1997; Johnson et al., 1998; Han et
al., 1999a; Prescott, Aggen & Kendler, 1999; Prescott & Kendler, 1999; Enoch
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& Goldman, 2001). Heritability estimates were 66% in women and 42–75% in
men for frequency of alcohol consumption (Heath et al., 1991; Heath
& Martin, 1994) and 57% in women and 24–61% in men for average quantity
consumed when drinking (Heath et al., 1991).
It is not clear if genetic risk is a major factor in the initiation of drinking or
drinking during adolescence (Han et al., 1999a; Maes et al., 1999; Stallings et
al., 1999). It may be that environmental effects explain most of the variation
in initiation of drinking but genetic factors are more important in explaining
the frequency of intoxication (Viken et al., 1999). Genetic factors contribute
to the stability over time (68–80%) in frequency and in the quantity of alcohol
consumed per drinking occasion (Kaprio et al., 1992; Carmelli et al., 1993).
Twin studies can also be used to examine other aspects of alcohol
dependence. Estimated heritability of early alcohol use was significantly
greater in boys (55%) than girls (11%) (Rose et al., 2001). Men (but not women)
who are at increased genetic risk of alcohol dependence exhibited reduced
sensitivity to alcohol (Heath et al., 1999b). The genetic risk for alcohol
dependence was increased in those reporting a history of conduct disorder
or major depression and in those with high neuroticism, social non-
conformity, “tough-mindedness”, novelty-seeking or (in women only)
extraversion scores (Heath et al., 1997). Specific genes are also likely to
influence the heritability for alcohol withdrawal syndrome (reviewed in
Schuckit, 2000). In addition, genetic influences also alter treatment seeking
(41%) for alcohol dependence, with shared environment explaining a further
40% of the variance (True et al., 1996).
These findings indicate further that there are genetic influences at many
stages in the development of substance dependence, and indeed factors that
influence treatment-seeking behaviour.  The defining criteria of the
phenotype in question can have major effects on the results of the study.
Although it is clear that there is a genetic component to many aspects of
alcohol drinking (e.g. initiation, frequency, quantity and response to alcohol),
the relationship between genes and alcohol drinking behaviour is not a simple
one.
Alcohol dependence and linkage studies
On chromosome 4q, one location identified was very close to the region of
the alcohol dehydrogenase (ADH) genes (Long et al., 1998; Reich et al., 1998;
Saccone et al., 2000); these genes have been associated with protective effects
in Asians, as will be discussed later in this chapter (Reich et al., 1998). The
finding of a linkage to 4q in a southwestern American Indian tribe and in
Americans of European descent strongly supports a role for genes in this
location in alcohol dependence. Linkage to chromosome 4p has also been
seen near the β
1
 GABA receptor gene (Long et al., 1998).
In a study of paired siblings (sib-pairs) in Finland, alcohol dependence
showed weak evidence of linkage with a location on chromosome 6 and
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significant evidence of linkage to the serotonin receptor 1B G861C (see below);
in a southwestern American Indian tribe, significant sib-pair linkage to
chromosome 6 was also seen (Lappalainen et al., 1998). The strongest
suggestions of linkage with susceptibility loci for alcohol dependence are on
chromosomes 1 and 7, and more modest evidence for a locus on chromo-
some 2 (Reich et al., 1998). The best evidence for linkage has been seen on
chromosome 11p (D11S1984), in close proximity to the dopamine receptor D4
(DRD4) and tyrosine hydroxylase (TH) genes (Long et al., 1998).
Candidate genes for alcohol dependence
Aldehyde dehydrogenase
Alcohol is metabolized to acetaldehyde, which in turn is metabolized to
acetate before elimination from the body. The mitochondrial form of aldehyde
dehydrogenase (ALDH2) is the enzyme primarily responsible for the
metabolism of acetaldehyde to acetate (for reviews of ethanol metabolism
and dependence see Agarwal (2001); Li (2000); Ramchandani et al. (2001).
ALDH2 deficiency leads to an aversive response to alcohol due to elevated
levels of acetaldehyde, resulting in increased hangover symptoms (Wall et
al., 2000) and the alcohol flushing response, or alcohol sensitivity (Box 5.2)
(Tanaka et al., 1997; Li, 2000). ALDH2 is found on chromosome 4p which has
been linked to alcohol dependence in Asians and Europeans.
BOX 5.2
Alcohol flushing response or “alcohol sensitivity”
Some individuals show a cluster of symptoms following alcohol consumption,
which have been related to elevated acetaldehyde levels. These elevations in
acetaldehyde are due to alterations in ethanol metabolism, and can lead to the
following symptoms:
– vasodilation, increased skin temperature, feeling of hotness, facial flushing
– increased heart rate and respiration
– decreased blood pressure
– bronchoconstriction
– nausea and headache
– euphoria or aversive reactions.
The neurotransmitters involved in this response are catecholamines, opioids,
prostaglandins, histamine and bradykinin.
Source: Eriksson, 2001.
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ALDH2*1 is a very active form found at high frequency among most ethnic
populations, while the ALDH2*2 is inactive (or has very low activity) and is
found at high frequency among Asians (e.g. Chinese, Japanese and Korean
people). The ALDH2*2 has been demonstrated to be associated with
substantial protection from alcohol in Japanese (Maezawa et al., 1995;
Nakamura et al., 1996; Okamoto et al., 2001), Han Chinese (Chen et al., 1999),
and Korean people (Lee et al., 2001). Genetic variation in ALDH2 in multiple
ethnic groups alters the amount of ethanol consumed ( Tanaka et al., 1997;
Sun et al., 1999; Okamoto et al., 2001) and risk for binge drinking (Luczak et
al., 2001). An association with liver disease was observed in some (Chao et
al., 1997) but not all studies (Maruyama et al., 1999; Lee et al., 2001), and may
be due to the effect on levels of consumption. Other variants of the ALDH2
are also under investigation.
Alcohol dehydrogenase
Alcohol dehydrogenase (ADH) metabolizes alcohol to acetaldehyde; it exists
as a polygene family on chromosome 4p, which has been linked to alcohol
dependence.
ADH2*2 allele frequency is lower in populations with alcohol dependence,
indicating a protective role for ADH2*2 (Thomasson et al., 1994; Maezawa et
al., 1995; Nakamura et al., 1996; Chen et al., 1999). For example, in aboriginal
peoples of Taiwan (Thomasson et al., 1994) who have low frequencies of the
protective allele ALDH2*2 (and thus would be more vulnerable), but who also
have high frequencies of ADH2*2, (which is also protective), the protective
effect of ADH2*2 is evident. This has also been seen in a Jewish population
(Neumark et al., 1998; Shea et al., 2001). One study found that the ADH2
genotype had significant effects on both consumption and dependence in
men, but not in women (Whitfield et al., 1998). ADH2 polymorphism was
also associated with the risk of chronic alcohol-induced pancreatitis
(Maruyama et al., 1999).
CYP2E1
Cytochrome P-450 2E1 (CYP2E1) is a hepatic enzyme that also metabolizes
ethanol to acetaldehyde. In humans, the levels of hepatic CYP2E1 activity
were found to vary by 15-fold. The 2E1 gene appears to be genetically
polymorphic and rare 2E1 variant alleles are associated with altered ethanol
metabolism (Watanabe, Hayashi & Kawajiri, 1994; Fairbrother et al., 1998;
McCarver et al., 1998; Hu et al., 1999; Sun et al., 1999; Yoshihara et al., 2000a).
Nicotine increases hepatic CYP2E1 in animal models, and smokers have
higher CYP2E1 activity than non-smokers (Benowitz, Jacob & Saunders, 1999;
Howard et al., 2001). Consistent with this, data from twin studies suggest that
cigarette smoking may contribute to the development of tolerance to the
effects of alcohol and a diminished sense of intoxication (Madden et al., 1995;
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Madden, Heath & Martin, 1997), suggesting that smoking induces increased
alcohol metabolism. While studies have not focused on whether genetic
variation in CYP2E1 alters the risk for smoking per se, an intriguing association
between a CYP2E1 polymorphism and levels of the nicotine metabolite
cotinine suggests that CYP2E1, directly or indirectly, may alter smoking and/
or nicotine/cotinine metabolism (Yang et al., 2001). The determination of a
role for genetic variation in CYP2E1 in the risk for smoking is currently being
investigated (Howard et al., 2002).
Chronic ethanol consumption results in the induction of CYP2E1, which
is believed to play an important role in the pathogenesis of alcohol-induced
liver disease and is responsible for the increased rates of ethanol metabolism
observed in those consuming relatively high amounts of alcohol (Oneta et
al., 2002). Genetic variants of CYP2E1 can alter the relative inducibility, which
may alter the impact on risk for alcohol dependence, or the resulting hepatic
damage (Lucas et al., 1995; Ueno et al., 1996).
Genetics of opioid dependence
Heritability of opioid dependence
Heritability for opioid dependence is high, estimated at almost 70% (Tsuang
et al., 2001). Twin studies consistently find higher concordance for opiate
dependence in monozygotic than in dizygotic twins, indicating a significant
genetic contribution (Lin et al., 1996; Tsuang et al., 1996;1999; 2001). Genetic
risk for dependence can be divided into a common, or shared, vulnerability
across different classes of drugs, and a genetic vulnerability to the specific
drug in question. Opiate dependence has the lowest extent of common
vulnerability to substance dependence, at 50%, indicating that there may be
specific opiate-related neurochemical components to heroin dependence.
It is clear from the above, that opiate use and dependence are at least in part
influenced by genetic factors.
Opioid dependence and linkage studies
There have been no family-based genetic linkage studies of opioid
dependence in humans.
Candidate genes for opioid dependence
The candidate gene approach requires the selection of genes with perceived
relevance to the trait in question. In the case of opioids this is easy, as the
receptor pharmacology is well understood and there are consequently good
candidate genes from the endogenous opioid system. Data from genetic
epidemiology tell us that the highest genetic contribution to opioid
dependence is from unique genetic effects – i.e. those not connected with
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dependence on other drugs – pointing to components of the endogenous
opioid system as good candidate genes. All three known receptors (mu, delta,
and kappa), and genes coding for opioid ligands have been screened for
genetic variation (Mayer & Hollt, 2001).
Mu opioid receptor
The mu opioid receptor subtype is the primary target of morphine and the
mediator of the reinforcement and reward effect of opioids, which makes
the mu opioid receptor gene the outstanding candidate for genetic
vulnerability. The data however, have not consistently associated this gene
with opioid dependence. Sequencing of the mu opioid receptor gene
identified five single nucleotide polymorphisms (single base pair changes in
nucleotide sequence) in the gene (Bond et al., 1998). However this
polymorphism was not associated with heroin dependence in a sample of
heroin-dependent individuals from China (Li et al., 1997) or Germany (Franke
et al., 2001). However a study among Hong Kong Chinese people found a
significant association (Szeto et al., 2001). Persons expressing a mu opioid
receptor variant have altered hypothalamic–pituitary–adrenal axis function
and altered responses to other physiological processes regulated through
activation of the mu opioid receptor (Wand et al., 2002). Natural sequence
variations in the mu opioid receptor gene have little influence on ligand
binding or receptor down-regulation but could modify receptor density and
signalling (Befort et al., 2001).
Kappa opioid receptor
The kappa opioid receptor has also been examined and positive association
was seen in one study (Mayer et al., 1997), but was not replicated in a second
(Franke et al., 1999). Seven allelic variants in the kappa-1 opioid receptor
gene have been discovered, (LaForge et al., 2000; Mayer & Hollt, 2001), but
there is no evidence that any are functional.
Dopamine D4 receptor
The dopamine D4 receptor (DRD4) has also shown evidence for association
with opioid dependence (Kotler et al., 1997; Li et al., 1997; Vandenbergh et
al., 2000) although this is not supported in another study (Franke et al., 2000).
Prodynorphin
Prodynorphin has also been examined (Zimprich et al., 2000). However,
prodynorphin allelic distributions were not significantly different in people
with heroin dependence and controls.
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CYP2D6
Opioid metabolizing enzymes are also strong candidate genes for involvement
in susceptibility. The most significant finding in opioid dependence is the
association found between oral codeine dependence and the metabolizing
enzyme CYP2D6 (Tyndale, Droll & Sellers, 1997). Many opioids (e.g. codeine,
oxycodone and hydrocodone) are metabolized by CYP2D6 to metabolites of
increased activity, principally morphine. It is estimated that 4–10% of
Caucasians lack CYP2D6 activity due to inheritance of two non-functional
alleles. Tyndale, Droll & Sellers (1997) found that of a group of people with
dependence on oral opiates, there were no poor metabolizers of CYP2D6
(Fisher’s exact test, p < or = 0.05). This is in contrast with 4% of people in the
non-dependent group being poor metabolizers of CYP2D6, suggesting that the
CYP2D6 variant genotype offers protection against oral opioid dependence.
However, this finding remains controversial (Mikus et al., 1998).
Genetics of the combined risk of dependence on tobacco,
alcohol, opioids and other psychoactive substances
Heritability of substance dependence
Genetic risk influences the predisposition to use and to the development of
dependence on alcohol, tobacco and opioids individually. However, there is
also a genetic contribution to use of, and dependence on, a combination of
alcohol, tobacco and other substances (Carmelli et al., 1992; Reed et al., 1994;
Swan, Carmelli & Cardon, 1996, 1997; Daeppen et al., 2000; Hopfer, Stallings
& Hewitt, 2001; Tsuang et al., 2001).
The classic adoption studies of Cadoret have been instrumental in defining
the importance of genetic factors in substance abuse (Cadoret et al., 1986,
1995). These studies demonstrated that substance abuse was significantly
greater in adoptees whose biological parents were dependent on alcohol or
other psychoactive substances, or who had a personality disorder. This led
to a model in which two genetic factors and an independent, environmental
factor from the adoptive family increase the risk of substance abuse.
The co-occurrence of lifetime tobacco and alcohol dependence has a
substantial genetic correlation suggesting a common genetic vulnerability
(True et al., 1999). Environmental features have a large influence on the
initiation of alcohol and tobacco use in adolescents, whereas alcohol and
tobacco use in slightly older young adults was more influenced by genetic
risk factors (Koopmans, van Doornen & Boomsma, 1997). People who smoke
are also at greater risk for severe alcohol dependence (Daeppen et al., 2000).
Significant genetic correlations exist between problem drinking and ever
smoking or using at least one half-pack (10 cigarettes) per day (Hopfer,
Stallings & Hewitt, 2001). The shared genetic influence on alcohol use and
smoking in women is clearest for those subjects with the highest severity of
alcohol use (Hopfer, Stallings & Hewitt, 2001).
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Smoking has been shown to be a significant risk factor for promoting the
progression of alcohol dependence (Bucholz, Heath & Madden, 2000). This
effect may occur by diminishing the effects of alcohol, because nicotine can
increase the activity of the alcohol-metabolizing enzyme CYP2E1 (Madden
et al., 1995). However, alcohol dependence is associated with more serious
nicotine withdrawal (Madden et al., 1997). This indicates that tobacco and
alcohol dependence share a considerable proportion of genes (Carmelli et
al., 1990; Hettema, Corey & Kendler, 1999; Vanyukov & Tarter, 2000). This
common genetic influence may partially explain the clinical and
epidemiological observations that people who are dependent on alcohol are
also often dependent on tobacco.
Family studies show strong familial aggregation of substance dependence
(Meller et al., 1988; Mirin et al., 1991; Kendler, Davis & Kessler, 1997; Bierut et
al., 1998; Merikangas et al., 1998). One estimate is that there is an eight-fold
increased risk of substance dependence amongst relatives of dependent
people compared to controls, which applied to a wide range of substances
including opioids, cannabis, sedatives and cocaine (Bierut et al., 1998;
Merikangas et al., 1998).
A major population-based twin study has been used to examine the role of
genes in the familial transmission of substance dependence (Kendler &
Prescott, 1998). This large-scale study showed that genetic factors substantially
influence vulnerability to substance dependence. Family environment is also
important, but family environment predominantly influences initiation,
whereas genetic factors have a stronger influence on heavy use and dependence
(van den Bree et al., 1998b; Kendler 2001). These studies place heritability
estimates for substance dependence at between 50% and 80%.
Few studies specifically address the interrelationship or overlap of
heritability between opioid dependence and alcohol dependence. There is
evidence of both common and specific additive factors transmitted in families
(Beirut et al., 1998). Overall the evidence suggests that independent causative
factors mainly operate for alcohol and opioid dependence, although there
may be some common genetic factors related to dependence in general.
Linkage studies of substance dependence
The well-established links between alcohol dependence and smoking have
been recently reviewed (Narahashi et al., 2001). Approximately one-third of
the loci that showed evidence for linkage to smoking behaviour also showed
evidence for linkage to alcohol dependence (Bergen et al., 1999). Strong
evidence for linkage to chromosome 15 was observed in a family study
involving people with alcohol dependence and heavy smokers (Merette et
al., 1999). Of note, linkage with alcohol was found on chromosome 19q12-
13, which may be due to linkage with smoking and the polymorphic CYP2A6
enzyme (19q13.2) which can inactivate nicotine (Messina, Tyndale & Sellers,
1997).
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Candidate genes involved in substance dependence
Candidate gene studies examine alleles that might reasonably be thought to
be involved in a disorder. Currently the best candidate allelic variants fulfil at
least two criteria: the variant has been shown to alter function, and the variant
has a good likelihood of being biologically relevant (Stoltenberg & Burmeister,
2000).
There are two main types of genes that have been associated with drug
dependence; those that are likely to be specific to the particular dependence
[e.g. nicotinic receptors and smoking, ethanol metabolism and alcohol
dependence (Grant et al., 1999)] and those that may play a common role in
either all or a subset of dependencies. Genetic alterations in various
combinations of the genes for neurotransmitters and receptors (i.e. serotonin,
norepinephrine, GABA, glutamate and opioid) that modify dopamine neuron
function may put individuals at risk for dependence (Comings & Blum, 2000;
Quattrocki, Baird & Yurgelun-Todd, 2000). Like other behavioural disorders,
substance dependence is polygenically (i.e. many genes) inherited and each
gene is likely to account for only a small percentage of the variance. In each
subsequent section, gene candidates that may affect dependence more
generally will follow the candidate genes specific to tobacco, alcohol and
opioid dependence.
GABAergic systems
Inhibition of GABAergic systems in the substantia nigra fine-tunes the amount
of dopamine released at the nucleus accumbens, an important site for the
effects of all psychoactive substances (see Chapters 3 and 4). GABA
A
 receptor
blockers reduce some ethanol-induced behaviours, such as motor
impairment and sedation. The role of this receptor in alcohol dependence is
further supported by effective alleviation of alcohol withdrawal symptoms
by GABA
A
 agonists (Parsian & Cloninger, 1997). In addition, one of the clusters
of GABA
A
 receptors is located on chromosome 4, at a locus which is thought
to feature prominently in alcohol dependence. Thus the GABAergic system
may alter risk for smoking and alcohol dependence (Loh & Ball, 2000).
Nicotine can stimulate the firing rate of dopamine neurons in the ventral
tegmental area (VTA), but GABAergic neurons may also be an important target
for the effects of nicotine on the central nervous system.
GABA
A
 receptor α1. No association has been found with any type of substance
dependence (Parsian & Cloninger, 1997).
GABA
A
 receptor α3. An association was found for alcohol dependence, but
not with its subtypes (Parsian & Cloninger, 1997).
GABA
A
 receptor α6. There is some evidence for the involvement of this receptor
subunit in alcohol dependence, in both animal and human studies. A locus
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for acute effects of alcohol is located on mouse chromosome 11 and encodes
the GABA
A
 receptor γ2, α1, α6, and β2 subunits, suggesting a role for these
subunits in response to alcohol (Hood & Buck, 2000). A GABA
A
 receptor variant
a6 subunit segregates in a rat line which voluntarily avoids alcohol
consumption, providing support for a possible role for variants of this
receptor subtype to alter genetic predisposition to alcohol preference (Saba
et al., 2001). Different variants of the α6 subunit are associated with lower
alcohol response (Iwata, Virkkunen & Goldman, 2000), alcohol dependence
(Loh et al., 2000) and with Korsakoff’s psychosis (Loh et al., 1999).
GABA
A
 receptor β1. GABA
A
 receptor β1 gene variants were associated with
alcohol dependence (Parsian & Zhang, 1999).
GABA
A
 receptor β2. GABA
A
 receptor β2 variants were tested and found not to
associate with alcohol dependence or alcohol withdrawal (Sander et al.,
1999a). The BanI RFLP at the GABA
A
 β2 receptor subunit gene associated with
both alcohol dependence and Korsakoff’s psychosis (Loh et al., 1999).
GABA
A
 receptor β3. An association of GABA
A
 receptor β3 variants was found
with severe alcohol dependence (Noble et al., 1998a).
GABA
A
 receptor γ2. Functionally relevant variation in GABA
A
 γ2, or a closely
linked gene, is correlated genetically with some behavioural responses to
alcohol in certain strains of mice (Hood & Buck, 2000). No association in
humans has been found (Hsu et al., 1998; Sander et al., 1999a), except in the
presence of antisocial personality disorder (see Box 6.1) (Loh et al, 2000).
GABA
B
 receptor R1. Data suggest that GABA
B
 R1 variants do not contribute a
substantial effect to the genetic variance of alcohol dependence (Sander et
al., 1999b). Nevertheless, possible evidence of potential allelic associations
emphasize the need for further studies to test more defined phenotype–
genotype relationships.
Dopamine system
Because of its importance in brain reward circuits, the mesolimbic
dopaminergic system has been implicated in the reinforcing effects of many
substances including nicotine and ethanol (Uhl et al., 1998; Merlo Pich,
Chiamulera & Carboni, 1999; Comings & Blum, 2000) (see also Chapter 3).
Accordingly, polymorphisms of genes in the dopaminergic system are
plausible functional candidate genes for tobacco and alcohol dependence.
Studies over the past decade have shown that alleles of the dopamine receptor
system are associated with alcohol and tobacco dependence, dependence
on other psychoactive substances, novelty-seeking, obesity, compulsive
gambling and several personality traits. This is an example of genetic variation
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in a system (e.g. dopamine), which may alter a number of behaviours
including alcohol and tobacco dependence.
Dopamine D1 receptor. As mentioned previously, smoking behaviour (as
defined by the number of cigarettes per day for one year) has been linked to
a genetic location on chromosome 5q (D5S1354) (Duggirala, Almasy
& Blangero, 1999) that is near the dopamine receptor D1 (DRD1) locus. An
association was made between a polymorphism, and smoking, alcohol use,
illicit drug use, compulsive shopping, compulsive eating and gambling
(Comings et al., 1997), although not all studies confirm a role for DRD1 in
alcohol use (Hietala et al., 1997; Sander et al., 1995). These results suggest a
role for genetic variants of the DRD1 gene in some dependence-related
behaviours, and further, suggest an interaction of genetic variants of the DRD1
and DRD2 genes (Comings et al., 1997).
Dopamine D2 receptor. Variants of the dopamine receptor D2 (DRD2) gene
have been associated with dependence on alcohol, nicotine, cocaine and
opioids, and with novelty-seeking, obesity and gambling, but the results have
not been consistent (Noble, 2000; Noble et al., 1998b). It is hypothesized that
the DRD2 gene is involved in reinforcement (see Chapter 3).
Among non-Hispanic Caucasians who smoked at least one pack of
cigarettes per day, had unsuccessfully attempted to stop smoking, and were
not dependent on alcohol or other drugs, the DRD2 A1 allele was more
prevalent than in controls (Comings et al., 1996), although this is not observed
in all studies (Singleton et al., 1998). There was a significant, inverse
relationship between the prevalence of the DRD2 A1 allele and the age of
onset of smoking and the maximum duration of time since the smokers had
quit smoking on their own (Comings et al., 1996). These results support the
concept that the DRD2 gene is one of a multifactorial set of risk factors
associated with smoking (Comings et al., 1996).
In summary, DRD2 may not alter risk for alcohol dependence, but alcohol-
dependent patients with the DRD2 A1 allele may have greater severity of their
disorder across a range of problem drinking indices (Connor et al., 2002).
There are a few examples where the DRD2 genetic variation has been
examined in conjunction with other genes. Variants of both the DRD2 and
GABA
A
 receptor subunit β3 genes have been associated with risk for alcohol
dependence; however, the risk for alcohol dependence is more robust when
these variants are combined than when they are considered separately (Noble
et al., 1998a). Similarly, DRD2 variant and ADH2 have been shown to have a
stronger association with risk for alcohol dependence when combined than
when alone (Amad et al., 2000).
Dopamine D3 receptor. The DRD3 receptor is found at high levels in the
nucleus accumbens, a region involved in drug reward and dependence (see
Chapter 3). A variant of the DRD3 gene has been shown in some studies to
Chapter_5 19.1.2004, 11:45142
143
5. GENETIC BASIS OF SUBSTANCE DEPENDENCE
alter function. The role of this variant in tobacco smoking has not been
studied, but it has been shown to alter use of some other substances and
psychiatric disorders. Studies of DRD3 and alcohol dependence
demonstrated no significant association (Parsian et al., 1997; Henderson et
al., 2000).
Dopamine D4 receptor. A variant of the DRD4 gene has been identified and is
thought to play a role in nicotine dependence. When exposed to smoking
cues before smoking either high-nicotine cigarettes or control cigarettes,
individuals with the DRD4 variant allele had greater craving, more arousal,
less positive affect, and more attention to the smoking cues than did those
without the variant allele (Hutchison et al., 2002a). These preliminary results
suggest that the rewarding effects of smoking and the beneficial effects of
nicotine replacement therapy may depend, in part, on genetic factors
involved in dopamine transmission.
An association study on the DRD4 gene showed that African-Americans
who had at least one variant allele had a higher risk of smoking, a shorter
time to the first cigarette in the morning, and an earlier age at smoking
initiation (Shields et al., 1998). After smoking cessation counselling, none of
the smokers with the variant allele were abstinent at 2 months, compared
with 35% of the smokers who were homozygous for the non-variant genotype.
The analysis of Caucasians did not suggest a similar risk.
Some studies have shown an association between alcohol dependence and
DRD4 receptor variation (George et al., 1993; Hutchison et al., 2002b), while
others have not (Parsian et al., 1997; Ishiguro et al., 2000; Albanese et al., 2001).
It is interesting that the DRD4 variation increased the risk for alcohol
dependence in individuals with protective ALDH2*2 variants, indicating the
overriding of the protective effects of ALDH2*2 by the DRD4 variant
(Muramatsu et al., 1996).
Dopamine D5 receptor. Several functional polymorphisms in DRD5 have been
identified (Cravchik & Gejman, 1999); however, for smoking initiation, there
was no significant association with the four DRD5 markers studied. While
these data are not consistent with a strong role for DRD5 in the etiology of
smoking behaviours, one study suggested the involvement of the locus in
the variation of risk of substance use and antisocial behaviour (Vanyukov et
al., 2000), indicating that further studies may be warranted.
Dopamine transporter. A polymorphism of the dopamine transporter has
been identified which can alter rates of transcription (production of
messenger RNA, mRNA) (Michelhaugh et al., 2001) and which is associated
with altered levels of the dopamine transporter protein in the brain (Heinz et
al., 2000), suggesting that the polymorphism results in functional differences.
However, no association with substance dependence has been found.
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Dopamine beta hydroxylase. Smokers with a particular dopamine beta
hydroxylase (DBH) genotype smoked fewer cigarettes when compared to
those without the genotype (McKinney et al., 2000). Heavy smokers
(>20 cigarettes per day) had a higher frequency of the DBH variant allele when
compared to light smokers (McKinney et al., 2000).
Monoamine Oxidase A. Central dopaminergic reward pathways give rise to
dependence and are activated by nicotine and alcohol indicating that allelic
variants in genes involved in dopamine metabolism may be important in
dependence. Monoamine oxidase (MAO) is involved in the metabolism of
neurotransmitters including dopamine, serotonin and norepinephrine. There
are two distinct forms of MAO: MAO-A and MAO-B; both are encoded in genes
on the X chromosome.
MAO activity is reduced by smoking (Checkoway et al., 1998). One study
found that smokers with a certain MAO-A genotype smoked more cigarettes
than those without that genotype (McKinney et al., 2000).
Low platelet MAO activity has been associated with alcohol dependence,
making genetic variation in these genes of interest. Variations in the MAO-A
and MAO-B genes differ between people with alcohol dependence and
controls (Parsian et al., 1995). A variant of the MAO-A gene is associated with
both a risk for alcohol dependence and lower age of onset of substance
dependence in males (Vanyukov et al., 1995).
Significant associations of alcohol dependence with MAO-A alleles were
found among the Han Chinese people, but not among aboriginal Taiwanese
groups (Hsu et al., 1996). A functional polymorphism in the MAO-A allele
was identified and the frequency was increased in males with antisocial
personality disorder and alcohol dependence, but not in those with alcohol
dependence alone or in controls (Samochowiec et al., 1999; Schmidt et al.,
2000).
Catechol-O-methyltransferase. Catechol-O-methyltransferase (COMT)
inactivates catecholamines and catechol drugs. A common genetic
polymorphism in humans is associated with a 3–4 fold variation in COMT
enzyme activity (Lachman et al., 1996). Since ethanol and nicotine use are
associated with rapid release of dopamine in limbic areas, it is conceivable
that subjects who inherit low activity alleles would inactivate dopamine more
slowly, thereby altering their vulnerability to the development of dependence.
A functional polymorphism resulting in increased enzyme activity has been
associated with alcohol dependence and polysubstance use (Vandenbergh
et al., 1997; Horowitz et al, 2000). No association was found between this
COMT polymorphism and smoking initiation, smoking persistence and
smoking cessation (David et al., 2002).
Men with a specific COMT genotype (30% of all subjects) reported 27%
higher weekly alcohol consumption compared with the two other genotype
groups (Kauhanen et al., 2000). The results indicate that COMT polymorphism
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may contribute to the amount of alcohol intake, not only in people with
alcohol dependence, but also in a general male population. Visual and
auditory disturbances among people with alcohol dependence in withdrawal
symptoms were significantly different among COMT genotypes (Nakamura
et al., 2001), suggesting that COMT activity could partially affect the
appearance of delirium tremens in these individuals.
Tyrosine Hydroxylase. Tyrosine hydroxylase (TH) is the rate-limiting enzyme
in the biosynthesis of catecholamines. Nicotine has been shown to regulate
TH, and mice with more TH are less sensitive to nicotine. No association was
found between a TH genetic polymorphism and cigarette smoking (Lerman
et al., 1997).
Results to date suggest that no major influence on alcohol dependence is
exerted through genes associated with the TH variants (Geijer et al., 1997;
Ishiguro et al., 1998; Albanese et al., 2001).
Serotonergic systems
Genes in the serotonin system are plausible candidates for association with
smoking or alcohol dependence because of the role of serotonin in mood
regulation, impulse control, appetite and aggression (Veenstra-VanderWeele
et al., 2000). Nicotine can increase serotonin release suggesting that some
aspects of smoking might be altered by variation in the serotonergic system
(e.g. variable mood disturbances during withdrawal resulting in altered
cessation rates). In addition, a number of serotonin reuptake inhibitors are
being examined for their utility in smoking cessation and in preventing weight
gain associated with smoking cessation. Alterations in the serotonergic
neurotransmission have been frequently described for patients suffering from
alcohol dependence, anxiety disorders and narcolepsy, thus the serotonergic
system provides additional candidate genes for genetic variation in alcohol
dependence and smoking.
Serotonin receptors. While functional polymorphisms have been identified
in serotonin receptors and associated with relevant personality dimensions
(e.g. harm-avoidance, reward dependence), there are no reports of
associations between serotonin receptors and smoking behaviour. In the
studies of serotonin receptor variants and alcohol dependence there are some
positive and many negative findings (Yoshihara et al., 2000b). A clearer
phenotype, including personality variables, may be required before a better
picture of the role of serotonin receptors in the genetic risk for alcohol-related
behaviours can be elucidated.
Serotonin Receptor 1B. The 5HT1B receptor gene variant (G861C) has not been
associated with alcohol dependence (Gorwood et al., 2002; Kranzler et al.,
2002), either alone or with a comorbid antisocial diagnosis (Kranzler et al.,
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2002). However for people with alcohol dependence with inactive ALDH2,
but not for those with active ALDH2, there was an association with the 5HT1B
receptor variant (G861GC), suggesting its involvement in the development
of some type of alcohol dependence (Hasegawa et al., 2002).
Serotonin Receptor 2A. Data suggest that there may be a relatively small
genetic variability in the HTR2A receptor gene involved in the development
of alcohol dependence (Nakamura et al., 1999; Hwu & Chen, 2000; Preuss et
al., 2001; Hasegawa et al., 2002).
Serotonin Receptor 2C. There is no evidence of HTR2C allele association with
alcohol dependence (Lappalainen et al., 1999; Schuckit et al., 1999; Fehr et
al., 2000; Parsian & Cloninger, 2001).
Serotonin Receptor 5. There was no evidence of HTR 5 allele differences in a
Finnish study of people with alcohol dependence and controls (Iwata et al.,
1998).
Serotonin Receptor 7. The HTR 7 L279 variant was not significantly associated
with alcohol dependence or impulsivity, however it may be a predisposing
allele in a subgroup of people with alcohol dependence and multiple
behavioural problems (Pesonen et al., 1998).
Tryptophan Hydroxylase. Genetic variation in tryptophan hydroxylase (TPH)
could significantly alter serotonergic neurotransmission and thus alter the
risk for dependence.
No association of TPH alleles with smoking status has been found (Lerman
et al., 2001), however, individuals with a specific genotype start smoking at
an earlier age (Lerman et al, 2001). In addition, another study found an
association with smoking initiation but not with progression to nicotine
dependence (Sullivan et al., 2001). These data suggest that variation in the
production of serotonin may be involved in the etiology of smoking initiation.
A higher frequency of the TPH A allele was found in Japanese people with
alcohol dependence and histories of drinking-related antisocial behaviours
(Ishiguro et al., 1999) and in Finnish people with alcohol dependence who
were also criminal offenders (Nielsen et al., 1998). However, no association
was found between the TPH A allele and alcohol dependence without
personality disorders (Han et al., 1999b; Ishiguro et al., 1999; Fehr et al., 2001).
Serotonin transporter. The serotonin transporter (5-HTT) gene (SLC6A4) is a
plausible candidate gene for smoking and predisposition to alcohol
dependence because of its association with psychological traits relevant to
smoking and drinking behaviour. A specific polymorphism of this gene has
been associated with numerous psychiatric disorders (e.g. depression, anxiety
disorders, bipolar disorders and schizophrenia).
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Other systems of interest
Cholecystokinin. The neuropeptide cholecystokinin (CCK) plays an important
role in the functioning of the central nervous system via an interaction with
dopamine and other neurotransmitters. The interaction of CCK with the
dopaminergic system has been implicated in the behaviours associated with
psychoactive drugs (Vaccarino, 1994; Crawley & Corwin, 1994).
Acute and chronic exposure to nicotine results in weight loss that is
associated with an increase in CCK in the hypothalamus; CCK antagonists
ameliorate symptoms of nicotine withdrawal, consistent with a role of the
CCK gene as a risk factor for smoking (Comings et al., 2001)
Opioid receptors. Both ethanol and opioids activate the mesolimbic dopamine
reward system, and genetic differences in the sensitivity of the endogenous
opioid system to alcohol may be an important factor in determining the risk
for the development of alcohol dependence or excessive alcohol consumption
(Gianoulakis, 2001). No consistent associations have been identified.
Glutamate transporter. Glutamate-mediated excitatory pathways play an
important role in the pathogenesis of alcohol dependence. The astroglial
glutamate transporter EAAT2 confers vulnerability to alcohol dependence;
however, no association of a polymorphism with alcohol dependence, or with
alcohol dependence with severe physiological withdrawal symptoms, or
alcohol dependence with antisocial behaviour, was observed (Sander et al.,
2000).
Confounding issues in linkage and candidate gene studies
Environment
Twin and family studies indicate a significant genetic risk for alcohol and
tobacco dependence and a substantial role for environmental factors
(Stoltenberg & Burmeister, 2000; Crabbe, 2002). It is important to remember
the latter source of variation in risk and to look for ways to integrate studies
of genetic and environmental influence (see later in this chapter). This
difficult task was reviewed for a series of complex disorders (Kiberstis &
Roberts, 2002). However, recent developments in genetics raise the possibility
of sorting out the complex interactions between genotype and environment
that determine the development of the individual behavioural phenotype.
This is clearly a direction that needs much attention.
Genetic heterogeneity
In addition to genetic and diagnostic heterogeneity, it is anticipated that
increased risk for many complex disorders such as substance dependence,
requires multiple genetic variants in combination (Stoltenberg & Burmeister,
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2000; Crabbe, 2002). Many psychiatric disorders are likely to be caused by
multiple genes that interact with each other (Cooper, 2001). This suggests
that having one predisposing allele does not imply high risk; in fact, the
majority of carriers are not expected to express the disorder (Stoltenberg
& Burmeister, 2000). Issues of genetic heterogeneity create complexity for
linkage studies, as well as for studies that examine only one gene, or allelic
variant at a time (Wahlsten, 1999).
Phenotype
At least some genetic defects appear to predispose populations to forms of
dependence that do not fall into the neatly defined categories in DSM-IV or
ICD-10 (Boxes 1.2 and 1.3). This is certainly the case for tobacco dependence
where other ways of determining dependence have been proposed and used
(e.g. Fagerstrom & Schneider, 1989; Heatherton et al., 1991). Likewise, it was
found that different symptoms of alcohol dependence yielded heritability
estimates ranging from 3% to 53% (Slutske et al., 1999), and the same has
been observed with alternative diagnostic tools for alcohol dependence (van
den Bree et al., 1998a). These findings indicate the need to clearly define the
phenotype of interest. In other words, clearly defining the endpoint (e.g.
relative risk for drinking over 8 drinks per day, alcohol withdrawal, relative
risk for initiation of smoking, initial tolerance) may improve the ability to
identify specific genes involved.
Comorbidity
Many psychiatric disorders co-occur with substance dependence (see
Chapter 6). Comorbidity among disorders will be understood only with
increased knowledge of the underlying neurobiology of the disorders.
Behavioural genetic approaches will allow investigators to directly test causes
of each disorder as well as the comorbidity, and to estimate the size of the
effect of each contributing factor.
Methodological issues
Candidate gene studies have often found conflicting results. The reasons for
differences in findings include:
— inconsistencies in the definitions of “smokers” (i.e. ever vs. never,
former, >100 cigarettes in lifetime, dependence) and “smoking
behaviour” (i.e. initiation, maintenance, quitting, cessation, relapse);
— issues concerning functionless polymorphisms, methodology (e.g.
erroneous genotyping techniques) and statistical power;
— ethnic ancestry.
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Differences in definitions of “smokers”, “drinkers” and “ethnic ancestry”
are likely to contribute substantially to the differing outcomes of studies.
Another issue is that “attractive” candidate genes will be studied in many
laboratories, and there is often a bias towards reporting positive findings.
A further issue is the practice of examining one gene and sometimes one
allele at a time. While this is simpler and requires smaller sample sizes,
examples exist which indicate that only when two or more genetically variable
genes (e.g. ALDH2 and ALD) are examined together, will meaningful results
be found. Another limitation of the candidate gene approach is the amount
of knowledge of the biology of the disorder being studied. This issue further
supports integrating research approaches, using chromosomal locations
identified by linkage or QTL studies, as well as candidate genes identified in
model systems such as Drosophila, to identify other potential candidate
genes. To understand the genetic contributions to smoking and drinking
behaviours, many aspects of the behaviour need to be assessed, as different
genes may affect the various behaviours differentially. Large studies of
multiple gene variants and clearly-defined phenotypes will lead to clearer
understanding of the specific genes and mechanisms involved.
Future directions
The genetic approaches and findings outlined in this chapter provide an
indication of the promise that genetic research offers. These genetic data can
be, and have been, used to improve our understanding of the etiology of
substance dependence and variation in risk between individuals. Once genes
are identified which alter the predisposition to dependence, a major challenge
will be to understand how the functions of these genes interact with the
environmental influences on dependence (Swan, 1999). Analysis of specific
genes will allow a rational exploration of biochemical underpinnings of the
actions of nicotine, alcohol and other substances, and makes possible a link
between behavioural change, genetic predisposition and biochemical action.
Such genes, and the proteins they encode, will become primary targets for
creating novel diagnostic tools as well as the basis of novel behavioural and
pharmacological treatments.
Genetic information may be useful for identifying individuals at increased
risk for substance dependence (and thus for refining prevention approaches),
and for predicting the health consequences of substance dependence (e.g.
hepatic toxicity). By gaining a better understanding of genes that are involved
in initiation, maintenance and cessation of substance dependence, novel
pharmacological and behavioural treatment approaches may be created
(Swan, 1999; Sellers & Tyndale, 2000; Marteau & Lerman, 2001; Johnstone,
York & Walton, 2002). This research field also offers great potential for using a
person’s genetic information to personalize treatment approaches (i.e.
choosing the appropriate treatment, drug and dose) and for minimizing
adverse reactions. Again, it is important to emphasize that a certain genetic
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make-up does not necessarily mean that a person will develop dependence,
but it may provide useful information for treatment and prevention
approaches.
In summary, the improved understanding of genetic influences on
substance dependence promises to increase our understanding of
dependence-producing processes, and should provide novel prevention and
treatment approaches.
Social and cultural aspects
It should be emphasized that complex genetic risk factors and protective
factors for dependence operate within a biological, social and cultural milieu,
which affects the outcome for each individual person. The following section
briefly highlights some of the relevant social and cultural factors.
Risk factors and protective factors for dependence: an overview
Research on risk factors for dependence involves comparisons of people with
and without dependence, and longitudinal studies with subjects who become
dependent or avoid dependence. There are both environmental risk factors
(e.g. social class, mobility, social change, peer culture, educational style and
occupational risk groups) and individual risk factors (e.g. genetic disposition,
child abuse, personality disorders) (Uchtenhagen, 2000a,b). Cultural norms,
attitudes and views about substance use (e.g. social acceptability, tolerance,
stigma) and local, national or regional policies on illicit drugs, tobacco and
alcohol may also be considered as environmental risk factors.
 Risk factors for problem drug use include family disruption and
dependence problems in the family, poor performance at school, social
deprivation, young age of onset of substance use, and depression and suicidal
behaviour during adolescence (Lloyd, 1998).
While risk factors emphasize negative influences and the importance of
prevention, protective factors stress positive alternatives and the necessity
of health promotion. Protective factors can have an independent main effect
or act as intervening variables between risk factors and behavioural outcome.
Individuals draw upon environmental or personal resources that may
enable them to cope better with stress and health-related challenges
(Antonovsky, 1987). This concept in social psychology is mirrored in sociology
in the theory of social capital. Social capital is the sum of the resources that
an individual or a group has access to through social, family or institutional
relationships (Klingemann et al., 2001).
Environmental resources include economic situation, social support,
social integration, learning models and temporal factors (Schmid, 2000). With
respect to temporal factors, age at onset of substance use is important as
well as events in life that can be characterized by a higher vulnerability to
substance use, such as experimenting with drugs when entering adolescence,
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compensating for stress factors when entering the professional adult world,
and facing retirement between the ages of 55 and 65 years (see Vogt, 2000a,b).
There is some empirical evidence that social inequality and class
differences are related to risky use of both licit and illicit psychoactive
substances. For example, the decline in smoking in some countries has been
more rapid in men and women from higher socioeconomic classes, and
drinking shows an inverse relationship with occupational status (Marmot,
1997). As regards illicit substances, ecological studies have shown that the
poverty status of communities is a powerful predictor of fatal drug overdoses
of cocaine and opioids in developed countries. For example, in a study in an
urban community in New York, 69 % of the variance in fatal drug overdoses
was explained by poverty status (Marzuk et al., 1997).
Poverty also is associated with problems of nutrition and a wide array of
negative contextual conditions: malnourished individuals are especially
vulnerable to adverse effects of consumption of licit and illicit substances
(Charness, 1999). General health status and nutritional state play an
important role: for example diabetes, hypertension and hepatitis C virus
increase vulnerability to alcohol (Regev & Jeffers, 1999; Weathermon & Crabb,
1999. More specifically, health-related knowledge about alcohol use and anti-
drinking attitudes lowered the odds of drinking (Epstein et al., 1995).
Personal resources include coping skills, self-efficacy, risk perception,
optimism, health-related behaviour, ability to resist social pressure and
general health behaviour. These resources will interact with and possibly be
enhanced by community programmes that can fulfil the needs of people to
resort less frequently to substance use, and that provide a healthy
environment in which the individual feels less pressured to use licit and illicit
substances.
Summary
Family, twin and adoption studies provide strong evidence for a significant,
but not exclusive, genetic contribution to the development of substance use
and dependence. Environmental factors, and individual specific experiences,
are also of major importance. Family and adoption studies that have focused
on general risk for substance use show that substance dependence is a familial
trait, which can be attributed to either shared environment or shared genes.
Twin studies consistently show higher monozygotic than dizygotic
concordance for substance dependence, indicating a genetic effect.
The significant and complex genetic contributions to substance
dependence continue to motivate efforts to identify allelic variants that
contribute to dependence vulnerability, even if each allelic variant contributes
only a modest fraction to the whole problem. Genotypes at loci containing
vulnerability alleles could provide improved approaches to treating
vulnerable individuals and thus maximize the use of resources for prevention
and treatment. Individual and societal suffering could be relieved by better
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understanding the complex human processes of dependence through careful
application of complex genetic approaches.
The two main approaches to estimate genetic and environmental
components of phenotypic variance are twin and adoption studies. Twin
studies strongly indicate the presence of genetic risk factors for multiple
aspects of smoking and alcohol dependence, including initiation,
continuation, amount consumed and cessation. Moreover a plethora of
studies indicate considerable commonality between tobacco and alcohol
dependence, making the identification of both common and substance-
unique genetic influences crucial and challenging. In addition to estimating
genetic liability, these studies provide further information about
environmental contributions, identifying that which is shared (i.e. that which
both twins have in common and which contributes to their similarity) and
that which is non-shared (contributing to the relative dissimilarity) (Heath,
Madden & Martin, 1998; Vanyukov & Tarter, 2000; Jacob et al., 2001).
Table 5.1 Summary of heritability of dependence on selected substances
Substance Heritability Linkage Candidate genes
 estimates
(%)
Nicotine 60–80 Chromosome 5q near D1 CYP2A6
receptor loci Dopamine D4 receptor
Dopamine Beta hydroxylase
Alcohol 52–63 Loci on chromosomes 4q, ALDH2
6, 1, 7, 2, 11p, 10q ADH
CYP2E1
GABAA α6, β1, β3, γ2
Dopamine D4 receptor
COMT (catechol-O
methyltransferase)
Serotonin 2A receptor
Opioids 70 None identified CYP2D6
Combined risk for 50–80 Loci on chromosome 15, Dopamine D1 receptor
substance 19q12-13 Dopamine D2 receptor
dependence Dopamine D4 receptor
in general Monoamine oxidase A
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CHAPTER 6
Concurrent Disorders
Introduction
Over the past decade, there has been increasing awareness that there is a
high degree of comorbidity (co-occurrence in the same individual) between
various psychiatric disorders. That is, individuals with a history of one
psychiatric disorder are much more likely than would be expected by chance
to have a history of another psychiatric disorder (Robins & Regier, 1991;
Kessler et al., 1994). Most relevant to this report are data indicating that there
is high comorbidity between any mental disorder and substance dependence.
Specifically, these data indicate that:
• Lifetime prevalence of alcohol disorder is 22.3% for individuals with
any mental disorder compared to 14% for the general population, and
that the odds of having an alcohol disorder if a person also has any
mental disorder are 2.3 times higher than if there is no mental disorder
(Regier et al., 1990).
• Among people with substance (except alcohol) use disorders, 53% also
suffer from at least one other mental disorder, with an odds ratio of 4.5
when compared to people without substance (other than alcohol)
disorders (Regier et al., 1990).
• Higher percentages of people with mental illness, particularly those
with schizophrenia, smoke tobacco than in the general population and
among people without mental illness. Depending on the particular
mental illness, it has been reported that 26–88% of psychiatric patients
smoke compared to 20–30% of the general population (Glassman et
al., 1990; Breslau, 1995; Hughes et al., 1986).
Despite the fact that the majority of studies were undertaken in a few
developed countries and the degree of comorbidity in many cultures is vastly
unknown, this high degree of comorbidity between mental disorders and
substance use disorders strongly suggests that these disorders are linked
because of shared neurobiological and behavioural abnormalities. Although
most scientists and clinicians would agree with this suggestion, it remains
unclear as to what the causal factors are. That is, does mental illness lead to
substance dependence, or does substance dependence lead to mental illness,
or are both mental illness and substance dependence independent
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symptomatic manifestations of the same underlying neuropathologies? These
are topics of considerable recent interest and research at both the clinical
and preclinical levels.
The purpose of this chapter is to present several hypotheses that may
explain the high degree of comorbidity between mental illness and substance
dependence. Emphasis will be placed on the comorbidity of schizophrenia
and depression with illicit drug dependence, tobacco smoking and alcohol
use, with particular reference to dependence on psychostimulants and
tobacco. Schizophrenia and depression were selected on the basis of high
societal and economic costs of these two disorders (Rupp & Keith, 1993;
Mauskopf et al., 1999; Meltzer, 1999; Wong & Licinio, 2001), and on the fact
that they appear to be highly associated with substance use disorders.
Generally, research findings over the past decade will be highlighted, although
older findings will also be referred to where relevant. Finally, directions for
future clinical and preclinical research will be discussed, as well as
considerations for treatment and prevention of substance use disorders.
It is also important to recognize that the effects of many psychoactive
substances can produce psychiatric-like syndromes. For example, as
discussed in Chapter 4, amphetamines and cocaine can induce psychotic-
like symptoms, and some drugs can produce hallucinations, which are an
aspect of some psychoses. Furthermore, psychoactive substances alter mood
states, producing either euphoria and feelings of well-being, or inducing
depression, especially during substance withdrawal. Psychoactive substances
can alter cognitive functioning, which is also a core feature of many mental
illnesses. These factors all suggest common neurobiological mechanisms to
both mental illnesses and substance dependence.
Research into the comorbidity of mental illness with substance dependence
will provide new insights into both disorders, and may provide improved
treatment and prevention strategies for both disorders independently, and
when they co-occur. Research in developing countries, among the general
population, and among people seeking or receiving treatment is also of extreme
importance for better understaning the relationship between biological and
environmental factors related to comorbidity.
Hypotheses that may explain the observed comorbidity
As discussed above, the high comorbidity between any mental illness and
substance dependence in humans in certain populations (Rounsaville et
al., 1982; Robins et al., 1984; Rounsaville et al., 1987; Robins & Regier, 1991;
Rounsaville et al., 1991; Kessler et al., 1994; Kosten, Markou & Koob, 1998)
is likely to reflect similarities in the neurobiology of these psychiatric
disorders.
Four neurobiological hypotheses can be postulated to explain this
comorbidity.
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1. Psychoactive substance use disorders and other mental illnesses are
different symptomatic expressions of the same pre-existing
neurobiological abnormalities.
2. Repeated substance administration leads – through possibly aberrant or
excessive neuroadaptations to acute substance effects – to biological
changes that have some common elements with the abnormalities
mediating other mental illnesses, such as depression.
3. Psychoactive substance use may reflect self-medication intended to reverse
some of the abnormalities associated with mental illness; these
abnormalities may have existed prior to substance use or may have been
caused by the substance use. This hypothesis is related closely to, and is
not independent of, the second hypothesis.
4. Substance dependence and other mental illnesses have different and
independent neurobiological mechanisms, and the observed comorbidity
is simply observed by chance. However, this hypothesis is unlikely,
considering the extensive epidemiological and neurobiological data
indicating the contrary.
There are also other possible non-neurobiological reasons for this
comorbidity, such as a common environmental factor; however, a detailed
discussion of these factors is beyond the scope of this report, which focuses
on neurobiological mechanisms. There is also strong neurobiological and
genetic evidence that at least some of the association has a neurobiological
basis, as discussed below.
It should be emphasized that the first three hypotheses are not necessarily
mutually exclusive: the first hypothesis may be true for one mental disorder
and one substance, while the second and third hypotheses may be true for
another disorder and another substance. Indeed, current neurobiological and
clinical data are consistent with the notion that different hypotheses may be
true for different mental disorders, as discussed below. Furthermore, the first
three hypotheses may be true in a single patient population. That is, a
particular mental illness and substance use disorder originally may be
symptomatic expressions of the same underlying neurobiological
abnormalities; while at the same time substance use may temporarily relieve
some symptoms (i.e. through self-medication), although in the long term the
same substance use may worsen the overall severity of the mental disorder.
These hypotheses will be explored in the context of schizophrenia and
depression.
Schizophrenia
Tobacco smoking and schizophrenia
There is a high degree of comorbidity of schizophrenia with tobacco smoking.
Where it has been studied, the prevalence of smoking among individuals with
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schizophrenia is 2–3 times higher than that in the general population and
considerably higher than the prevalence among any other psychiatric
population (Masterson & O’Shea, 1984; Goff, Henderson & Amico, 1992; de
Leon et al., 1995; Hughes, 1996). Estimates indicate that in some countries,
more than 80–90% of patients with schizophrenia smoke, compared to 20–
30% in the general population (Masterson & O’Shea, 1984; Goff, Henderson
& Amico, 1992; de Leon et al., 1995; Hughes, 1996; Diwan et al., 1998).
Furthermore, individuals with schizophrenia are commonly heavy smokers
(defined as an individual smoking more than 1.5 packs of cigarettes per day),
smoke high-tar cigarettes (which are also high in nicotine content), and
extract more nicotine from cigarettes than smokers without schizophrenia
(Masterson & O’Shea, 1984; Hughes et al., 1986; Olincy, Young & Freedman,
1997).
Hypotheses to explain the high incidence of cigarette smoking among
patients with schizophrenia
The first hypothesis postulates that the high prevalence of cigarette smoking
among patients with schizophrenia reflects an attempt to reduce neuroleptic-
induced side-effects, such as Parkinsonism (difficulty initiating movements)
and tardive dyskinesias (explained below) (Jarvik, 1991). Schizophrenia is
associated with excessive activity in mesolimbic and mesocortical dopamine
pathways (see Chapter 2). Neuroleptic drugs used to treat schizophrenia block
dopamine receptors; however, they block both the affected pathways
(mesolimbic, mesocortical) as well as unaffected pathways such as the
nigrostriatal pathway which is involved in motor function. Therefore,
neuroleptic medications can lead to side-effects such as Parkinsonism. Long-
term use of neuroleptics can also lead to side-effects associated with the
changes in the brain that occur in response to long-term blockade of
dopamine receptors, such as an increase in the number or sensitivity of these
receptors. Such changes result in excessive involuntary movements, most
often in the mouth and facial area and extremities, called tardive dyskinesias.
Anecdotal evidence indicates that a small proportion of patients with
schizophrenia report that smoking helps reduce the side-effects of their
antipsychotic medication (Glynn & Sussman, 1990). Patients with
schizophrenia who are smokers are usually prescribed higher levels of
neuroleptic medication compared with nonsmokers (Goff, Henderson
& Amico, 1992; Ziedonis et al., 1994) because cigarette smoking increases the
metabolism of these medications. This change in metabolism is caused not
by nicotine but by the “tar” (polynuclear aromatic hydrocarbons) in cigarettes
that induces hepatic microsomal enzymes (Glassman, 1993; Ziedonis et al.,
1994). Results from studies on smoking and the side-effects of antipsychotic
medications have been mixed, with reports of increased side-effects,
decreased side-effects, and no change in side-effects (Binder et al., 1987; Yassa
et al., 1987; Decina et al., 1990; Menza et al., 1991; Goff, Henderson & Amico,
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1992; Sandyk, 1993; Ziedonis et al., 1994). Nicotine could help to decrease
these side-effects through its stimulatory effects on dopamine, and it could
also reduce them through its effects on acetylcholine, which acts in the basal
ganglia (see Chapter 2) and other brain areas to help coordinate movements.
However, the exact mechanism is not currently known. This will be discussed
in more detail at the end of this section.
The second hypothesis regarding tobacco dependence and schizophrenia
postulates that nicotine administration through tobacco smoking ameliorates
the sensory gating deficits and perhaps even more generalized cognitive
deficits (Dalack, Healy & Meador-Woodruff, 1998) that are characteristic of
patients with schizophrenia. (Freedman et al., 1997). Again, the exact
mechanisms responsible for this are not currently known, but the stimulatory
effects of nicotine on dopaminergic and cholinergic systems are strong
candidates.
The third hypothesis postulates that nicotine administration through
tobacco smoking ameliorates the negative symptoms of schizophrenia that
are most resistant to the majority of currently available antipsychotic
treatments (Marder, Wirshing & Van Putten, 1991; Dalack, Healy & Meador-
Woodruff, 1998; Jibson & Tandon, 1998; Moller, 1998). Schizophrenia is
characterized by the so-called positive and negative symptoms (American
Psychiatric Association, 1994). Positive symptoms reflect an excess or
distortion of normal functions, such as hallucinations, delusions and
disorganized thought and speech. Negative symptoms reflect a diminution
or loss of normal functions, such as loss of pleasure in normally pleasurable
activities, loss of motivation, reluctance to speak or impoverished speech,
and flattening of emotions. These symptoms appear to result from alterations
in reward and motivational processes associated with mesolimbic and
mesocortical dopamine. Accruing clinical evidence over the past decade
provides some support for the hypothesis that patients with schizophrenia
self-medicate negative symptoms with cigarette smoking (Marder, Wirshing
& Van Putten, 1991; Dalack, Healy & Meador-Woodruff, 1998; Jibson & Tandon,
1998; Moller, 1998). In a study of 182 patients with schizophrenia, heavy
smokers had significantly fewer negative symptoms than non-smokers with
schizophrenia (Ziedonis et al., 1994). Further, patients with negative
symptoms were less likely to quit smoking than other schizophrenia patients
who exhibited few negative symptoms, while no such relationship was shown
for positive symptoms and smoking cessation (Hall et al., 1995). Interestingly,
patients treated with atypical antipsychotic drugs such as clozapine,
risperidone and olanzapine, which are considered to be more effective against
the negative symptoms than traditional neuroleptic antipsychotic
medications such as haloperidol (Claghorn et al., 1987), reduced their
smoking by 25–30% compared with patients who received traditional typical
medications (George et al., 1995; McEvoy et al., 1995; McEvoy et al., 1999;
George et al., 2000). If indeed atypical antipsychotic drugs are more effective
against the negative symptoms than neuroleptic medications (Claghorn et
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al., 1987), this may reflect diminished need to self-medicate negative
symptoms with cigarette smoking after the more efficacious treatment of
these symptoms with atypical antipsychotics. This may also be related to the
fact that atypical antipsychotics do not stay on the dopamine D2 receptor as
long as do the traditional neuroleptics, thereby allowing more physiological
dopamine transmission (Kapur & Seeman, 2001). Thus atypical antipsychotics
do not have as many side-effects, and the need for nicotine to reduce these
side-effects is decreased. Taken together, the above results suggest that
nicotine has a beneficial effect on negative symptoms in patients with
schizophrenia, and this effect may be one of the reasons why these patients
smoke excessively. The most likely neurobiological mechanism for this effect
is the increase in dopaminergic and cholinergic function in the brain. Further
research on this subject is necessary to determine the exact mechanisms that
will provide insight into the etiology and treatment of both schizophrenia
and nicotine dependence.
Although the available clinical data do not offer support for one versus
the other two interpretations for reduced smoking with atypical antipsychotic
medications, such findings have led to promising speculations that these
medications “may play a unique role in the treatment of substance-using
patients with schizophrenia” for reasons that are poorly understood (Wilkins,
1997; Krystal et al., 1999; McEvoy, Freudenreich & Wilson, 1999). In addition,
as indicated above, patients with schizophrenia may smoke for improvement
in all three domains, that is negative symptoms, cognitive deficits, and
extrapyramidal side-effects induced by neuroleptic medications. Finally, it
must be emphasized that the degree of comorbidity between smoking and
schizophrenia will also depend on the levels of smoking in the general
population of a given country. Comparative international studies are needed
to clarify the relative role of neurobiology and environment on comorbidity
between smoking and schizophrenia.
Psychostimulant (cocaine and amphetamine) dependence and
schizophrenia
There is a high degree of comorbidity between schizophrenia and
psychostimulant use in countries with high high rates of cocaine and
amphetamine use. Psychostimulant use is 2–5 times higher among patients
with schizophrenia compared with the general population, and more
prevalent than in other psychiatric populations (LeDuc & Mittleman, 1995).
It was estimated that 19–50% of patients with schizophrenia use
psychostimulant drugs (Cuffel, 1992; Ziedonis et al., 1992; LeDuc &
Mittleman, 1995; Patkar et al., 1999). Interestingly, however, patients with
schizophrenia appear to prefer psychostimulants to psychoactive
substances with sedative properties, such as opiates, barbiturates and
alcohol (Schneier & Siris, 1987; Dixon et al., 1990; Mueser et al., 1990).
Certain symptoms of psychostimulant withdrawal also resemble the
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negative symptoms of schizophrenia (American Psychiatric Association,
1994; Markou, Kosten & Koob, 1998; Green et al., 1999; Ellenbroek & Cools,
2000). Together, these observations have led to several hypotheses that
attempt to explain the high incidence of psychostimulant use among
patients with schizophrenia. These hypotheses are not mutually exclusive
and parallel those postulated to explain the high incidence of tobacco
smoking among patients with schizophrenia. The commonalities in these
hypotheses are not surprising considering that cocaine and amphetamine
are psychomotor stimulant drugs, and nicotine is considered also to be a
relatively mild psychostimulant.
Hypotheses to explain the high rate of psychostimulant use among
patients with schizophrenia
The first hypothesis postulates that the high rate of psychostimulant use
among patients with schizophrenia reflects an attempt to reduce the
unpleasant side-effects of chronic neuroleptic treatment, including the motor
side-effects (Schneier & Siris, 1987; Robinson et al., 1991). The reasons for
this are likely to be the same as for nicotine. Briefly, since neuroleptic drugs
block dopamine, and excessive dopamine blockade results in motor and other
side-effects, the use of substances that increase dopamine function may
provide relief from such effects.
The second hypothesis postulates that administration of psychostimulants
ameliorates the cognitive deficits associated with schizophrenia (Cesarec
& Nyman, 1985; Krystal et al., 1999). Again, the mechanism of this effect is
likely to be through increasing mesolimbic and mesocortical dopamine
transmission; however, there is very little evidence in support of, or against,
these two hypotheses.
The third hypothesis postulates that administration of psychostimulants
ameliorates the negative symptoms of schizophrenia that are most resistant
to the majority of currently available antipsychotic treatments (Khantzian,
1985, 1997; Schneier & Siris, 1987; Dixon et al., 1990; Sevy et al., 1990;
Rosenthal, Hellerstein & Miner, 1994; Krystal et al., 1999). Experimental
studies over several decades in humans have clearly indicated that although
acute amphetamine administration exacerbates the positive symptoms of
schizophrenia, chronic administration diminishes the negative symptoms
(Angrist, Rotrosen & Gershon, 1980, 1982; Desai et al., 1984; Khantzian, 1985;
van Kammen & Boronow, 1988; LeDuc & Mittleman, 1995; Sanfilipo et al.,
1996; Krystal et al. 1999). Furthermore, patients with schizophrenia who use
psychostimulants exhibit less severe negative symptoms than patients who
do not (Dixon et al., 1991; Soni & Brownlee, 1991; Buckley et al., 1994; Lysaker
et al., 1994). Interestingly, clozapine, a neuroleptic drug that helps reduce
the negative symptoms of schizophrenia, reduced substance use, including
psychostimulant use, in more than 85% of the patients, and prevented re-
initiation of substance use (Zimmet et al., 2000).
Chapter_6 19.1.2004, 11:48175
NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE
176
Alcohol use and schizophrenia
Similar links are also observed between schizophrenia and alcohol
dependence as those between schizophrenia and nicotine or psychostimulant
use. As reported in one large study, an individual with alcohol dependence is
3.3 times more likely to also have schizophrenia, while a patient with
schizophrenia is 3.8 times more likely to exhibit alcohol dependence than in
the general population (Regier et al., 1990). Nonetheless, it is not clear what
the factors leading to this comorbidity are, and few hypotheses have been
advanced to explain this association.
Hypotheses to explain the high rate of alcohol use among patients with
schizophrenia
As with other psychoactive substances, it has been suggested that alcohol
use may be self-medication for symptoms of schizophrenia; however, the
available data do not support this self-medication hypothesis. Most clinical
studies, patient reports and anecdotal clinical observations indicate that
excessive use of alcohol leads to a clear exacerbation of schizophrenia
symptomatology (Soyka, 1994; Tsuang & Lohr 1994; Pristach & Smith, 1996;
Gerding et al., 1999). Furthermore, it appears that approximately 30% of
comorbid patients show harmful use of alcohol before the first signs of
schizophrenia emerge (Hambrecht & Hafner, 1996). In terms of schizophrenia
and alcohol dependence, the hypothesis that best explains the available data
is that alcohol dependence and schizophrenia are different symptomatic
expressions of the same underlying neurobiological abnormalities, with
alcohol use exacerbating symptoms of schizophrenia. The precise nature of
the neurobiological basis of this association is not known, but more research
will help to clarify the epidemiology, etiology and treatment of schizophrenia
and alcohol dependence. Hypotheses regarding the neurobiological basis of
this association are discussed below.
Neurobiological interactions between schizophrenia and the effects of
psychoactive substances
There are several brain systems where schizophrenia-related abnormalities
and the effects of psychoactive substances may interact to lead to the high
degree of comorbidity of schizophrenia with substance dependence. One of
these systems is the mesolimbic dopamine system together with its efferent
and afferent connections to other brain sites and systems. This system is
comprised of dopaminergic projections from an area in the midbrain, called
the ventral tegmental area (VTA), to the forebrain region of the nucleus
accumbens (also called the ventral striatum) (Mogenson et al., 1980) (see
Chapter 2). There is considerable evidence that increased activity of the
mesolimbic dopamine system is critically involved in mediating the
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rewarding effects of most psychoactive substances (Koob, 1992; Koob et al.,
1993; Wise, 1998), and possibly drug craving (Markou et al., 1993; Self, 1998;
Kilts et al., 2001), although “memory” systems may also be critically involved
in craving and dependence (Holden, 2001; Vorel et al., 2001) (see Chapter 3).
It has been shown that administration of most psychoactive substances, such
as cocaine, amphetamine, nicotine and opioids, increases dopamine levels
in the nucleus accumbens (e.g. DiChiara et al., 1999) (see Chapters 3 and 4).
Moreover, similar increases in dopamine levels are seen in the amygdala, a
limbic brain site believed to be involved in the rewarding effects of
psychoactive substances and interconnected with the nucleus accumbens.
Increased functioning of the mesolimbic dopamine system has long been
implicated in the pathophysiology of schizophrenia (Snyder, 1976; Carlsson,
1977). Neuroleptic antipsychotic medications are dopamine receptor
antagonists, and thus, their therapeutic effects are believed to involve
dampening of an overactive dopaminergic system (Carlsson, 1978).
Consistent with this notion is the finding that administration of high doses
of psychostimulant drugs that increase dopamine levels in the nucleus
accumbens can induce a transient psychotic state in healthy individuals (Bell,
1965; Angrist & Gershon, 1970; Griffith et al., 1972). Thus it has been argued
that the overactive dopamine systems, or hyperdopaminergia, of patients with
schizophrenia renders them more likely to seek and use psychoactive
substances, and to be more susceptible to their rewarding effects (Chambers,
Krystal & Self, 2001).
In addition, developmental abnormalities in the hippocampus and the
prefrontal cortex associated with schizophrenia may further contribute to
the malfunctioning of the nucleus accumbens system (Chambers, Krystal
& Self, 2001). There is accruing evidence that patients with schizophrenia
exhibit a disruption in the distribution of cells in the hippocampus (Scheibel
& Conrad, 1993; Fatemi, Earle & McMenomy, 2000; Webster et al., 2001), and
reductions in hippocampal volume (Bogerts et al., 1993; Razi et al., 1999;
Heckers, 2001; Rajarethinam et al., 2001). In the healthy brain, glutamate
projections from the hippocampus and the prefrontal cortex have been shown
to modulate both the activity of dopamine neurons in the nucleus accumbens
(together with inputs from other brain sites such as the amygdala, the
thalamus and the entorhinal cortex) and the behavioural output of the
nucleus accumbens (Wilkinson et al., 1993; Grace, 1995; Finch,1996; Blaha
et al., 1997; Mittleman, Bratt & Chase, 1998; Legault, Rompre & Wise, 2000). It
is hypothesized that in schizophrenia there is malfunction of the normal
inhibitory glutamatergic control exerted by projections from the
hippocampus and the prefrontal cortex on the nucleus accumbens, resulting
in increased drug-seeking and drug-taking behaviour. That is, the
neuropathology of schizophrenia may contribute to the vulnerability to
substance use, and eventually dependence, by increasing the sensitivity of
patients with schizophrenia to the positive rewarding effects of psychoactive
substances. In support of this hypothesis preliminary data indicated that
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patients with schizophrenia exhibited more intense craving for cocaine
during the first three days of abstinence compared with cocaine users who
do not have schizophrenia (Carol et al., 2001). The above theoretical
conceptualization is consistent with the first hypothesis discussed at the
beginning of this chapter; that schizophrenia and substance dependence are
different symptomatic expressions of the same neuropathology.
In addition to excess dopamine function in mesolimbic and mesocortical
brain regions, another neurobiological abnormality that characterizes
schizophrenia is decreased functioning of cortical dopaminergic systems. It
has been suggested that this hypofrontality contributes to the cognitive
deficits associated with schizophrenia (Knable & Weinberger, 1997; Dalack,
Healy & Meador-Woodruff, 1998; Hazlett et al., 2000). Atypical antipsychotic
medications that are relatively effective in ameliorating the cognitive deficits
in patients with schizophrenia also increase dopamine activity in the frontal
cortex (Nomikos et al., 1994; Meltzer, Park & Kessler, 1999; Pallanti, Quercioli
& Pazzagli, 1999; Rowley et al., 2000; Cuesta, Peralta & Zarzuela, 2001; Harvey
& Keefe, 2001). Increases in the functioning of the cortical dopaminergic
system can also be induced through administration of a variety of
psychoactive substances that are used by patients with schizophrenia.
Specifically, psychostimulants such as amphetamine, cocaine and nicotine
increase dopamine levels in the frontal cortex (Sorg & Kalivas, 1993; Marshall
et al., 1997; Tanda et al., 1997; Beyer & Steketee 2000; Balla et al., 2001). Indeed,
it has been shown that nicotine administration through tobacco smoking
ameliorated some cognitive deficits of patients with schizophrenia (George
et al., 2002), which have been shown to involve activation of the prefrontal
cortex (Funahashi & Kubota, 1994; Goldman-Rakic, 1995; Kikuchi-Yorioka &
Sawagushi, 2000; Manoach et al., 2000). In conclusion, the above speculation
that psychoactive substances increase the functioning of the frontal cortex,
and thus lead to improved cognitive function in patients with schizophrenia
is consistent with a self-medication hypothesis of comorbidity of
schizophrenia with substance dependence.
Another neurotransmitter system that has recently been strongly
implicated in both schizophrenia and substance dependence is the
glutamatergic system. It has been hypothesized that alterations in
glutamatergic neurotransmission are critically involved in the mediation of
schizophrenia symptoms, based on the well-established observation that
phencyclidine (PCP) administration induces both positive and negative
symptoms of schizophrenia in PCP users and human volunteers, and
exacerbates both positive and negative symptoms in patients with
schizophrenia resembling an acute psychotic episode (Allen & Young, 1978;
Snyder, 1980; Javitt & Zukin, 1991; Duncan, Sheitman & Lieberman, 1999;
Jentsch & Roth, 1999). PCP is a non-competitive antagonist at the N-methyl-
D-aspartate (NMDA) receptor (Lodge & Johnson, 1990) (see Chapter 4). PCP-
induced psychosis can last for weeks despite abstinence (Allen & Young, 1978;
Luisada 1978). Similarly, ketamine, a PCP analogue that exhibits higher
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selectivity than PCP for the NMDA receptor (Lodge & Johnson, 1990), also
induces psychosis-like effects in healthy volunteers (Newcomer et al., 1999),
and exacerbates symptoms in patients with schizophrenia (Lahti et al., 1995;
Malhotra et al., 1997). Based on the above, it is speculated that decreased
glutamatergic actions at NMDA receptors may mediate symptoms of
psychosis. In support of the argument that PCP- and ketamine-induced
psychoses are neurobiologically similar to schizophrenia, data exist showing
that PCP and ketamine effects are reversed by atypical antipsychotic
medications in both humans and in animal subjects (Malhotra et al., 1997),
but not by the typical neuroleptic haloperidol (Lahti et al., 1995).
If decreased glutamatergic neurotransmission is involved in schizophrenia,
then the administration of psychoactive substances such as cocaine,
amphetamine and nicotine would reverse this deficit by acutely enhancing
glutamatergic neurotransmission in limbic areas. It has been shown that
administration of NMDA receptor antagonists together with psychoactive
substances blocks the development of behavioural sensitization (see Chapter
3) to the locomotor-activating effects of psychoactive substances, such as
cocaine (Kalivas & Alesdatter, 1993; Wolf & Jeziorski, 1993) and nicotine
(Shoaib & Stolerman, 1992); and the development and/or expression of
dependence on opioids (Gonzalez et al., 1997), ethanol (Liljequist, 1991) and
benzodiazepine (Steppuhn & Turski, 1993). These findings suggest that
glutamatergic actions at NMDA receptors are involved in the development
of substance dependence. This hypothesis is supported by data
demonstrating that acute administration of psychoactive substances, such
as cocaine or amphetamine, increases glutamate levels in the VTA and the
nucleus accumbens which in turn increases dopaminergic neurotransmission
in limbic areas, such as the nucleus accumbens (Smith et al., 1995; Kalivas
& Duffy, 1998) that partly mediates the rewarding effects of psychoactive
substances (Koob, 1992; Koob et al., 1993; Wise, 1998). In turn, this enhanced
glutamatergic neurotransmission would lead to alterations in dopaminergic
neurotransmission (increases or decreases depending on the brain site) that
would produce rewarding effects, but may potentially worsen some
symptoms of schizophrenia if indeed hyperdopaminergia is one of the core
abnormalities of schizophrenia.
One brain site where the multiple interactions discussed above may occur
is the VTA (Mogenson, Jones & Yim, 1980). Glutamatergic afferents to the VTA,
originating in the prefrontal cortex, increase firing of dopamine neurons in
the VTA, which results in increased dopamine levels in the nucleus accumbens
(Kalivas, Duffy & Barrow, 1989; Suaud-Chagny et al., 1992; Taber & Fibiger,
1995). There are presynaptic α7 nicotinic acetylcholine receptors located
upon these glutamatergic afferents (Mansvelder & McGehee, 2000), that when
stimulated increase glutamate release. This enhanced glutamate release then
acts at NMDA and non-NMDA receptor sites on postsynaptic dopamine
neurons and increases their firing rate (Fu et al., 2000; Grillner & Svensson,
2000; Mansvelder & McGehee, 2000). These interactions between glutamate
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and dopamine systems, and nicotinic acetylcholine receptors are particularly
relevant because of the extremely high rate of smoking among patients with
schizophrenia. In addition to increased glutamate release in the VTA, nicotine
also increases glutamate release in other limbic sites, such as the nucleus
accumbens (Reid et al., 2000), the prefrontal cortex (Gioanni et al., 1999) and
the hippocampus (Gray et al., 1996). Finally, there is preclinical and clinical
evidence to suggest that some forms of cognitive deficits that patients with
schizophrenia exhibit may depend critically on α7 nicotinic acetylcholine
receptors in the hippocampus (Adler et al., 1998). Although nicotine has low
affinity for α7 nicotinic acetylcholine receptors (Clarke et al., 1985), it may
activate these α7 receptors in the hippocampus, which leads to increased
glutamate release to counteract this deficit (Dalack, Healy & Meador-
Woodruff, 1998), and thus leads to self-medication through smoking. All of
the above data suggest ways by which the use of psychoactive substances
would self-medicate symptoms of schizophrenia by enhancing glutamatergic
neurotransmission in order to counteract a possible hypoglutamatergia that
may characterize this disease.
The above represents a small subset of sites and mechanisms where the
effects of psychoactive substances and the neurobiology of schizophrenia
may overlap and/or interact to lead to the high degree of comorbidity between
the two disorders. Although many of the above neurobiological mechanisms
are speculative and most of the studies were conducted in the USA, the recent
attention to the issue of comorbidity has led to the initiation of multiple
preclinical and clinical studies. These studies will directly investigate the
neurobiology of how and why so many patients with schizophrenia use
psychoactive substances compared with people without schizophrenia or
patients having any other psychiatric disorder, in different countries and
settings.
Depression
The comorbidity of depression with substance use is of great importance
because of the high overall lifetime prevalence of affective and mood
disorders. Approximately 8–13% of the general population experience
clinical depression in their lifetime (Regier et al., 1990; Kessler et al., 1994).
The comorbidity with substance use is 32% with an odds ratio of 2.6. That
is, individuals with an affective disorder are 2.6 times more likely to use
psychoactive substances than those without affective disorder (Regier et
al., 1990). Considering the various affective disorders separately, bipolar
disorder has the highest comorbidity value, with more than 60% of those
suffering from this illness using psychoactive substances compared with
more than 27% of those suffering from unipolar major depression. The
discussion below will focus on unipolar major depression because it is the
most common among affective disorders (Regier et al., 1990; Kessler et al.,
1994).
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Tobacco smoking and depression
There are several close links between major depressive disorder and tobacco
smoking. Studies have shown that up to 60% of heavy smokers have a history
of mental illness (Hughes et al., 1986; Glassman et al., 1988), and the
prevalence of major depressive disorder among smokers is twice that of non-
smokers (Glassman et al., 1990). Moreover, smokers who had a history of
clinical depression were half as likely to succeed in quitting smoking than
smokers without such a history (14% versus 28%) (Glassman et al., 1990).
Cessation of smoking results in an aversive withdrawal syndrome in
humans (Shiffman & Jarvik, 1976; Hughes et al., 1991), components of which
may be manifest for 1–10 weeks (Hughes, 1992). Depressed mood is one of the
core symptoms of the tobacco withdrawal syndrome that is experienced by a
large proportion of the people who attempt to quit smoking (Hughes et al.,
1984; West et al., 1984; Glassman et al., 1990; Hughes, 1992; Hughes
& Hatsukami, 1992; Glassman 1993; Parrott 1993; American Psychiatric
Association 1994; Hughes, Higgins & Bickel, 1994). The majority of researchers
in the field postulate self-medication of depressive symptoms with tobacco
smoking; this depressive symptomatology may have either pre-dated the
cigarette smoking or was induced by chronic cigarette smoking (Pomerleau,
Adkins & Pertschuk, 1978; Waal-Manning & de Hamel, 1978; Hughes et al., 1986;
Glassman, 1993; Markou, Kosten & Koob, 1998; Watkins, Koob & Markou, 2000).
The link between tobacco smoking, the tobacco abstinence syndrome and
depression is also supported by the fact that bupropion, an antidepressant
compound (Feighner et al., 1984; Caldecott-Hazard & Schneider, 1992) that
is a weak norepinephrine and dopamine reuptake inhibitor (Ascher et al.,
1995), and a nicotinic acetylcholine receptor antagonist (Fryer & Lukas, 1999;
Slemmer, Martin & Damaj, 2000), has been shown to be twice as effective as
placebo in clinical smoking cessation trials (Hurt et al., 1997; Jorenby et al.,
1999), and has been approved for this indication by the United States Food
and Drug Administration (FDA). Bupropion is the only non-nicotine based
therapy approved by the FDA as an antismoking agent. Trials have been
conducted also using the antidepressants fluoxetine, doxepin, and
moclobemide, a monoamine oxidase inhibitor (MAOI) (Robbins, 1993; Ferry
& Burchette, 1994; Dalack et al., 1995; Aubin, Tilikete & Barrucand, 1996).
These studies demonstrated modest effects of these antidepressants on
tobacco withdrawal symptoms. That is, patients treated with antidepressants
showed better abstinence rates than those treated with placebo at 4 weeks,
although relapse rates at 3 and 6 months remained high. Most interestingly,
however, patients with higher baseline depression remained abstinent for
longer periods of time than those with no depression when treated with the
antidepressant fluoxetine, although their mild depression could not be
considered clinically significant (Hitsman et al., 1999).
In conclusion, most antidepressant agents have some usefulness in
reducing relapse to smoking after the smoker with depression stops smoking,
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with bupropion having the highest efficacy overall, and fluoxetine (a selective
serotonin reuptake inhibitor) being most effective in people with depression.
The efficacy of antidepressant drugs, particularly bupropion and fluoxetine,
as anti-smoking agents supports the hypothesis that pre-existing depressive
symptomatology or depression associated with protracted nicotine
abstinence contributes to the perpetuation of substance dependence (West
et al., 1984; Glassman et al., 1990; Hughes et al., 1991; Hughes & Hatsukami,
1992; Parrott, 1993; West & Gossop, 1994; Markou, Kosten & Koob, 1998).
From most of the studies reviewed above, it is unclear whether individuals
who suffer from depressive symptomatology are more likely to initiate
smoking or whether depressive symptoms are induced or exacerbated by
long-term smoking and withdrawal from smoking (Markou, Kosten & Koob,
1998). Epidemiological data support both processes (Breslau, Kilbey
& Andreski, 1993, 1998), suggesting that smoking and depression share the
same neurobiological substrates (Breslau et al., 1998). Although the
mechanisms are not currently known, candidate neurotransmitter systems
are serotonin and dopamine, both of which may be dysregulated in
depression, and are increased by nicotine. The mesolimbic dopamine
pathway is strongly associated with reward and dependence (see Chapter 3),
but is also a candidate pathway that is dysregulated in depression (Nestler et
al., 2002).
Other clinical evidence that supports a linkage between smoking and
depression comes from a potential familial aggregation. It was shown that
dizygotic twin pairs, who share only about half of their genes, had an
intermediate level of association of smoking and depression, which fell
between that of the monozygotic twin pairs (which had a higher level) and
that of the general population (which had a lower level) (Kendler et al., 1993b).
These data are consistent with the hypothesis that common or shared genes
are a source of the association between depression and smoking.
Psychostimulant dependence and depression
Epidemiological data from the USA indicate that the lifetime rates of major
depression were 32% in cocaine users, and only 8–13% among non-cocaine
users (Robins et al., 1984; Regier et al., 1990; Robins & Reiger, 1991; Rounsaville
et al., 1991; Kessler et al., 1994). Similar to tobacco smoking, antidepressant
treatment of people with substance dependence results in greater
improvement in both mood and reduction in the use of psychostimulants in
those who also suffer from depression, than among those who do not.
Treatment with antidepressants appears to decrease cocaine use, as well
as depression. Treatment with the tricyclic antidepressant desmethyli-
mipramine resulted in a 90% reduction in cocaine use in users with
depression, while users who were not depressed showed a 50% reduction in
their use of cocaine (Ziedonis & Kosten, 1991). Similarly, 26% of cocaine users
with depression who were treated with imipramine (another tricyclic
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antidepressant) had at least three consecutive cocaine-free weeks compared
with only 5% of those treated with placebo (Nunes et al., 1995). These results
suggest that psychostimulant users may consume psychostimulants in an
attempt to self-medicate an underlying negative affective state (Khantzian,
1997; Markou, Kosten & Koob, 1998).
In humans psychostimulant withdrawal is characterized by severe mood
disturbances including depressive symptoms combined with irritability and
anxiety (Gawin & Kleber, 1986; Weddington et al., 1990; Satel et al., 1991;
American Psychiatric Association, 1994). These symptoms last from several
hours to days, one of the most salient being anhedonia (i.e. diminished
interest or pleasure), which is also a core symptom of depression.This
anhedonia may be one of the motivating factors in the etiology and
maintenance of the cycle of psychostimulant dependence. Thus, the similarity
between a major depressive episode and psychostimulant withdrawal further
supports the hypothesis that there are overlapping neurobiological substrates
that mediate these depressive symptoms that are common to the two
disorders. Again, the mesolimbic dopamine system seems to be a likely
candidate that mediates both the reward of substance use, and the lack of
pleasure associated with substance withdrawal and depression. In the case
of psychostimulant dependence, it is clear that, at least in some cases, the
depressive symptoms are drug-induced. Substance use may also reflect an
attempt to self-medicate a pre-existing depression.
Alcohol use and depression
Studies in the United States over the past 20 years indicated that lifetime rates
of major depressive disorder were 38–44% in people with alcohol dependence
compared with only 7% in non-dependent individuals (Rounsaville et al.,
1982; Myers et al., 1984; Robins et al., 1984; Rounsaville, 1987; Robins & Reiger,
1991; Rounsaville et al., 1991; Kessler et al., 1994; Miller et al., 1996b; Schuckit
et al., 1997a, 1997b). Furthermore, approximately 80% of people with alcohol
dependence had symptoms of depression (Schuckit, 1985; Regier et al., 1990;
Roy et al., 1991; Kessler et al., 1996). Thus, there is substantial data indicating
that the rates of depression among people with alcohol dependence and the
rates of alcohol use among people with depression are substantially higher
than expected from the individual rates of these disorders.
Although not consistent, other evidence supporting the hypothesis that
depression and alcohol dependence are linked disorders comes from clinical
studies indicating that in some cases antidepressant treatment resulted in
both improvement in mood and reduction in alcohol use. People with
depression who are dependent on alcohol show lower rates of relapse to
alcohol use when treated with antidepressants (e.g. imipramine or fluoxetine),
compared with subjects who were given a placebo, either with or without
depression (Nunes et al., 1993; Cornelius et al., 1995; McGrath et al., 1996;
Mason et al., 1996). These observations in people with depression and alcohol
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dependence are significant considering that 80% of people with alcohol
dependence have symptoms of depression, one-third of whom meet the
criteria for a major depressive episode (Schuckit, 1985; Regier et al., 1990;
Roy et al., 1991; Kessler et al., 1996).
In summary, epidemiological and clinical evidence suggests that
depression and alcohol dependence are associated. Nevertheless, the
majority of these clinical and epidemiological studies were unable to
determine whether the depression was primary (i.e. appearing before the
onset of alcohol dependence) or secondary (i.e. appearing after the initiation
of alcohol use) and thus potentially alcohol-induced. Such a distinction is
critical in establishing whether alcohol dependence and depression are
different symptomatic expressions of the same neurobiological
abnormalities, or whether the depression is alcohol-induced, and how self-
medication may lead to the observed comorbidity. A recent study designed
to examine this issue suggested that alcohol dependence and depression were
divided nearly evenly between primary and secondary disorders (Compton
et al., 2000a). Other data suggest that alcohol dependence leads to depression
(i.e. that depression is secondary) and that once the alcohol use ceases then
the symptoms of depression remit (Schuckit, 1994).
Considering the above summarized data and the various hypotheses put
forward that attempt to explain the comorbidity of psychiatric disorders with
substance use, in the case of alcohol and depression it appears that there is
some familiar aggregation that would support the first hypothesis of common
neurobiological substrates with different symptomatic expressions, although
there is much data that are not supportive of this genetic linkage. A self-
medication hypothesis is not supported because alcohol does not improve
symptoms of depression (Hendrie, Sairally & Starkey, 1998). In fact, there are
ample data to suggest that excessive alcohol use leads to depression (Schuckit,
1994), supporting the hypothesis of drug-induced depression that explains
the high degree of comorbidity observed between alcohol dependence and
depression.
Neurobiological interactions between depression and the effects
of psychoactive substances
Substance withdrawal, one of the syndromes that may be associated with
substance dependence (Himmelsbach, 1943; Wikler, 1973; Koob & LeMoal,
2001) (see Chapter 1), exhibits similarities with depression. Cessation of
chronic drug use induces the behavioural and physical expression of the
neuroadaptations that develop as a response to drug exposure. These are
expressed as withdrawal syndromes that are distinct for each class of
psychoactive substances (Koob et al., 1993; Markou, Kosten & Koob, 1998)
(see Chapter 4). Interestingly, however, depression is a common symptom of
withdrawal from substances from a variety of pharmacological classes
including psychostimulants (Gawin & Kleber, 1986; Weddington et al., 1990;
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Satel et al., 1991), opioids (Haertzen & Hooks, 1969; Henningfield, Johnson
& Jasinski, 1987; Jaffe, 1990), ethanol (Jaffee, 1990; Edwards, 1990; Bokstrom
& Balldin, 1992; Goodwin, 1992; West & Gossop, 1994; Schuckit et al., 1997)
and nicotine (West et al., 1984; West & Gossop, 1994). This depressive
symptomatology is conceptualized to reflect alterations in reward and
motivational processes (Markou, Kosten & Koob, 1998). This similarity and
neurobiological evidence (reviewed below) suggest several commonalities
in the neurobiology of the symptomatology of depression and substance
dependence that support either of the first two hypotheses described at the
beginning of this chapter.
Alterations in the neurotransmission of serotonin, norepinephrine,
acetylcholine, dopamine, GABA, corticotropin-releasing factor (CRF),
neuropeptide Y(NPY) and somatostatin have been observed in individuals
with depression (Caldecott-Hazard et al., 1991; Markou, Kosten & Koob, 1998).
In animals most of these neurotransmitter systems are also modulated by
antidepressant treatment, suggesting their involvement in the mode of action
of antidepressant drugs. Many of these same systems have also been
implicated in withdrawal from psychoactive substances, though not all
systems have been implicated in withdrawal from every psychoactive
substance. Furthermore, some of these systems are implicated directly in the
affective/depressive aspects of substance withdrawal that constitute the
common symptomatology of substance dependence and depression
(Markou, Kosten & Koob, 1998).
Serotonin
Decreased serotonergic neurotransmission is one of the most consistent
changes occurring during withdrawal from a variety of substances, such as
stimulants (Parsons, Smith & Justice, 1991; Imperato et al., 1992; Rossetti,
Hmaidan & Gessa, 1992; Weiss et al., 1992; Parsons, Koob & Weiss, 1995),
ethanol (Rossetti, Hmaidan & Gessa, 1992; Weiss et al., 1996) and
benzodiazepines (Lima, Salazar & Trejo, 1993). Interestingly, in the case of
stimulant withdrawal, the decreases in serotonin levels in the nucleus
accumbens were larger and appeared earlier than the decreases in dopamine
(Parsons, Smith & Justice, 1995); and during ethanol withdrawal, the decreases
in serotonin levels were more resistant to reversal by further ethanol self-
administration than the decreases in dopamine (Weiss et al., 1996).
Serotonin appears to be critically involved in depression and it is
hypothesized that reduced serotonegic neurotransmission mediates
depression (Schildkraut, 1965; Coppen, 1967). Cerebrospinal fluid measures
reflecting central serotonin activity in humans with depression provided
evidence of reduced serotonergic activity (Caldecott-Hazard et al., 1991).
Accordingly, some of the most effective antidepressants are serotonin
selective reuptake inhibitors (SSRIs), with almost all SSRIs thus far tested
being effective in treating depression (Caldecott-Hazard & Schneider, 1992).
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Altering levels of serotonin produces dysphoric mood in both healthy
individuals (Young et al., 1985; Benkelfat et al., 1994; Ellenbogen et al., 1996)
and those with depression (Shopsin et al., 1975; Shopsin, Friedman
& Gershon, 1976; Delgado et al., 1990, 1991, 1993; Lam et al., 1996; Miller et
al., 1996a), suggesting a role of serotonin in depression (however, not all
studies have reported such effects (Delgado et al., 1994; Heninger et al., 1996).
Finally, chronic treatment with a variety of antidepressant treatments, such
as tricyclics, MAOIs, electroconvulsive therapy, atypical antidepressants and
SSRIs, produce robust changes in serotonin function through both
presynaptic and postsynaptic mechanisms (Willner, 1985; Green, 1987; Blier,
de Montigny & Chaput, 1990; Caldecott-Hazard et al., 1991; Blier & de
Montigny, 1994). The neurochemical changes observed in the serotonin
system consist primarily of changes at the serotonin
1A
 and serotonin
2A
receptors (Blier & de Montigny, 1994; Stahl, 1994).
Recent experiments with rats provided strong evidence for a link between
psychostimulant and nicotine withdrawal, and depression. The reward
deficits observed during either amphetamine or nicotine withdrawal were
reversed by a drug treatment that increased serotonin function (Allen et al.,
1997), with no effect on the somatic aspects of withdrawal (Harrison, Liem
& Markou, 2001). The reversal of the depression-like aspects of withdrawal
from two different substances (i.e. amphetamine and nicotine) with different
primary mechanisms of action, by a clinically-proven antidepressant
serotonergic drug treatment supports the hypothesis of overlapping
neurobiological abnormalities mediating depressive symptomatology as
observed across psychiatric diagnostic categories (Geyer & Markou, 1995;
Markou, Kosten & Koob, 1998; Geyer & Markou, 2002).
In the case of substance dependence, most available evidence emphasizes
the critical role of dopamine neurotransmission, rather than serotonin, in
the mediation of the acute rewarding effects of several psychoactive
substances, such as stimulants, opioids, nicotine and ethanol (Koob & Le
Moal, 2001). By contrast, a critical role for dopamine in depression has not
been persuasively shown (Markou, Kosten & Koob, 1998), because direct and
indirect dopaminergic agonists do not appear to be effective antidepressant
treatments (Caldecott-Hazard et al., 1991; Caldecott-Hazard & Schneider,
1992; Kapur & Mann, 1992). It may be hypothesized that decreased
dopaminergic neurotransmission may lead to some symptoms of depression,
but that most of the symptoms may be mediated by other neurotransmitter
systems.
Peptide systems
Another intriguing commonality between the neurobiology of depression and
substance dependence is the consistent observation of increased CRF
neurotransmission in both depression (Post et al., 1982; Nemeroff et al., 1984)
and withdrawal from all psychoactive substances investigated thus far
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(Richter & Weiss, 1999; Koob & Le Moal, 2001). Further, there is evidence
indicating blunted neurotransmission of neuropeptide Y (NPY) and
somatostatin in depression (Heilig & Widerlov, 1990; Rubinow, 1986), and
blunted neurotransmission of NPY in psychostimulant withdrawal
(Wahlestedt et al., 1991). Based on the hypothesis that NPY and somatostatin
systems act in opposition to the CRF system (Heilig et al., 1994), there is heuristic
value in further investigating the role of NPY and somatostatin in substance
dependence. One hypothesis is that NPY and somatostatin may be endogenous
“buffers” against the stressor-induced release of CRF. Given the role of CRF
and NPY in behavioural responses to stress (Heilig et al., 1994), it is conceivable
that neurotransmission of CRF, NPY and somatostatin is mostly related to the
anxiety or stress-like symptomatology seen in both a subgroup of people with
depression and in those in substance withdrawal. The same argument can also
be made about the GABA system that has also been implicated in depression
(Lloyd et al., 1989; Petty, 1995), and alcohol and benzodiazepine dependence
(Andrews & File, 1993; Roberts, Cole & Koob, 1996), considering that
benzodiazepines that enhance GABAergic neurotransmission are anxiolytics.
Administration of psychoactive substances, such as cocaine and alcohol,
modulate neurotransmission of CRF (Goeders, Bienvenu & de Souza, 1990;
Merlo Pich et al., 1995; Richter et al., 1995; Richter & Weiss, 1999) and NPY
(Wahlestedt et al., 1991), and thus could potentially restore temporarily the
hypothesized imbalance between the two systems.
Role of limbic structures in depression and substance dependence
Another common element between depression and substance dependence
is that most changes observed following antidepressant treatment or
administration of psychoactive substances are seen in limbic-related
structures, such as the frontal cortex, nucleus accumbens, olfactory
tubercle, hippocampus, amygdala, and the hypothalamus. For instance, in
the frontal cortex antidepressants alter the numbers of serotonin
1A
 receptors
(Peroutka & Snyder, 1980), and increase serotonin levels (Bel & Artigas,
1993). Antidepressants also produce supersensitive serotonin
1A
 receptors
in the amygdala (Wang & Aghajanian, 1980) and the hippocampus (de
Montigny & Aghajanian, 1978; Chaput, de Montigny & Blier, 1991). Chronic
antidepressant treatments also enhance dopaminergic activity in the
nucleus accumbens (Nomikos et al., 1991) and upregulate GABA
A
 receptors
in the frontal cortex (Lloyd, Thuret & Pilc, 1985). In addition, CRF receptors
are decreased in the frontal cortex of individuals with depression (Nemeroff
et al., 1988); electroconvulsive shock increases NPY brain levels in the frontal
cortex, the hypothalamus and the hippocampus (Wahlestedt et al., 1990);
and desmethylimipramine increases the numbers of somatostatin receptors
in the nucleus accumbens (Gheorvassaki et al., 1992).
Similarly, considerable evidence suggests an important role for limbic-
related structures in substance dependence and withdrawal. For example,
Chapter_6 19.1.2004, 11:48187
NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE
188
during withdrawal from psychostimulants (Parsons, Smith & Justice, 1995;
Richter & Weiss, 1999) or ethanol (Rossetti, Hmaidan & Gessa, 1992; Merlo
Pich et al., 1995; Weiss et al., 1996) dopamine and serotonin levels are
decreased in the nucleus accumbens, while CRF levels are elevated in the
amygdala. Furthermore, blockade of opioid receptors in the nucleus
accumbens or the amygdala readily induces some affective signs of opioid
withdrawal (Koob, Wall & Bloom, 1989; Stinus, Le Moal & Koob, 1990), while
blockade of dopamine receptors in the nucleus accumbens produces at least
the somatic signs of opioid withdrawal (Harris & Aston-Jones, 1994). Limbic
structures, such as the VTA, nucleus accumbens, hippocampus and the frontal
cortex are also critically involved in nicotine dependence (Dani & Heinemann,
1996; Kenny & Markou, 2001). Taken together, these data suggest that
alterations in several neurotransmitter systems implicated in depression may
also mediate dependence on psychoactive substances, and these
commonalities may underlie the comorbidity between these psychiatric
disorders.
Discussion and conclusions
In summary, clinical, epidemiological and neurobiological evidence, together
with theoretical considerations, suggest several commonalities in the
neurobiology of substance dependence, and of schizophrenia and depression
that support the first three hypotheses discussed at the beginning of this
chapter. The most likely neurobiological substrate underlying mental illnesses
and substance dependence in general is dysfunction in the mesolimbic
dopamine system. However, the many neurochemical effects of psychoactive
substances, and the many behavioural expressions of mental illnesses suggest
that there may be a number of causative factors. Research into the
comorbidity of substance dependence and mental illness will illuminate
common causative, preventative, and treatment factors. Few epidemiological
studies directly address this issue and international research is lacking.
Breslau and colleagues determined that in terms of depression and tobacco
smoking, it appears that both processes are operating, i.e. depression
predisposes to tobacco smoking and tobacco smoking predisposes to
depression (Breslau, Kilbey & Andreski, 1993; Breslau, 1995; Breslau et al.,
1998). In terms of other psychiatric disorders and substance dependence in
general, a retrospective study concluded that antisocial personality disorder
(see Box 6.1) and phobias generally appeared before the onset of substance
dependence, while for all other psychiatric disorders, the disorder appeared
before the onset of substance dependence for almost half of the cases, and
for the remaining half the reverse was true. Finally, a study on schizophrenia
and substance dependence concluded that a unidirectional causality for the
two disorders was not supported by the data (Hambrecht & Hafner, 1996).
These investigators found that 30% of patients with both schizophrenia and
substance dependence use alcohol or illicit drugs before the first signs of
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schizophrenia, while the rest start substance use around or after the first signs
of schizophrenia. In conclusion, although a clear association is indicated
between schizophrenia and depression, and substance dependence, there
are insufficient data to favour any specific hypothesis of shared neurobiology;
it is also possible that all three hypotheses are true. Future longitudinal
epidemiological studies are needed to directly address these questions.
An extension of the three hypotheses of shared neurobiology is that
substance dependence may involve, at least in some cases, self-medication
to reverse some of the neurotransmitter abnormalities associated with
depression or schizophrenia that either existed before or were induced by
substance use. None of the psychoactive substances are considered as
clinically effective antidepressant or antipsychotic medications by practising
clinicians. Nevertheless, the possibility remains that simultaneous or
sequential use of various substances – as “self-prescribed” by the emotional
or cognitive needs of the individual – leads to an adequate therapeutic effect
for specific symptoms, while the substance use may simultaneously worsen
other symptoms or the self-medicated symptoms in the long term. There are
indeed reports that substance dependence is associated with poorer outcome
and worse prognosis for patients with schizophrenia compared with patients
who are not users (Khantzian, 1985; Dixon, 1999). Thus, it may be possible
that psychoactive substances may provide short-term relief from some
symptoms but that the long-term outcome is worse than if the patient did
not use any drugs (Kosten & Ziedonis, 1997).
BOX 6.1
Substance use and the development of antisocial personality
disorder (ASPD)
Adolescents with depression often develop substance use disorders (SUD),
probably through efforts at self-medication. Substance use effects such as
impulsivity and aggressive or irresponsible behaviours, and substance use
consequences such as failure at school, and impairment of social functioning,
and the subsequent exposure to antisocial models of social cognition and
behaviour, may contribute to the development of antisocial personality disorder
(ASPD). Substance use may be the major mediator between depression and
ASPD during adolescence and young adulthood.
Recent research showed some evidence that SUD is a correlate of major
depressive disorders in adolescents and ASPD in young adults. Other correlates
may include poor social functioning or failure at school. Comparable correlates
support causal relationships between heterotypic disorders and, in the case of
ASPD, may provide useful leads for understanding the mechanisms involved in
the development of personality disorders.
Source: Chabrol & Armitage, 2002.
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The best clinical support for the self-medication hypothesis is provided
by evidence that:
— antidepressant treatment is more effective in reducing substance use
in users suffering from depression than in users who are not, suggesting
that antidepressant medication may replace the need for consumption
of psychoactive substances;
— atypical antipsychotic medications that are most effective against the
negative symptoms and cognitive deficits associated with schizo-
phrenia reduce substance use as though the need for self-medication
has been reduced;
— these studies emphasize the importance of treating comorbid psychiatric
illness, and  show that this treatment can be efficacious in managing
substance dependence.
The preclinical and clinical investigations of the factors that may lead to the
high degree of comorbidity are likely to provide valuable information about
the neurobiology of schizophrenia and depression which in turn would lead
to the development of better treatments for these debilitating disorders. If
indeed patients with schizophrenia and depression self-medicate various
symptoms with psychoactive substances, then insights could be gained from
the patients’ patterns of substance use in terms of novel medications that can
be developed that may have beneficial effects for these disorders. Accordingly,
owing to the recent awareness of the comorbidity of substance dependence
with psychiatric disorders, preclinical animal studies have been initiated to
investigate the neurobiological substrates that may explain this comorbidity.
Future studies should continue to directly address the hypotheses of shared
neurobiological substrates using animal models of depression, schizophrenia
and substance dependence, based on the current understanding of the
neurobiology of these three psychiatric disorders. Generally, it would be
fruitful to design research programmes that would explicitly test, with similar
experimental approaches, hypotheses generated in the field of depression
and schizophrenia in animal models of substance dependence and vice versa.
Considering that all psychiatric disorders, including depression,
schizophrenia and substance dependence, involve primarily behavioural
symptoms that reflect underlying neurobiological abnormalities, progress
in understanding these diseases at any level of analysis will certainly involve
a multidisciplinary approach to research. Emphasis should be placed on both
clinical and preclinical studies in the study of specific behavioural dimensions
or psychological processes (e.g. specific symptoms) that are thought to be
affected by the disorder of interest (Geyer & Markou, 1995, 2002). Long-term
prospective studies that follow individuals from an early age would also be
very informative, though difficult in practice.
Another area that requires greater research attention is the role of gender
in the presence of comorbidity among people with substance use disorders.
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Though this is an area with practical implications for treatment, few sytematic
studies of gender specific prevalence of substance dependence and
psychiatric disorders have been conducted. Findings from available studies
show that gender differences in the prevalence of psychiatric disorders among
people with substance dependence tend be consistent with findings from
general population surveys (Compton et al., 2000b; Frye et al., 2003). In one
of these studies (Frye et al., 2003), the risk of alcohol dependence in patients
with bipolar disorder was shown to be higher among women than among
men, when compared to risk in the general population. Escamilla et al. (2002)
also showed that among patients with bipolar disorder in Costa Rica, gender
was strongly associated with substance use disorders, primarily alcohol
dependence. Among adolescents with substance use problems, there were
no gender differences in the rate of bipolar disorder, but female users
exhibited a higher rate of major depression than male users (Latimer et al.,
2002).
Crosscultural studies are urgently needed to better assess and understand
the association between the use of psychoactive substances and the various
other mental disorders. The availability and increasing use of different
substances in various cultures, and specific policies related to these
substances are likely to influence the rates of comorbidity. Understanding
cultural differences that might be present will help to clarify the role of
neurobiology in the etiology of concurrent disorders.
Finally, the comorbidity of psychiatric disorders with substance
dependence, and the apparent neurobiological link between these disorders
has important implications for both the treatment of these diseases and
for public health policy. It is important for the community, health care
practitioners and policy-makers to recognize that this neurobiological link
clearly indicates that psychiatric disorders and substance dependence are
diseases stemming from underlying neuropathologies. Furthermore,
comorbidity indicates that many heavy users of psychoactive substances
have active mental disorders that would greatly benefit from psychiatric or
psychological services and treatments. There are several effective treatments
for depression and schizophrenia. Providing pharmacological and
behavioural therapies to patients with mental disorders would facilitate
abstinence or reduction of substance use, which would eventually improve
the patients’ prognosis. It should also be recognized that many of the
patients with substance dependence who are refractory to current
interventions may be so because abstinence worsens their psychiatric
symptoms. Thus, more intensive interventions may be required for people
with comorbidity to facilitate abstinence, including pharmacological
treatment to help with withdrawal symptoms. In conclusion, understanding
that there is a high degree of comorbidity of substance dependence with
psychiatric disorders will greatly facilitate the implementation of medical
treatments and public health policies that would directly address this social
and medical issue.
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CHAPTER 7
Ethical Issues in Neuroscience Research
on Substance Dependence Treatment
and Prevention
Introduction
Previous chapters have presented the latest findings in neuroscience research,
and have pointed to potential treatment and prevention strategies. However,
there are many ethical implications of the research itself, as well as the
treatment and prevention strategies, that must be considered. The rapid pace
of change in the field of neuroscience brings with it a host of new ethical
issues, which need to be addressed. This chapter considers the important
ethical and human rights issues that are raised by neuroscience research on
psychoactive substance dependence.
Types of research on the neuroscience of substance
dependence
Neuroscience research on substance dependence is classified here into five
broad categories: animal experiments; epidemiological research on substance
dependence; human experiments; clinical trials of pharmacological
treatments for substance dependence; and trials of preventive
pharmacological interventions.
Animal experiments
Animal experiments investigate the biological processes underlying
substance dependence using animal models of human substance
dependence. The major reasons for carrying out these studies are that much
greater experimental control is possible with animals, and more invasive
experiments can be done on animals than would be permitted in humans.
Epidemiological research on substance dependence
Although not strictly neuroscience research per se, epidemiological research
informs and complements neuroscience research. Epidemiological research
on patterns of substance use and dependence includes: surveys in the general
population and within the special population of drug users and dependent
persons (Anthony & Helzer, 1991; Kessler et al., 1994; Andrews, Henderson
& Hall, 2001), family studies (Swendsen et al., 2002), adoption studies (Hjern,
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Lindblad & Vinnerljung, 2002), twin studies of the genetics of substance
dependence (Heath, 1995) and longitudinal studies of substance use and its
consequences (Fergusson & Horwood, 2000; Kandel & Chen, 2000) and among
persons who have been treated for substance dependence (Hser et al., 2001).
The findings of such studies inform neuroscience research by describing
substance dependence phenomena that need to be explained by
neuroscience theories, for example, the individual characteristics that predict
substance use and the development of substance dependence and other
drug-related problems, and the genetic epidemiology of substance
dependence found in twin and adoption studies. The distinction between
epidemiological and neuroscience research on substance dependence is also
likely to become blurred when epidemiological studies include biological
measures, such as DNA, from which specific susceptibility genes can be
tested, as well as other biological markers of risk.
Experimental studies in humans
Human neuroscience experiments typically involve laboratory studies under
controlled conditions of the effects of chronic drug exposure on current brain
function or the acute effects of exposure to drugs, drug analogues, or drug-
related cues (e.g. the presence of injecting equipment) on behaviour and brain
function (Adler, 1995). An increasingly common type of study involves the
use of brain imaging technologies, such as PET, SPECT and fMRI (Gilman,
1998; Fu & McGuire, 1999) to study the acute effects of drugs and the
neurobiological consequences of chronic substance use and dependence (Sell
et al., 1999; Kling et al., 2000; Martin-Soelch et al., 2001) (see Chapters 2 and 4).
Clinical trials of pharmacotherapy for substance dependence
Clinical trials of pharmacotherapies for substance dependence compare the
effects of different drug treatments, and sometimes placebos, on the patterns
of drug use, on health, social adjustment and well-being of persons who are
dependent on drugs (Brody, 1998). The drugs that are trialed are increasingly
identified as potential treatments for substance dependence as a result of
neuroscience research on the biological mechanisms underlying substance
dependence. These may include trials of drugs that assist in completing the
withdrawal from a psychoactive substance; drugs that are intended to reduce
relapse to substance dependence after withdrawal; and drugs that are
intended to provide long-term maintenance of abstinence or psychosocial
stability.
Clinical trials have some chance of benefiting participants in the study
(Brody, 1998). This may be by obtaining access to good-quality treatment
for substance dependence (in the event of their receiving standard
treatment or a placebo) or access to a promising experimental treatment
for substance dependence (if they are assigned to the new treatment). As
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with participants in experimental studies, they may also be exposed to risks
of the drug treatment, such as side-effects and toxicity (Brody, 1998; Gorelick
et al., 1999).
Trials of pharmacotherapies to prevent substance dependence
Preventive trials involve controlled evaluations of pharmacological
treatments that aim to prevent the development of substance dependence.
This might be achieved by using a drug to treat a condition that increases a
person’s risks of developing substance dependence (e.g. attention deficit
hyperactivity disorder (ADHD), see Chapter 4). It could conceivably involve
the administration of a drug immunotherapy (e.g. against nicotine or cocaine)
to young people who are at risk of substance dependence in order to reduce
their chances of developing substance dependence.
Trials of preventive pharmacotherapies are more a prospect on the
horizon than a major undertaking at present; however, two research
developments suggest that such trials may soon be advocated. One is the
development of immunotherapies against cocaine and nicotine (see
Chapter 4). The initial motive for developing these immunotherapies has
been to reduce relapse to substance use in persons who have been treated
for substance dependence (Fox, 1997). However, these immunotherapies
could be administered to children and adolescents with the intention of
reducing their likelihood of becoming dependent. The second development
is that of “early interventions”, which so far have involved persons at high
risk of developing schizophrenia, but it is likely that the same could be
proposed for substance dependence. These involve a combination of
psychosocial and pharmacological interventions. Because this work has
been controversial in the field of psychiatry, neuroscience researchers on
substance dependence would benefit from discussions of issues that may
arise in trials of preventive pharmacological treatments for substance
dependence.
Approach to ethical analysis
Over the past 30 years or so, an influential set of moral principles has emerged
in Anglo-American analyses of the ethics of biomedical research (Brody, 1998;
Jonsen, 1998). These are the principles of autonomy, non-maleficence,
beneficence, and justice (Beauchamp & Childress, 2001). They have also been
included in influential international statements of ethical principles for
medical research, such as the Helsinki Declaration (see Box 7.1) and the
declarations of United Nations organizations (Brody, 1998). These principles
can be regarded as a moral baseline for the ethical analysis of neuroscience
research on substance dependence; with the proviso that they may need to
be supplemented to deal with newly-emerging issues.
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BOX 7.1
Declaration of Helsinki1
Ethical principles for medical research involving human subjects
A. Introduction
1. The World Medical Association has developed the Declaration of Helsinki as
a statement of ethical principles to provide guidance to physicians and other
participants in medical research involving human subjects. Medical research
involving human subjects includes research on identifiable human material or
identifiable data.
2. It is the duty of the physician to promote and safeguard the health of the
people. The physician’s knowledge and conscience are dedicated to the
fulfillment of this duty.
3. The Declaration of Geneva of the World Medical Association binds the physician
with the words, “The health of my patient will be my first consideration”, and
the International Code of Medical Ethics declares that, “A physician shall act
only in the patient’s interest when providing medical care which might have
the effect of weakening the physical and mental condition of the patient”.
4. Medical progress is based on research which ultimately must rest in part on
experimentation involving human subjects.
5. In medical research on human subjects, considerations related to the well-
being of the human subject should take precedence over the interests of
science and society.
6. The primary purpose of medical research involving human subjects is to improve
prophylactic, diagnostic and therapeutic procedures and the understanding of
the aetiology and pathogenesis of disease. Even the best proven prophylactic,
diagnostic, and therapeutic methods must continuously be challenged through
research for their effectiveness, efficiency, accessibility and quality.
7. In current medical practice and in medical research, most prophylactic,
diagnostic and therapeutic procedures involve risks and burdens.
8. Medical research is subject to ethical standards that promote respect for all
human beings and protect their health and rights. Some research populations
are vulnerable and need special protection. The particular needs of the
economically and medically disadvantaged must be recognized. Special
attention is also required for those who cannot give or refuse consent for
themselves, for those who may be subject to giving consent under duress,
for those who will not benefit personally from the research and for those for
whom the research is combined with care.
9. Research Investigators should be aware of the ethical, legal and regulatory
requirements for research on human subjects in their own countries as well
as applicable international requirements. No national ethical, legal or regulatory
requirement should be allowed to reduce or eliminate any of the protections
for human subjects set forth in this Declaration.
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B. Basic principles for all medical research
10. It is the duty of the physician in medical research to protect the life, health,
privacy, and dignity of the human subject.
11. Medical research involving human subjects must conform to generally
accepted scientific principles, be based on a thorough knowledge of the
scientific literature, other relevant sources of information, and on adequate
laboratory and, where appropriate, animal experimentation.
12. Appropriate caution must be exercised in the conduct of research which
may affect the environment, and the welfare of animals used for research
must be respected.
13. The design and performance of each experimental procedure involving human
subjects should be clearly formulated in an experimental protocol. This
protocol should be submitted for consideration, comment, guidance, and
where appropriate, approval to a specially appointed ethical review
committee, which must be independent of the investigator, the sponsor or
any other kind of undue influence. This independent committee should be in
conformity with the laws and regulations of the country in which the research
experiment is performed. The committee has the right to monitor ongoing
trials. The researcher has the obligation to provide monitoring information
to the committee, especially any serious adverse events. The researcher
should also submit to the committee, for review, information regarding
funding, sponsors, institutional affiliations, other potential conflicts of interest
and incentives for subjects.
14. The research protocol should always contain a statement of the ethical
considerations involved and should indicate that there is compliance with
the principles enunciated in this Declaration.
15.  Medical research involving human subjects should be conducted only by
scientifically qualified persons and under the supervision of a clinically
competent medical person. The responsibility for the human subject must
always rest with a medically qualified person and never rest on the subject
of the research, even though the subject has given consent.
16. Every medical research project involving human subjects should be preceded
by careful assessment of predictable risks and burdens in comparison with
foreseeable benefits to the subject or to others. This does not preclude the
participation of healthy volunteers in medical research. The design of all
studies should be publicly available.
17. Physicians should abstain from engaging in research projects involving
human subjects unless they are confident that the risks involved have
been adequately assessed and can be satisfactorily managed. Physicians
should cease any investigation if the risks are found to outweigh the
potential benefits or if there is conclusive proof of positive and beneficial
results.
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18. Medical research involving human subjects should only be conducted if the
importance of the objective outweighs the inherent risks and burdens to the
subject. This is especially important when the human subjects are healthy
volunteers.
19. Medical research is only justified if there is a reasonable likelihood that the
populations in which the research is carried out stand to benefit from the
results of the research.
20. The subjects must be volunteers and informed participants in the research
project.
21. The right of research subjects to safeguard their integrity must always be
respected. Every precaution should be taken to respect the privacy of the
subject, the confidentiality of the patient’s information and to minimize the
impact of the study on the subject’s physical and mental integrity and on
the personality of the subject.
22. In any research on human beings, each potential subject must be adequately
informed of the aims, methods, sources of funding, any possible conflicts
of interest, institutional affiliations of the researcher, the anticipated benefits
and potential risks of the study and the discomfort it may entail. The subject
should be informed of the right to abstain from participation in the study or
to withdraw consent to participate at any time without reprisal. After ensuring
that the subject has understood the information, the physician should then
obtain the subject’s freely-given informed consent, preferably in writing. If
the consent cannot be obtained in writing, the non-written consent must be
formally documented and witnessed.
23. When obtaining informed consent for the research project the physician
should be particularly cautious if the subject is in a dependent relationship
with the physician or may consent under duress. In that case the informed
consent should be obtained by a well-informed physician who is not
engaged in the investigation and who is completely independent of this
relationship.
24. For a research subject who is legally incompetent, physically or mentally
incapable of giving consent or is a legally incompetent minor, the investigator
must obtain informed consent from the legally authorized representative in
accordance with applicable law. These groups should not be included in
research unless the research is necessary to promote the health of the
population represented and this research cannot instead be performed on
legally competent persons.
25. When a subject deemed legally incompetent, such as a minor child, is able
to give assent to decisions about participation in research, the investigator
must obtain that assent in addition to the consent of the legally authorized
representative.
26. Research on individuals from whom it is not possible to obtain consent,
including proxy or advance consent, should be done only if the physical/
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mental condition that prevents obtaining informed consent is a necessary
characteristic of the research population. The specific reasons for involving
research subjects with a condition that renders them unable to give informed
consent should be stated in the experimental protocol for consideration
and approval of the review committee. The protocol should state that consent
to remain in the research should be obtained as soon as possible from the
individual or a legally authorized surrogate.
27. Both authors and publishers have ethical obligations. In publication of the
results of research, the investigators are obliged to preserve the accuracy
of the results. Negative as well as positive results should be published or
otherwise publicly available. Sources of funding, institutional affiliations and
any possible conflicts of interest should be declared in the publication.
Reports of experimentation not in accordance with the principles laid down
in this Declaration should not be accepted for publication.
C. Additional principles for medical research combined with medical
care
28. The physician may combine medical research with medical care, only to
the extent that the research is justified by its potential prophylactic,
diagnostic or therapeutic value. When medical research is combined with
medical care, additional standards apply to protect the patients who are
research subjects.
29. The benefits, risks, burdens and effectiveness of a new method should be
tested against those of the best current prophylactic, diagnostic, and
therapeutic methods. This does not exclude the use of placebo, or no
treatment, in studies where no proven prophylactic, diagnostic or therapeutic
method exists.
30. At the conclusion of the study, every patient entered into the study should
be assured of access to the best proven prophylactic, diagnostic and
therapeutic methods identified by the study.
31. The physician should fully inform the patient which aspects of the care are
related to the research. The refusal of a patient to participate in a study
must never interfere with the patient-physician relationship.
32. In the treatment of a patient, where proven prophylactic, diagnostic and
therapeutic methods do not exist or have been ineffective, the physician,
with informed consent from the patient, must be free to use unproven or
new prophylactic, diagnostic and therapeutic measures, if in the physician’s
judgement it offers hope of saving life, re-establishing health or alleviating
suffering. Where possible, these measures should be made the object of
research, designed to evaluate their safety and efficacy. In all cases, new
information should be recorded, and, where appropriate, published. The
other relevant guidelines of this Declaration should be followed.
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Principles of biomedical ethics
i. Respect for autonomy
Respecting autonomy means that people respect and do not interfere with
the actions of rational persons that have a capacity for autonomous action,
that is, adults who are able to freely decide upon a course of action without
influence, coercion or force (Beauchamp & Childress, 2001). In the context
of biomedical research, the principle of respect for autonomy is usually taken
to require the following: informed consent to treatment or research
participation, voluntariness in research participation, and maintenance of
confidentiality and privacy of information provided to a researcher
(Beauchamp & Childress, 2001).
ii. Non-maleficence
The principle of non-maleficence simply means, do no harm (Beauchamp
& Childress, 2001). Following the principle of non-maleficence requires
people to refrain from causing harm or injury, or from placing others at risk
of harm or injury. In the context of biomedical research, the principle of non-
Note of clarification on Paragraph 29
The WMA hereby reaffirms its position that extreme care must be taken in making
use of a placebo-controlled trial and that in general this methodology should only
be used in the absence of existing proven therapy. However, a placebo-controlled
trial may be ethically acceptable, even if proven therapy is available, under the
following circumstances:
— Where for compelling and scientifically sound methodological reasons its use
is necessary to determine the efficacy or safety of a prophylactic, diagnostic
or therapeutic method; or
— Where a prophylactic, diagnostic or therapeutic method is being investigated
for a minor condition and the patients who receive placebo will not be subject
to any additional risk of serious or irreversible harm.
All other provisions of the Declaration of Helsinki must be adhered to, especially
the need for appropriate ethical and scientific review.
1 The Declaration of Helsinki is an official policy document of the World Medical Association,
the global representative body for physicians. It was first adopted in 1964 (Helsinki, Finland)
and revised in 1975 (Tokyo, Japan), 1983 (Venice, Italy), 1989 (Hong Kong), 1996
(Sommerset-West, South Africa) and 2000 (Edinburgh, Scotland). Note of clarification on
Paragraph 29 added by the WMA General Assembly, Washington, 2002.
Source: World Medical Association, 2002 (available on web site http://www.wma.net/e/
policy17-e_e.html).
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maleficence requires researchers to minimize the risks associated with
participation in research (Brody, 1998; Beauchamp & Childress, 2001).
iii. Beneficence
Beauchamp and Childress have identified “positive beneficence” and “utility”
as two elements of the principle of beneficence (Beauchamp & Childress,
2001). Positive beneficence requires people to perform actions that result in
benefit. Utility requires that the benefits of peoples’ actions outweigh the
burdens they impose upon others. The principle of beneficence therefore
requires that an action produces benefits and that its benefits outweigh its
burdens. In the context of biomedical research, this means that the benefits
of the research to society should outweigh its risks to participants.
iv. Distributive justice
Justice is probably the most controversial of the four moral principles. For
the purpose of this discussion, “justice” refers to “distributive justice” rather
than retributive (criminal) or rectificatory (compensatory) justice (Beauchamp
& Childress, 2001). In bioethics, the principle of distributive justice has been
central to debates about how to ensure equitable access to health care and to
reduce unequal health outcomes. In the case of research, the principle of
distributive justice refers to the equitable distribution of the risks, as well as
the benefits of research participation (Brody, 1998). A fair and just research
policy would aim to achieve a distribution of the benefits and burdens of
research participation that is as fair and equitable as possible.
Human rights
In 1948 the Universal Declaration of Human Rights (UDHR) set out an
international set of human rights that would be honoured by all nations which
signed the declaration (United Nations General Assembly, 10 December,
1948). The UDHR recognised that all people have rights by virtue of being
human and that these were universal in the sense of applying equally to all
people around the world, regardless of who they are or where they live
(International Federation of Red Cross and Red Crescent Societies and
François-Xavier Bagnoud Center for Health and Human Rights, 1999; Mann
et al., 1999). The UDHR enjoined nations to treat all people as equal and to
promote and protect the right to life, liberty and security of person. It included
“negative rights” such as the rights not to be enslaved or in servitude, not be
to be tortured or subject to cruel, inhuman and degrading treatment or
punishment. It also obliged signatory states to afford people equal treatment
before the law and the equal protection of the law, without discrimination,
by requiring that everyone charged with a penal offence should be presumed
innocent until proved guilty (UDHR, 1948, article 11).
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Ethical principles in medicine and human rights both embody injunctions
to behave in specific ways but they differ in to whom they apply (Mann, 1999).
Ethical principles typically apply to individuals, usually health care workers
and researchers, whereas human rights impose obligations on states and
governments to promote and protect the rights of their citizens from
infringements by the state or by others (Mann, 1999). Human rights are most
relevant to the way in which treatments and interventions derived from
neuroscience research are used to treat and prevent substance dependence.
This is because treatment and prevention may involve the use of the coercive
powers of the state to threaten the human rights of persons who are
dependent on psychoactive substances (Gostin & Mann, 1999).
Ethics of animal experimentation in neuroscience research
The use of animals in biomedical research has traditionally been justified
by the argument that the harm inflicted upon animals in the course of
research is outweighed by the gains in scientific knowledge to humans (and
animals) (Resnik, 1998). The scientific community has generally accepted
this defence, but it has not received similar support from the public as a
result of media reporting of controversial examples of animal experimen-
tation (Brody, 1998).
Animal research has provided some significant benefits to humans, for
example, the identification of mechanisms that cause disease and the
improvement of treatments (Naquet, 1993).
Although there are alternatives to animal models in some situations, such
as tissue cultures and computer simulation (Resnik, 1998), these models
cannot replace the use of animals in research because they cannot model
the rich behavioural and physiological environment of live animals (American
Psychological Association Science Directorate, 2001).
A criticism of animal experimentation is that the animals used do not
provide good models of human biology, physiology and psychology (Resnik,
1998). For example, research has shown that cortical organization in the brain
varies between species and that some primates lack characteristics found in
humans (Preuss, 2000). It has also been argued that the psychology and
neurobiology of substance dependence are not well-modelled in commonly
used animals such as mice and rats (Resnik, 1998), and that non-human
primate models are more desirable because the cortical anatomy and
behavioural repertoire of primates more closely resembles those of humans
(National Academy of Science, 1996). However, much of the current
knowledge regarding the neuroscience of substance dependence has come
from animal experimentation using a number of different species. Genetically
engineered mice, for example, have been used to identify initial targets for
drugs, such as the CB1 cannabinoid receptor, and biochemical pathways
involved in cocaine metabolism have been investigated (Nestler, 2000). Rats
and other non-primate species have provided good models for certain aspects
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of the psychology and neurobiology of substance dependence, thus reducing
the number of primates needed in research.
It seems that a societal compromise exists between those who oppose
animal experimentation and those who deem it necessary (Varner, 1994).
The moral objections to animal experimentation have increased the burden
of proof that defenders of research must meet (Varner, 1994). This is a
reasonable outcome as long as the burden of proof is not insurmountable.
In most countries, legislation adopts one of two perspectives which
acknowledge the need for animal experimentation while placing restrictions
on the practice (Brody, 1998). Legislation in Europe and America takes a
“human priority” position in which animal suffering and loss are minimized
but the interests of humans take precedence over those of animals when they
conflict (Brody, 1998). In contrast, legislation in Australia and the United
Kingdom is based on a “balancing” position in which the interests of humans
are generally regarded as more important than those of animals but they can
sometimes be overridden in order to protect animals (Brody, 1998). Unlike
legislation in America and Europe, legislation in Australia and the United
Kingdom requires that during the ethical review process, the benefits of the
proposed experiments be weighed against the harm that will be inflicted on
the animals (Brody, 1998).
Ethical principles in human biomedical research
Since the Nuremberg trials of German medical researchers after World War
II, a consensus has been developed about the basic ethical requirements for
biomedical research on humans (Brody, 1998; Jonsen, 1998). In most
developed countries, national ethical codes set out obligations that
investigators must adhere to if their research is to be ethically and scientifically
legitimate. Although specific conditions for ethical approval may differ from
country to country the same basic set of ethical principles is found in most
national guidelines (Brody, 1998). These include independent ethical review
of research proposals, respect for patient privacy, informed consent to
participate in research, and protection of privacy and confidentiality of
information (Brody, 1998).
Independent ethical review of risks and benefits
In order for any human research to gain approval, investigators must obtain
ethical approval from an independent ethical review committee, usually
an institutional ethical review committee. An external review of a study
protocol provides an independent assessment of whether the benefits of
the proposed trial outweigh any risks that it poses to participants (Brody,
1998).
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Informed consent
Informed consent to participate in a research study is usually a matter of
asking the research participant to consent to their participation after a
detailed discussion of what it will entail and a description of any adverse
events that may occur (Brody, 1998). The participation of persons under the
age of 18 years would normally require the consent of a parent or guardian,
along with the assent of the participant. Any uncertainty about the risks of
participation must be accurately communicated and there must be close
monitoring of any adverse events, with medical care promptly provided for
any adverse outcomes. The inclusion of persons with cognitive impairments
in a study may require special consideration (see below). Consent may need
to be obtained from a surrogate who makes a decision on behalf of the
impaired research participant (Brody, 1998). This has implications for research
involving persons with substance dependence if the person has long-term
cognitive, psychiatric, or neurological dysfunction as a result of substance
use (see Chapter 4), or if the person has a concurrent psychiatric illness (see
Chapter 6).
All forms of consent must be given after the participants are informed of
what their involvement in the research will require of them. Research
participants should have time to reflect on and consider their obligations at
each stage of the consent procedure. Ideally, the consent process should
include a third party, usually a clinician not involved in the study, to ensure
the integrity of the process. Participants must be allowed to withdraw from
the study at any time. If they decide to withdraw, their decision must be
respected and they must be informed that they will not suffer any
consequences, such as refusal of routine counselling or medical care (Brody,
1998). If any participant withdraws from the study, the data collected from
them must be omitted from the final results.
Recruitment of subjects
The conditions under which persons are recruited into a study must not
involve any form of coercion or the use of excessive inducements to
participate (Brody, 1998). In recent years, it has become common to reimburse
participants for their involvement in some research studies. The most
common justification is that reimbursements maximize initial recruitment
and retention of participants in a study. Small reimbursements are offered to
compensate participants for the time spent participating in a trial or for their
travel expenses. Reimbursements may be interpreted by some potential
subjects as rewards for participation, and by researchers as a way of increasing
the number of trial participants. Ashcroft argues that inducements are
ethically acceptable if the inducement serves to recompense a participant
for the inconvenience, as long as it is not seen as a payment for any harm
caused (Ashcroft, 2001). In Australia, for example, it has been common
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practice since the early 1980s for drug researchers to pay drug users A$20 if
they participate in research interviews. The money is intended to compensate
participants for their time, travel expenses and inconvenience. Payment of
research participants is also standard practice in drug research in Canada
and the USA.
In Australia this strategy has proved to be a successful way of recruiting
illicit drug users for research studies of risk factors for the transmission of
HIV, hepatitis C and other infectious blood-borne diseases; patterns of illicit
amphetamine use (including injecting use, the reasons for making the
transition to injecting, and the prevalence of psychological and health
problems caused by injecting use); the prevalence and correlates of drug
overdoses among heroin users; and national monitoring of trends in illicit
drug use since 1996. The information collected in these studies could not be
easily obtained in any other way. Interviewing drug users in treatment, for
example, would be of limited use because many drug users do not seek
treatment, and those who do usually do so after several years of problem
drug use. Obtaining information in this way provides advance warning of
emerging trends in illicit drug use. It also creates an opportunity to provide
drug users with information about the risks of their drug use, and such
information may also help in the design of educational campaigns aimed at
illicit drug users. The findings of these studies are also regularly presented to
staff at treatment centres to alert them to problems emerging among persons
seeking their help.
A concern expressed by critics of this practice of paying participants is
that the money will serve as an inducement because of its potential for buying
drugs. The first question is whether drug users have the same rights as anyone
else to be compensated for the time and inconvenience of being interviewed.
The money may well be used to pay for tobacco, alcohol or illicit drugs, but
so may any income that drug users obtain by employment, social welfare, or
crime. In terms of the daily pattern of drug use of most injecting drug users,
$20 buys only a very small amount of the street drugs normally used per day.
This issue is controversial and remains unresolved.
Privacy and confidentiality
Researchers are obligated to protect the privacy of study participants.
Participants’ personal information must not be divulged to any individual or
group of individuals without their direct consent, and they should not be
identifiable from the published results of the study (Brody, 1998). These rules
are especially important when study participants have a stigmatized
condition such as mental illness or substance dependence.
Protecting the privacy of participants and the confidentiality of the
information that they provide is critical in research where data are collected
on substance use. The use of some psychoactive substances (e.g. cannabis,
cocaine and heroin) is illegal, as is the use of alcohol by persons who are
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under the minimum legal drinking age. Surveys of drug use may also ask about
illicit drug use and the commission of other illegal acts, such as driving while
intoxicated, selling illicit drugs or engaging in theft, fraud or violence to
finance drug use. If such data were linked to an identified individual and
given to the police then the participant could face criminal charges. In the
USA researchers can obtain certificates of confidentiality that provide subjects
with an assurance that this will not happen. However, the legal status of these
certificates is unclear, given that the certificate is issued federally; it is unclear
if it would have legal status in state courts. Furthermore, the threat of access
to these documents from civil law suits is also unclear. The legal situation in
most other countries is similarly unclear.
Confidentiality is much less of a problem when data are collected in a single
cross-sectional interview. The information provided usually does not
contain participants name or other identifiers because this information need
not be collected. Confidentiality becomes more of an issue if interviews are
recorded (e.g. on tape) because this could be used in a court of law.
Confidentiality becomes a potentially serious issue in longitudinal studies
in which data that permit identification of subjects (e.g. the participant’s name
and address, and the names and addresses of their family and friends) are
collected so that individuals may be recontacted for further interviews at a
later date. A standard precaution is to store names and identifiers so that
they are secure, and to keep them separate from the survey data.
Confidentiality will become an even more important issue when DNA samples
(or biological tissues from which DNA can be obtained) are collected because
DNA provides a unique way of identifying all individuals (except identical
twins). When linked with questionnaire or interview data, DNA permits
information on self-reported illegal acts to be reliably linked to an individual.
Special precautions will therefore be necessary to protect privacy in
epidemiological studies of illicit drug use that also collect biological samples.
This may require legislation similar to that which applies in the USA.
Emerging ethical issues in neuroscience research
Research on vulnerable persons
Research involving persons who have cognitive or physical impairments
requires special ethical consideration (Brody, 1998). A major ethical issue is
whether vulnerable persons are capable of providing informed consent,
specifically whether they are able understand the rationale behind a clinical
trial (Mora, 2000), understand exactly what is required of them and why (Stahl,
1996), and give their free and informed consent to participate in the study
(Anthony & Helzer, 1991).
A person may be vulnerable for one or more of the following three reasons:
personal limitations to their freedom (intrinsic), environmental factors that
limit their freedom (extrinsic), and limitations on their freedom by virtue of
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a relationship with another person or group (relational) (Roberts & Roberts,
1999).
Are substance dependent people vulnerable persons?
Few studies have been conducted on whether persons who are substance
dependent have an impaired capacity to consent to participation in research
(Adler, 1995; Gorelick et al., 1999). Most of the recent controversy about
neuroscience research on vulnerable populations has been about research
on persons with schizophrenia (Shamoo, 1998) and stroke (Alves
& Macciocchi, 1996). In these cases, there are serious doubts about the
capacity of some patients to give free and informed consent because they
are cognitively impaired, either intermittently or chronically. There are some
analogies between these cases and issues concerning experimental research
on persons who are substance dependent. There are long-term neurological,
cognitive and psychiatric consequences of some types of substance use (see
Chapter 4), which may affect the ability of some individuals to give informed
consent.
Drug dependent persons may be vulnerable to coercion and inducement
to participate in research when they are intoxicated or when they are
experiencing acute withdrawal symptoms (Adler, 1995; Gorelick et al., 1999).
Persons who are severely intoxicated by alcohol and cocaine, for example,
suffer similar impairments to a person who is acutely psychotic. Similarly, a
person who is experiencing acute withdrawal symptoms could be induced
to consent to participate in research studies by offering them the substance
on which they are dependent, or medication to relieve their withdrawal
symptoms (Adler, 1995; Gorelick et al., 1999). Intoxicated persons should
normally be excluded from experimental studies on the grounds of good
research design, apart from the ethical problems associated with their
inclusion. Issues of informed consent arise in conducting controlled trials of
drugs that are used to treat symptoms of drug toxicity or overdose. In such
cases where a person is unable to give consent, proxy consent may be
required.
Provocation studies
Provocation studies in neuroscience research on dependence often use
neuroimaging to study the effects of a psychoactive substance on brain
function in substance users and substance dependent persons. For example,
persons dependent on heroin may be injected with a radioactively-labelled
substance, placed in a PET or SPECT scan (Fu & McGuire, 1999), and then
given an opioid drug or exposed to drug-related stimuli, with the aim of
identifying sites in the brain at which the drug acts (Sell et al., 1999; Kling et
al., 2000; Martin-Soelch et al., 2001). These provocation studies involve little
or no immediate prospect of therapeutic gain to participants. Their most likely
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benefits are an improved understanding of substance dependence that may
benefit future patients by improving treatment outcome.
Informed-consent procedures for provocation studies on substance
dependence need to make clear to potential participants the absence of any
therapeutic gain, and the risks of participation. Participants who were seeking
treatment should be actively referred to a treatment service (Gorelick et al.,
1999). Steps also need to be taken to ensure that the capacity to give voluntary
consent is not impaired because participants are intoxicated or experiencing
withdrawal symptoms. This may require screening for symptoms of
intoxication and withdrawal at the time of recruitment (Adler, 1995).
Drug administration in these studies is considerably less risky than drug
use that occurs outside the laboratory setting. Significantly lower doses of
pharmaceutically pure drugs are used in laboratory studies, in the absence
of concurrent drug use which occurs in the community. In addition, the drug
is administered under medical supervision with protocols in place to deal
with any adverse events (Adler, 1995). The risks of drug administration can
be further reduced by screening out persons who have experienced adverse
effects from drugs such as the psychostimulants. The use of stimuli associated
with substance use is much less invasive and poses fewer risks than exposure
to drugs. The radioactively-labelled substances used in some forms of
neuroimaging pose very little risk to participants, and the newer imaging
methods, such as fMRI, do not involve exposure to radiation or radioactive
substances (Gilman, 1998).
Ethical issues in epidemiological research on substance
dependence
The major ethical issues in epidemiological research are: ensuring that
participants give free and informed consent, and protecting their privacy and
the confidentiality of any information that is collected. There are also
considerations unique to epidemiological studies. Since no experimental
procedures are involved, the major risks that research participants face arise
from the possible mis-use of any information that they provide. These risks
may potentially include social ostracism and stigmatization, if their drug use
becomes known to family, friends or neighbours; and criminal prosecution,
if any information that they provide about illegal drug use or other criminal
behaviour becomes known to the police in a way that can be linked to the
individual.
Justice and the criteria for good epidemiological research both require that
a representative sample of the population at risk is recruited into studies of
patterns of substance use and dependence in the population. There may be
issues raised by poorer retention in longitudinal studies of the indigent and
homeless, who may be at higher risk of developing substance dependence.
Justice may also be an issue if there is a preponderance of studies of persons
entering publicly-funded treatment for substance dependence, and a lack of
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representation of those who are treated by private health services or private
specialist physicians and psychiatrists. It is also possible that the results of a
study may potentially lead to stigmatization of a group, if for example, a study
identifies a high rate of substance dependence in a particular social, cultural
or ethnic group.
Ethical issues in clinical trials of pharmacological treatments
for substance dependence
Clinical trials of new therapeutic drugs are required for drug registration in
most developed countries and are a now widely accepted part of medical
practice. There is international agreement on the criteria for the ethical
conduct of such studies. In addition to the previously discussed issues of
independent ethical review – i.e. free and informed consent by study
participants; an acceptable risk–benefit ratio for participants; and protection
of patient privacy and confidentiality (Brody, 1998) – there are also issues of
trial design, conflict of interest and distributive justice.
Trial design
A randomized controlled trial is widely accepted as the “gold standard” for
treatment evaluation in medicine because it minimizes bias in determining
which patients receive which treatments (Cochrane, 1972). Random
assignment to treatment is ethically acceptable if there is genuine uncertainty
about the comparative worth of the two treatments; if trial participants are
aware that they will be randomized; and if they are informed about the type
of treatment to which they may be assigned (e.g. active or placebo), and the
risks of these treatments in the course of obtaining their informed consent
to participate in the trial.
The choice of a comparison condition for a randomized controlled trial raises
the issue of when is it ethically acceptable to compare the effectiveness of a
new drug treatment for substance dependence with a placebo. Some authors
have argued that it is unethical to provide only a placebo treatment, if there is
an existing treatment that is effective for the condition (Brody, 1998). This
argument is relevant in the case of substance dependence, some forms of which
can be life-threatening in the absence of treatment. It would be ethically
acceptable, however, to use a placebo comparison condition if there was no
effective pharmacotherapy for the condition, and if both treatment groups
received the best available psychosocial treatment (Gorelick et al., 1999). In
this case, the clinical trial would answer the question: does adding
pharmacotherapy to good quality psychosocial care improve outcome by
comparison with adding a placebo? Since it is likely that any pharmacotherapy
will ultimately be used in combination with good quality psychosocial
treatment (Fox, 1997), this is usually the most relevant question to ask in a
randomized controlled trial of a new pharmacotherapy for drug dependence.
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Distributive justice
Justice and the criteria for sound clinical trials both require that a represen-
tative sample of the population at risk is recruited into such studies (Brody,
1998). Special efforts may need to be made to ensure that women, children
and minority groups are included in clinical trials to ensure that they have
access to the benefits of research participation and that the results of research
studies can be applied to these groups if drugs that are trialed are eventually
approved and registered for clinical use (Brody, 1998).
Conflicts of interest
An ethical issue of increasing significance, given the extent of funding of
clinical trials by pharmaceutical companies, is ensuring public confidence
in the results (Davidoff et al., 2001; DeAngelis, Fontanarosa & Flanagin, 2001).
Public trust has been undermined in recent years because investigators have
failed to disclose their personal financial interests in the outcomes of clinical
trials (e.g. as a result of being paid large consultancy fees for promoting
pharmaceuticals or shares in a pharmaceutical company). This has become
an increasingly larger problem as public funding for medical research and
universities has declined and pharmaceutical companies have become a
major source of research funds. Moreover, research funded by these
companies has been conducted by contract research organizations, with the
conditions in which data can be published being controlled by
pharmaceutical sponsors (DeAngelis, Fontanarosa & Flanagin, 2001; Anon,
2001).
No matter how scientifically rigorous and ethically conducted a study may
be, its findings are of limited use if the public does not have confidence in
their validity (Davidoff et al., 2001; DeAngelis, Fontanarosa & Flanagin, 2001).
A number of policies have been implemented by editors of leading medical
journals in an effort to restore trust in clinical research. One is the decision
by these editors to require that authors disclose funding sources and potential
conflicts of interest, and assert that they have had complete control over the
study data and their analysis (Davidoff et al., 2001; DeAngelis, Fontanarosa
& Flanagin, 2001). Another policy has been the creation of a register of clinical
trial protocols before the start of the study to minimize the suppression of
unfavourable results or ex post facto selection of results and methods of
analysis in order to make a drug look its best (Horton, 1997).
Additional policy recommendations have been made that have not so far
been implemented. These include: independent monitoring of compliance
with the study protocol, especially with reporting of any adverse events
experienced by participants; and a requirement that investigators and the
sponsors of a trial commit to publishing its results within two years of
completing data collection, as a condition of the study protocol being
approved by an ethics committee (Reidenberg, 2001). The latter seems well
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based given that the major ethical justification for undertaking research
studies is to contribute to scientific knowledge (Brody, 1998), and this cannot
happen if trial results are not published (Reidenberg, 2001).
Trials of preventive pharmacological interventions
for substance dependence
Psychosocial and educational interventions have been widely used with the
aim of preventing young people from using drugs (Spooner & Hall, 2002).
Universal interventions are aimed at all young people, while indicated,
targeted or selective interventions are aimed at those young people who are
identified as being at higher risk of initiating drug use. The impact of both
universal and selective educational interventions on rates of drug use has
often been modest (National Research Council, 2001).
Psychosocial preventive interventions raise ethical issues. Universal
interventions (those directed at all young people) raise concerns about
unintended adverse consequences, such as encouraging drug
experimentation in young people. Targeted or indicated interventions raise
additional ethical issues because they require the identification of young
people who are at increased risk of using drugs. Their consent and that of
their parents is required for them to participate in preventive interventions.
In the process of obtaining such consent, the parents and their children may
become acquainted with their risk status. Participation in trials of preventive
interventions may also expose the children to social stigmatization and
discrimination, if it becomes known to their teachers, peers and their peers’
parents. For example, parents whose children are judged to be at “low risk”
may actively discourage their children from associating with “high-risk”
children, or they may insist that high-risk children be excluded or removed
from schools.
The same ethical issues of stigmatization and discrimination are also raised
by pharmacological or immunological interventions that aim to prevent
substance dependence. Two such interventions are discussed below: early
pharmacological interventions in persons at risk of substance dependence
that may be inspired by similar efforts to prevent psychoses (McGorry, Yung
& Phillips, 2001); and the preventive use of immunotherapies against drug
effects to reduce risk of substance dependence (Cohen, 1997).
Early intervention studies
Early interventions for substance dependence have been discussed which
would be analogous to studies of schizophrenia that identify persons who are
at increased risk of developing the disorder because they have a family history
of schizophrenia or they have psychological symptoms that may be early or
“prodromal” symptoms of the disorder. The aim of this approach is to prevent
the development of schizophrenia by a combination of good quality
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psychosocial care and low doses of the neuroleptic drugs that are used to treat
schizophrenia (McGorry, Yung & Phillips, 2001). Studies in Australia and the
USA have shown that it is possible, using standardized criteria, to identify a
group of young people who have a high risk (30–40%) of developing
schizophrenia in the ensuing 6 to 12 months (McGlashan, 2001; McGorry, Yung
& Phillips, 2001). A number of quasi-experiments and randomized controlled
trials suggest that the combined intervention reduces the rate at which
schizophrenia occurs and reduces its severity (McGorry, Yung & Phillips, 2001).
Similar trials can be foreseen for substance dependence, once research clarifies
the risk and protective factors, genetic predisposition, and treatment options.
Critics of these studies have raised a number of ethical issues (Cornblatt,
Lencz & Kane, 2001; DeGrazia, 2001). These include the fact that there is a
high false positive rate: 60% of those who are identified as being at risk of
developing schizophrenia do not develop the disorder. This can also be seen
to apply to the development of substance dependence. There is also the
potential for stigmatization and discrimination against those who are
identified as being at risk. Even if there is no discrimination, there is the
possibility that there will be adverse effects on individuals of being labelled
as at risk. There is also concern about the capacity of children and adolescents
to consent to participate in such studies, and doubts about the acceptability
of using proxy parental consent. Long-term preventive treatment with drugs
may have health consequences. McGorry, Yung & Phillips (2001) have
countered, with respect to schizophrenia, that the potential benefits (the
prevention of schizophrenia and early treatment of cases that do occur)
outweigh the potential risks of neuroleptic medication and stigmatization,
both of which they suggest (on the basis of controlled studies) have been
exaggerated.
Analogous approaches to early interventions could be taken for substance
dependence, although to date no trials have been explicitly undertaken with
the aim of using pharmacotherapies as preventive interventions for substance
dependence. It is likely that many of the same ethical issues would arise.
Psychostimulant drugs, such as methylphenidate and dexamphetamine, have
been used to treat children and adolescents with attention deficit
hyperactivity disorder (ADHD), an intervention that is controversial (Levy,
1997). Since ADHD in combination with conduct disorders increases the risks
of developing substance use disorders (Lynskey & Hall, 2001), and
psychostimulant drugs reduce symptoms of ADHD (Swanson et al., 1998),
an unintended by-product of psychostimulant medication may be the
prevention of substance use disorders. However, no one has so far argued for
the use of psychostimulant medication to prevent substance dependence,
and it is unlikely that anyone would do so. Public concern about the long-
term use of stimulant drugs to treat ADHD suggests that any such proposal
will be opposed and support for the chronic use of drugs in late childhood or
adolescence to prevent the development of substance dependence would
seem to be even less likely.
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Preventive use of drug immunotherapies
Animal studies have shown that it is possible to induce the formation of
antibodies to substances such as cocaine (Fox et al., 1996; Carrera et al., 2000).
These antibodies in the blood combine with the substance to prevent it
reaching the brain to exert its effects (Fox et al., 1996) (see Chapter 4). Animal
studies show that antibodies against cocaine markedly attenuate its stimulant
effects and block self-administration in rats (Carrera et al., 1995; Johnson
& Ettinger, 2000). If cocaine immunotherapies prove safe and effective in
treating persons with cocaine dependence, they could be used to prevent
cocaine dependence in adolescents and young adults, as well as in adults
and in legally coerced treatment. Such possibilities have been raised and
briefly discussed (Cohen, 1997, 2000). Similar arguments will no doubt arise
with the proposed preventive use of nicotine immunotherapies.
If a controlled clinical trial demonstrates that nicotine and cocaine
immunotherapies are safe and effective treatments of these types of substance
dependence, then a number of ethical issues concerning their use in
voluntary treatment of substance dependent adults need to be addressed
(Cohen, 1997; Hall & Carter, 2002). The preventive use of cocaine and nicotine
immunotherapies would be ethical in the case of adults who voluntarily
decided to use them after being informed of any risks. The immunotherapies
would need to be shown to be safe and effective for this purpose, with higher
standards of proof generally required for the safety and efficacy of preventive
measures (Hall & Carter, 2002). The foreseeable risks of using the
immunotherapy would have to be communicated to the person, who would
have given informed consent to its use, and steps would need to be taken to
protect the person’s privacy. Under these conditions, the voluntary
administration of a cocaine immunotherapy to consenting adults who
considered themselves to be susceptible to cocaine dependence would be
ethically acceptable (Hall & Carter, 2002). However, such use is likely to be
unusual.
A potentially unique feature of active immunization against cocaine is that
it may, in principle, have long-lasting consequences, namely, creating
antibodies that can be detected in the blood of treated patients for some
months or years. These antibody levels may not be sufficiently high to be
therapeutic but the fact that they could be detected raises the ethical issues
of privacy and discrimination (Cohen, 1997).
Of special concern is the possible loss of privacy by recovering cocaine-
dependent individuals if employers and insurance companies had access to
this information. Employers and insurance companies often obtain detailed
personal medical information and, on occasion, blood samples from potential
employees or clients. Because the community often strongly disapproves of
cocaine dependence, the loss of privacy by a recovering cocaine-dependent
individual may lead to embarrassment, at best, and to social stigmatization
and ostracism by people in their social environment and in the wider
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community. In the future, increasing social stigmatization of smokers, and
the possibility of discrimination by employers and the health insurance
industry, may raise similar issues for smokers who use nicotine immunization
to stop smoking.
Discrimination may arise if workplace-based drug testing were to screen
for cocaine antibodies before and during employment. A recovering cocaine-
dependent person would be at risk of losing an employment opportunity or
his or her job if cocaine antibodies were detected in a blood sample. If this
information were more widely disseminated to other workers it could have a
devastating effect on the employment prospects and recovery of the
individual (Cohen, 1997).
One way of avoiding these outcomes may be to accept Cohen’s proposal
that a society that wishes to have the benefits of a cocaine immunotherapy
“must institute legal and behavioural changes that preserve privacy and
confidentiality” (Cohen, 1997). This requires a culture that encourages and
supports the recovery of persons with substance dependence. Legislation that
punishes discriminatory behaviour towards recovering persons has been
adopted in the case of HIV-infected persons. The adoption of a similar
approach to people who have been treated for cocaine dependence would
be an important step towards reducing discrimination and protecting privacy.
The risks of loss of privacy and discrimination could also be minimized by
using “passive” rather than “active” immunization to prevent relapse (e.g. by
administering antibodies to cocaine rather than an immunization). This
approach would not produce an enduring change in the person’s immune
system and the antibodies would disappear over a period of weeks. These
advantages would be gained at the expense of a shorter period of protection
(without a booster injection) that may reduce treatment effectiveness. This
may be a trade-off that a patient concerned about privacy would be prepared
to make, but it is a choice that they should be offered (Hall & Carter, 2002).
The preventive “immunization” of children and adolescents against
cocaine dependence is a much more ethically complex issue. Children would
presumably be immunized against cocaine dependence at the request of their
parents. Their parents would consent on behalf of their children who, as
minors, would not be legally able to give informed consent. Parents already
make choices on behalf of their children that will affect their future (e.g.
regarding diet and education). Some have argued, therefore, that
immunization against cocaine dependence would simply be another decision
that some parents would make for their children (Cohen, 1997). On the basis
of this argument, a parent would have the right to immunize their children
against cocaine dependence in much the same way as they have the right to
immunize them against measles or other infectious diseases (Kaebnick, 2000).
Cocaine use may begin in adolescence. Adolescents under the age of majority
have sufficient capacity to be involved in decisions about their future, such as
whether they want to be immunized against cocaine dependence. Even if it is
ethically acceptable for parents to consent on behalf of their children, the assent
Chapter_7 19.1.2004, 11:50230
231
7. ETHICAL ISSUES IN NEUROSCIENCE RESEARCH ON SUBSTANCE DEPENDENCE TREATMENT AND PREVENTION
of an adolescent or an older child should be sought, and if they fail to give it,
their decision should rarely be overridden and only if there is a strong reason
for doing so (Brody, 1998). It must be remembered that not everyone who uses
cocaine for the first time goes on to become dependent.
Implications of neuroscience research for models of substance
dependence
There has been a long-standing conflict between moral and medical models
of substance dependence (Gerstein & Harwood, 1990; Leshner, 1997). A moral
model of substance dependence sees it as largely a voluntary behaviour in
which people freely engage. Drug users who offend against the criminal code
are therefore to be prosecuted and imprisoned if found guilty (Szasz, 1985).
A medical model of substance dependence, by contrast, recognizes that, while
many people use certain psychoactive drugs without developing substance
dependence, a small proportion of users develop substance dependence that
requires specific treatment (Leshner, 1997).
Medical models of substance dependence may not be a wholly positive
development if they lead to over-simplified social policies. For example, the
idea that substance dependence is a categorical disease entity lends itself to
a simplification in the case of alcohol, namely, that if people who are
genetically vulnerable to alcohol dependence are identified, then there may
be an assumption that the rest of the population can use alcohol without
developing dependence (Hall & Sannibale, 1996). This view does not take
into account the adverse public health effects of alcohol intoxication. It is
also at odds with the multi-dimensional nature of alcohol and illicit drug use
and symptoms of substance dependence, and with the genetic evidence that
multiple genes are involved in vulnerability to substance dependence (see
Chapter 5). It can also lead users to abdicate responsibility for their behaviour
(Nelkin & Lindee, 1996), and to a preoccupation with individual explanation
of behaviour with a corresponding lack of attention towards remediable social
causes and social policy options for reducing the prevalence of substance
dependence, including drug control policies.
The implications of a neuroscience view of substance dependence for drug
control policy (discussed below) are also not as simple as they may seem.
Exposure to drug use remains a necessary condition for the development of
substance dependence. Thus societal efforts still need to be made (whether
by criminal law or public health measures) to limit access to drugs by young
people (Leshner, 1997). Social disapproval remains a potent means of
discouraging drug use. It is hoped that neuroscience explanations of
substance dependence may temper social stigmatization and ostracism of
people with substance dependence. Demonstrations of the greater cost-
effectiveness of treatment compared with imprisonment may also provide
an economic justification for a more humane, as well as a more effective and
efficient, societal response to substance dependence.
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The challenge for the neuroscience community in the field of substance
dependence is to explain substance dependence in biological terms without
depicting people with substance dependence as automatons under the
control of receptors in their brains (Valenstein, 1998). This means viewing
substance dependence as the result, in part, of choices that are made by
individuals, not always independently. In the case of young people, many of
them operate with a short-term view, a sense of personal invulnerability, and
with scepticism towards their elders’ warnings about the risks of substance
use. Adolescents are particularly vulnerable to marketing pressures, especially
with regard to tobacco and alcohol use. It will also mean viewing substance
dependence as a matter of degree, with dependent drug users retaining the
capacity to choose to become abstinent and to seek help to do so. It will also
mean acknowledging that pharmacological treatment is only the beginning
of the process of recovery and reintegration of the drug dependent person
into the community. Moreover it will require attention to a broader range of
social policies in seeking to prevent drug use by young people (Spooner &
Hall, 2002).
Implications of neuroscience research for the treatment
of substance dependence
Access to treatment
If pharmacological treatments derived from neuroscience research prove to
be effective, the issue of ensuring equal access to treatment for all those who
may need it is an ethical issue that needs to be addressed. If a substantial
proportion of substance-dependent persons are unable to access treatment
because they cannot afford it, public funding may be needed (Gerstein
& Harwood, 1990). Public provision of such treatment will require economic
justification, especially in the case of persons who are dependent on illicit
drugs, many of whom will be indigent and unable to pay for their treatment.
Advocates for publicly subsidized drug treatment will need to make clear the
comparative economic and social costs of treating drug dependent people,
as against the current policy in many countries of dealing with substance
dependence solely through the criminal justice system (Gerstein & Harwood,
1990; National Research Council, 2001).
Legally coerced treatment
The potential use of a pharmacological treatment for substance dependence
or a drug immunotherapy under legal coercion needs to be considered
(Cohen, 1997). It is often the first possible use raised when the concept of a
drug immunotherapy is mentioned; community concern about this way of
using drug immunotherapies may also adversely affect attitudes towards
other therapeutic uses. The issue accordingly needs to be discussed, even if
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it is a long way from being realized. There are good reasons for caution about
any coerced use of a pharmacological treatment or a drug immunotherapy.
The community has little sympathy for drug dependent offenders who engage
in property-related and other crimes, so particular attention must be paid to
protecting the legal and human rights of drug offenders.
The rationale for treatment under legal coercion
Legally coerced drug treatment is entered into by persons charged with or
convicted of an offence to which their substance dependence has
contributed. It is most often provided as an alternative to imprisonment, and
usually under the threat of imprisonment if the person fails to comply with
treatment (Hall, 1997; Spooner et al., 2001).
One of the major justifications for treatment under coercion is that it is an
effective way of treating offenders’ substance dependence that will reduce
the likelihood of their re-offending (Gerstein & Harwood, 1990; Inciardi
& McBride, 1991). This approach has historically been most often used in
the treatment of offenders who are dependent on heroin (Leukefeld & Tims,
1988) although it has most recently been used with cocaine-dependent
offenders in “drug courts” in the USA (National Research Council, 2001). One
issue is whether there should be a higher standard of proven effectiveness
for coerced rather than for voluntary treatment. Another issue is that if the
treatment is court-mandated, there may be a tendency for the treatment
period to last at least as long as would the jail term. Thus, the form and
duration of the treatment are being set by criteria which relate to the judicial
system, and not necessarily to therapeutic best practice.
The advent of HIV/AIDS has provided an additional argument for treating
rather than imprisoning drug-dependent offenders. Prisoners who inject
drugs are at higher risk of having contracted HIV and hepatitis C virus by
needle-sharing prior to imprisonment (Dolan, 1996). They are at risk of
transmitting these infectious diseases to other inmates by needle-sharing
and penetrative sexual acts while they are in prison (Vlahov & Polk, 1988)
and also to their sexual partners before or after imprisonment. Providing drug
treatment under coercion in the community is one way of reducing HIV
transmission. The correctional and public health arguments for drug
treatment under coercion are reinforced by the economic argument that it is
less costly to treat offenders who are drug dependent in the community than
it is to imprison them (Gerstein & Harwood, 1990).
Forms of legal coercion
Offenders may be coerced into drug treatment in a variety of ways (Gostin,
1991; Spooner et al., 2001). After an offence has been detected the police may
decide not to charge the offender if he or she agrees to enter drug treatment.
This form of coercion is not generally favoured because it is not under judicial
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oversight and thus is open to abuse. Coercion into treatment may also occur
after an offender has been charged and before being processed by the court.
This is the case in USA drug courts, where adjudication may be postponed
until treatment has been completed (General Accounting Office, 1995).
An offender may be coerced into treatment after conviction. If this is done
before sentencing, the court may make completion of treatment a condition
of a suspended sentence. Alternatively, an offender may be encouraged to
enter drug treatment to help him or her to remain abstinent while a sentence
is suspended. Drug treatment may also be required after part of a sentence
has been served: enrolment in drug treatment may be made a condition of
release on parole. Alternatively, enrolment in drug treatment may be
encouraged as a way of remaining free of illicit drugs while on parole.
Ethical issues in coerced treatment
Coerced treatment involves the use of state power to force people to receive
treatment and so unavoidably raises ethical and human rights issues (Mann,
1999). Evidence from the USA suggests that treatment for heroin dependence,
such as methadone maintenance, therapeutic communities and drug free
counselling, is of benefit to those who receive it (Gerstein & Harwood, 1990).
However, the benefits for any individual are still uncertain since treatment
assists only about 50% of those who receive it (Gerstein & Harwood, 1990),
and relapse to heroin use after treatment is high. The treatment of cocaine
dependence is much less effective than treatment for opioid dependence
(Platt, 1997). This weakens the ethical justification for “civil commitment”
for cocaine dependence but it may not rule out less coercive forms of
treatment.
A consensus view on drug treatment under coercion prepared for WHO
(Porter, Arif & Curran, 1986) concluded that such treatment was legally and
ethically justified only if the rights of the individuals were protected by “due
process” (in accordance with human rights principles) (Mora, 2000), and if
effective and humane treatment was provided (Stahl, 1996).
The uncertain benefits of coerced treatment have led some proponents to
argue that offenders should be allowed two “constrained choices” (Fox, 1992).
The first constrained choice would be whether they participate in drug
treatment or not. If they declined to be treated, they would be dealt with by
the criminal justice system in the same way as anyone charged with the same
offence. The second constrained choice would be given to those who agreed
to participate in drug treatment: they would be given the choice of the type
of treatment that they received. There is some empirical support for these
recommendations in that there is better evidence for the effectiveness of
coerced treatment that requires some “voluntary interest” by the offender
(Gerstein & Harwood, 1990).
The most ethically defensible form of legally coerced treatment for drug
dependent offenders is the use of imprisonment as an incentive for treatment
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entry, and fear of return to prison as a reason for complying with drug
treatment. Offenders should have a constrained choice as to whether they
take up treatment or not, and, if they choose to do so, they should be able to
choose from a range of treatment options. Moreover, the process should be
subject to judicial oversight and review.
If drug immunotherapies and pharmacological treatments are used under
legal coercion, their safety, effectiveness and cost-effectiveness should be
rigorously evaluated (National Research Council, 2001). Any such use should
be cautiously trialed and evaluated, and only after considerable experience
has been acquired in their therapeutic use with voluntary patients.
Summary and conclusions
Substance dependence is a serious personal and public health issue
throughout the world. Many forms of substance dependence are difficult to
treat because of a lack of effective psychosocial or pharmacological
treatments.
Experimental studies on humans of the neurobiological basis of substance
dependence raise a number of ethical issues, one of which is the capacity of
dependent persons to give their consent to participate in such studies. As
long as participants are not intoxicated or suffering acute withdrawal
symptoms at the time they give consent, there is no compelling reason for
believing that persons who are substance dependent cannot give free and
informed consent. The risks of administration of drugs, and the use of
neuroimaging methods in these experiments, generally do not pose a serious
risk to participants.
The ethical issues raised by clinical trials of new pharmacotherapies have
been extensively debated and a consensus has evolved on the conditions that
must be met. These include free and informed consent, an acceptable risk–
benefit ratio, and protection of participant privacy and confidentiality. Trials
with substance dependent persons require special attention to informed
consent in order to ensure that persons are not intoxicated or experiencing
withdrawal symptoms when deciding to participate in trials. Placebo
comparisons may be ethically acceptable in such trials if there is no effective
pharmacotherapy and if participants are also offered good quality
psychosocial care.
Preventive pharmacological interventions for substance dependence do
not yet exist and are likely to be highly controversial if they are developed. It
is a possibility that may loom larger in the future with the development of
interventions that have a potential preventive use, foremost among which
are drug immunotherapies. The ethical issues raised by these approaches
need to be debated now. The risks of stigmatization and discrimination that
are raised by any preventive intervention that identifies high-risk subjects
will need to be dealt with. So too will issues of consent in minors, and the
potential risks to participants of immunological interventions.
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The use of pharmacotherapies and drug immunotherapies under legal
coercion is likely to be contentious. It is an arguably ethical policy if the
process is under judicial oversight and if offenders are offered constrained
choices of whether or not to accept treatment, and of the type of treatment
that they accept. Any coerced use of a cocaine immunotherapy should be
done cautiously and only after considerable clinical experience of its use with
voluntary patients. It should be trialed, and its safety, effectiveness and cost-
effectiveness should be rigorously evaluated. Such an evaluation also needs
to examine any adverse social or ethical consequences.
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CHAPTER 8
Conclusion and Implications for Public
Health Policy
Introduction
There is now a much better understanding of the mechanisms of action of
different psychoactive substances in the brain, and of why people experience
pleasure or the relief of pain from using the substances. Substances differ
with respect to the particular class of receptors they affect in the brain, but
there are also considerable commonalities between them. The neural
pathways that psychoactive substances affect are also those which are affected
by many other human behaviours, including eating a meal, having sex, and
gambling for money. In this sense, the use of psychoactive substances, at
least initially, is one part of the spectrum of human behaviours which
potentially bring pleasure or avoid pain. Depending on the route of
administration, the substances may have an especially intense effect and high
concentrations of some of them are lethal.
Advances in the neuroscience of psychoactive substance use
and dependence and their implications
Psychoactive substances also differ in their non-neural biological effects. The
form and means of administration of the substance are important in this
dimension. Thus the potential for adverse health effects from nicotine taken
in as cigarette smoke is high compared with that from nicotine in chewing
gum. There is thus a strong public health interest in differentiating the
availability of different forms of the substance according to their adverse
health effects.
Apart from their toxic biological effects, there are two other mechanisms
by which psychoactive substances may have adverse health and social effects,
as outlined in Chapter 1 (Fig. 1.2). One is through their psychoactive effects,
and particularly through intoxication. Different psychoactive substances
differ in the nature and severity of their intoxicating effects. Those of alcohol,
for instance, are great, and the potential for adverse casualty consequences
accordingly large, while the effects of nicotine as usually consumed are small.
Limiting the harm from intoxication, not only to the substance user but also
to others, is an important objective for public health-oriented controls of
the use of psychoactive substances.
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The third major mechanism by which psychoactive substances may have
adverse effects is through dependence. As technically defined, the concept of
dependence includes elements which are directly biologically measurable, such
as tolerance and withdrawal and those which are cognitive and experiential,
such as craving and impairment or loss of control. These latter elements can
be modelled in or inferred from biological measurements, but cannot yet be
directly measured. Thus, while neuroscience research can directly measure
states and effects which are relevant to concepts of dependence it cannot
measure dependence itself. Dependence is seen as a major contributor to the
health and social harm from psychoactive substance use according to its
definition as the motor of continuing use. In fact, one element of the definition
of dependence is by imputation back from the occurrence of harm: that use
has continued despite knowledge of the harm (Chapter 1, Box 1.2, Criterion 3).
The strength of effect on the various components of dependence differs
between different psychoactive substances, and according to the dosage and
dosage schedule. The potential of a given substance to produce various aspects
of dependence is also affected by the sociocultural circumstances in which it
is used and by individual genetic inheritance.
Dependence is a complex disorder; how an individual becomes dependent
on drugs is probably as complex as the brain itself. Some aspects of the
syndrome are clear, but much remains to be learned, for instance in the areas
of craving and loss of control. There is no linear relationship between the
amount of a substance used and the severity of dependence, no single
relationship between pattern of use and onset of dependence, and no fixed
relationship between experimentation and dependence. Thus, despite our
knowledge about such matters as vulnerability, mechanisms of tolerance,
withdrawal and craving, we presently cannot predict who will lose control
over use and become dependent. A lot thus remains to be learned about these
processes when studying the neuroscience and social science of dependence-
related behaviours.
Thus far, one side of the findings from neuroscience has been emphasized:
how psychoactive substances act in terms of the common biological
inheritance shared by all humans. The other side of the neuroscience research,
reflected in Chapter 5 and partly in Chapter 6, is to some extent a counterpoint
to this. The genetic research focuses on the differences in action of the
substances between one human and another which are attributable to
different genetic inheritances. The findings from this literature suggest that
genetics modulates many aspects of the actions of psychoactive substances
in humans. Thus genetic differences can make the use of the substance more
or less pleasurable or aversive to a particular individual and can affect the
toxicity of the substance, both in terms of overdose and of chronic health
effects. Genetics can also affect the intensity of psychoactive effects of a given
formulation and dose of a substance, as well as the likelihood of the
occurrence of different aspects of dependence, i.e. tolerance and withdrawal,
and those aspects which are not directly biologically measurable.
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As with our knowledge of mechanisms of dependence, much remains to
be learned about the genetics of dependence. We are far from genetically
identifying which individuals will become dependent or will experiment with
drugs. Genetic vulnerability tells little about the individual probability of
psychoactive substance use and its related problems.
There is a need for governments to support, to whatever extent possible,
neuroscience research, to develop a cadre of expertise, and to facilitate linking
neuroscience with social science. Governments in developed countries
should provide support for international collaborations and aid to developing
countries to build local capacity.
Potential advances in policy, prevention and treatment from
the neuroscience findings
Neuroscience findings in recent years have transformed our understanding
of the actions of psychoactive substances. This knowledge should be used
not only for the prevention and treatment of disorders and problems arising
from acute and long-term use of these substances, but also for updating how
they are controlled both under international drug conventions and in national
and local laws and policies.
In the light of the neuroscience findings, there is increasing understanding
that substance use disorders are like many other disorders in having
biological, psychological and social determinants. However, a major
difference in the case of substance dependence is the extreme stigma with
which the disorder is regarded in many societies. A WHO study of attitudes
to 18 disabilities in 14 countries found that “drug addiction” ranked at or near
the top in terms of social disapproval or stigma, and that “alcoholism” ranked
closely behind in most of the societies (Room et al., 2001). Reintegrating back
into society persons treated for problems with psychoactive substance use
will require developing and disseminating effective approaches to reducing
this stigma.
With respect to prevention strategies, the main potential application of
neuroscience findings so far would be from the genetic studies. Genetic
screening, based on the research findings, can potentially identify
subgroups of the population with a greater susceptibility to dependence or
harm from a particular psychoactive substance. At present, such
identification is in terms of probabilities rather than certainties. Actions
which could be taken on the basis of a positive screen might include
notification of the affected person (or of the person’s parents or guardian,
in the case of a child), and preventive interventions such as therapeutic
education, or those targeted at reducing vulnerability to substance use and
dependence. Possible preventive measures resulting from other
neuroscientific research include preventive immunotherapies, e.g. against
cocaine or nicotine, performed either on the general population or on those
identified genetically or otherwise as being at high risk. As discussed in
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Chapter 7 and below, there are important ethical considerations in any such
genetic screening or preventive immunotherapy.
With respect to treatment strategies deriving from neuroscience research,
immunotherapies could also presumably be applied to cases coming to
treatment. Future developments in neuroscience may produce genetic
modifications which would alter susceptibility to use of or dependence on
particular classes of substances, though such developments presently seem
quite far in the future.
Apart from the above, there seem to be two main choices in terms of
biological interventions. Both of these are already on the scene, and the main
pay-off from the neuroscience research is likely to be in improvements in the
particular medication or formulation used. The first choice is the use of
medications or procedures which interfere in one way or another with the
action of the substance in the body, taking away the positive rewards from
using the substance or making its use aversive. Such medications have been
in use for more than half a century. Extensive experience suggests that the
main problem with these interventions is lack of patient compliance, where
those with a history of extensive use of a substance often prove unable to
keep to any commitment they have made to continual use of the antagonist
or aversive substance.
The other choice is the use of substances which are wholly or partially agonists,
replacing the problematic substance or mode of administration with another
which produces at least some of the same biological and experiential effects.
This choice has been most widely explored and used for opioids, with codeine,
methadone, buprenorphine and other substances substituting for heroin or
other opiates. Nicotine replacement therapy, which substitutes for cigarettes, is
now widely used thereby eliminating most of the public health harm.
Ethical issues in the application of the neuroscience findings
In the broadest sense, ethical issues have always been important in the use
of psychoactive substances, and in societal responses to their use. Whether
they should be used at all continues to be a contentious issue. Thus, for
instance, Islam and some branches of other major world religions forbid the
use of alcohol to faithful adherents. Ethical judgements are written into the
major international drug control conventions (see Box 1.1). On the other
hand, arguments against the criminalization of substance use are also
frequently couched in ethical terms (e.g. Husak, 2002).
Within the somewhat narrower frame of ethics in health and human
services, research and interventions, Chapter 7 has considered in some detail
many of the ethical issues which are relevant to neuroscience research and
the application of its findings. Only a few of these are emphasized here, with
particular reference to their potential applications mentioned above.
Perhaps the most urgent ethical considerations arise around the issue
of genetic screening, which is already on the horizon. A person identified
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by a genetic screen as being vulnerable or at risk is potentially
disadvantaged by that identification in a number of ways. In the first place,
the person’s self-esteem may be reduced; as a minimum requirement, a
substantial tangible benefit from the identification would be needed to
balance this risk. The person’s financial and status interests may be
adversely affected if the identification is available to anyone else; for
example, an insurance company may refuse insurance, an employer may
choose not to employ, a person may refuse to marry. At present, in many
countries, these adverse effects of such identification are not at all
theoretical: for instance, insurance companies may have routine access to
health records, or may require such access as a condition for issuing an
insurance (thereby coercing consent).
There is an urgent need to consider the ethical issues raised by such genetic
identifications in the course of providing health services in an international
context, as well as at national and local levels. The issue is not limited to the
field of psychoactive substance use and dependence, and WHO has given
general consideration to these issues in the context of genetic counselling.
For instance, “proposed ethical guidelines for genetic screening and testing”
(WHO, 1998) provide that “results should not be disclosed to employers,
insurers, schools or others without the individual’s consent, in order to avoid
possible discrimination”. However, as the genetic research improves its
predictive power, the stigmatization of and discrimination often associated
with psychoactive substance use make it a particularly urgent issue that
requires action beyond such general guidelines, as the genetic research
improves its predictive power.
As discussed in Chapter 5, the use of immunotherapies and other
neurological interventions, especially to the extent that they are irreversible,
would raise difficult ethical issues. The neuroscience findings that the use of
psychoactive substances shares many pathways in the brain with other
human activities raise the question of what other pleasures or activities might
be adversely affected by such interventions. The application of genetic
modifications, particularly if heritable, would raise many of the same ethical
issues currently being discussed in the context of human cloning.
The main ethical issues concerning therapies which interfere with the
psychoactive effects of substance use, or which are aversive, are the
requirement for patient consent to treatment, the patient’s ability to give it,
and the ethics of coerced treatment (see Chapter 7). The medications or other
biological interventions at issue here are only one aspect of the means by
which societies or groups coerce individuals regarding unwanted behaviours,
and all such means are subject to similar ethical considerations. One
additional consideration for prescription medications and medical
procedures is the special ethical injunctions and constraints by which the
medical profession and other health professions are guided (e.g. Declaration
of Helsinki, see Box 7.1). Moreover, any treatment modality which is coerced
should presumably have been shown to be effective.
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Substitution therapy—using a medicine that is pharmacologically
related to the dependence-producing substance—has often been contro-
versial, with the argument stated in ethical terms. On the one hand, it is stated
to be unethical for the state, or a treatment professional, to contribute to the
continuation of the dependence, even if on a substitute regime. On the other
hand, the counter-arguments of the demonstrated reductions in harm to
society (e.g. criminal activity) or to the individual (e.g. HIV infection) from
the substitute therapy are also ethical at their core. The general acceptance
of nicotine replacement therapy might be regarded as indicating a gradual
shift away from regarding the dependence itself as the harm, and towards a
public health focus on the health and social harm which come from the use,
whether dependent or not.
It should be noted that the topics discussed here and in Chapter 7 do not
exhaust the range of ethical issues around psychoactive substances in the
context of health practice and research. For instance, special ethical problems
arise when psychoactive medications are used to treat behavioural problems
in children; this may set up lifelong problems (i.e. predisposing them to later
problematic drug use) and may reflect over-prescription of these substances.
Another example is the ethics of “wash-out” studies to study psychoactive
medications, in which patients in treatment facilities are entered into trials
in which they are first taken off all the psychoactive medications they have
been taking (whether as self-medication or by prescription), to evaluate their
“baseline” condition.
A number of conceptual and policy issues might be addressed by scientific
organizations and intergovernmental agencies in light of these developments
in neuro-scientific and other research. These include such matters as the
conceptual basis and empirical findings relevant to definitions of dependence
and other substance use disorders in the International Classification of
Diseases (ICD-10) and the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV ); the effectiveness of treatments for substance use
disorders, and their place in systems of health and social services; and in
particular the effectiveness, availability, and ethics of the use of medications
and other biomedical interventions in treatment. As discussed earlier in this
chapter, each such therapy which is currently in effect or still on the horizon,
carries its own set of ethical issues, and these should be considered in the
context of developing international standards for human rights in health
services.
WHO already plays the role of a scientific arbiter on “scientific and medical”
aspects in the classification of controlled substances under the international
drug control treaties (Bruun, Pan & Rexed, 1975; Bayer & Ghodse, 1999). It
exercises this role primarily through an Expert Committee on Drug
Dependence, which meets every two years. As the intergovernmental agency
with primary responsibility for global public health, WHO has responsibilities
and interests concerning psychoactive substances which extend beyond the
scope of the international treaties. One means for addressing these wider
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responsibilities has been to expand the scope of the Expert Committee, at
least in some years (WHO, 1993), in order to cover the whole range of
psychoactive substances and to consider a broader public health approach.
However, reaching an expert judgement and building a global response
concerning these matters will require other resources and expertise alongside
the existing mechanism of the WHO Expert Committee.
Implications for public health policy
A substantial portion of the global burden of disease and disability is
attributable to psychoactive substance use. In turn, a substantial portion of
the burden attributable to substance use is associated with dependence.
Tobacco and alcohol use are particularly prominent contributors to the total
burden. Measures to reduce the harm from tobacco, alcohol and other
psychoactive substances are thus an important part of health policy.
Neuroscience is a fast growing field of scientific research. Though the
knowledge base is far from complete, there is a considerable amount of useful
data with enormous potential for influencing policies to reduce the burden
of disease and disability associated with substance use. The following
recommendations are made to facilitate greater openness and assist all
stakeholders in mobilizing action:
• All psychoactive substances can be harmful to health, depending on
how they are taken, in which amounts and how frequently. The harm
differs between substances and the public health response to substance
use should be proportional to the health-related harm that they cause.
• Use of psychoactive substances is to be expected because of their
pleasurable effects as well as peer pressure and the social context of
their use. Experimentation does not necessarily lead to dependence
but the greater the frequency and amount of substance used, the higher
the risk of becoming dependent.
• Harm to society is not only caused by individuals with substance
dependence. Significant harm also comes from non-dependent
individuals, stemming from acute intoxication and overdose, and from
the form of administration (e.g. through unsafe injections). There are,
however, effective public health policies and programmes which can
be implemented and which will lead to a significant reduction in the
overall burden related to substance use.
• Substance dependence is a complex disorder with biological
mechanisms affecting the brain and its capacity to control substance
use. It is not only determined by biological and genetic factors, but
psychological, social, cultural and environmental factors as well.
Currently, there are no means of identifying those who will become
dependent, either before or after they start using drugs.
Chapter_8 19.1.2004, 11:51247
NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE
248
• Substance dependence is not a failure of will or of strength of character
but a medical disorder that could affect any human being. Dependence
is a chronic and relapsing disorder, often co-occurring with other
physical and mental conditions.
• There is significant comorbidity of substance dependence with various
other mental illnesses; assessment, treatment and research would be
most effective if an integrated approach were adopted. Treatment and
prevention insights from other mental illnesses or substance
dependence can be used to inform treatment and prevention strategies
in the domain of the other. Attention to comorbidity of substance use
disorders and other mental disorders is thus required as an element of
good practice in treating or intervening in either mental illness or
substance dependence.
• Treatment for substance dependence is not only aimed at stopping drug
use—it is a therapeutic process that involves behaviour changes,
psychosocial interventions and often, the use of substitute psychotropic
drugs. Dependence can be treated and managed cost-effectively, saving
lives, improving the health of affected individuals and their families,
and reducing costs to society.
• Treatment must be accessible to all in need. Effective interventions exist
and can be integrated into health systems, including primary health
care. The health care sector needs to provide the most cost-effective
treatments.
• One of the main barriers to treatment and care of people with substance
dependence and related problems is the stigma and discrimination
against them. Regardless of the level of substance use and which
substance an individual takes, they have the same rights to health,
education, work opportunities and reintegration into society, as does
any other individual.
• Investments in neuroscience research must continue and expand to
include investments in social science, prevention, treatment and policy
research. The reduction in the burden from substance use and related
disorders must rely on evidence-based policies and programmes which
are the result of research and its application.
Conclusion
This report has summarized the advances in our understanding of the
neuroscience of psychoactive substance use and dependence in recent
decades, and has considered some of the ethical issues which are connected
with these advances. The developments in neuroscience have greatly
increased our knowledge about substance use and dependence, and the new
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knowledge poses substantial challenges for us to make ethical choices in
applying the fruits of this knowledge, both globally and locally. Relevant
organizational and professional bodies should play a leading role in meeting
these challenges at global and regional levels.
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Pavlovian incentive learning  44–45, 51
PCP, see Phencyclidine
Pemoline, see Amphetamines
Peptide neurotransmitters  35
Peptide systems, depression  186–187
PET, see Positron emission tomography
Phencyclidine (PCP)  104
NMDA glutamate receptor antagonist  109, 178–179
Phenylethylamine drugs  104
PMA, see Paramethoxyamphetamine
Pons  20
Positron emission tomography (PET)  40
Prevention studies
ethical issues  227–231
drug immunotherapies  229–231
early intervention studies  227–228
pharmacotherapy, clinical trials  211
genetics  243–244
Privacy and confidentiality, ethical issues  221–222, 230
Prodynorphin  137
Prosencephalon  20
Protein synthesis  27
Provocation studies, ethical issues  223–224
Pseudoephedrine, see Amphetamines
Psilocybin  104
Psychoactive substances (see also Dependence; specific substances)
adverse effects  10–12
behavioural effects  110
cellular effects  36–38
classification of use  2
craving, defined  56
definitions  15
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dependence
criteria  13
and depression  182–183
reward and dependence issues  46, 48–49, 53–54
and depression  184–185
development of antisocial personality disorder (ASPD)  189
global use  4–10
heritability  152
neuronal effects  38–39
and neuroscience  12–15
prevalence of use  9
psychopharmacology  67–69
shared neurobiology hypothesis  170–171, 188–191
sociolegal status  1–4
as surrogates of conventional reinforcers  51–52
total global mortality  17
treatment, ethical issues  232–235
withdrawal, with/without dependence  50
Psychotherapies  60
Public health policy  241–249
advances in neuroscience  241–244
ethical issues  244–247
recommendations  247–248
Quantitative trait loci (QTL)  129–130
Receptors  31–32
targeting by drugs  38
Recruitment of subjects for research, ethical issues  220–221
Reinforcement  47, 57
and dopamine  50–52
drugs as surrogates of conventional reinforcers  51–52
Relapse prevention  60
Research, see Ethical issues
Reward stimulus  46
drug reward, and dependence  48–49
incentive sensitization and dopamine  53–54
Rhombencephalon  20
Schizophrenia  171–180
alcohol use  176
clozapine  175–176
high incidence of smoking  172–174
positive/negative symptoms  173
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psychostimulant use  175
dependence  174–175
neurobiological interactions  176–180
side-effects, neuroleptic-induced  172
tobacco smoking  171–174
Scopolamine  104–105
Sedatives and hypnotics  73–75, 107
adaptations to prolonged use  75
behavioural effects  73
mechanism of action  74
tolerance and withdrawal  74–75
Sensitization (see also Incentive sensitization and dopamine; Tolerance)
defined  57
neural, persistence  58
Serotonergic systems  145–146
Serotonin  35
and depression  185–186
Serotonin autoreceptor agonist, LSA  109
Serotonin receptors  145–146
5HT1B variant  145–146
Serotonin transporter  146
Shared neurobiology hypothesis, psychoactive substance use  170–171, 188–
191
Signal transduction  31–32
Single photon emission computed tomography (SPECT)  40
Smoking, see Tobacco
Sociocultural factors, genetics  150–151
Sociolegal status of psychoactive substances  1–4
Solvents, see Volatile solvents
Somatostatin, neurotransmission in depression  187
SPECT, see Single photon emission computed tomography
Stimulants, behavioural effects  110
Substance use, see Psychoactive substances
Substitution therapy  246
treatment of opioid dependence  82
Synapse
chemical  31
structure and organization  28–29
Synaptic plasticity  38
Synaptic structure, alterations, substance use  38–39
TA-CD, cocaine vaccine  92–93
Tardive dyskinesia, side-effect in schizophrenia  172
Telencephalon  22
Terminal buttons  28–29
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Thalamus  24
TMA, see Trimethoxyamphetamine
Tobacco (see also Nicotine)  4–5, 75–78, 107
and alcohol use, linkage studies  139
behavioural effects  75–76
and depression  181–182
genetic studies  130–132
combined risk with other psychoactive substances  138–147
mechanism of action  76–77
PAHs in, hepatic enzyme induction  172
placebo, bupropion  181
prevalence of smoking
mortality  17
and schizophrenia  172–174
selected countries  5
tolerance and withdrawal  77–78
treatment of dependence  78
Tolerance (see also Specific substances)
defined  54–55, 57
development  54–55
and incentive sensitization  54–55
Tranquillizers, see Sedatives and hypnotics
Transcriptional regulator Fos  37–38
Transgenic animals  128–129
Treatment studies, ethical issues  232–235
access to treatment  232
legally coerced treatment  232
Trimethoxyamphetamine (TMA)  104
Tryptophan hydroxylase  146
Twinning and adoption studies  127, 132–133
Tyrosine hydroxylase  145
United Nations, drug control conventions  3
Universal Declaration of Human Rights  217–218
Vaccines, treatment of dependence, cocaine  92–93
Ventral tegmental area (VTA)  21
glutamatergic afferents  179
and mesolimbic system  174–175
Volatile solvents  100–104, 109
behavioural effects  101–102
environmental exposure  104
mechanism of action  102–103
tolerance and withdrawal  103
use  101–102
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VTA, see Ventral tegmental area
Vulnerable persons, identification and definition  222–223
WHO, Expert Committee  246–247
Withdrawal of drugs (see also Specific substances)
defined  57
and depression  184–185
with/without dependence  50
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Neuroscience of psychoactive
substance use and dependence
The Neuroscience of psychoactive substance use and dependence
provides an authoritative summary of current knowledge of the
biological basis of substance use and dependence, and discus-
ses the relationship of these behaviours with environmental fac-
tors. The book focuses on specific brain mechanisms governing
craving, tolerance, withdrawal, and dependence on a wide range
of psychoactive substances, including tobacco, alcohol and illicit
drugs. The ethical implications of new developments for preven-
tion and treatment are also discussed, and the public health
implications of this knowledge are translated into recommenda-
tions for policy and programmes at national and international
levels. Relying on contributions from many international experts,
the best available evidence is presented from the various schools
of thought and areas of research in this rapidly growing field.
Neuroscience of psychoactive substance use and dependence is
written for individuals with more than a basic knowledge of the
field, including scientists from a variety of disciplines. The book
should be of interest to health care workers, clinicians, social
workers, university students, science teachers and policy makers.
ISBN 92 4 156235 8
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